<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE pdf2xml SYSTEM "pdf2xml.dtd">

<pdf2xml producer="poppler" version="0.62.0">
<page number="1" position="absolute" top="0" left="0" height="1160" width="864">
	<fontspec id="0" size="11" family="Times" color="#ffffff"/>
	<fontspec id="1" size="26" family="Times" color="#0e2a52"/>
	<fontspec id="2" size="9" family="Times" color="#000000"/>
	<fontspec id="3" size="9" family="Times" color="#4c4c4c"/>
	<fontspec id="4" size="9" family="Times" color="#327eb1"/>
	<fontspec id="5" size="6" family="Times" color="#000000"/>
	<fontspec id="6" size="6" family="Times" color="#327eb1"/>
	<fontspec id="7" size="5" family="Times" color="#000000"/>
	<fontspec id="8" size="5" family="Times" color="#327eb1"/>
<text top="142" left="161" width="221" height="17" font="0">ACC/AHA FOCUSED UPDATE</text>
<text top="185" left="159" width="356" height="31" font="1">2016 ACC/AHA Guideline</text>
<text top="221" left="159" width="441" height="31" font="1">Focused Update on Duration of</text>
<text top="257" left="159" width="513" height="31" font="1">Dual Antiplatelet Therapy in Patients</text>
<text top="293" left="159" width="418" height="31" font="1">With Coronary Artery Disease</text>
<text top="342" left="161" width="421" height="12" font="2">A Report of the American College of Cardiology/American Heart Association</text>
<text top="360" left="161" width="232" height="12" font="2">Task Force on Clinical Practice Guidelines</text>
<text top="389" left="161" width="484" height="12" font="3">An Update of the 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention,</text>
<text top="408" left="161" width="514" height="12" font="3">2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery, 2012 ACC/AHA/ACP/AATS/</text>
<text top="428" left="161" width="531" height="12" font="3">PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart</text>
<text top="447" left="161" width="508" height="12" font="3">Disease, 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction,</text>
<text top="466" left="161" width="364" height="12" font="3">2014 AHA/ACC Guideline for the Management of Patients With Non</text>
<text top="464" left="525" width="159" height="16" font="3">–ST-Elevation Acute Coronary</text>
<text top="486" left="161" width="479" height="12" font="3">Syndromes, and 2014 ACC/AHA Guideline on Perioperative Cardiovascular Evaluation and</text>
<text top="505" left="161" width="305" height="12" font="3">Management of Patients Undergoing Noncardiac Surgery</text>
<text top="534" left="161" width="419" height="12" font="3">Developed in Collaboration With the American Association for Thoracic Surgery,</text>
<text top="553" left="161" width="509" height="12" font="3">American Society of Anesthesiologists, Society for Cardiovascular Angiography and Interventions,</text>
<text top="573" left="161" width="410" height="12" font="3">Society of Cardiovascular Anesthesiologists, and Society of Thoracic Surgeons.</text>
<text top="601" left="161" width="480" height="12" font="3">Endorsed by Preventive Cardiovascular Nurses Association and Society for Vascular Surgery</text>
<text top="676" left="57" width="88" height="12" font="3">Focused Update</text>
<text top="694" left="57" width="77" height="12" font="3">Writing <a href="">Group</a></text>
<text top="694" left="134" width="6" height="12" font="4"><a href="">*</a></text>
<text top="676" left="161" width="231" height="12" font="2">Glenn N. Levine, MD, FACC, FAHA, Chair</text>
<text top="674" left="392" width="5" height="15" font="4"><a href="">y</a></text>
<text top="712" left="161" width="215" height="12" font="2">Eric R. Bates, MD, FACC, FAHA, FSCAI</text>
<text top="712" left="376" width="5" height="12" font="4"><a href="">*</a></text>
<text top="710" left="381" width="5" height="15" font="4"><a href="">z</a></text>
<text top="729" left="161" width="133" height="12" font="2">John A. Bittl, MD, <a href="">FACC</a></text>
<text top="728" left="294" width="5" height="15" font="4"><a href="">x</a></text>
<text top="747" left="161" width="232" height="12" font="2">Ralph G. Brindis, MD, MPH, MACC, <a href="">FAHA</a></text>
<text top="746" left="393" width="5" height="15" font="4"><a href="">z</a></text>
<text top="765" left="161" width="150" height="12" font="2">Stephan D. Fihn, MD, <a href="">MPH</a></text>
<text top="764" left="311" width="5" height="15" font="4"><a href="">z</a></text>
<text top="783" left="161" width="187" height="12" font="2">Lee A. Fleisher, MD, FACC, FAHA</text>
<text top="781" left="348" width="6" height="15" font="4"><a href="">k</a></text>
<text top="801" left="161" width="231" height="12" font="2">Christopher B. Granger, MD, FACC, FAHA</text>
<text top="801" left="392" width="5" height="12" font="4"><a href="">*</a></text>
<text top="799" left="397" width="5" height="15" font="4"><a href="">z</a></text>
<text top="819" left="161" width="193" height="12" font="2">Richard A. Lange, MD, MBA, FACC</text>
<text top="817" left="354" width="5" height="15" font="4"><a href="">z</a></text>
<text top="837" left="161" width="153" height="12" font="2">Michael J. Mack, MD, FACC</text>
<text top="837" left="314" width="5" height="12" font="4"><a href="">*</a></text>
<text top="835" left="319" width="7" height="15" font="4"><a href="">{</a></text>
<text top="855" left="161" width="118" height="12" font="2">Laura Mauri, MD, MS</text>
<text top="858" left="279" width="5" height="8" font="5">C</text>
<text top="855" left="285" width="118" height="12" font="2">, FACC, FAHA, FSCAI</text>
<text top="855" left="403" width="5" height="12" font="4"><a href="">*</a></text>
<text top="853" left="408" width="5" height="15" font="4"><a href="">z</a></text>
<text top="873" left="161" width="232" height="12" font="2">Roxana Mehran, MD, FACC, FAHA, FSCAI</text>
<text top="873" left="393" width="12" height="12" font="4"><a href="">*#</a></text>
<text top="891" left="161" width="263" height="12" font="2">Debabrata Mukherjee, MD, FACC, FAHA, FSCAI</text>
<text top="889" left="424" width="5" height="15" font="4"><a href="">z</a></text>
<text top="909" left="161" width="231" height="12" font="2">L. Kristin Newby, MD, MHS, FACC, FAHA</text>
<text top="909" left="392" width="5" height="12" font="4"><a href="">*</a></text>
<text top="907" left="397" width="5" height="15" font="4"><a href="">z</a></text>
<text top="676" left="488" width="65" height="12" font="2">Patrick T. O</text>
<text top="674" left="553" width="133" height="15" font="2">’Gara, MD, FACC, FAHA</text>
<text top="674" left="686" width="5" height="15" font="4"><a href="">z</a></text>
<text top="694" left="488" width="230" height="12" font="2">Marc S. Sabatine, MD, MPH, FACC, <a href="">FAHA</a></text>
<text top="694" left="718" width="5" height="12" font="4"><a href="">*</a></text>
<text top="692" left="723" width="5" height="15" font="4"><a href="">z</a></text>
<text top="712" left="488" width="144" height="12" font="2">Peter K. Smith, MD, FACC</text>
<text top="710" left="633" width="5" height="15" font="4"><a href="">z</a></text>
<text top="729" left="488" width="101" height="12" font="2">Sidney C. Smith, J</text>
<text top="732" left="589" width="6" height="8" font="5">R</text>
<text top="729" left="595" width="104" height="12" font="2">, MD, FACC, FAHA</text>
<text top="728" left="699" width="5" height="15" font="4"><a href="">z</a></text>
<text top="780" left="488" width="274" height="9" font="5">*Focused Update writing group members are required to recuse</text>
<text top="795" left="488" width="241" height="9" font="5">themselves from voting on sections to which their speci</text>
<text top="793" left="729" width="68" height="12" font="5">ﬁc relationships</text>
<text top="809" left="488" width="125" height="9" font="5">with industry may apply; see</text>
<text top="809" left="616" width="48" height="9" font="6"><a href="1082.full.html#28">Appendix 1</a></text>
<text top="809" left="667" width="106" height="9" font="5">for detailed information.</text>
<text top="822" left="488" width="311" height="12" font="5"><a href="1082.full.html#28">y</a>ACC/AHA Task Force on Clinical Practice Guidelines Liaison. <a href="1082.full.html#28">z</a>ACC/AHA</text>
<text top="837" left="488" width="67" height="9" font="5">Representative.</text>
<text top="836" left="557" width="244" height="12" font="5"><a href="1082.full.html#28">xEvidence </a>Review Committee Chair. <a href="1082.full.html#28">kAmerican </a>Society of</text>
<text top="851" left="488" width="262" height="9" font="5">Anesthesiologists/Society of Cardiovascular Anesthesiologists</text>
<text top="866" left="488" width="67" height="9" font="5">Representative.</text>
<text top="864" left="558" width="233" height="12" font="5"><a href="1082.full.html#28">{</a>American Association for Thoracic Surgery/Society of</text>
<text top="880" left="488" width="267" height="9" font="5">Thoracic Surgeons Representative. #Society for Cardiovascular</text>
<text top="894" left="488" width="203" height="9" font="5">Angiography and Interventions Representative.</text>
<text top="966" left="170" width="631" height="9" font="5">This document was approved by the American College of Cardiology Board of Trustees and the American Heart Association Science Advisory and</text>
<text top="981" left="161" width="501" height="9" font="5">Coordinating Committee in February 2016, and the American Heart Association Executive Committee in March 2016.</text>
<text top="995" left="170" width="631" height="9" font="5">The American College of Cardiology Foundation requests that this document be cited as follows: Levine GN, Bates ER, Bittl JA, Brindis RG, Fihn SD, Fleisher</text>
<text top="1009" left="161" width="348" height="9" font="5">LA, Granger CB, Lange RA, Mack MJ, Mauri L, Mehran R, Mukherjee D, Newby LK, O</text>
<text top="1008" left="509" width="293" height="12" font="5">’Gara PT, Sabatine MS, Smith PK, Smith SC Jr. 2016 ACC/AHA guideline</text>
<text top="1023" left="161" width="640" height="9" font="5">focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology/American</text>
<text top="1037" left="161" width="640" height="9" font="5">Heart Association Task Force on Clinical Practice Guidelines: an update of the 2011 ACCF/AHA/SCAI guideline for percutaneous coronary intervention, 2011</text>
<text top="1052" left="161" width="640" height="9" font="5">ACCF/AHA guideline for coronary artery bypass graft surgery, 2012 ACC/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of</text>
<text top="1066" left="161" width="640" height="9" font="5">patients with stable ischemic heart disease, 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction, 2014 ACC/AHA guideline</text>
<text top="1080" left="161" width="169" height="9" font="5">for the management of patients with non</text>
<text top="1079" left="330" width="471" height="12" font="5">–ST-elevation acute coronary syndromes, and 2014 ACC/AHA guideline on perioperative cardiovascular evaluation</text>
<text top="1094" left="161" width="436" height="9" font="5">and management of patients undergoing noncardiac surgery. J Am Coll Cardiol 2016;68:1082</text>
<text top="1093" left="596" width="19" height="12" font="5">–115;</text>
<text top="1094" left="622" width="176" height="9" font="6"><a href="http://dx.doi.org/10.1016/j.jacc.2016.03.513">http://dx.doi.org/10.1016/j.jacc.2016.03.513</a></text>
<text top="1094" left="799" width="3" height="9" font="5"><a href="http://dx.doi.org/10.1016/j.jacc.2016.03.513">.</a></text>
<text top="54" left="161" width="256" height="7" font="7">J O U R N A L O F T H E A M E R I C A N C O L L E G E O F C A R D I O L O G Y</text>
<text top="54" left="701" width="100" height="7" font="7">V O L . 6 8 , N O . 1 0 , 2 0 1 6</text>
<text top="66" left="161" width="331" height="10" font="7">ª 2 0 1 6 B Y T H E A M E R I C A N C O L L E G E O F C A R D I O L O G Y F O U N D A T I O N A N D</text>
<text top="81" left="161" width="195" height="7" font="7">T H E A M E R I C A N H E A R T A S S O C I A T I O N , I N C .</text>
<text top="67" left="694" width="107" height="7" font="7">I S S N 0 7 3 5 - 1 0 9 7 / $ 3 6 . 0 0</text>
<text top="81" left="600" width="201" height="7" font="8"><a href="http://dx.doi.org/10.1016/j.jacc.2016.03.513">h t t p : / / d x . d o i . o r g / 1 0 . 1 0 1 6 / j . j a c c . 2 0 1 6 . 0 3 . 5 1 3</a></text>
<text top="94" left="161" width="113" height="7" font="7">P U B L I S H E D B Y E L S E V I E R</text>
</page>
<page number="2" position="absolute" top="0" left="0" height="1160" width="864">
	<fontspec id="9" size="11" family="Times" color="#e3202b"/>
	<fontspec id="10" size="8" family="Times" color="#e3202b"/>
	<fontspec id="11" size="8" family="Times" color="#000000"/>
	<fontspec id="12" size="9" family="Times" color="#0e2a52"/>
	<fontspec id="13" size="5" family="Times" color="#0e2a52"/>
	<fontspec id="14" size="7" family="Times" color="#000000"/>
<text top="143" left="63" width="80" height="12" font="3">ACC/AHA Task</text>
<text top="161" left="63" width="84" height="12" font="3">Force Members</text>
<text top="143" left="167" width="258" height="12" font="2">Jonathan L. Halperin, MD, FACC, FAHA, Chair</text>
<text top="161" left="167" width="261" height="12" font="2">Glenn N. Levine, MD, FACC, FAHA, Chair-Elect</text>
<text top="197" left="167" width="238" height="12" font="2">Sana M. Al-Khatib, MD, MHS, FACC, FAHA</text>
<text top="215" left="167" width="100" height="12" font="2">Kim K. Birtcher, P</text>
<text top="217" left="267" width="25" height="8" font="5">HARM</text>
<text top="215" left="292" width="71" height="12" font="2">D, MS, AACC</text>
<text top="233" left="167" width="129" height="12" font="2">Biykem Bozkurt, MD, P</text>
<text top="235" left="296" width="6" height="8" font="5">H</text>
<text top="233" left="302" width="86" height="12" font="2">D, FACC, FAHA</text>
<text top="250" left="167" width="232" height="12" font="2">Ralph G. Brindis, MD, MPH, MACC, FAHA</text>
<text top="268" left="167" width="172" height="12" font="2">Joaquin E. Cigarroa, MD, FACC</text>
<text top="286" left="167" width="102" height="12" font="2">Lesley H. Curtis, P</text>
<text top="289" left="269" width="6" height="8" font="5">H</text>
<text top="286" left="275" width="48" height="12" font="2">D, FAHA</text>
<text top="143" left="469" width="187" height="12" font="2">Lee A. Fleisher, MD, FACC, FAHA</text>
<text top="161" left="469" width="155" height="12" font="2">Federico Gentile, MD, FACC</text>
<text top="178" left="469" width="154" height="12" font="2">Samuel Gidding, MD, FAHA</text>
<text top="196" left="469" width="188" height="12" font="2">Mark A. Hlatky, MD, FACC, FAHA</text>
<text top="214" left="469" width="147" height="12" font="2">John S. Ikonomidis, MD, P</text>
<text top="217" left="615" width="6" height="8" font="5">H</text>
<text top="214" left="622" width="48" height="12" font="2">D, FAHA</text>
<text top="232" left="469" width="179" height="12" font="2">José A. Joglar, MD, FACC, FAHA</text>
<text top="250" left="469" width="106" height="12" font="2">Susan J. Pressler, P</text>
<text top="253" left="575" width="6" height="8" font="5">H</text>
<text top="250" left="581" width="72" height="12" font="2">D, RN, FAHA</text>
<text top="268" left="469" width="187" height="12" font="2">Duminda N. Wijeysundera, MD, P</text>
<text top="271" left="656" width="6" height="8" font="5">H</text>
<text top="268" left="662" width="8" height="12" font="2">D</text>
<text top="355" left="63" width="160" height="17" font="9">TABLE OF CONTENTS</text>
<text top="397" left="63" width="66" height="14" font="10">PREAMBLE</text>
<text top="397" left="131" width="235" height="14" font="11">. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .</text>
<text top="398" left="371" width="25" height="11" font="2">1084</text>
<text top="433" left="67" width="106" height="14" font="10">1. INTRODUCTION</text>
<text top="433" left="178" width="189" height="14" font="11">. . . . . . . . . . . . . . . . . . . . . . . . . . . . .</text>
<text top="434" left="371" width="25" height="11" font="2">1086</text>
<text top="458" left="78" width="218" height="12" font="12">1.1. Methodology and Evidence Review</text>
<text top="458" left="299" width="69" height="14" font="11">. . . . . . . . . . .</text>
<text top="459" left="371" width="25" height="11" font="2">1086</text>
<text top="483" left="77" width="213" height="12" font="12">1.2. Organization of the Writing Group</text>
<text top="483" left="299" width="69" height="14" font="11">. . . . . . . . . . .</text>
<text top="484" left="372" width="24" height="11" font="2">1087</text>
<text top="508" left="77" width="142" height="12" font="12">1.3. Review and Approval</text>
<text top="508" left="226" width="142" height="14" font="11">. . . . . . . . . . . . . . . . . . . . . .</text>
<text top="509" left="372" width="24" height="11" font="2">1087</text>
<text top="543" left="65" width="309" height="14" font="10">2. CRITICAL QUESTIONS AND SYSTEMATIC REVIEW</text>
<text top="561" left="77" width="59" height="14" font="10">FINDINGS</text>
<text top="561" left="145" width="222" height="14" font="11">. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .</text>
<text top="562" left="372" width="24" height="11" font="2">1087</text>
<text top="587" left="80" width="240" height="12" font="12">2.1. Critical Questions on Duration of DAPT</text>
<text top="586" left="325" width="42" height="14" font="11">. . . . . . .</text>
<text top="587" left="372" width="24" height="11" font="2">1087</text>
<text top="612" left="78" width="275" height="12" font="12">2.2. Studies of Shorter-Duration DAPT After Stent</text>
<text top="627" left="103" width="72" height="12" font="12">Implantation</text>
<text top="626" left="179" width="188" height="14" font="11">. . . . . . . . . . . . . . . . . . . . . . . . . . . . .</text>
<text top="627" left="372" width="24" height="11" font="2">1087</text>
<text top="652" left="78" width="273" height="12" font="12">2.3. Studies of Longer-Duration DAPT After Stent</text>
<text top="666" left="103" width="72" height="12" font="12">Implantation</text>
<text top="666" left="179" width="188" height="14" font="11">. . . . . . . . . . . . . . . . . . . . . . . . . . . . .</text>
<text top="667" left="372" width="24" height="11" font="2">1087</text>
<text top="691" left="77" width="203" height="12" font="12">2.4. Other Studies Relevant to DAPT</text>
<text top="705" left="103" width="92" height="15" font="12">&gt;1 Year After MI</text>
<text top="706" left="199" width="169" height="14" font="11">. . . . . . . . . . . . . . . . . . . . . . . . . .</text>
<text top="707" left="371" width="25" height="11" font="2">1088</text>
<text top="731" left="78" width="197" height="12" font="12">2.5. Prolonged/Extended DAPT and</text>
<text top="746" left="103" width="79" height="12" font="12">Mortality Rate</text>
<text top="746" left="186" width="182" height="14" font="11">. . . . . . . . . . . . . . . . . . . . . . . . . . . .</text>
<text top="747" left="371" width="25" height="11" font="2">1088</text>
<text top="781" left="65" width="190" height="14" font="10">3. OVERRIDING CONCEPTS AND</text>
<text top="799" left="77" width="222" height="14" font="10">RECOMMENDATIONS FOR DAPT AND</text>
<text top="817" left="77" width="146" height="14" font="10">DURATION OF THERAPY</text>
<text top="817" left="231" width="135" height="14" font="11">. . . . . . . . . . . . . . . . . . . . .</text>
<text top="818" left="371" width="25" height="11" font="2">1089</text>
<text top="843" left="80" width="182" height="12" font="12">3.1. General Overriding Concepts</text>
<text top="842" left="265" width="102" height="14" font="11">. . . . . . . . . . . . . . . .</text>
<text top="843" left="371" width="25" height="11" font="2">1089</text>
<text top="868" left="78" width="291" height="12" font="12">3.2. Factors Associated With Increased Ischemic and</text>
<text top="883" left="103" width="75" height="12" font="12">Bleeding Risk</text>
<text top="882" left="186" width="182" height="14" font="11">. . . . . . . . . . . . . . . . . . . . . . . . . . . .</text>
<text top="883" left="371" width="25" height="11" font="2">1089</text>
<text top="907" left="78" width="53" height="12" font="12">3.3. Speci</text>
<text top="906" left="132" width="38" height="15" font="12">ﬁc P2Y</text>
<text top="913" left="169" width="8" height="8" font="13">12</text>
<text top="907" left="181" width="164" height="12" font="12">Inhibitors: Recommendations</text>
<text top="907" left="352" width="16" height="14" font="11">. . .</text>
<text top="908" left="371" width="25" height="11" font="2">1090</text>
<text top="932" left="77" width="286" height="12" font="12">3.4. Platelet Function Testing, Genetic Testing, and</text>
<text top="947" left="103" width="93" height="12" font="12">Switching of P2Y</text>
<text top="952" left="196" width="8" height="8" font="13">12</text>
<text top="947" left="208" width="53" height="12" font="12">Inhibitors</text>
<text top="947" left="265" width="102" height="14" font="11">. . . . . . . . . . . . . . . .</text>
<text top="948" left="371" width="25" height="11" font="2">1090</text>
<text top="395" left="439" width="214" height="12" font="12">3.5. Proton Pump Inhibitors and DAPT</text>
<text top="394" left="659" width="69" height="14" font="11">. . . . . . . . . . .</text>
<text top="395" left="731" width="25" height="11" font="2">1090</text>
<text top="420" left="438" width="284" height="12" font="12">3.6. Aspirin Dosing in Patients Treated With DAPT:</text>
<text top="435" left="463" width="97" height="12" font="12">Recommendation</text>
<text top="434" left="566" width="162" height="14" font="11">. . . . . . . . . . . . . . . . . . . . . . . . .</text>
<text top="435" left="731" width="25" height="11" font="2">1090</text>
<text top="460" left="439" width="181" height="12" font="12">3.7. Triple Therapy (Aspirin, P2Y</text>
<text top="465" left="620" width="8" height="8" font="13">12</text>
<text top="460" left="632" width="103" height="12" font="12">Inhibitor, and Oral</text>
<text top="475" left="463" width="81" height="12" font="12">Anticoagulant)</text>
<text top="474" left="553" width="175" height="14" font="11">. . . . . . . . . . . . . . . . . . . . . . . . . . .</text>
<text top="475" left="732" width="24" height="11" font="2">1092</text>
<text top="513" left="424" width="284" height="14" font="10">4. PERCUTANEOUS CORONARY INTERVENTION</text>
<text top="513" left="718" width="9" height="14" font="11">. .</text>
<text top="514" left="732" width="24" height="11" font="2">1092</text>
<text top="538" left="439" width="293" height="12" font="12">4.1. Duration of DAPT in Patients With SIHD Treated</text>
<text top="553" left="463" width="159" height="12" font="12">With PCI: Recommendations</text>
<text top="552" left="626" width="102" height="14" font="11">. . . . . . . . . . . . . . . .</text>
<text top="553" left="732" width="24" height="11" font="2">1092</text>
<text top="578" left="438" width="289" height="12" font="12">4.2. Duration of DAPT in Patients With ACS Treated</text>
<text top="593" left="463" width="159" height="12" font="12">With PCI: Recommendations</text>
<text top="592" left="626" width="102" height="14" font="11">. . . . . . . . . . . . . . . .</text>
<text top="593" left="732" width="24" height="11" font="2">1093</text>
<text top="618" left="438" width="299" height="12" font="12">4.3. Duration of DAPT in Patients With SIHD and ACS</text>
<text top="633" left="463" width="93" height="12" font="12">Treated with PCI</text>
<text top="632" left="559" width="168" height="14" font="11">. . . . . . . . . . . . . . . . . . . . . . . . . .</text>
<text top="633" left="731" width="25" height="11" font="2">1094</text>
<text top="678" left="425" width="257" height="14" font="10">5. RECOMMENDATIONS FOR DURATION OF</text>
<text top="696" left="438" width="239" height="14" font="10">DAPT IN PATIENTS UNDERGOING CABG</text>
<text top="696" left="684" width="42" height="14" font="11">. . . . . . .</text>
<text top="697" left="732" width="24" height="11" font="2">1095</text>
<text top="740" left="424" width="258" height="14" font="10">6. RECOMMENDATIONS FOR DURATION OF</text>
<text top="758" left="438" width="182" height="14" font="10">DAPT IN PATIENTS WITH SIHD</text>
<text top="758" left="625" width="102" height="14" font="11">. . . . . . . . . . . . . . . .</text>
<text top="759" left="732" width="24" height="11" font="2">1097</text>
<text top="802" left="425" width="200" height="14" font="10">7. ACUTE CORONARY SYNDROME</text>
<text top="820" left="438" width="143" height="14" font="10">(NSTE-ACS AND STEMI)</text>
<text top="820" left="585" width="142" height="14" font="11">. . . . . . . . . . . . . . . . . . . . . .</text>
<text top="821" left="732" width="25" height="11" font="2">1099</text>
<text top="845" left="440" width="286" height="12" font="12">7.1. Duration of DAPT in Patients With ACS Treated</text>
<text top="860" left="463" width="212" height="12" font="12">With Medical Therapy Alone (Without</text>
<text top="875" left="463" width="237" height="12" font="12">Revascularization or Fibrinolytic Therapy):</text>
<text top="890" left="463" width="103" height="12" font="12">Recommendations</text>
<text top="889" left="573" width="155" height="14" font="11">. . . . . . . . . . . . . . . . . . . . . . . .</text>
<text top="890" left="732" width="25" height="11" font="2">1099</text>
<text top="915" left="439" width="300" height="12" font="12">7.2. Duration of DAPT in Patients With STEMI Treated</text>
<text top="930" left="463" width="147" height="12" font="12">With Fibrinolytic Therapy:</text>
<text top="945" left="463" width="103" height="12" font="12">Recommendations</text>
<text top="944" left="573" width="155" height="14" font="11">. . . . . . . . . . . . . . . . . . . . . . . .</text>
<text top="945" left="732" width="25" height="11" font="2">1099</text>
<text top="1010" left="176" width="536" height="9" font="5">This article has been copublished in Circulation. It has been reprinted by the Journal of Thoracic and Cardiovascular Surgery.</text>
<text top="1024" left="176" width="444" height="9" font="5">Copies: This document is available on the World Wide Web sites of the American College of Cardiology (</text>
<text top="1024" left="620" width="55" height="9" font="6"><a href="http://www.acc.org">www.acc.org</a></text>
<text top="1024" left="675" width="81" height="9" font="5"><a href="http://www.acc.org">) </a>and the American</text>
<text top="1038" left="167" width="81" height="9" font="5">Heart Association (</text>
<text top="1038" left="248" width="93" height="9" font="6"><a href="http://professional.heart.org">professional.heart.org</a></text>
<text top="1038" left="341" width="416" height="9" font="5"><a href="http://professional.heart.org">). </a>For copies of this document, please contact Elsevier Reprint Department, fax (212) 633-3820 or</text>
<text top="1053" left="167" width="27" height="9" font="5">e-mail</text>
<text top="1053" left="196" width="95" height="9" font="6"><a href="mailto:reprints@elsevier.com">reprints@elsevier.com</a></text>
<text top="1053" left="292" width="3" height="9" font="5"><a href="mailto:reprints@elsevier.com">.</a></text>
<text top="1067" left="176" width="149" height="9" font="5">Permissions: Multiple copies, modi</text>
<text top="1065" left="324" width="432" height="12" font="5">ﬁcation, alteration, enhancement, and/or distribution of this document are not permitted without the</text>
<text top="1081" left="167" width="537" height="9" font="5">express permission of the American College of Cardiology Foundation. Requests may be completed online via the Elsevier site (</text>
<text top="1081" left="704" width="53" height="9" font="6"><a href="http://www.elsevier.com/about/policies/author-agreement/obtaining-permission">http://www.</a></text>
<text top="1095" left="167" width="291" height="9" font="6"><a href="http://www.elsevier.com/about/policies/author-agreement/obtaining-permission">elsevier.com/about/policies/author-agreement/obtaining-permission</a></text>
<text top="1095" left="457" width="6" height="9" font="5">).</text>
<text top="54" left="63" width="132" height="7" font="7">J A C C V O L . 6 8 , N O . 1 0 , 2 0 1 6</text>
<text top="54" left="705" width="52" height="9" font="14">Levine et al.</text>
<text top="69" left="63" width="117" height="7" font="7">S E P T E M B E R 6 , 2 0 1 6 : 1 0 8 2</text>
<text top="67" left="182" width="17" height="10" font="7">– 1 1 5</text>
<text top="69" left="514" width="243" height="9" font="14">Focused Update on Duration of Dual Antiplatelet Therapy</text>
<text top="53" left="787" width="20" height="9" font="5">1083</text>
</page>
<page number="3" position="absolute" top="0" left="0" height="1160" width="864">
	<fontspec id="15" size="9" family="Times" color="#e3202b"/>
<text top="143" left="123" width="287" height="12" font="12">7.3. Duration of DAPT in Patients With ACS Treated</text>
<text top="158" left="147" width="159" height="12" font="12">With PCI: Recommendations</text>
<text top="157" left="310" width="102" height="14" font="11">. . . . . . . . . . . . . . . .</text>
<text top="158" left="417" width="24" height="11" font="2">1100</text>
<text top="182" left="122" width="288" height="12" font="12">7.4. Duration of DAPT in Patients With ACS Treated</text>
<text top="197" left="147" width="167" height="12" font="12">With CABG: Recommendation</text>
<text top="197" left="317" width="95" height="14" font="11">. . . . . . . . . . . . . . .</text>
<text top="198" left="417" width="24" height="11" font="2">1100</text>
<text top="222" left="123" width="241" height="12" font="12">7.5. Duration of DAPT in Patients With ACS</text>
<text top="222" left="370" width="42" height="14" font="11">. . . . . . .</text>
<text top="223" left="417" width="24" height="11" font="2">1100</text>
<text top="258" left="109" width="273" height="14" font="10">8. PERIOPERATIVE MANAGEMENT–TIMING OF</text>
<text top="275" left="122" width="289" height="14" font="10">ELECTIVE NONCARDIAC SURGERY IN PATIENTS</text>
<text top="293" left="122" width="187" height="14" font="10">TREATED WITH PCI AND DAPT:</text>
<text top="311" left="122" width="126" height="14" font="10">RECOMMENDATIONS</text>
<text top="311" left="256" width="155" height="14" font="11">. . . . . . . . . . . . . . . . . . . . . . . .</text>
<text top="312" left="420" width="21" height="11" font="2">1101</text>
<text top="347" left="108" width="80" height="14" font="10">REFERENCES</text>
<text top="347" left="196" width="215" height="14" font="11">. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .</text>
<text top="348" left="417" width="23" height="11" font="2">1104</text>
<text top="383" left="108" width="71" height="14" font="10">APPENDIX 1</text>
<text top="408" left="122" width="301" height="12" font="12">Author Relationships With Industry and Other Entities</text>
<text top="423" left="122" width="57" height="12" font="12">(Relevant)</text>
<text top="423" left="184" width="228" height="14" font="11">. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .</text>
<text top="424" left="418" width="23" height="11" font="2">1109</text>
<text top="459" left="108" width="73" height="14" font="10">APPENDIX 2</text>
<text top="484" left="122" width="270" height="12" font="12">Reviewer Relationships With Industry and Other</text>
<text top="499" left="122" width="102" height="12" font="12">Entities (Relevant)</text>
<text top="498" left="231" width="188" height="14" font="11">. . . . . . . . . . . . . . . . . . . . . . . . . . . . .</text>
<text top="499" left="422" width="19" height="11" font="2">1111</text>
<text top="533" left="108" width="73" height="16" font="15">PREAMBLE</text>
<text top="571" left="108" width="333" height="12" font="2">Incorporation of new study results, medications, or de-</text>
<text top="589" left="108" width="127" height="12" font="2">vices that merit modi</text>
<text top="587" left="234" width="207" height="15" font="2">ﬁcation of existing clinical practice</text>
<text top="607" left="108" width="333" height="12" font="2">guideline recommendations, or the addition of new rec-</text>
<text top="625" left="108" width="333" height="12" font="2">ommendations, is critical to ensuring that guidelines</text>
<text top="643" left="108" width="11" height="12" font="2">re</text>
<text top="641" left="119" width="322" height="15" font="2">ﬂect current knowledge, available treatment options,</text>
<text top="661" left="108" width="333" height="12" font="2">and optimum medical care. To keep pace with evolving</text>
<text top="679" left="108" width="333" height="12" font="2">evidence, the American College of Cardiology (ACC)/</text>
<text top="697" left="108" width="333" height="12" font="2">American Heart Association (AHA) Task Force on Clinical</text>
<text top="715" left="108" width="118" height="12" font="2">Practice Guidelines (</text>
<text top="713" left="226" width="215" height="15" font="2">“Task Force”) has issued this focused</text>
<text top="733" left="108" width="333" height="12" font="2">update to revise existing guideline recommendations on</text>
<text top="751" left="108" width="333" height="12" font="2">the basis of recently published study data. This update</text>
<text top="768" left="108" width="333" height="12" font="2">has been subject to rigorous, multilevel review and</text>
<text top="786" left="108" width="319" height="12" font="2">approval, similar to the full guidelines. For speci</text>
<text top="785" left="427" width="13" height="15" font="2">ﬁc</text>
<text top="804" left="108" width="333" height="12" font="2">focused update criteria and additional methodological</text>
<text top="822" left="108" width="333" height="12" font="2">details, please see the ACC/AHA guideline methodology</text>
<text top="840" left="108" width="43" height="12" font="2">manual</text>
<text top="840" left="155" width="14" height="12" font="4"><a href="1082.full.html#23">(1)</a></text>
<text top="840" left="169" width="3" height="12" font="2"><a href="1082.full.html#23">.</a></text>
<text top="880" left="108" width="76" height="11" font="12">Modernization</text>
<text top="902" left="108" width="333" height="12" font="2">Processes have evolved over time in response to pub-</text>
<text top="920" left="108" width="274" height="12" font="2">lished reports from the Institute of Medicine</text>
<text top="920" left="388" width="25" height="12" font="4"><a href="1082.full.html#23">(2,3)</a></text>
<text top="920" left="419" width="21" height="12" font="2">and</text>
<text top="938" left="108" width="121" height="12" font="2">ACC/AHA mandates</text>
<text top="938" left="238" width="11" height="12" font="4"><a href="1082.full.html#23">(4</a></text>
<text top="936" left="250" width="16" height="15" font="4"><a href="1082.full.html#23">–7)</a></text>
<text top="938" left="266" width="175" height="12" font="2">, leading to adoption of a</text>
<text top="954" left="108" width="333" height="15" font="2">“knowledge byte” format. This process entails delinea-</text>
<text top="974" left="108" width="272" height="12" font="2">tion of a recommendation addressing a speci</text>
<text top="972" left="380" width="61" height="15" font="2">ﬁc clinical</text>
<text top="991" left="108" width="257" height="12" font="2">question, followed by concise text (ideally</text>
<text top="990" left="371" width="70" height="15" font="2">&lt;250 words</text>
<text top="1009" left="108" width="333" height="12" font="2">per recommendation) and hyperlinked to supportive ev-</text>
<text top="1027" left="108" width="333" height="12" font="2">idence. This approach better accommodates time con-</text>
<text top="1045" left="108" width="333" height="12" font="2">straints on busy clinicians, facilitates easier access to</text>
<text top="1063" left="108" width="333" height="12" font="2">recommendations via electronic search engines and other</text>
<text top="1081" left="108" width="333" height="12" font="2">evolving technology, and supports the evolution of</text>
<text top="143" left="468" width="75" height="12" font="2">guidelines as</text>
<text top="141" left="547" width="255" height="15" font="2">“living documents” that can be dynamically</text>
<text top="161" left="468" width="114" height="12" font="2">updated as needed.</text>
<text top="199" left="468" width="258" height="11" font="12">Class of Recommendation and Level of Evidence</text>
<text top="220" left="468" width="333" height="12" font="2">The Class of Recommendation (COR) and Level of</text>
<text top="238" left="468" width="333" height="12" font="2">Evidence (LOE) are derived independently of each</text>
<text top="256" left="468" width="333" height="12" font="2">other according to established criteria. The COR in-</text>
<text top="274" left="468" width="333" height="12" font="2">dicates the strength of recommendation, encompassing</text>
<text top="292" left="468" width="290" height="12" font="2">the estimated magnitude and certainty of bene</text>
<text top="290" left="758" width="43" height="15" font="2">ﬁt of a</text>
<text top="310" left="468" width="333" height="12" font="2">clinical action in proportion to risk. The LOE rates the</text>
<text top="328" left="468" width="104" height="12" font="2">quality of scienti</text>
<text top="326" left="572" width="229" height="15" font="2">ﬁc evidence supporting the interven-</text>
<text top="346" left="468" width="333" height="12" font="2">tion on the basis of the type, quantity, and consistency</text>
<text top="364" left="468" width="283" height="12" font="2">of data from clinical trials and other sources (</text>
<text top="364" left="751" width="42" height="11" font="4"><a href="1082.full.html#4">Table 1</a></text>
<text top="364" left="793" width="8" height="12" font="2">).</text>
<text top="382" left="468" width="281" height="12" font="2">Recommendations in this focused update re</text>
<text top="380" left="749" width="52" height="15" font="2">ﬂect the</text>
<text top="400" left="468" width="333" height="12" font="2">new 2015 COR/LOE system, in which LOE B and C</text>
<text top="418" left="468" width="333" height="12" font="2">are subcategorized for the purpose of increased granu-</text>
<text top="436" left="468" width="30" height="12" font="2">larity</text>
<text top="436" left="504" width="35" height="12" font="4"><a href="1082.full.html#23">(1,7,8)</a></text>
<text top="436" left="539" width="3" height="12" font="2">.</text>
<text top="477" left="468" width="248" height="11" font="12">Relationships With Industry and Other Entities</text>
<text top="498" left="468" width="333" height="12" font="2">The ACC and AHA exclusively sponsor the work of</text>
<text top="516" left="468" width="333" height="12" font="2">guideline writing committees (GWCs) without commer-</text>
<text top="534" left="468" width="333" height="12" font="2">cial support, and members volunteer time for this ac-</text>
<text top="552" left="468" width="333" height="12" font="2">tivity. Selected organizations and professional societies</text>
<text top="570" left="468" width="333" height="12" font="2">with related interests and expertise are invited to</text>
<text top="588" left="468" width="333" height="12" font="2">participate as partners or collaborators. The Task Force</text>
<text top="606" left="468" width="37" height="12" font="2">makes</text>
<text top="606" left="516" width="32" height="12" font="2">every</text>
<text top="606" left="560" width="32" height="12" font="2">effort</text>
<text top="606" left="604" width="11" height="12" font="2">to</text>
<text top="606" left="627" width="32" height="12" font="2">avoid</text>
<text top="606" left="671" width="39" height="12" font="2">actual,</text>
<text top="606" left="722" width="56" height="12" font="2">potential,</text>
<text top="606" left="789" width="12" height="12" font="2">or</text>
<text top="624" left="468" width="83" height="12" font="2">perceived con</text>
<text top="622" left="551" width="250" height="15" font="2">ﬂicts of interest that might arise through</text>
<text top="642" left="468" width="333" height="12" font="2">relationships with industry or other entities (RWI). All</text>
<text top="660" left="468" width="333" height="12" font="2">GWC members and reviewers are required to fully</text>
<text top="678" left="468" width="333" height="12" font="2">disclose current industry relationships or personal in-</text>
<text top="696" left="468" width="333" height="12" font="2">terests, beginning 12 months before initiation of the</text>
<text top="714" left="468" width="333" height="12" font="2">writing effort. Management of RWI involves selecting a</text>
<text top="731" left="468" width="333" height="12" font="2">balanced GWC and requires that both the chair and a</text>
<text top="749" left="468" width="333" height="12" font="2">majority of GWC members have no relevant RWI (see</text>
<text top="767" left="468" width="67" height="12" font="4"><a href="1082.full.html#28">Appendix 1</a></text>
<text top="767" left="540" width="60" height="12" font="2">for the de</text>
<text top="765" left="601" width="200" height="15" font="2">ﬁnition of relevance). GWC mem-</text>
<text top="785" left="468" width="333" height="12" font="2">bers are restricted with regard to writing or voting on</text>
<text top="803" left="468" width="333" height="12" font="2">sections to which RWI apply. Members of the GWC who</text>
<text top="821" left="468" width="333" height="12" font="2">recused themselves from voting are indicated and spe-</text>
<text top="839" left="468" width="10" height="12" font="2">ci</text>
<text top="837" left="478" width="186" height="15" font="2">ﬁc section recusals are noted in</text>
<text top="839" left="668" width="77" height="12" font="4"><a href="1082.full.html#28">Appendixes 1</a></text>
<text top="839" left="749" width="22" height="12" font="2">and</text>
<text top="839" left="775" width="6" height="12" font="4"><a href="1082.full.html#30">2</a></text>
<text top="839" left="782" width="20" height="12" font="2"><a href="1082.full.html#30">. </a>In</text>
<text top="857" left="468" width="254" height="12" font="2">addition, for transparency, GWC members</text>
<text top="855" left="722" width="79" height="15" font="2">’ comprehen-</text>
<text top="875" left="468" width="287" height="12" font="2">sive disclosure information is available as an</text>
<text top="875" left="763" width="38" height="12" font="4"><a href="http://jaccjacc.acc.org/Clinical_Document/DAPT_Author_Relationships_With_Industry_and_Other_Entities_Comprehensive.pdf">Online</a></text>
<text top="893" left="468" width="70" height="12" font="4"><a href="http://jaccjacc.acc.org/Clinical_Document/DAPT_Author_Relationships_With_Industry_and_Other_Entities_Comprehensive.pdf">Supplement</a></text>
<text top="893" left="538" width="263" height="12" font="2"><a href="http://jaccjacc.acc.org/Clinical_Document/DAPT_Author_Relationships_With_Industry_and_Other_Entities_Comprehensive.pdf">. </a>Comprehensive disclosure information for</text>
<text top="911" left="468" width="193" height="12" font="2">the Task Force is also available</text>
<text top="911" left="666" width="36" height="12" font="4"><a href="http://www.acc.org/guidelines/about-guidelines-and-clinical-documents/guidelines-and-documents-task-forces">online</a></text>
<text top="911" left="702" width="99" height="12" font="2">. The Task Force</text>
<text top="929" left="468" width="333" height="12" font="2">strives to avoid bias by selecting experts from a broad array</text>
<text top="947" left="468" width="333" height="12" font="2">of backgrounds representing different geographic regions,</text>
<text top="965" left="468" width="333" height="12" font="2">genders, ethnicities, intellectual perspectives, and scopes</text>
<text top="983" left="468" width="115" height="12" font="2">of clinical activities.</text>
<text top="1024" left="468" width="71" height="11" font="12">Intended Use</text>
<text top="1045" left="468" width="333" height="12" font="2">Guidelines provide recommendations applicable to pa-</text>
<text top="1063" left="468" width="333" height="12" font="2">tients with or at risk of developing cardiovascular disease.</text>
<text top="1081" left="468" width="333" height="12" font="2">The focus is on medical practice in the United States, but</text>
<text top="53" left="108" width="52" height="9" font="14">Levine et al.</text>
<text top="54" left="670" width="132" height="7" font="7">J A C C V O L . 6 8 , N O . 1 0 , 2 0 1 6</text>
<text top="68" left="108" width="243" height="9" font="14">Focused Update on Duration of Dual Antiplatelet Therapy</text>
<text top="69" left="665" width="117" height="7" font="7">S E P T E M B E R 6 , 2 0 1 6 : 1 0 8 2</text>
<text top="67" left="784" width="17" height="10" font="7">– 1 1 5</text>
<text top="53" left="57" width="21" height="9" font="5">1084</text>
</page>
<page number="4" position="absolute" top="0" left="0" height="1160" width="864">
	<fontspec id="16" size="8" family="Times" color="#ffffff"/>
	<fontspec id="17" size="8" family="Times" color="#0e2a52"/>
<text top="983" left="63" width="333" height="12" font="2">guidelines developed in collaboration with other organi-</text>
<text top="1001" left="63" width="333" height="12" font="2">zations may have a broader target. Although guidelines</text>
<text top="1019" left="63" width="333" height="12" font="2">may be used to inform regulatory or payer decisions, the</text>
<text top="1037" left="63" width="333" height="12" font="2">intent is to improve quality of care and align with pa-</text>
<text top="1055" left="63" width="33" height="12" font="2">tients</text>
<text top="1053" left="96" width="300" height="15" font="2">’ interests. The guidelines are reviewed annually</text>
<text top="1073" left="63" width="171" height="12" font="2">by the Task Force and are of</text>
<text top="1071" left="234" width="162" height="15" font="2">ﬁcial policy of the ACC and</text>
<text top="1091" left="63" width="333" height="12" font="2">AHA. Each guideline is considered current unless and</text>
<text top="983" left="423" width="333" height="12" font="2">until it is updated, revised, or superseded by a published</text>
<text top="1001" left="423" width="66" height="12" font="2">addendum.</text>
<text top="1036" left="423" width="76" height="11" font="12">Related Issues</text>
<text top="1057" left="423" width="333" height="12" font="2">For additional information pertaining to the methodology</text>
<text top="1075" left="423" width="253" height="12" font="2">for grading evidence, assessment of bene</text>
<text top="1073" left="676" width="80" height="15" font="2">ﬁt and harm,</text>
<text top="1093" left="423" width="39" height="12" font="2">shared</text>
<text top="1093" left="474" width="48" height="12" font="2">decision</text>
<text top="1093" left="534" width="43" height="12" font="2">making</text>
<text top="1093" left="589" width="49" height="12" font="2">between</text>
<text top="1093" left="651" width="19" height="12" font="2">the</text>
<text top="1093" left="681" width="41" height="12" font="2">patient</text>
<text top="1093" left="735" width="22" height="12" font="2">and</text>
<text top="156" left="71" width="46" height="10" font="16">T A B L E 1</text>
<text top="149" left="135" width="585" height="10" font="17">Applying Class of Recommendation and Level of Evidence to Clinical Strategies, Interventions, Treatments, or</text>
<text top="163" left="135" width="313" height="10" font="17">Diagnostic Testing in Patient Care* (Updated August 2015)</text>
<text top="54" left="63" width="132" height="7" font="7">J A C C V O L . 6 8 , N O . 1 0 , 2 0 1 6</text>
<text top="54" left="705" width="52" height="9" font="14">Levine et al.</text>
<text top="69" left="63" width="117" height="7" font="7">S E P T E M B E R 6 , 2 0 1 6 : 1 0 8 2</text>
<text top="67" left="182" width="17" height="10" font="7">– 1 1 5</text>
<text top="69" left="514" width="243" height="9" font="14">Focused Update on Duration of Dual Antiplatelet Therapy</text>
<text top="53" left="787" width="20" height="9" font="5">1085</text>
</page>
<page number="5" position="absolute" top="0" left="0" height="1160" width="864">
<text top="143" left="108" width="333" height="12" font="2">clinician, structure of evidence tables and summaries,</text>
<text top="161" left="108" width="333" height="12" font="2">standardized terminology for articulating recommenda-</text>
<text top="178" left="108" width="333" height="12" font="2">tions, organizational involvement, peer review, and pol-</text>
<text top="196" left="108" width="333" height="12" font="2">icies regarding periodic assessment and updating of</text>
<text top="214" left="108" width="333" height="12" font="2">guideline documents, we encourage readers to consult</text>
<text top="232" left="108" width="264" height="12" font="2">the ACC/AHA guideline methodology manual</text>
<text top="232" left="376" width="14" height="12" font="4"><a href="1082.full.html#23">(1)</a></text>
<text top="232" left="390" width="3" height="12" font="2"><a href="1082.full.html#23">.</a></text>
<text top="250" left="211" width="230" height="12" font="2">Jonathan L. Halperin, MD, FACC, FAHA</text>
<text top="268" left="123" width="318" height="12" font="2">Chair, ACC/AHA Task Force on Clinical Practice Guidelines</text>
<text top="302" left="108" width="120" height="16" font="15">1. INTRODUCTION</text>
<text top="340" left="108" width="333" height="12" font="2">The scope of this focused update is limited to addressing</text>
<text top="358" left="108" width="333" height="12" font="2">recommendations on duration of dual antiplatelet therapy</text>
<text top="376" left="108" width="161" height="12" font="2">(DAPT) (aspirin plus a P2Y</text>
<text top="381" left="269" width="9" height="8" font="7">12</text>
<text top="376" left="284" width="157" height="12" font="2">inhibitor) in patients with</text>
<text top="394" left="108" width="333" height="12" font="2">coronary artery disease (CAD). Recommendations consid-</text>
<text top="412" left="108" width="193" height="12" font="2">ered are those in 6 guidelines:</text>
<text top="410" left="308" width="133" height="15" font="2">“2011 ACCF/AHA/SCAI</text>
<text top="430" left="108" width="301" height="12" font="2">Guideline for Percutaneous Coronary Intervention</text>
<text top="428" left="409" width="6" height="15" font="2">”</text>
<text top="430" left="422" width="15" height="12" font="4"><a href="1082.full.html#23">(9)</a></text>
<text top="430" left="437" width="3" height="12" font="2">,</text>
<text top="446" left="108" width="333" height="15" font="2">“2011 ACCF/AHA Guideline for Coronary Artery Bypass</text>
<text top="465" left="108" width="80" height="12" font="2">Graft Surgery</text>
<text top="464" left="188" width="6" height="15" font="2">”</text>
<text top="465" left="201" width="21" height="12" font="4"><a href="1082.full.html#23">(10)</a></text>
<text top="465" left="223" width="3" height="12" font="2"><a href="1082.full.html#23">,</a></text>
<text top="464" left="233" width="208" height="15" font="2">“2012 ACCF/AHA/ACP/AATS/PCNA/</text>
<text top="483" left="108" width="333" height="12" font="2">SCAI/STS Guideline for the Diagnosis and Management of</text>
<text top="501" left="108" width="251" height="12" font="2">Patients With Stable Ischemic Heart Disease</text>
<text top="499" left="359" width="6" height="15" font="2">”</text>
<text top="501" left="368" width="34" height="12" font="4"><a href="1082.full.html#23">(11,12)</a></text>
<text top="501" left="403" width="3" height="12" font="2"><a href="1082.full.html#23">,</a></text>
<text top="499" left="409" width="32" height="15" font="2">“2013</text>
<text top="519" left="108" width="333" height="12" font="2">ACC/AHA Guideline for the Management of ST-Elevation</text>
<text top="537" left="108" width="125" height="12" font="2">Myocardial Infarction</text>
<text top="535" left="233" width="6" height="15" font="2">”</text>
<text top="537" left="242" width="20" height="12" font="4"><a href="1082.full.html#23">(13)</a></text>
<text top="537" left="263" width="3" height="12" font="2"><a href="1082.full.html#23">,</a></text>
<text top="535" left="270" width="171" height="15" font="2">“2014 ACC/AHA Guideline for</text>
<text top="555" left="108" width="24" height="12" font="2">Non</text>
<text top="553" left="132" width="252" height="15" font="2">–ST-Elevation Acute Coronary Syndromes”</text>
<text top="555" left="389" width="21" height="12" font="4"><a href="1082.full.html#23">(14)</a></text>
<text top="555" left="411" width="30" height="12" font="2"><a href="1082.full.html#23">, </a>and</text>
<text top="571" left="108" width="333" height="15" font="2">“2014 ACC/AHA Guideline on Perioperative Cardiovascular</text>
<text top="591" left="108" width="333" height="12" font="2">Evaluation and Management of Patients Undergoing</text>
<text top="609" left="108" width="113" height="12" font="2">Noncardiac Surgery</text>
<text top="607" left="221" width="6" height="15" font="2">”</text>
<text top="609" left="230" width="20" height="12" font="4"><a href="1082.full.html#24">(15)</a></text>
<text top="609" left="251" width="3" height="12" font="2"><a href="1082.full.html#24">.</a></text>
<text top="627" left="123" width="318" height="12" font="2">The impetus for this focused update review is 11 studies</text>
<text top="645" left="108" width="16" height="12" font="4"><a href="1082.full.html#24">(16</a></text>
<text top="643" left="124" width="22" height="15" font="4"><a href="1082.full.html#24">–27)</a></text>
<text top="645" left="151" width="290" height="12" font="2">of patients treated with coronary stent implanta-</text>
<text top="663" left="108" width="333" height="12" font="2">tion (predominantly with drug-eluting stents [DES])</text>
<text top="681" left="108" width="333" height="12" font="2">assessing shorter-duration or longer-duration DAPT, as</text>
<text top="699" left="108" width="333" height="12" font="2">well as a large, randomized controlled trial (RCT) of pa-</text>
<text top="716" left="108" width="334" height="12" font="2">tients 1 to 3 years after myocardial infarction (MI)</text>
<text top="734" left="108" width="98" height="12" font="2">assessing the ef</text>
<text top="733" left="206" width="235" height="15" font="2">ﬁcacy of DAPT compared with aspirin</text>
<text top="752" left="108" width="78" height="12" font="2">monotherapy</text>
<text top="752" left="189" width="22" height="12" font="4"><a href="1082.full.html#24">(28)</a></text>
<text top="752" left="211" width="230" height="12" font="2"><a href="1082.full.html#24">. </a>These studies were published after the</text>
<text top="770" left="108" width="333" height="12" font="2">formulation of recommendations for duration of DAPT in</text>
<text top="788" left="108" width="165" height="12" font="2">prior guidelines. The speci</text>
<text top="786" left="273" width="168" height="15" font="2">ﬁc mandate of the present</text>
<text top="806" left="108" width="333" height="12" font="2">writing group is to evaluate, update, harmonize, and,</text>
<text top="824" left="108" width="333" height="12" font="2">when possible, simplify recommendations on duration of</text>
<text top="842" left="108" width="36" height="12" font="2">DAPT.</text>
<text top="860" left="123" width="318" height="12" font="2">Although there are several potential combinations of</text>
<text top="878" left="108" width="333" height="12" font="2">antiplatelet therapy, the term and acronym DAPT has</text>
<text top="896" left="108" width="106" height="12" font="2">been used to speci</text>
<text top="894" left="214" width="227" height="15" font="2">ﬁcally refer to combination antiplatelet</text>
<text top="914" left="108" width="185" height="12" font="2">therapy with aspirin and a P2Y</text>
<text top="919" left="293" width="9" height="8" font="7">12</text>
<text top="914" left="307" width="134" height="12" font="2">receptor inhibitor (clo-</text>
<text top="932" left="108" width="333" height="12" font="2">pidogrel, prasugrel, or ticagrelor) and will be used simi-</text>
<text top="950" left="108" width="333" height="12" font="2">larly in this focused update. Recommendations in this</text>
<text top="968" left="108" width="333" height="12" font="2">focused update on duration of DAPT, aspirin dosing in</text>
<text top="985" left="108" width="333" height="12" font="2">patients treated with DAPT, and timing of elective</text>
<text top="1003" left="108" width="333" height="12" font="2">noncardiac surgery in patients treated with percutaneous</text>
<text top="1021" left="108" width="333" height="12" font="2">coronary intervention (PCI) and DAPT supersede prior</text>
<text top="1039" left="108" width="83" height="12" font="2">corresponding</text>
<text top="1039" left="203" width="104" height="12" font="2">recommendations</text>
<text top="1039" left="320" width="11" height="12" font="2">in</text>
<text top="1039" left="343" width="19" height="12" font="2">the</text>
<text top="1039" left="374" width="7" height="12" font="2">6</text>
<text top="1039" left="393" width="48" height="12" font="2">relevant</text>
<text top="1057" left="108" width="333" height="12" font="2">guidelines. These recommendations for duration of DAPT</text>
<text top="1075" left="108" width="333" height="12" font="2">apply to newer-generation stents and, in general, only to</text>
<text top="1093" left="108" width="333" height="12" font="2">those not treated with oral anticoagulant therapy. For the</text>
<text top="143" left="468" width="333" height="12" font="2">purposes of this focused update, patients with a history of</text>
<text top="161" left="468" width="187" height="12" font="2">acute coronary syndrome (ACS)</text>
<text top="159" left="661" width="140" height="15" font="2">&gt;1 year prior who have</text>
<text top="178" left="468" width="333" height="12" font="2">since remained free of recurrent ACS are considered to</text>
<text top="196" left="468" width="333" height="12" font="2">have transitioned to stable ischemic heart disease (SIHD)</text>
<text top="214" left="468" width="333" height="12" font="2">and are addressed in the section on SIHD. Issues and</text>
<text top="232" left="468" width="230" height="12" font="2">recommendations with regard to P2Y</text>
<text top="237" left="698" width="9" height="8" font="7">12</text>
<text top="232" left="714" width="50" height="12" font="2">inhibitor</text>
<text top="230" left="771" width="30" height="15" font="2">“pre-</text>
<text top="250" left="468" width="61" height="12" font="2">treatment,</text>
<text top="248" left="529" width="272" height="15" font="2">” “preloading,” and loading are beyond the</text>
<text top="268" left="468" width="333" height="12" font="2">scope of this document but are addressed in other</text>
<text top="286" left="468" width="60" height="12" font="2">guidelines</text>
<text top="286" left="532" width="49" height="12" font="4"><a href="1082.full.html#23">(9,14,29)</a></text>
<text top="286" left="582" width="3" height="12" font="2"><a href="1082.full.html#23">.</a></text>
<text top="304" left="483" width="318" height="12" font="2">This focused update is designed to function both as a</text>
<text top="322" left="468" width="333" height="12" font="2">standalone document and to serve as an update to the</text>
<text top="340" left="468" width="333" height="12" font="2">relevant sections on duration of DAPT in the 6 clinical</text>
<text top="358" left="468" width="258" height="12" font="2">practice guidelines, replacing relevant text,</text>
<text top="356" left="732" width="70" height="15" font="2">ﬁgures, and</text>
<text top="376" left="468" width="333" height="12" font="2">recommendations. Thus, by necessity, there is some</text>
<text top="394" left="468" width="333" height="12" font="2">redundancy in different sections of this document. When</text>
<text top="412" left="468" width="74" height="12" font="2">possible, the</text>
<text top="410" left="547" width="255" height="15" font="2">“knowledge byte” format was used for rec-</text>
<text top="430" left="468" width="333" height="12" font="2">ommendations. In some cases, the complexity of this</text>
<text top="447" left="468" width="155" height="12" font="2">document required a modi</text>
<text top="446" left="624" width="178" height="15" font="2">ﬁcation of the knowledge byte</text>
<text top="465" left="468" width="43" height="12" font="2">format,</text>
<text top="465" left="523" width="26" height="12" font="2">with</text>
<text top="465" left="562" width="41" height="12" font="2">several</text>
<text top="465" left="616" width="68" height="12" font="2">interrelated</text>
<text top="465" left="697" width="104" height="12" font="2">recommendations</text>
<text top="483" left="468" width="333" height="12" font="2">grouped together, followed by concise associated text</text>
<text top="501" left="468" width="4" height="12" font="2">(</text>
<text top="499" left="472" width="244" height="15" font="2">&lt;250 words of text per recommendation).</text>
<text top="534" left="468" width="208" height="11" font="12">1.1. Methodology and Evidence Review</text>
<text top="555" left="468" width="313" height="12" font="2">Clinical trials published since the 2011 PCI guideline</text>
<text top="555" left="786" width="15" height="12" font="4"><a href="1082.full.html#23">(9)</a></text>
<text top="573" left="468" width="333" height="12" font="2">and the 2011 coronary artery bypass graft (CABG) guide-</text>
<text top="591" left="468" width="22" height="12" font="2">line</text>
<text top="591" left="496" width="21" height="12" font="4"><a href="1082.full.html#23">(10)</a></text>
<text top="591" left="517" width="284" height="12" font="2">, published in a peer-reviewed format through</text>
<text top="609" left="468" width="333" height="12" font="2">December 2015, were reviewed by the Task Force to</text>
<text top="627" left="468" width="333" height="12" font="2">identify trials and other key data that might affect</text>
<text top="645" left="468" width="333" height="12" font="2">guideline recommendations. The information considered</text>
<text top="663" left="468" width="333" height="12" font="2">important enough to prompt updated recommendations</text>
<text top="681" left="468" width="248" height="12" font="2">is included in evidence tables in the</text>
<text top="681" left="727" width="75" height="12" font="4"><a href="http://jaccjacc.acc.org/Clinical_Document/DAPT_Data_Supplement_1.pdf">Online Data</a></text>
<text top="699" left="468" width="70" height="12" font="4"><a href="http://jaccjacc.acc.org/Clinical_Document/DAPT_Data_Supplement_1.pdf">Supplement</a></text>
<text top="699" left="538" width="3" height="12" font="2"><a href="http://jaccjacc.acc.org/Clinical_Document/DAPT_Data_Supplement_1.pdf">.</a></text>
<text top="716" left="483" width="318" height="12" font="2">In accord with recommendations by the Institute of</text>
<text top="734" left="468" width="53" height="12" font="2">Medicine</text>
<text top="734" left="525" width="25" height="12" font="4"><a href="1082.full.html#23">(2,3)</a></text>
<text top="734" left="553" width="248" height="12" font="2">and the ACC/AHA Task Force Methodology</text>
<text top="752" left="468" width="45" height="12" font="2">Summit</text>
<text top="752" left="520" width="25" height="12" font="4"><a href="1082.full.html#23">(1,6)</a></text>
<text top="752" left="545" width="257" height="12" font="2"><a href="1082.full.html#23">, </a>3 critical (PICOTS-formatted; population,</text>
<text top="770" left="468" width="333" height="12" font="2">intervention, comparison, outcome, timing, setting)</text>
<text top="788" left="468" width="333" height="12" font="2">questions were developed to address the critical ques-</text>
<text top="806" left="468" width="333" height="12" font="2">tions related to duration of DAPT. These 3 critical ques-</text>
<text top="824" left="468" width="333" height="12" font="2">tions were the basis of a formal systematic review and</text>
<text top="842" left="468" width="333" height="12" font="2">evaluation of the relevant study data by an Evidence</text>
<text top="860" left="468" width="148" height="12" font="2">Review Committee (ERC)</text>
<text top="860" left="620" width="22" height="12" font="4"><a href="1082.full.html#24">(30)</a></text>
<text top="860" left="643" width="158" height="12" font="2"><a href="1082.full.html#24">. </a>Concurrent with this pro-</text>
<text top="878" left="468" width="333" height="12" font="2">cess, writing group members evaluated study data rele-</text>
<text top="896" left="468" width="333" height="12" font="2">vant to the numerous current recommendations in the 6</text>
<text top="914" left="468" width="333" height="12" font="2">guidelines, including topics not covered in the 3 critical</text>
<text top="932" left="468" width="238" height="12" font="2">questions (e.g., DAPT after CABG). The</text>
<text top="930" left="712" width="89" height="15" font="2">ﬁndings of the</text>
<text top="950" left="468" width="333" height="12" font="2">ERC and the writing group members were formally pre-</text>
<text top="968" left="468" width="218" height="12" font="2">sented and discussed, and then modi</text>
<text top="966" left="686" width="115" height="15" font="2">ﬁcations to existing</text>
<text top="985" left="468" width="333" height="12" font="2">recommendations were considered. Recommendations</text>
<text top="1003" left="468" width="333" height="12" font="2">that are based on a body of evidence that includes a</text>
<text top="1021" left="468" width="333" height="12" font="2">systematic review conducted by the ERC are denoted by</text>
<text top="1039" left="468" width="200" height="12" font="2">the superscript SR (e.g., LOE B-R</text>
<text top="1037" left="674" width="11" height="8" font="7">SR</text>
<text top="1039" left="686" width="116" height="12" font="2">). See the ERC sys-</text>
<text top="1057" left="468" width="137" height="12" font="2">tematic review report,</text>
<text top="1055" left="613" width="188" height="15" font="2">“Duration of Dual Antiplatelet</text>
<text top="1075" left="468" width="333" height="12" font="2">Therapy: A Systematic Review for the 2016 ACC/AHA</text>
<text top="1093" left="468" width="56" height="12" font="2">Guideline</text>
<text top="1093" left="538" width="48" height="12" font="2">Focused</text>
<text top="1093" left="600" width="41" height="12" font="2">Update</text>
<text top="1093" left="656" width="14" height="12" font="2">on</text>
<text top="1093" left="684" width="51" height="12" font="2">Duration</text>
<text top="1093" left="749" width="11" height="12" font="2">of</text>
<text top="1093" left="775" width="26" height="12" font="2">Dual</text>
<text top="53" left="108" width="52" height="9" font="14">Levine et al.</text>
<text top="54" left="670" width="132" height="7" font="7">J A C C V O L . 6 8 , N O . 1 0 , 2 0 1 6</text>
<text top="68" left="108" width="243" height="9" font="14">Focused Update on Duration of Dual Antiplatelet Therapy</text>
<text top="69" left="665" width="117" height="7" font="7">S E P T E M B E R 6 , 2 0 1 6 : 1 0 8 2</text>
<text top="67" left="784" width="17" height="10" font="7">– 1 1 5</text>
<text top="53" left="57" width="21" height="9" font="5">1086</text>
</page>
<page number="6" position="absolute" top="0" left="0" height="1160" width="864">
<text top="143" left="63" width="333" height="12" font="2">Antiplatelet Therapy in Patients With Coronary Artery</text>
<text top="161" left="63" width="43" height="12" font="2">Disease</text>
<text top="159" left="106" width="245" height="15" font="2">” for the complete evidence review report</text>
<text top="161" left="356" width="22" height="12" font="4"><a href="1082.full.html#24">(30)</a></text>
<text top="161" left="379" width="3" height="12" font="2"><a href="1082.full.html#24">.</a></text>
<text top="193" left="63" width="205" height="11" font="12">1.2. Organization of the Writing Group</text>
<text top="214" left="63" width="333" height="12" font="2">Recommendations on duration of DAPT are currently</text>
<text top="232" left="63" width="333" height="12" font="2">included in 6 clinical practice guidelines, which are</text>
<text top="250" left="63" width="333" height="12" font="2">interrelated and overlapping because they address the</text>
<text top="268" left="63" width="333" height="12" font="2">management of patients with CAD. Therefore, the writing</text>
<text top="286" left="63" width="333" height="12" font="2">group consisted of the chairs/vice chairs and/or members</text>
<text top="304" left="63" width="215" height="12" font="2">of all 6 guidelines, representing the</text>
<text top="302" left="283" width="113" height="15" font="2">ﬁelds of cardiovas-</text>
<text top="322" left="63" width="333" height="12" font="2">cular medicine, interventional cardiology, cardiac sur-</text>
<text top="340" left="63" width="333" height="12" font="2">gery, internal medicine, and cardiovascular anesthesia, as</text>
<text top="358" left="63" width="322" height="12" font="2">well as expertise in trial design and statistical analysis.</text>
<text top="390" left="63" width="135" height="11" font="12">1.3. Review and Approval</text>
<text top="412" left="63" width="333" height="12" font="2">This focused update was reviewed by the writing com-</text>
<text top="430" left="63" width="284" height="12" font="2">mittee members from the 6 guidelines; by 5 of</text>
<text top="428" left="347" width="49" height="15" font="2">ﬁcial re-</text>
<text top="447" left="63" width="333" height="12" font="2">viewers from the ACC and AHA; 2 reviewers each from the</text>
<text top="465" left="63" width="333" height="12" font="2">American Association for Thoracic Surgery, American</text>
<text top="483" left="63" width="333" height="12" font="2">College of Emergency Physicians, American Society of</text>
<text top="501" left="63" width="333" height="12" font="2">Anesthesiologists, Preventive Cardiovascular Nurses As-</text>
<text top="519" left="63" width="333" height="12" font="2">sociation, Society for Cardiovascular Angiography and</text>
<text top="537" left="63" width="333" height="12" font="2">Interventions, Society of Cardiovascular Anesthesiolo-</text>
<text top="555" left="63" width="333" height="12" font="2">gists, and the Society of Thoracic Surgeons; and by 23</text>
<text top="573" left="63" width="242" height="12" font="2">additional content reviewers. Reviewers</text>
<text top="571" left="305" width="91" height="15" font="2">’ RWI informa-</text>
<text top="591" left="63" width="209" height="12" font="2">tion is published in this document (</text>
<text top="591" left="272" width="66" height="12" font="4"><a href="1082.full.html#30">Appendix 2</a></text>
<text top="591" left="339" width="8" height="12" font="2"><a href="1082.full.html#30">).</a></text>
<text top="609" left="78" width="318" height="12" font="2">This document was approved for publication by the</text>
<text top="627" left="63" width="333" height="12" font="2">governing bodies of the ACC and the AHA and was</text>
<text top="645" left="63" width="333" height="12" font="2">endorsed by the American Association for Thoracic Sur-</text>
<text top="663" left="63" width="333" height="12" font="2">gery, American Society of Anesthesiologists, Preventive</text>
<text top="681" left="63" width="333" height="12" font="2">Cardiovascular Nurses Association, Society for Cardio-</text>
<text top="698" left="63" width="333" height="12" font="2">vascular Angiography and Interventions, Society of</text>
<text top="716" left="63" width="333" height="12" font="2">Cardiovascular Anesthesiologists, Society of Thoracic</text>
<text top="734" left="63" width="255" height="12" font="2">Surgeons, and Society for Vascular Surgery.</text>
<text top="764" left="63" width="198" height="16" font="15">2. CRITICAL QUESTIONS AND</text>
<text top="782" left="63" width="215" height="16" font="15">SYSTEMATIC REVIEW FINDINGS</text>
<text top="820" left="63" width="230" height="11" font="12">2.1. Critical Questions on Duration of DAPT</text>
<text top="842" left="63" width="333" height="12" font="2">The 3 critical (PICOTS-formatted) questions on DAPT</text>
<text top="860" left="63" width="122" height="12" font="2">duration are listed in</text>
<text top="860" left="189" width="41" height="11" font="4"><a href="1082.full.html#6">Table 2</a></text>
<text top="860" left="230" width="166" height="12" font="2">. Most contemporary studies</text>
<text top="878" left="63" width="333" height="12" font="2">of DAPT have compared either shorter (3 to 6 months)</text>
<text top="896" left="63" width="16" height="12" font="4"><a href="1082.full.html#24">(17</a></text>
<text top="894" left="79" width="21" height="15" font="4"><a href="1082.full.html#24">–21)</a></text>
<text top="896" left="105" width="161" height="12" font="2">or longer (18 to 48 months)</text>
<text top="896" left="270" width="33" height="12" font="4"><a href="1082.full.html#24">(16,22</a></text>
<text top="894" left="303" width="23" height="15" font="4"><a href="1082.full.html#24">–26)</a></text>
<text top="896" left="331" width="66" height="12" font="2">duration of</text>
<text top="914" left="63" width="333" height="12" font="2">therapy with 12 months of DAPT, which is the recom-</text>
<text top="932" left="63" width="333" height="12" font="2">mended or minimal duration of therapy for most patients</text>
<text top="950" left="63" width="70" height="12" font="2">in ACC/AHA</text>
<text top="950" left="137" width="48" height="12" font="4"><a href="1082.full.html#23">(9,13,14)</a></text>
<text top="950" left="188" width="208" height="12" font="2">and European Society of Cardiology</text>
<text top="968" left="63" width="16" height="12" font="4"><a href="1082.full.html#24">(31</a></text>
<text top="966" left="79" width="23" height="15" font="4"><a href="1082.full.html#24">–33)</a></text>
<text top="968" left="110" width="286" height="12" font="2">guidelines published between 2011 and 2014.</text>
<text top="985" left="63" width="186" height="12" font="2">Recommendations based on the</text>
<text top="984" left="252" width="144" height="15" font="2">ﬁndings from the critical</text>
<text top="1003" left="63" width="50" height="12" font="2">question</text>
<text top="1002" left="113" width="283" height="15" font="2">–focused systemic reviews are provided in</text>
<text top="1021" left="63" width="86" height="12" font="4"><a href="1082.full.html#11">Sections 4 to 8</a></text>
<text top="1021" left="153" width="148" height="12" font="2">of the present document.</text>
<text top="1054" left="63" width="333" height="11" font="12">2.2. Studies of Shorter-Duration DAPT After Stent Implantation</text>
<text top="1075" left="63" width="333" height="12" font="2">Five RCTs of patients treated with elective DES implan-</text>
<text top="1093" left="63" width="333" height="12" font="2">tation have compared shorter-duration (3 to 6 months)</text>
<text top="444" left="423" width="171" height="12" font="2">DAPT with 12 months of DAPT</text>
<text top="444" left="597" width="16" height="12" font="4"><a href="1082.full.html#24">(17</a></text>
<text top="443" left="613" width="21" height="15" font="4"><a href="1082.full.html#24">–21)</a></text>
<text top="444" left="637" width="4" height="12" font="2">(</text>
<text top="444" left="642" width="107" height="12" font="4"><a href="http://jaccjacc.acc.org/Clinical_Document/DAPT_Data_Supplement_1.pdf">Data Supplement 1</a></text>
<text top="444" left="749" width="8" height="12" font="2"><a href="http://jaccjacc.acc.org/Clinical_Document/DAPT_Data_Supplement_1.pdf">).</a></text>
<text top="462" left="423" width="333" height="12" font="2">The trials primarily enrolled low-risk (non-ACS) patients,</text>
<text top="480" left="423" width="333" height="12" font="2">with only a small proportion having had a recent MI. The</text>
<text top="498" left="423" width="333" height="12" font="2">main endpoints of these noninferiority trials were com-</text>
<text top="516" left="423" width="333" height="12" font="2">posite ischemic events (or net composite events) and stent</text>
<text top="534" left="423" width="333" height="12" font="2">thrombosis. These studies, as well as several meta-</text>
<text top="552" left="423" width="49" height="12" font="2">analyses</text>
<text top="552" left="476" width="18" height="12" font="4"><a href="1082.full.html#24">(34</a></text>
<text top="550" left="495" width="22" height="15" font="4"><a href="1082.full.html#24">–37)</a></text>
<text top="552" left="521" width="159" height="12" font="2">and an analysis by the ERC</text>
<text top="552" left="684" width="22" height="12" font="4"><a href="1082.full.html#24">(30)</a></text>
<text top="552" left="707" width="50" height="12" font="2"><a href="1082.full.html#24">, </a>did not</text>
<text top="568" left="423" width="333" height="15" font="2">ﬁnd any increased risk of stent thrombosis with shorter-</text>
<text top="588" left="423" width="333" height="12" font="2">duration DAPT. A shorter duration of DAPT results in</text>
<text top="606" left="423" width="172" height="12" font="2">fewer bleeding complications.</text>
<text top="606" left="597" width="36" height="12" font="4"><a href="1082.full.html#24">(30,34</a></text>
<text top="604" left="634" width="23" height="15" font="4"><a href="1082.full.html#24">–36)</a></text>
<text top="606" left="659" width="97" height="12" font="2">Shorter-duration</text>
<text top="624" left="423" width="333" height="12" font="2">DAPT may be most reasonable in patients currently being</text>
<text top="642" left="423" width="75" height="12" font="2">treated with</text>
<text top="640" left="507" width="250" height="15" font="2">“newer-generation” (e.g., everolimus- or</text>
<text top="660" left="423" width="333" height="12" font="2">zotarolimus-eluting) DES, which are associated with lower</text>
<text top="677" left="423" width="252" height="12" font="2">stent thrombosis and MI rates than those of</text>
<text top="676" left="679" width="78" height="15" font="2">“ﬁrst-genera-</text>
<text top="695" left="423" width="23" height="12" font="2">tion</text>
<text top="694" left="446" width="310" height="15" font="2">” (e.g., sirolimus- and paclitaxel-eluting) DES, which</text>
<text top="713" left="423" width="333" height="12" font="2">are rarely, if ever, used in current clinical practice</text>
<text top="731" left="423" width="56" height="12" font="4"><a href="1082.full.html#24">(16,36,38)</a></text>
<text top="731" left="479" width="3" height="12" font="2">.</text>
<text top="767" left="423" width="333" height="11" font="12">2.3. Studies of Longer-Duration DAPT After Stent Implantation</text>
<text top="788" left="423" width="333" height="12" font="2">Six RCTs, consisting predominantly of patients treated</text>
<text top="806" left="423" width="333" height="12" font="2">with elective DES implantation, compared prolonged</text>
<text top="824" left="423" width="333" height="12" font="2">DAPT (total therapy duration: 18 to 48 months) with 6 to</text>
<text top="842" left="423" width="333" height="12" font="2">12 months of DAPT to determine whether extended</text>
<text top="860" left="423" width="333" height="12" font="2">therapy reduces late and very late stent thrombosis and</text>
<text top="878" left="423" width="333" height="12" font="2">prevents ischemic events associated with disease pro-</text>
<text top="896" left="423" width="333" height="12" font="2">gression and plaque rupture at other nonstented sites</text>
<text top="914" left="423" width="33" height="12" font="4"><a href="1082.full.html#24">(16,22</a></text>
<text top="912" left="456" width="22" height="15" font="4"><a href="1082.full.html#24">–27)</a></text>
<text top="914" left="484" width="4" height="12" font="2">(</text>
<text top="914" left="489" width="113" height="12" font="4"><a href="http://jaccjacc.acc.org/Clinical_Document/DAPT_Data_Supplement_1.pdf">Data Supplement 2</a></text>
<text top="914" left="602" width="155" height="12" font="2"><a href="http://jaccjacc.acc.org/Clinical_Document/DAPT_Data_Supplement_1.pdf">). </a>In the Dual Antiplatelet</text>
<text top="932" left="423" width="86" height="12" font="2">Therapy study</text>
<text top="930" left="509" width="247" height="15" font="2">—the largest of these trials—patients who</text>
<text top="950" left="423" width="333" height="12" font="2">had undergone DES implantation, had been treated with</text>
<text top="968" left="423" width="333" height="12" font="2">DAPT for 12 months, and were without ischemic or</text>
<text top="985" left="423" width="333" height="12" font="2">bleeding events during this period were randomized to an</text>
<text top="1003" left="423" width="333" height="12" font="2">additional 18 months of DAPT or to aspirin monotherapy</text>
<text top="1021" left="423" width="21" height="12" font="4"><a href="1082.full.html#24">(16)</a></text>
<text top="1021" left="444" width="312" height="12" font="2">. Extended DAPT resulted in a 0.7% absolute reduc-</text>
<text top="1039" left="423" width="333" height="12" font="2">tion in very late stent thrombosis, a 2.0% absolute</text>
<text top="1057" left="423" width="333" height="12" font="2">reduction in MI, a 1.6% absolute reduction in major</text>
<text top="1075" left="423" width="333" height="12" font="2">adverse cardiac events (MACE), and a 0.9% absolute in-</text>
<text top="1093" left="423" width="333" height="12" font="2">crease in moderate or severe bleeding. In the subgroup of</text>
<text top="156" left="431" width="47" height="10" font="16">T A B L E 2</text>
<text top="149" left="495" width="253" height="10" font="17">Critical (PICOTS-Formatted) Questions on DAPT</text>
<text top="163" left="495" width="46" height="10" font="17">Duration</text>
<text top="185" left="423" width="177" height="9" font="14">Q1: In patients treated with newer (non-</text>
<text top="184" left="601" width="155" height="12" font="14">ﬁrst) generation DES for (1) SIHD or</text>
<text top="197" left="442" width="213" height="9" font="14">(2) ACS, compared with 12 months of DAPT, is 3</text>
<text top="196" left="656" width="98" height="12" font="14">–6 months of DAPT as</text>
<text top="209" left="442" width="294" height="9" font="14">effective in preventing stent thrombosis, preventing MACE and/or</text>
<text top="221" left="442" width="147" height="9" font="14">reducing bleeding complications?</text>
<text top="240" left="423" width="182" height="9" font="14">Q2: In patients treated with newer (non-</text>
<text top="239" left="606" width="141" height="12" font="14">ﬁrst) generation DES, compared</text>
<text top="252" left="443" width="134" height="9" font="14">with 12 months of DAPT, does</text>
<text top="251" left="580" width="169" height="12" font="14">&gt;12 (18–48) months of DAPT result in</text>
<text top="264" left="443" width="279" height="9" font="14">differences in mortality rate, decreased MACE, decreased stent</text>
<text top="276" left="443" width="174" height="9" font="14">thrombosis, and/or increased bleeding?</text>
<text top="295" left="423" width="314" height="9" font="14">Q3: In post-MI (NSTEMI or STEMI) patients who are clinically stable and</text>
<text top="294" left="740" width="16" height="12" font="14">&gt;12</text>
<text top="307" left="443" width="311" height="9" font="14">months past their event, does continued DAPT, compared with aspirin</text>
<text top="319" left="443" width="314" height="9" font="14">monotherapy, result in differences in mortality rate, decreased nonfatal</text>
<text top="331" left="443" width="215" height="9" font="14">MI, decreased MACE, and/or increased bleeding?</text>
<text top="355" left="423" width="333" height="8" font="5">ACS indicates acute coronary syndrome; DAPT, dual antiplatelet therapy; DES, drug-</text>
<text top="367" left="423" width="333" height="8" font="5">eluting stents; MACE, major adverse cardiac events; MI, myocardial infarction;</text>
<text top="379" left="423" width="52" height="8" font="5">NSTEMI, non</text>
<text top="377" left="475" width="281" height="11" font="5">–ST-elevation myocardial infarction; PICOTS, population, intervention,</text>
<text top="391" left="423" width="333" height="8" font="5">comparison, outcome, timing, and setting; SIHD, stable ischemic heart disease; and</text>
<text top="403" left="423" width="164" height="8" font="5">STEMI, ST-elevation myocardial infarction.</text>
<text top="54" left="63" width="132" height="7" font="7">J A C C V O L . 6 8 , N O . 1 0 , 2 0 1 6</text>
<text top="54" left="705" width="52" height="9" font="14">Levine et al.</text>
<text top="69" left="63" width="117" height="7" font="7">S E P T E M B E R 6 , 2 0 1 6 : 1 0 8 2</text>
<text top="67" left="182" width="17" height="10" font="7">– 1 1 5</text>
<text top="69" left="514" width="243" height="9" font="14">Focused Update on Duration of Dual Antiplatelet Therapy</text>
<text top="53" left="788" width="20" height="9" font="5">1087</text>
</page>
<page number="7" position="absolute" top="0" left="0" height="1160" width="864">
<text top="143" left="108" width="271" height="12" font="2">patients treated with everolimus-eluting stents</text>
<text top="141" left="379" width="62" height="15" font="2">—currently</text>
<text top="161" left="108" width="182" height="12" font="2">the most commonly used stent</text>
<text top="159" left="289" width="151" height="15" font="2">—extended DAPT resulted</text>
<text top="178" left="108" width="333" height="12" font="2">in a 0.4% absolute reduction in stent thrombosis, a 1.1%</text>
<text top="196" left="108" width="333" height="12" font="2">absolute reduction in MI, and a 1.2% absolute increase in</text>
<text top="214" left="108" width="150" height="12" font="2">moderate/severe bleeding</text>
<text top="214" left="261" width="22" height="12" font="4"><a href="1082.full.html#24">(39)</a></text>
<text top="214" left="283" width="3" height="12" font="2">.</text>
<text top="232" left="123" width="35" height="12" font="2">Taken</text>
<text top="232" left="172" width="12" height="12" font="2">as</text>
<text top="232" left="197" width="6" height="12" font="2">a</text>
<text top="232" left="217" width="39" height="12" font="2">whole,</text>
<text top="232" left="269" width="41" height="12" font="2">studies</text>
<text top="232" left="324" width="11" height="12" font="2">of</text>
<text top="232" left="350" width="91" height="12" font="2">longer-duration</text>
<text top="250" left="108" width="4" height="12" font="2">(</text>
<text top="248" left="112" width="215" height="15" font="2">“prolonged” or “extended”) DAPT</text>
<text top="250" left="336" width="33" height="12" font="4"><a href="1082.full.html#24">(16,22</a></text>
<text top="248" left="370" width="22" height="15" font="4"><a href="1082.full.html#24">–27)</a></text>
<text top="250" left="401" width="40" height="12" font="2">for an</text>
<text top="268" left="108" width="333" height="12" font="2">additional 18 to 36 months after DES found an absolute</text>
<text top="286" left="108" width="333" height="12" font="2">decrease in late stent thrombosis and ischemic compli-</text>
<text top="304" left="108" width="56" height="12" font="2">cations of</text>
<text top="302" left="167" width="274" height="15" font="2">z1% to 2% and an absolute increase in bleeding</text>
<text top="322" left="108" width="99" height="12" font="2">complications of</text>
<text top="320" left="214" width="39" height="15" font="2">z1% (</text>
<text top="322" left="253" width="164" height="12" font="4"><a href="http://jaccjacc.acc.org/Clinical_Document/DAPT_Data_Supplement_1.pdf">Data Supplements 2 and 3</a></text>
<text top="322" left="418" width="23" height="12" font="2"><a href="http://jaccjacc.acc.org/Clinical_Document/DAPT_Data_Supplement_1.pdf">). </a>A</text>
<text top="340" left="108" width="113" height="12" font="2">weighted risk-bene</text>
<text top="338" left="221" width="220" height="15" font="2">ﬁt analysis by the ERC of studies of</text>
<text top="358" left="108" width="333" height="12" font="2">patients treated with DES found 6 fewer MIs and 3 fewer</text>
<text top="376" left="108" width="333" height="12" font="2">stent thromboses but 5 additional major bleeds per 1,000</text>
<text top="394" left="108" width="273" height="12" font="2">patients treated with prolonged DAPT per year</text>
<text top="394" left="385" width="22" height="12" font="4"><a href="1082.full.html#24">(30)</a></text>
<text top="394" left="408" width="3" height="12" font="2"><a href="1082.full.html#24">.</a></text>
<text top="426" left="108" width="196" height="11" font="12">2.4. Other Studies Relevant to DAPT</text>
<text top="424" left="308" width="87" height="15" font="12">&gt;1 Year After MI</text>
<text top="447" left="108" width="334" height="12" font="2">The CHARISMA (Clopidogrel for High Atherothrombotic</text>
<text top="465" left="108" width="24" height="12" font="2">Risk</text>
<text top="465" left="144" width="21" height="12" font="2">and</text>
<text top="465" left="177" width="51" height="12" font="2">Ischemic</text>
<text top="465" left="240" width="76" height="12" font="2">Stabilization,</text>
<text top="465" left="329" width="79" height="12" font="2">Management,</text>
<text top="465" left="419" width="21" height="12" font="2">and</text>
<text top="483" left="108" width="333" height="12" font="2">Avoidance) trial randomized patients with established</text>
<text top="501" left="108" width="333" height="12" font="2">atherosclerosis or at high risk of clinical atherosclerotic</text>
<text top="519" left="108" width="333" height="12" font="2">disease to either DAPT (with clopidogrel) or aspirin</text>
<text top="537" left="108" width="210" height="12" font="2">monotherapy; with DAPT, no signi</text>
<text top="535" left="318" width="123" height="15" font="2">ﬁcant reduction was</text>
<text top="555" left="108" width="333" height="12" font="2">found in ischemic effects at a median follow-up of 28</text>
<text top="573" left="108" width="333" height="12" font="2">months, but there was a 0.4% absolute increase in severe</text>
<text top="591" left="108" width="50" height="12" font="2">bleeding</text>
<text top="591" left="162" width="23" height="12" font="4"><a href="1082.full.html#24">(40)</a></text>
<text top="591" left="185" width="256" height="12" font="2">. A post hoc analysis of patients enrolled in</text>
<text top="609" left="108" width="334" height="12" font="2">the study with prior MI found a 1.7% absolute decrease in</text>
<text top="627" left="108" width="333" height="12" font="2">the composite endpoint of cardiovascular death, MI, or</text>
<text top="645" left="108" width="236" height="12" font="2">stroke events with DAPT, with no bene</text>
<text top="643" left="344" width="97" height="15" font="2">ﬁt in those with</text>
<text top="663" left="108" width="126" height="12" font="2">CAD without prior MI</text>
<text top="663" left="237" width="40" height="12" font="4"><a href="1082.full.html#24">(40,41)</a></text>
<text top="663" left="278" width="3" height="12" font="2"><a href="1082.full.html#24">.</a></text>
<text top="681" left="123" width="318" height="12" font="2">Patients in the PEGASUS-TIMI 54 (Prevention of Car-</text>
<text top="699" left="108" width="333" height="12" font="2">diovascular Events in Patients with Prior Heart Attack</text>
<text top="716" left="108" width="333" height="12" font="2">Using Ticagrelor Compared to Placebo on a Background of</text>
<text top="734" left="108" width="42" height="12" font="2">Aspirin</text>
<text top="733" left="149" width="291" height="15" font="2">—Thrombolysis In Myocardial Infarction 54) trial</text>
<text top="752" left="108" width="333" height="12" font="2">were randomized 1 to 3 years after MI with additional</text>
<text top="770" left="108" width="334" height="12" font="2">high-risk features to either DAPT (with ticagrelor 60 mg or</text>
<text top="788" left="108" width="304" height="12" font="2">90 mg twice daily) or continued aspirin monotherapy</text>
<text top="788" left="415" width="22" height="12" font="4"><a href="1082.full.html#24">(28)</a></text>
<text top="788" left="437" width="3" height="12" font="2">.</text>
<text top="806" left="108" width="333" height="12" font="2">After a mean of 33 months of therapy, DAPT, when</text>
<text top="824" left="108" width="333" height="12" font="2">compared with aspirin monotherapy, resulted in a 1.2% to</text>
<text top="842" left="108" width="334" height="12" font="2">1.3% absolute reduction in the primary composite</text>
<text top="860" left="108" width="333" height="12" font="2">endpoint of cardiovascular death, MI, or stroke and a 1.2%</text>
<text top="878" left="108" width="333" height="12" font="2">to 1.5% absolute increase in major bleeding, with no</text>
<text top="896" left="108" width="333" height="12" font="2">excess in fatal bleeding or intracranial hemorrhage. In</text>
<text top="914" left="108" width="333" height="12" font="2">subgroup analysis, the greatest reduction in ischemic</text>
<text top="932" left="108" width="333" height="12" font="2">events with prolonged DAPT was in patients in whom</text>
<text top="950" left="108" width="21" height="12" font="2">P2Y</text>
<text top="955" left="129" width="9" height="8" font="7">12</text>
<text top="950" left="142" width="299" height="12" font="2">inhibitor therapy either had not been discontinued</text>
<text top="968" left="108" width="173" height="12" font="2">or had been discontinued for</text>
<text top="966" left="286" width="155" height="15" font="2">#30 days (absolute reduc-</text>
<text top="985" left="108" width="224" height="12" font="2">tion in MACE: 1.9% to 2.5%). No bene</text>
<text top="984" left="332" width="109" height="15" font="2">ﬁt was seen in pa-</text>
<text top="1003" left="108" width="135" height="12" font="2">tients in whom P2Y</text>
<text top="1008" left="243" width="9" height="8" font="7">12</text>
<text top="1003" left="263" width="178" height="12" font="2">inhibitor therapy had been</text>
<text top="1021" left="108" width="76" height="12" font="2">discontinued</text>
<text top="1020" left="187" width="224" height="15" font="2">&gt;1 year before enrollment in the study</text>
<text top="1021" left="415" width="22" height="12" font="4"><a href="1082.full.html#24">(42)</a></text>
<text top="1021" left="437" width="3" height="12" font="2">.</text>
<text top="1039" left="123" width="280" height="12" font="2">In the Dual Antiplatelet Therapy study, the bene</text>
<text top="1037" left="403" width="38" height="15" font="2">ﬁt/risk</text>
<text top="1057" left="108" width="333" height="12" font="2">ratio for prolonged DAPT was more favorable for those</text>
<text top="1075" left="108" width="260" height="12" font="2">presenting with MI than those with SIHD</text>
<text top="1075" left="375" width="22" height="12" font="4"><a href="1082.full.html#24">(43)</a></text>
<text top="1075" left="397" width="44" height="12" font="2">. In an</text>
<text top="1093" left="108" width="333" height="12" font="2">analysis of patients with a history of prior MI enrolled in 6</text>
<text top="143" left="468" width="333" height="12" font="2">RCTs of extended/prolonged DAPT, extended DAPT</text>
<text top="161" left="468" width="27" height="12" font="2">signi</text>
<text top="159" left="496" width="306" height="15" font="2">ﬁcantly decreased the absolute risk of MACE by 1.1%</text>
<text top="178" left="468" width="56" height="12" font="2">and signi</text>
<text top="177" left="525" width="276" height="15" font="2">ﬁcantly increased the absolute risk of major</text>
<text top="196" left="468" width="101" height="12" font="2">bleeding by 0.8%</text>
<text top="196" left="573" width="23" height="12" font="4"><a href="1082.full.html#24">(44)</a></text>
<text top="196" left="597" width="3" height="12" font="2"><a href="1082.full.html#24">.</a></text>
<text top="214" left="483" width="319" height="12" font="2">Taken as a whole, trials of prolonged or extended DAPT</text>
<text top="232" left="468" width="124" height="12" font="2">suggest that the bene</text>
<text top="230" left="592" width="209" height="15" font="2">ﬁt/risk ratio of prolonged DAPT may</text>
<text top="250" left="468" width="333" height="12" font="2">be more favorable for those with prior MI, with an abso-</text>
<text top="268" left="468" width="203" height="12" font="2">lute decrease in ischemic events of</text>
<text top="266" left="674" width="127" height="15" font="2">z1% to 3% at the cost</text>
<text top="286" left="468" width="270" height="12" font="2">of an absolute increase in bleeding events of</text>
<text top="284" left="743" width="58" height="15" font="2">z1% over</text>
<text top="304" left="468" width="333" height="12" font="2">the course of several years of prolonged or extended</text>
<text top="322" left="468" width="333" height="12" font="2">therapy (median durations of therapy: 18 to 33 months)</text>
<text top="340" left="468" width="4" height="12" font="2">(</text>
<text top="340" left="472" width="164" height="12" font="4"><a href="http://jaccjacc.acc.org/Clinical_Document/DAPT_Data_Supplement_1.pdf">Data Supplements 3 and 4</a></text>
<text top="340" left="637" width="165" height="12" font="2"><a href="http://jaccjacc.acc.org/Clinical_Document/DAPT_Data_Supplement_1.pdf">). </a>This appears biologically</text>
<text top="358" left="468" width="333" height="12" font="2">plausible because patients with prior MI (usually medi-</text>
<text top="376" left="468" width="333" height="12" font="2">ated by plaque rupture) may be at greater risk for future</text>
<text top="394" left="468" width="254" height="12" font="2">plaque rupture than those without prior MI</text>
<text top="394" left="726" width="56" height="12" font="4"><a href="1082.full.html#24">(37,40,41)</a></text>
<text top="394" left="783" width="3" height="12" font="2"><a href="1082.full.html#24">.</a></text>
<text top="426" left="468" width="270" height="11" font="12">2.5. Prolonged/Extended DAPT and Mortality Rate</text>
<text top="447" left="468" width="89" height="12" font="2">An unexpected</text>
<text top="446" left="562" width="239" height="15" font="2">ﬁnding in the Dual Antiplatelet Therapy</text>
<text top="465" left="468" width="32" height="12" font="2">study</text>
<text top="465" left="504" width="21" height="12" font="4"><a href="1082.full.html#24">(16)</a></text>
<text top="465" left="529" width="129" height="12" font="2">was a borderline-signi</text>
<text top="464" left="658" width="143" height="15" font="2">ﬁcant increase in overall</text>
<text top="483" left="468" width="333" height="12" font="2">mortality rate (0.5% absolute increase) with 30 months of</text>
<text top="501" left="468" width="333" height="12" font="2">DAPT versus 12 months of DAPT in DES-treated patients,</text>
<text top="519" left="468" width="147" height="12" font="2">which was due to signi</text>
<text top="517" left="615" width="186" height="15" font="2">ﬁcantly increased deaths from</text>
<text top="537" left="468" width="333" height="12" font="2">noncardiovascular causes (most commonly cancer), with</text>
<text top="555" left="468" width="301" height="12" font="2">no increase in cardiovascular deaths, and no signi</text>
<text top="553" left="769" width="32" height="15" font="2">ﬁcant</text>
<text top="573" left="468" width="155" height="12" font="2">increase in fatal bleeding</text>
<text top="573" left="630" width="22" height="12" font="4"><a href="1082.full.html#24">(45)</a></text>
<text top="573" left="652" width="149" height="12" font="2">. Five subsequent meta-</text>
<text top="591" left="468" width="49" height="12" font="2">analyses</text>
<text top="591" left="527" width="17" height="12" font="4"><a href="1082.full.html#24">(35</a></text>
<text top="589" left="544" width="58" height="15" font="4"><a href="1082.full.html#24">–37,46,47)</a></text>
<text top="591" left="612" width="189" height="12" font="2">restricted to RCTs of studies</text>
<text top="609" left="468" width="333" height="12" font="2">enrolling patients treated with predominantly newer</text>
<text top="627" left="468" width="333" height="12" font="2">generation DES, published prior to the presentation of the</text>
<text top="645" left="468" width="333" height="12" font="2">OPTIDUAL (Optimal Dual Antiplatelet Therapy) trial,</text>
<text top="663" left="468" width="109" height="12" font="2">found numerically</text>
<text top="663" left="583" width="39" height="12" font="4"><a href="1082.full.html#24">(36,47)</a></text>
<text top="663" left="629" width="84" height="12" font="2">or statistically</text>
<text top="663" left="719" width="56" height="12" font="4"><a href="1082.full.html#24">(35,37,46)</a></text>
<text top="663" left="781" width="21" height="12" font="2">sig-</text>
<text top="681" left="468" width="11" height="12" font="2">ni</text>
<text top="679" left="479" width="322" height="15" font="2">ﬁcant increased risk of all-cause (though not cardio-</text>
<text top="699" left="468" width="333" height="12" font="2">vascular) death associated with prolonged duration of</text>
<text top="716" left="468" width="40" height="12" font="2">DAPT (</text>
<text top="716" left="508" width="153" height="12" font="4"><a href="http://jaccjacc.acc.org/Clinical_Document/DAPT_Data_Supplement_1.pdf">Data Supplements 3 and 4</a></text>
<text top="716" left="661" width="8" height="12" font="2">).</text>
<text top="734" left="483" width="318" height="12" font="2">In contrast, a meta-analysis that combined studies of</text>
<text top="752" left="468" width="333" height="12" font="2">DAPT duration after stent implantation with studies of</text>
<text top="770" left="468" width="211" height="12" font="2">DAPT duration for other indications</text>
<text top="770" left="683" width="23" height="12" font="4"><a href="1082.full.html#24">(48)</a></text>
<text top="770" left="711" width="91" height="12" font="2">and an analysis</text>
<text top="788" left="468" width="333" height="12" font="2">of 6 trials restricted to post-MI patients treated with DAPT</text>
<text top="806" left="468" width="23" height="12" font="4"><a href="1082.full.html#24">(44)</a></text>
<text top="806" left="503" width="299" height="12" font="2">found no increase in cardiovascular or non-</text>
<text top="824" left="468" width="333" height="12" font="2">cardiovascular mortality rate associated with prolonged</text>
<text top="842" left="468" width="41" height="12" font="2">DAPT (</text>
<text top="842" left="509" width="111" height="12" font="4"><a href="http://jaccjacc.acc.org/Clinical_Document/DAPT_Data_Supplement_1.pdf">Data Supplement 3</a></text>
<text top="842" left="620" width="181" height="12" font="2">). A US Food and Drug Admin-</text>
<text top="860" left="468" width="333" height="12" font="2">istration drug safety communication, based on an evalu-</text>
<text top="878" left="468" width="333" height="12" font="2">ation of long-term clinical trials of patients with</text>
<text top="896" left="468" width="333" height="12" font="2">cardiovascular disease or stroke treated with clopidogrel,</text>
<text top="914" left="468" width="333" height="12" font="2">concluded that long-term clopidogrel treatment did not</text>
<text top="932" left="468" width="333" height="12" font="2">increase the risk of all-cause death or cancer-related</text>
<text top="950" left="468" width="33" height="12" font="2">death</text>
<text top="950" left="506" width="23" height="12" font="4"><a href="1082.full.html#24">(49)</a></text>
<text top="950" left="529" width="272" height="12" font="2">. The primary analysis by the ERC of 11 RCTs</text>
<text top="968" left="468" width="333" height="12" font="2">(including OPTIDUAL) compared use of DAPT for 18 to 48</text>
<text top="985" left="468" width="333" height="12" font="2">months with use of DAPT for 6 to 12 months in patients</text>
<text top="1003" left="468" width="333" height="12" font="2">who had received predominantly newer-generation DES</text>
<text top="1021" left="468" width="191" height="12" font="2">and found no statistically signi</text>
<text top="1020" left="660" width="141" height="15" font="2">ﬁcant difference in all-</text>
<text top="1039" left="468" width="116" height="12" font="2">cause mortality rate</text>
<text top="1039" left="588" width="22" height="12" font="4"><a href="1082.full.html#24">(30)</a></text>
<text top="1039" left="611" width="3" height="12" font="2">.</text>
<text top="1057" left="483" width="318" height="12" font="2">A majority of writing group members believe the data</text>
<text top="1075" left="468" width="333" height="12" font="2">as a whole do not seem to suggest prolonged DAPT results</text>
<text top="1093" left="468" width="132" height="12" font="2">in increased mortality.</text>
<text top="53" left="108" width="52" height="9" font="14">Levine et al.</text>
<text top="54" left="670" width="132" height="7" font="7">J A C C V O L . 6 8 , N O . 1 0 , 2 0 1 6</text>
<text top="68" left="108" width="243" height="9" font="14">Focused Update on Duration of Dual Antiplatelet Therapy</text>
<text top="69" left="665" width="117" height="7" font="7">S E P T E M B E R 6 , 2 0 1 6 : 1 0 8 2</text>
<text top="67" left="784" width="17" height="10" font="7">– 1 1 5</text>
<text top="53" left="57" width="21" height="9" font="5">1088</text>
</page>
<page number="8" position="absolute" top="0" left="0" height="1160" width="864">
	<fontspec id="18" size="4" family="Times" color="#000000"/>
	<fontspec id="19" size="7" family="Times" color="#327eb1"/>
<text top="141" left="63" width="215" height="16" font="15">3. OVERRIDING CONCEPTS AND</text>
<text top="159" left="63" width="248" height="16" font="15">RECOMMENDATIONS FOR DAPT AND</text>
<text top="177" left="63" width="164" height="16" font="15">DURATION OF THERAPY</text>
<text top="215" left="63" width="174" height="11" font="12">3.1. General Overriding Concepts</text>
<text top="236" left="63" width="333" height="12" font="2">Overriding concepts and relevant recommendations for</text>
<text top="254" left="63" width="333" height="12" font="2">DAPT and duration of therapy are summarized in</text>
<text top="272" left="63" width="46" height="11" font="4"><a href="1082.full.html#8">Table 3</a></text>
<text top="272" left="109" width="53" height="12" font="2">. Intensi</text>
<text top="270" left="163" width="233" height="15" font="2">ﬁcation of antiplatelet therapy, with</text>
<text top="290" left="63" width="146" height="12" font="2">the addition of a P2Y</text>
<text top="295" left="209" width="9" height="8" font="7">12</text>
<text top="290" left="227" width="169" height="12" font="2">inhibitor to aspirin mono-</text>
<text top="308" left="63" width="333" height="12" font="2">therapy, necessitates a fundamental tradeoff between</text>
<text top="326" left="63" width="333" height="12" font="2">decreasing ischemic risk and increasing bleeding risk</text>
<text top="344" left="63" width="53" height="12" font="4"><a href="1082.full.html#24">(40,41,50</a></text>
<text top="342" left="117" width="23" height="15" font="4"><a href="1082.full.html#24">–52)</a></text>
<text top="344" left="139" width="257" height="12" font="2">. Similarly, longer compared with shorter</text>
<text top="362" left="63" width="50" height="12" font="2">duration</text>
<text top="362" left="126" width="11" height="12" font="2">of</text>
<text top="362" left="150" width="32" height="12" font="2">DAPT</text>
<text top="362" left="195" width="53" height="12" font="2">generally</text>
<text top="362" left="262" width="39" height="12" font="2">results</text>
<text top="362" left="314" width="11" height="12" font="2">in</text>
<text top="362" left="338" width="58" height="12" font="2">decreased</text>
<text top="380" left="63" width="333" height="12" font="2">ischemic risk at the expense of increased bleeding risk</text>
<text top="398" left="63" width="92" height="12" font="4"><a href="1082.full.html#24">(16,24,28,30,46)</a></text>
<text top="398" left="155" width="167" height="12" font="2">. Use of more potent P2Y</text>
<text top="403" left="323" width="9" height="8" font="7">12</text>
<text top="398" left="340" width="56" height="12" font="2">inhibitors</text>
<text top="415" left="63" width="333" height="12" font="2">(ticagrelor or prasugrel) in place of clopidogrel also</text>
<text top="433" left="63" width="39" height="12" font="2">results</text>
<text top="433" left="114" width="11" height="12" font="2">in</text>
<text top="433" left="139" width="58" height="12" font="2">decreased</text>
<text top="433" left="209" width="50" height="12" font="2">ischemic</text>
<text top="433" left="273" width="21" height="12" font="2">risk</text>
<text top="433" left="307" width="21" height="12" font="2">and</text>
<text top="433" left="341" width="55" height="12" font="2">increased</text>
<text top="451" left="63" width="76" height="12" font="2">bleeding risk</text>
<text top="451" left="145" width="17" height="12" font="4"><a href="1082.full.html#24">(53</a></text>
<text top="450" left="162" width="23" height="15" font="4"><a href="1082.full.html#24">–55)</a></text>
<text top="451" left="185" width="3" height="12" font="2"><a href="1082.full.html#24">.</a></text>
<text top="469" left="78" width="318" height="12" font="2">In general, recommendations for duration of DAPT in</text>
<text top="487" left="63" width="19" height="12" font="2">the</text>
<text top="487" left="93" width="43" height="12" font="2">present</text>
<text top="487" left="148" width="45" height="12" font="2">focused</text>
<text top="487" left="205" width="40" height="12" font="2">update</text>
<text top="487" left="257" width="40" height="12" font="2">consist</text>
<text top="487" left="310" width="11" height="12" font="2">of</text>
<text top="487" left="333" width="6" height="12" font="2">a</text>
<text top="487" left="351" width="29" height="12" font="2">Class</text>
<text top="487" left="392" width="4" height="12" font="2">I</text>
<text top="143" left="423" width="111" height="12" font="2">recommendation (</text>
<text top="141" left="534" width="222" height="15" font="2">“should be given”) for a minimum</text>
<text top="161" left="423" width="333" height="12" font="2">period of time (in most cases 6 to 12 months) and a Class</text>
<text top="178" left="423" width="128" height="12" font="2">IIb recommendation (</text>
<text top="177" left="552" width="205" height="15" font="2">“may be considered”) for continu-</text>
<text top="196" left="423" width="333" height="12" font="2">ation of DAPT beyond that period of time. Shorter-</text>
<text top="214" left="423" width="333" height="12" font="2">duration DAPT can be considered for patients at lower</text>
<text top="232" left="423" width="333" height="12" font="2">ischemic risk with high bleeding risk, whereas longer-</text>
<text top="250" left="423" width="333" height="12" font="2">duration DAPT may be reasonable for patients at higher</text>
<text top="268" left="423" width="333" height="12" font="2">ischemic risk with lower bleeding risk. These recom-</text>
<text top="286" left="423" width="333" height="12" font="2">mendations do not generally apply to patients treated</text>
<text top="304" left="423" width="333" height="12" font="2">with oral anticoagulant therapy, who were excluded from</text>
<text top="322" left="423" width="333" height="12" font="2">almost all studies of DAPT duration and who are at</text>
<text top="340" left="423" width="27" height="12" font="2">signi</text>
<text top="338" left="451" width="306" height="15" font="2">ﬁcantly increased bleeding risk (as discussed in</text>
<text top="358" left="423" width="65" height="12" font="4"><a href="1082.full.html#9">Section 3.4</a></text>
<text top="358" left="489" width="268" height="12" font="2"><a href="1082.full.html#9">)</a>. Decisions about duration of DAPT are best</text>
<text top="376" left="423" width="333" height="12" font="2">made on an individual basis and should integrate clinical</text>
<text top="394" left="423" width="207" height="12" font="2">judgment, assessment of the bene</text>
<text top="392" left="630" width="127" height="15" font="2">ﬁt/risk ratio, and pa-</text>
<text top="412" left="423" width="333" height="12" font="2">tient preference. Aspirin therapy is almost always</text>
<text top="430" left="423" width="89" height="12" font="2">continued inde</text>
<text top="428" left="512" width="244" height="15" font="2">ﬁnitely in patients with CAD, and recom-</text>
<text top="447" left="423" width="333" height="12" font="2">mendations on duration of DAPT should be taken to mean</text>
<text top="465" left="423" width="201" height="12" font="2">the recommended duration of P2Y</text>
<text top="470" left="625" width="9" height="8" font="7">12</text>
<text top="465" left="637" width="119" height="12" font="2">inhibitor therapy (in</text>
<text top="483" left="423" width="166" height="12" font="2">addition to aspirin therapy).</text>
<text top="484" left="593" width="45" height="11" font="4"><a href="1082.full.html#10">Figure 1</a></text>
<text top="483" left="642" width="114" height="12" font="2">summarizes recom-</text>
<text top="501" left="423" width="333" height="12" font="2">mendations for duration of DAPT according to clinical</text>
<text top="519" left="423" width="38" height="12" font="2">status.</text>
<text top="552" left="423" width="277" height="11" font="12">3.2. Factors Associated With Increased Ischemic and</text>
<text top="569" left="447" width="72" height="11" font="12">Bleeding Risk</text>
<text top="591" left="423" width="333" height="12" font="2">Factors that have been associated with increased ischemic</text>
<text top="609" left="423" width="333" height="12" font="2">risk (including increased risk of stent thrombosis) and</text>
<text top="627" left="423" width="215" height="12" font="2">increased bleeding risk are listed in</text>
<text top="627" left="644" width="43" height="11" font="4"><a href="1082.full.html#11">Table 4</a></text>
<text top="627" left="688" width="69" height="12" font="2"><a href="1082.full.html#11">. </a>Individual</text>
<text top="645" left="423" width="333" height="12" font="2">patients may have factors for both increased ischemic and</text>
<text top="663" left="423" width="333" height="12" font="2">bleeding risk, and some factors are associated with both</text>
<text top="681" left="423" width="303" height="12" font="2">increased ischemic and bleeding risk, making it dif</text>
<text top="679" left="727" width="30" height="15" font="2">ﬁcult</text>
<text top="699" left="423" width="216" height="12" font="2">in many patients to assess the bene</text>
<text top="697" left="640" width="117" height="15" font="2">ﬁt/risk ratio of pro-</text>
<text top="716" left="423" width="79" height="12" font="2">longed DAPT.</text>
<text top="734" left="438" width="124" height="12" font="2">A new risk score (the</text>
<text top="733" left="566" width="190" height="15" font="2">“DAPT score”), derived from the</text>
<text top="752" left="423" width="333" height="12" font="2">Dual Antiplatelet Therapy study, may be useful for de-</text>
<text top="770" left="423" width="333" height="12" font="2">cisions about whether to continue (prolong or extend)</text>
<text top="788" left="423" width="333" height="12" font="2">DAPT in patients treated with coronary stent implanta-</text>
<text top="806" left="423" width="333" height="12" font="2">tion. Analysis of study data suggests that in patients</text>
<text top="824" left="423" width="247" height="12" font="2">treated for 1 year with DAPT without signi</text>
<text top="822" left="670" width="86" height="15" font="2">ﬁcant bleeding</text>
<text top="842" left="423" width="169" height="12" font="2">or ischemic events, the bene</text>
<text top="840" left="593" width="164" height="15" font="2">ﬁt/risk ratio with prolonged</text>
<text top="860" left="423" width="333" height="12" font="2">DAPT may be favorable for those with a high DAPT score</text>
<text top="878" left="423" width="4" height="12" font="2">(</text>
<text top="876" left="427" width="329" height="15" font="2">$2) because prolonged DAPT reduces net (ischemic plus</text>
<text top="896" left="423" width="333" height="12" font="2">bleeding) events when compared with nonprolonged</text>
<text top="914" left="423" width="32" height="12" font="2">DAPT</text>
<text top="914" left="461" width="21" height="12" font="4"><a href="1082.full.html#25">(61)</a></text>
<text top="914" left="482" width="275" height="12" font="2"><a href="1082.full.html#25">. </a>Conversely, in those with a low DAPT score</text>
<text top="932" left="423" width="4" height="12" font="2">(</text>
<text top="930" left="427" width="329" height="15" font="2">&lt;2), the beneﬁt/risk ratio with prolonged DAPT is not</text>
<text top="950" left="423" width="333" height="12" font="2">favorable (increased bleeding without a reduction in</text>
<text top="968" left="423" width="333" height="12" font="2">ischemic events). Factors that contribute to a high DAPT</text>
<text top="985" left="423" width="333" height="12" font="2">score include diabetes mellitus, current cigarette use,</text>
<text top="1003" left="423" width="333" height="12" font="2">prior PCI or prior MI, congestive heart failure or left</text>
<text top="1021" left="423" width="167" height="12" font="2">ventricular ejection fraction</text>
<text top="1020" left="597" width="160" height="15" font="2">&lt;30%, MI at presentation,</text>
<text top="1039" left="423" width="214" height="12" font="2">vein graft PCI, and stent diameter</text>
<text top="1037" left="644" width="112" height="15" font="2">&lt;3 mm; older age</text>
<text top="1057" left="423" width="333" height="12" font="2">contributes to a low (less favorable) DAPT score. Factors</text>
<text top="1075" left="423" width="333" height="12" font="2">and their weighting used to calculate a DAPT score are</text>
<text top="1093" left="423" width="67" height="12" font="2">provided in</text>
<text top="1093" left="495" width="41" height="11" font="4"><a href="1082.full.html#11">Table 5</a></text>
<text top="1093" left="536" width="3" height="12" font="2"><a href="1082.full.html#11">.</a></text>
<text top="559" left="71" width="47" height="10" font="16">T A B L E 3</text>
<text top="552" left="135" width="178" height="10" font="17">Overriding Concepts and Updated</text>
<text top="566" left="135" width="221" height="10" font="17">Recommendations for DAPT and Duration</text>
<text top="588" left="63" width="28" height="9" font="14">Intensi</text>
<text top="587" left="91" width="245" height="12" font="14">ﬁcation of antiplatelet therapy, with the addition of a P2Y</text>
<text top="592" left="335" width="7" height="6" font="18">12</text>
<text top="588" left="345" width="47" height="9" font="14">inhibitor to</text>
<text top="600" left="77" width="291" height="9" font="14">aspirin monotherapy, as well as prolongation of DAPT, necessitates a</text>
<text top="612" left="77" width="295" height="9" font="14">fundamental tradeoff between decreasing ischemic risk and increasing</text>
<text top="624" left="77" width="319" height="9" font="14">bleeding risk. Decisions about treatment with and duration of DAPT require a</text>
<text top="636" left="77" width="144" height="9" font="14">thoughtful assessment of the bene</text>
<text top="634" left="221" width="175" height="12" font="14">ﬁt/risk ratio, integration of study data, and</text>
<text top="648" left="77" width="150" height="9" font="14">consideration of patient preference.</text>
<text top="667" left="63" width="311" height="9" font="14">In general, shorter-duration DAPT can be considered for patients at lower</text>
<text top="679" left="78" width="318" height="9" font="14">ischemic risk with high bleeding risk, whereas longer-duration DAPT may be</text>
<text top="691" left="78" width="300" height="9" font="14">reasonable for patients at higher ischemic risk with lower bleeding risk.</text>
<text top="711" left="63" width="333" height="9" font="14">Prior recommendations for duration of DAPT for patients treated with DES were</text>
<text top="723" left="78" width="82" height="9" font="14">based on data from</text>
<text top="721" left="163" width="228" height="12" font="14">“ﬁrst-generation” DES, which are rarely if ever used in</text>
<text top="735" left="78" width="167" height="9" font="14">current clinical practice. Compared with</text>
<text top="733" left="248" width="129" height="12" font="14">ﬁrst-generation stents, newer-</text>
<text top="747" left="78" width="197" height="9" font="14">generation stents have an improved safety pro</text>
<text top="745" left="274" width="112" height="12" font="14">ﬁle and lower risk of stent</text>
<text top="759" left="78" width="295" height="9" font="14">thrombosis. Recommendations in this focused update apply to newer-</text>
<text top="771" left="78" width="76" height="9" font="14">generation stents.</text>
<text top="790" left="63" width="322" height="9" font="14">Updated recommendations for duration of DAPT are now similar for patients</text>
<text top="802" left="78" width="292" height="9" font="14">with NSTE-ACS and STEMI, as both are part of the spectrum of acute</text>
<text top="814" left="78" width="83" height="9" font="14">coronary syndrome.</text>
<text top="834" left="63" width="115" height="9" font="14">A Class I recommendation (</text>
<text top="832" left="178" width="215" height="12" font="14">“should be given”) in most clinical settings is made</text>
<text top="846" left="78" width="54" height="9" font="14">for at least 6</text>
<text top="844" left="132" width="264" height="12" font="14">–12 months of DAPT (depending on the setting), and a Class IIb</text>
<text top="858" left="78" width="76" height="9" font="14">recommendation (</text>
<text top="856" left="154" width="242" height="12" font="14">“may be reasonable”) is made for prolonged DAPT beyond</text>
<text top="869" left="78" width="141" height="9" font="14">this initial 6- to 12-month period.</text>
<text top="889" left="63" width="323" height="9" font="14">In studies of prolonged DAPT after DES implantation or after MI, duration of</text>
<text top="901" left="78" width="318" height="9" font="14">therapy was limited to several years (akin to many other studied therapies).</text>
<text top="913" left="78" width="151" height="9" font="14">Thus, in patients for whom the bene</text>
<text top="911" left="229" width="167" height="12" font="14">ﬁt/risk ratio seemingly favors prolonged</text>
<text top="925" left="78" width="244" height="9" font="14">therapy, the true optimal duration of therapy is unknown.</text>
<text top="944" left="63" width="198" height="9" font="14">Recommendations in the document apply speci</text>
<text top="943" left="261" width="105" height="12" font="14">ﬁcally to duration of P2Y</text>
<text top="948" left="366" width="7" height="6" font="18">12</text>
<text top="956" left="78" width="274" height="9" font="14">inhibitor therapy in patients with CAD treated with DAPT. Aspirin</text>
<text top="968" left="78" width="203" height="9" font="14">therapy should almost always be continued inde</text>
<text top="966" left="281" width="76" height="12" font="14">ﬁnitely in patients</text>
<text top="980" left="78" width="42" height="9" font="14">with CAD.</text>
<text top="1000" left="63" width="307" height="9" font="14">Lower daily doses of aspirin, including in patients treated with DAPT, are</text>
<text top="1012" left="78" width="298" height="9" font="14">associated with lower bleeding complications and comparable ischemic</text>
<text top="1023" left="78" width="43" height="9" font="14">protection</text>
<text top="1023" left="124" width="14" height="9" font="19"><a href="1082.full.html#25">(56</a></text>
<text top="1022" left="138" width="20" height="12" font="19"><a href="1082.full.html#25">–60)</a></text>
<text top="1023" left="161" width="216" height="9" font="14">than are higher doses of aspirin. The recommended</text>
<text top="1035" left="78" width="312" height="9" font="14">daily dose of aspirin in patients treated with DAPT is 81 mg (range, 75 mg</text>
<text top="1047" left="78" width="51" height="9" font="14">to 100 mg).</text>
<text top="1071" left="63" width="333" height="8" font="5">CAD indicates coronary artery disease; DAPT, dual antiplatelet therapy; DES, drug-</text>
<text top="1083" left="63" width="220" height="8" font="5">eluting stent; MI, myocardial infarction; NSTE-ACS, non</text>
<text top="1081" left="282" width="114" height="11" font="5">–ST-elevation acute coronary</text>
<text top="1095" left="63" width="223" height="8" font="5">syndrome; and STEMI, ST-elevation myocardial infarction.</text>
<text top="54" left="63" width="132" height="7" font="7">J A C C V O L . 6 8 , N O . 1 0 , 2 0 1 6</text>
<text top="54" left="705" width="52" height="9" font="14">Levine et al.</text>
<text top="69" left="63" width="117" height="7" font="7">S E P T E M B E R 6 , 2 0 1 6 : 1 0 8 2</text>
<text top="67" left="182" width="17" height="10" font="7">– 1 1 5</text>
<text top="69" left="514" width="243" height="9" font="14">Focused Update on Duration of Dual Antiplatelet Therapy</text>
<text top="53" left="786" width="21" height="9" font="5">1089</text>
</page>
<page number="9" position="absolute" top="0" left="0" height="1160" width="864">
	<fontspec id="20" size="9" family="Times" color="#ffffff"/>
	<fontspec id="21" size="5" family="Times" color="#ffffff"/>
<text top="143" left="108" width="51" height="11" font="12">3.3. Speci</text>
<text top="141" left="159" width="36" height="15" font="12">ﬁc P2Y</text>
<text top="148" left="195" width="8" height="8" font="13">12</text>
<text top="143" left="208" width="155" height="11" font="12">Inhibitors: Recommendations</text>
<text top="164" left="108" width="20" height="12" font="2">See</text>
<text top="164" left="134" width="156" height="12" font="4"><a href="http://jaccjacc.acc.org/Clinical_Document/DAPT_Data_Supplement_1.pdf">Online Data Supplement 5</a></text>
<text top="164" left="297" width="144" height="12" font="2">for evidence supporting</text>
<text top="182" left="108" width="143" height="12" font="2">these recommendations.</text>
<text top="463" left="123" width="318" height="12" font="2">In the PLATO (Platelet Inhibition and Patient Out-</text>
<text top="481" left="108" width="71" height="12" font="2">comes) trial</text>
<text top="481" left="185" width="21" height="12" font="4"><a href="1082.full.html#24">(53)</a></text>
<text top="481" left="206" width="234" height="12" font="2">, patients with ACS were treated with</text>
<text top="499" left="108" width="333" height="12" font="2">either medical therapy alone or medical therapy plus</text>
<text top="517" left="108" width="333" height="12" font="2">PCI. Treatment with ticagrelor 90 mg twice daily,</text>
<text top="535" left="108" width="333" height="12" font="2">compared with clopidogrel 75 mg once daily, resulted in</text>
<text top="553" left="108" width="333" height="12" font="2">fewer ischemic complications and stent thromboses but</text>
<text top="571" left="108" width="30" height="12" font="2">more</text>
<text top="571" left="154" width="50" height="12" font="2">frequent</text>
<text top="571" left="221" width="22" height="12" font="2">non</text>
<text top="569" left="243" width="84" height="15" font="2">–CABG-related</text>
<text top="571" left="344" width="50" height="12" font="2">bleeding</text>
<text top="571" left="411" width="4" height="12" font="2">(</text>
<text top="571" left="415" width="26" height="12" font="4"><a href="http://jaccjacc.acc.org/Clinical_Document/DAPT_Data_Supplement_1.pdf">Data</a></text>
<text top="589" left="108" width="85" height="12" font="4"><a href="http://jaccjacc.acc.org/Clinical_Document/DAPT_Data_Supplement_1.pdf">Supplement 5</a></text>
<text top="589" left="193" width="248" height="12" font="2"><a href="http://jaccjacc.acc.org/Clinical_Document/DAPT_Data_Supplement_1.pdf">). </a>In the TRITON-TIMI 38 (Therapeutic</text>
<text top="607" left="108" width="333" height="12" font="2">Outcomes by Optimizing Platelet Inhibition With Pra-</text>
<text top="625" left="108" width="35" height="12" font="2">sugrel</text>
<text top="623" left="143" width="268" height="15" font="2">–Thrombolysis In Myocardial Infarction 38)</text>
<text top="625" left="419" width="22" height="12" font="4"><a href="1082.full.html#24">(54)</a></text>
<text top="643" left="108" width="333" height="12" font="2">study, patients with ACS undergoing planned PCI were</text>
<text top="661" left="108" width="333" height="12" font="2">treated with prasugrel 10 mg daily, compared with clo-</text>
<text top="679" left="108" width="334" height="12" font="2">pidogrel 75 mg daily. Prasugrel treatment resulted in</text>
<text top="696" left="108" width="333" height="12" font="2">fewer ischemic complications and stent thromboses but</text>
<text top="714" left="108" width="333" height="12" font="2">more frequent bleeding, including life-threatening and</text>
<text top="732" left="108" width="333" height="12" font="2">fatal bleeding. Because of increased rates of major</text>
<text top="750" left="108" width="333" height="12" font="2">bleeding with prasugrel (compared with clopidogrel),</text>
<text top="768" left="108" width="156" height="12" font="2">there was no net bene</text>
<text top="766" left="264" width="177" height="15" font="2">ﬁt of prasugrel therapy in</text>
<text top="786" left="108" width="31" height="12" font="2">those</text>
<text top="784" left="144" width="297" height="15" font="2">$75 years of age and those &lt;60 kg, and there was</text>
<text top="804" left="108" width="19" height="12" font="2">net</text>
<text top="804" left="138" width="30" height="12" font="2">harm</text>
<text top="804" left="180" width="59" height="12" font="2">(including</text>
<text top="804" left="251" width="55" height="12" font="2">increased</text>
<text top="804" left="318" width="21" height="12" font="2">risk</text>
<text top="804" left="351" width="11" height="12" font="2">of</text>
<text top="804" left="374" width="67" height="12" font="2">intracranial</text>
<text top="822" left="108" width="333" height="12" font="2">hemorrhage) in those with prior stroke or transient</text>
<text top="840" left="108" width="333" height="12" font="2">ischemic attack (TIA). The Class IIa preferential recom-</text>
<text top="858" left="108" width="333" height="12" font="2">mendations for ticagrelor 90 mg twice daily and for</text>
<text top="876" left="108" width="333" height="12" font="2">prasugrel 10 mg once daily (compared with clopidogrel)</text>
<text top="894" left="108" width="111" height="12" font="2">in the 2014 Non</text>
<text top="892" left="219" width="222" height="15" font="2">–ST-Elevation Acute Coronary Syn-</text>
<text top="912" left="108" width="333" height="12" font="2">dromes (NSTE-ACS) guideline are continued in this</text>
<text top="930" left="108" width="333" height="12" font="2">focused update and are now included in relevant PCI</text>
<text top="948" left="108" width="333" height="12" font="2">and ST-Elevation Myocardial Infarction (STEMI) recom-</text>
<text top="965" left="108" width="123" height="12" font="2">mendations, as well.</text>
<text top="983" left="123" width="318" height="12" font="2">In the PEGASUS-TIMI 54 study of post-MI patients, both</text>
<text top="1001" left="108" width="333" height="12" font="2">60-mg and 90-mg twice-daily doses of ticagrelor were</text>
<text top="1019" left="108" width="57" height="12" font="2">evaluated</text>
<text top="1019" left="174" width="22" height="12" font="4"><a href="1082.full.html#24">(28)</a></text>
<text top="1019" left="196" width="72" height="12" font="2">. The bene</text>
<text top="1017" left="268" width="172" height="15" font="2">ﬁt/risk ratio appears to be</text>
<text top="1037" left="108" width="333" height="12" font="2">numerically more favorable for the 60-mg dose, although</text>
<text top="1055" left="108" width="333" height="12" font="2">no formal statistical comparison was made between</text>
<text top="1073" left="108" width="333" height="12" font="2">results of the 2 dosing regimens. The 60-mg twice-daily</text>
<text top="1091" left="108" width="333" height="12" font="2">dose has now been approved by the US Food and Drug</text>
<text top="463" left="468" width="333" height="12" font="2">Administration for reduction in ischemic events in patients</text>
<text top="481" left="468" width="153" height="12" font="2">with ACS or a history of MI</text>
<text top="481" left="624" width="21" height="12" font="4"><a href="1082.full.html#25">(73)</a></text>
<text top="481" left="645" width="3" height="12" font="2">.</text>
<text top="508" left="468" width="330" height="11" font="12">3.4. Platelet Function Testing, Genetic Testing, and Switching</text>
<text top="526" left="492" width="35" height="11" font="12">of P2Y</text>
<text top="531" left="528" width="8" height="8" font="13">12</text>
<text top="526" left="540" width="50" height="11" font="12">Inhibitors</text>
<text top="547" left="468" width="333" height="12" font="2">The role of platelet function testing and genetic testing in</text>
<text top="565" left="468" width="333" height="12" font="2">patients treated with DAPT is addressed in the 2011 ACCF/</text>
<text top="583" left="468" width="333" height="12" font="2">AHA/SCAI PCI guideline and the 2014 ACC/AHA NSTE-ACS</text>
<text top="601" left="468" width="54" height="12" font="2">guideline</text>
<text top="601" left="527" width="32" height="12" font="4"><a href="1082.full.html#23">(9,14)</a></text>
<text top="601" left="559" width="242" height="12" font="2">. To date, no RCT has demonstrated that</text>
<text top="619" left="468" width="333" height="12" font="2">routine platelet function testing or genetic testing to</text>
<text top="637" left="468" width="60" height="12" font="2">guide P2Y</text>
<text top="642" left="528" width="9" height="8" font="7">12</text>
<text top="637" left="543" width="258" height="12" font="2">inhibitor therapy improves outcome; thus,</text>
<text top="655" left="468" width="333" height="12" font="2">the routine use of platelet function and genetic testing is</text>
<text top="673" left="468" width="218" height="12" font="2">not recommended (Class III: No Bene</text>
<text top="671" left="686" width="20" height="15" font="2">ﬁt).</text>
<text top="691" left="483" width="318" height="12" font="2">No randomized data are available on the long-term</text>
<text top="709" left="468" width="74" height="12" font="2">safety or ef</text>
<text top="707" left="542" width="259" height="15" font="2">ﬁcacy of “switching” patients treated for</text>
<text top="727" left="468" width="160" height="12" font="2">weeks or months with a P2Y</text>
<text top="731" left="628" width="9" height="8" font="7">12</text>
<text top="727" left="640" width="152" height="12" font="2">inhibitor to a different P2Y</text>
<text top="731" left="793" width="9" height="8" font="7">12</text>
<text top="744" left="468" width="54" height="12" font="2">inhibitor.</text>
<text top="780" left="468" width="205" height="11" font="12">3.5. Proton Pump Inhibitors and DAPT</text>
<text top="801" left="468" width="333" height="12" font="2">The use of proton pump inhibitors (PPIs) in patients</text>
<text top="819" left="468" width="333" height="12" font="2">treated with DAPT is discussed in a 2010 ACCF/ACG/AHA</text>
<text top="837" left="468" width="167" height="12" font="2">expert consensus document</text>
<text top="837" left="641" width="22" height="12" font="4"><a href="1082.full.html#25">(74)</a></text>
<text top="837" left="663" width="138" height="12" font="2">. Recommendations on</text>
<text top="855" left="468" width="333" height="12" font="2">the use of PPIs are given in the 2011 ACCF/AHA/SCAI PCI</text>
<text top="873" left="468" width="54" height="12" font="2">guideline</text>
<text top="873" left="525" width="15" height="12" font="4"><a href="1082.full.html#23">(9)</a></text>
<text top="873" left="540" width="261" height="12" font="2">. PPIs should be used in patients with a history</text>
<text top="891" left="468" width="333" height="12" font="2">of prior gastrointestinal bleeding treated with DAPT (Class</text>
<text top="909" left="468" width="333" height="12" font="2">I). In patients with increased risk of gastrointestinal</text>
<text top="927" left="468" width="333" height="12" font="2">bleeding, including those with advanced age and those</text>
<text top="945" left="468" width="333" height="12" font="2">with concomitant use of warfarin, steroids, or nonsteroidal</text>
<text top="963" left="468" width="39" height="12" font="2">anti-in</text>
<text top="961" left="507" width="294" height="15" font="2">ﬂammatory drugs, use of PPIs is reasonable (Class</text>
<text top="981" left="468" width="333" height="12" font="2">IIa). Routine use of PPIs is not recommended for patients at</text>
<text top="999" left="468" width="313" height="12" font="2">low risk of gastrointestinal bleeding (Class III: No Bene</text>
<text top="997" left="781" width="20" height="15" font="2">ﬁt).</text>
<text top="1034" left="468" width="272" height="11" font="12">3.6. Aspirin Dosing in Patients Treated With DAPT:</text>
<text top="1052" left="492" width="92" height="11" font="12">Recommendation</text>
<text top="1074" left="468" width="20" height="12" font="2">See</text>
<text top="1074" left="491" width="146" height="12" font="4"><a href="http://jaccjacc.acc.org/Clinical_Document/DAPT_Data_Supplement_1.pdf">Online Data Supplement 6</a></text>
<text top="1074" left="639" width="162" height="12" font="2">for evidence supporting this</text>
<text top="1091" left="468" width="102" height="12" font="2">recommendation.</text>
<text top="209" left="57" width="155" height="11" font="20">Recommendations for Speci</text>
<text top="207" left="212" width="38" height="15" font="20">ﬁc P2Y</text>
<text top="213" left="250" width="9" height="7" font="21">12</text>
<text top="209" left="263" width="54" height="11" font="20">Inhibitors</text>
<text top="250" left="83" width="19" height="10" font="14">COR</text>
<text top="250" left="156" width="18" height="10" font="14">LOE</text>
<text top="250" left="227" width="96" height="10" font="14">RECOMMENDATIONS</text>
<text top="287" left="88" width="10" height="9" font="5">IIa</text>
<text top="287" left="157" width="15" height="9" font="5">B-R</text>
<text top="274" left="227" width="574" height="11" font="12">In patients with ACS (NSTE-ACS or STEMI) treated with DAPT after coronary stent implantation and in patients with</text>
<text top="289" left="227" width="553" height="11" font="12">NSTE-ACS treated with medical therapy alone (without revascularization), it is reasonable to use ticagrelor in</text>
<text top="305" left="227" width="236" height="11" font="12">preference to clopidogrel for maintenance P2Y</text>
<text top="309" left="464" width="8" height="7" font="13">12</text>
<text top="305" left="475" width="84" height="11" font="12">inhibitor therapy</text>
<text top="305" left="563" width="48" height="11" font="4"><a href="1082.full.html#24">(53,71,72)</a></text>
<text top="305" left="612" width="3" height="11" font="12"><a href="1082.full.html#24">.</a></text>
<text top="349" left="88" width="10" height="9" font="5">IIa</text>
<text top="349" left="157" width="15" height="9" font="5">B-R</text>
<text top="337" left="227" width="574" height="11" font="12">In patients with ACS (NSTE-ACS or STEMI) treated with DAPT after coronary stent implantation who are not at high</text>
<text top="352" left="227" width="574" height="11" font="12">risk for bleeding complications and who do not have a history of stroke or TIA, it is reasonable to choose prasugrel</text>
<text top="367" left="227" width="190" height="11" font="12">over clopidogrel for maintenance P2Y</text>
<text top="372" left="418" width="8" height="7" font="13">12</text>
<text top="367" left="430" width="84" height="11" font="12">inhibitor therapy</text>
<text top="367" left="517" width="36" height="11" font="4"><a href="1082.full.html#24">(54,55)</a></text>
<text top="367" left="553" width="3" height="11" font="12">.</text>
<text top="413" left="76" width="35" height="9" font="5">III: Harm</text>
<text top="413" left="157" width="15" height="9" font="5">B-R</text>
<text top="401" left="227" width="431" height="11" font="12">Prasugrel should not be administered to patients with a prior history of stroke or TIA</text>
<text top="401" left="662" width="21" height="11" font="4"><a href="1082.full.html#24">(54)</a></text>
<text top="401" left="683" width="3" height="11" font="12">.</text>
<text top="53" left="108" width="52" height="9" font="14">Levine et al.</text>
<text top="54" left="670" width="132" height="7" font="7">J A C C V O L . 6 8 , N O . 1 0 , 2 0 1 6</text>
<text top="68" left="108" width="243" height="9" font="14">Focused Update on Duration of Dual Antiplatelet Therapy</text>
<text top="69" left="665" width="117" height="7" font="7">S E P T E M B E R 6 , 2 0 1 6 : 1 0 8 2</text>
<text top="67" left="784" width="17" height="10" font="7">– 1 1 5</text>
<text top="53" left="57" width="21" height="9" font="5">1090</text>
</page>
<page number="10" position="absolute" top="0" left="0" height="1160" width="864">
	<fontspec id="22" size="6" family="Times" color="#e3202b"/>
	<fontspec id="23" size="6" family="Times" color="#0e2a52"/>
	<fontspec id="24" size="3" family="Times" color="#0e2a52"/>
	<fontspec id="25" size="4" family="Times" color="#231f20"/>
	<fontspec id="26" size="4" family="Times" color="#231f20"/>
<text top="304" left="78" width="47" height="12" font="2">Because</text>
<text top="304" left="138" width="40" height="12" font="2">aspirin</text>
<text top="304" left="191" width="38" height="12" font="2">dosing</text>
<text top="304" left="243" width="104" height="12" font="2">recommendations</text>
<text top="304" left="361" width="36" height="12" font="2">across</text>
<text top="322" left="63" width="333" height="12" font="2">ACC/AHA clinical practice guidelines are not consistent</text>
<text top="340" left="63" width="333" height="12" font="2">with regard to dose or class of recommendation, and</text>
<text top="358" left="63" width="333" height="12" font="2">because aspirin is a component of DAPT, a comprehensive</text>
<text top="376" left="63" width="333" height="12" font="2">review of these issues was undertaken. Large overviews,</text>
<text top="394" left="63" width="333" height="12" font="2">including studies of nearly 200,000 persons, have consis-</text>
<text top="412" left="63" width="225" height="12" font="2">tently shown that lower aspirin doses (</text>
<text top="410" left="288" width="108" height="15" font="2">#100 mg daily) are</text>
<text top="430" left="63" width="333" height="12" font="2">associated with less major and total bleeding than are</text>
<text top="143" left="423" width="333" height="12" font="2">higher doses, either when used as monotherapy or</text>
<text top="161" left="423" width="192" height="12" font="2">when combined with the P2Y</text>
<text top="166" left="616" width="8" height="8" font="7">12</text>
<text top="161" left="634" width="122" height="12" font="2">inhibitor clopidogrel</text>
<text top="178" left="423" width="88" height="12" font="4"><a href="1082.full.html#25">(56,58,75,76,78)</a></text>
<text top="178" left="512" width="245" height="12" font="2"><a href="1082.full.html#25">. </a>Daily aspirin doses as low as 30 mg to 50 mg</text>
<text top="196" left="423" width="333" height="12" font="2">inactivate the platelet cyclo-oxygenase-1 enzyme and</text>
<text top="214" left="423" width="181" height="12" font="2">inhibit thromboxane production</text>
<text top="214" left="607" width="17" height="12" font="4"><a href="1082.full.html#25">(79</a></text>
<text top="213" left="624" width="22" height="15" font="4"><a href="1082.full.html#25">–81)</a></text>
<text top="214" left="646" width="110" height="12" font="2">. Studies comparing</text>
<text top="232" left="423" width="333" height="12" font="2">lower (75 mg to 150 mg) with higher aspirin doses have</text>
<text top="250" left="423" width="333" height="12" font="2">consistently found comparable ischemic event rates with</text>
<text top="268" left="423" width="333" height="12" font="2">either dose when used as monotherapy or when combined</text>
<text top="286" left="423" width="71" height="12" font="2">with the P2Y</text>
<text top="291" left="494" width="8" height="8" font="7">12</text>
<text top="286" left="505" width="115" height="12" font="2">inhibitor clopidogrel</text>
<text top="286" left="624" width="17" height="12" font="4"><a href="1082.full.html#25">(56</a></text>
<text top="284" left="641" width="41" height="15" font="4"><a href="1082.full.html#25">–60,78)</a></text>
<text top="286" left="682" width="41" height="12" font="2">. The ef</text>
<text top="284" left="724" width="32" height="15" font="2">ﬁcacy</text>
<text top="304" left="423" width="333" height="12" font="2">of ticagrelor seems to be decreased in patients treated</text>
<text top="322" left="423" width="160" height="12" font="2">with higher aspirin doses (</text>
<text top="320" left="584" width="173" height="15" font="2">$300 mg daily) versus lower</text>
<text top="340" left="423" width="80" height="12" font="2">aspirin doses (</text>
<text top="338" left="504" width="85" height="15" font="2">#100 mg daily)</text>
<text top="340" left="592" width="22" height="12" font="4"><a href="1082.full.html#25">(82)</a></text>
<text top="340" left="614" width="143" height="12" font="2"><a href="1082.full.html#25">. </a>On the basis of available</text>
<text top="358" left="423" width="333" height="12" font="2">data, the optimal range of aspirin dose in patients treated</text>
<text top="376" left="423" width="333" height="12" font="2">with DAPT that provides maximal protection from ischemic</text>
<text top="394" left="423" width="333" height="12" font="2">events and minimizes bleeding risk appears to be 75 mg to</text>
<text top="412" left="423" width="45" height="12" font="2">100 mg <a href="http://jaccjacc.acc.org/Clinical_Document/DAPT_Data_Supplement_1.pdf">(</a></text>
<text top="412" left="468" width="105" height="12" font="4"><a href="http://jaccjacc.acc.org/Clinical_Document/DAPT_Data_Supplement_1.pdf">Data Supplement 6</a></text>
<text top="412" left="574" width="183" height="12" font="2"><a href="http://jaccjacc.acc.org/Clinical_Document/DAPT_Data_Supplement_1.pdf">). </a>For practical purposes, because</text>
<text top="430" left="423" width="333" height="12" font="2">the relevant aspirin dose available in the United States is</text>
<text top="470" left="80" width="44" height="11" font="22">FIGURE 1</text>
<text top="471" left="132" width="217" height="9" font="23">Master Treatment Algorithm for Duration of P2Y</text>
<text top="474" left="350" width="7" height="6" font="24">12</text>
<text top="471" left="360" width="261" height="9" font="23">Inhibitor Therapy in Patients With CAD Treated With DAPT</text>
<text top="506" left="431" width="13" height="7" font="25">CAD</text>
<text top="551" left="286" width="15" height="7" font="25">SIHD</text>
<text top="546" left="550" width="53" height="7" font="25">Acute/Recent ACS </text>
<text top="554" left="545" width="63" height="7" font="25">(NSTE-ACS or STEMI)</text>
<text top="605" left="173" width="55" height="7" font="25">No Hx of MI, PCI or </text>
<text top="612" left="171" width="57" height="7" font="25">recent (within 12 mo)</text>
<text top="619" left="191" width="17" height="7" font="25">CABG</text>
<text top="611" left="380" width="29" height="7" font="25">S/P CABG</text>
<text top="611" left="455" width="45" height="7" font="25">Medical Therapy</text>
<text top="611" left="525" width="37" height="7" font="25">Lytic (STEMI)</text>
<text top="611" left="584" width="51" height="7" font="25">PCI (BMS or DES)</text>
<text top="611" left="667" width="17" height="7" font="25">CABG</text>
<text top="652" left="187" width="25" height="7" font="26"><b>Class III:</b></text>
<text top="659" left="183" width="32" height="7" font="26"><b> No Benefit</b></text>
<text top="751" left="127" width="14" height="7" font="25">6 mo</text>
<text top="849" left="126" width="17" height="7" font="25">12 mo</text>
<text top="598" left="282" width="22" height="7" font="25">S/P PCI</text>
<text top="628" left="256" width="13" height="7" font="25">BMS</text>
<text top="628" left="316" width="13" height="7" font="25">DES</text>
<text top="867" left="503" width="78" height="7" font="25">No high risk of bleeding and </text>
<text top="875" left="490" width="102" height="7" font="25">no significant overt bleeding on DAPT</text>
<text top="645" left="127" width="14" height="7" font="25">0 mo</text>
<text top="770" left="253" width="76" height="7" font="25">No high risk of bleeding and</text>
<text top="777" left="239" width="104" height="7" font="25"> no significant overt bleeding on DAPT</text>
<text top="801" left="311" width="27" height="7" font="26"><b>Class IIb:</b></text>
<text top="808" left="305" width="41" height="7" font="25">&gt;6 mo may be </text>
<text top="815" left="309" width="32" height="7" font="25">reasonable </text>
<text top="690" left="312" width="22" height="7" font="26"><b>Class I:</b></text>
<text top="698" left="305" width="37" height="7" font="25">At least 6 mo </text>
<text top="705" left="306" width="34" height="7" font="25">(clopidogrel)</text>
<text top="660" left="251" width="22" height="7" font="26"><b>Class I:</b></text>
<text top="668" left="244" width="39" height="7" font="25"> At least 1 mo </text>
<text top="675" left="245" width="34" height="7" font="25">(clopidogrel)</text>
<text top="737" left="467" width="22" height="7" font="26"><b>Class I:</b></text>
<text top="744" left="458" width="42" height="7" font="25">At least 12 mo  </text>
<text top="752" left="461" width="33" height="7" font="25">(clopidogrel,</text>
<text top="759" left="464" width="27" height="7" font="25">ticagrelor)</text>
<text top="733" left="533" width="22" height="7" font="26"><b>Class I:</b></text>
<text top="741" left="525" width="41" height="7" font="25">Minimum 14 d </text>
<text top="748" left="526" width="38" height="7" font="25">and ideally at </text>
<text top="755" left="527" width="37" height="7" font="25">least 12 mos </text>
<text top="763" left="527" width="34" height="7" font="25">(clopidogrel)</text>
<text top="733" left="598" width="22" height="7" font="26"><b>Class I:</b></text>
<text top="741" left="589" width="41" height="7" font="25">At least 12 mo </text>
<text top="748" left="592" width="33" height="7" font="25">(clopidogrel,</text>
<text top="755" left="595" width="27" height="7" font="25">prasugrel,</text>
<text top="763" left="595" width="27" height="7" font="25">ticagrelor)</text>
<text top="733" left="665" width="22" height="7" font="26"><b>Class I:</b></text>
<text top="741" left="659" width="34" height="7" font="25">After CABG,</text>
<text top="748" left="656" width="34" height="7" font="25">resume P2Y</text>
<text top="755" left="661" width="30" height="7" font="25">inhibitor to </text>
<text top="763" left="655" width="43" height="7" font="25">complete 1 y of </text>
<text top="770" left="667" width="18" height="7" font="25">DAPT </text>
<text top="902" left="529" width="27" height="7" font="26"><b>Class IIb:</b></text>
<text top="910" left="505" width="76" height="7" font="25">&gt;12 mo may be reasonable </text>
<text top="737" left="381" width="27" height="7" font="26"><b>Class IIb:</b></text>
<text top="745" left="376" width="40" height="6" font="25">12 mo may be </text>
<text top="752" left="380" width="32" height="7" font="25">reasonable </text>
<text top="759" left="378" width="34" height="7" font="25">(clopidogrel)</text>
<text top="802" left="246" width="22" height="6" font="26"><b>Class IIb:</b></text>
<text top="809" left="239" width="37" height="6" font="25">&gt;1 mo may be </text>
<text top="816" left="243" width="29" height="6" font="25">reasonable </text>
<text top="968" left="80" width="210" height="9" font="14">Colors correspond to Class of Recommendation in</text>
<text top="968" left="293" width="30" height="9" font="19"><a href="1082.full.html#4">Table 1</a></text>
<text top="968" left="323" width="182" height="9" font="14">. Clopidogrel is the only currently used P2Y</text>
<text top="972" left="505" width="7" height="6" font="18">12</text>
<text top="968" left="515" width="211" height="9" font="14">inhibitor studied in patients with SIHD undergoing</text>
<text top="983" left="80" width="219" height="9" font="14">PCI. Aspirin therapy is almost always continued inde</text>
<text top="981" left="300" width="433" height="12" font="14">ﬁnitely in patients with CAD. Patients with a history of ACS &gt;1 year prior who have since remained free</text>
<text top="998" left="80" width="637" height="9" font="14">of recurrent ACS are considered to have transitioned to SIHD. In patients treated with DAPT after DES implantation who develop a high risk of bleeding</text>
<text top="1013" left="80" width="610" height="9" font="14">(e.g., treatment with oral anticoagulant therapy), are at high risk of severe bleeding complication (e.g., major intracranial surgery), or develop signi</text>
<text top="1011" left="690" width="48" height="12" font="14">ﬁcant overt</text>
<text top="1027" left="80" width="137" height="9" font="14">bleeding, discontinuation of P2Y</text>
<text top="1032" left="217" width="7" height="6" font="18">12</text>
<text top="1027" left="227" width="490" height="9" font="14">inhibitor therapy after 3 months for SIHD or after 6 months for ACS may be reasonable. Arrows at the bottom of the</text>
<text top="1041" left="80" width="658" height="12" font="14">ﬁgure denote that the optimal duration of prolonged DAPT is not established. ACS indicates acute coronary syndrome; BMS, bare metal stent; CABG, coronary</text>
<text top="1057" left="80" width="561" height="9" font="14">artery bypass graft surgery; CAD, coronary artery disease; DAPT, dual antiplatelet therapy; DES, drug-eluting stent; Hx, history; lytic,</text>
<text top="1056" left="644" width="83" height="12" font="14">ﬁbrinolytic therapy;</text>
<text top="1072" left="80" width="64" height="9" font="14">NSTE-ACS, non</text>
<text top="1071" left="145" width="587" height="12" font="14">–ST-elevation acute coronary syndrome; PCI, percutaneous coronary intervention; SIHD, stable ischemic heart disease; S/P, status post; and</text>
<text top="1087" left="80" width="179" height="9" font="14">STEMI, ST-elevation myocardial infarction.</text>
<text top="149" left="63" width="325" height="11" font="20">Recommendation for Aspirin Dosing in Patients Treated</text>
<text top="164" left="63" width="60" height="11" font="20">With DAPT</text>
<text top="205" left="89" width="19" height="10" font="14">COR</text>
<text top="205" left="161" width="18" height="10" font="14">LOE</text>
<text top="205" left="233" width="91" height="10" font="14">RECOMMENDATION</text>
<text top="241" left="97" width="3" height="9" font="5">I</text>
<text top="241" left="160" width="21" height="9" font="5">B-NR</text>
<text top="229" left="233" width="161" height="11" font="12">In patients treated with DAPT, a</text>
<text top="244" left="233" width="136" height="11" font="12">daily aspirin dose of 81 mg</text>
<text top="260" left="233" width="143" height="11" font="12">(range, 75 mg to 100 mg) is</text>
<text top="275" left="233" width="71" height="11" font="12">recommended</text>
<text top="275" left="308" width="17" height="11" font="4"><a href="1082.full.html#25">(56</a></text>
<text top="273" left="325" width="56" height="15" font="4"><a href="1082.full.html#25">–60,75–78)</a></text>
<text top="275" left="381" width="3" height="11" font="12">.</text>
<text top="54" left="63" width="132" height="7" font="7">J A C C V O L . 6 8 , N O . 1 0 , 2 0 1 6</text>
<text top="54" left="705" width="52" height="9" font="14">Levine et al.</text>
<text top="69" left="63" width="117" height="7" font="7">S E P T E M B E R 6 , 2 0 1 6 : 1 0 8 2</text>
<text top="67" left="182" width="17" height="10" font="7">– 1 1 5</text>
<text top="69" left="514" width="243" height="9" font="14">Focused Update on Duration of Dual Antiplatelet Therapy</text>
<text top="53" left="788" width="19" height="9" font="5">1091</text>
</page>
<page number="11" position="absolute" top="0" left="0" height="1160" width="864">
	<fontspec id="27" size="8" family="Times" color="#327eb1"/>
	<fontspec id="28" size="3" family="Times" color="#000000"/>
<text top="655" left="108" width="333" height="12" font="2">81 mg, this maintenance dose is recommended in patients</text>
<text top="673" left="108" width="333" height="12" font="2">with CAD treated with DAPT. The ongoing ADAPTABLE</text>
<text top="691" left="108" width="316" height="12" font="2">(Aspirin Dosing: A Patient-Centric Trial Assessing Bene</text>
<text top="689" left="423" width="18" height="15" font="2">ﬁts</text>
<text top="709" left="108" width="333" height="12" font="2">and Long-term Effectiveness) trial, which the present</text>
<text top="727" left="108" width="333" height="12" font="2">writing group endorses, is expected to yield additional in-</text>
<text top="745" left="108" width="333" height="12" font="2">formation on optimal aspirin dosing in patients with</text>
<text top="763" left="108" width="213" height="12" font="2">atherosclerotic cardiovascular disease</text>
<text top="763" left="324" width="22" height="12" font="4"><a href="1082.full.html#25">(83)</a></text>
<text top="763" left="346" width="3" height="12" font="2"><a href="1082.full.html#25">.</a></text>
<text top="791" left="108" width="173" height="11" font="12">3.7. Triple Therapy (Aspirin, P2Y</text>
<text top="796" left="281" width="8" height="8" font="13">12</text>
<text top="791" left="293" width="71" height="11" font="12">Inhibitor, and</text>
<text top="809" left="131" width="104" height="11" font="12">Oral Anticoagulant)</text>
<text top="830" left="108" width="289" height="12" font="2">The recommended management of patients on</text>
<text top="828" left="404" width="37" height="15" font="2">“triple</text>
<text top="848" left="108" width="44" height="12" font="2">therapy</text>
<text top="846" left="152" width="83" height="15" font="2">” (aspirin, P2Y</text>
<text top="853" left="236" width="9" height="8" font="7">12</text>
<text top="848" left="248" width="193" height="12" font="2">inhibitor, and oral anticoagulant)</text>
<text top="866" left="108" width="333" height="12" font="2">is beyond the scope of this focused update. However, a</text>
<text top="884" left="108" width="333" height="12" font="2">brief discussion of the topic is included for the purposes</text>
<text top="902" left="108" width="241" height="12" font="2">of completeness and end-user education.</text>
<text top="494" left="483" width="318" height="12" font="2">Compared with oral anticoagulation therapy alone, the</text>
<text top="512" left="468" width="333" height="12" font="2">addition of DAPT to oral anticoagulant therapy results in</text>
<text top="530" left="468" width="333" height="12" font="2">at least a 2- to 3-fold increase in bleeding complications</text>
<text top="548" left="468" width="19" height="12" font="4"><a href="1082.full.html#25">(84</a></text>
<text top="546" left="487" width="23" height="15" font="4"><a href="1082.full.html#25">–87)</a></text>
<text top="548" left="511" width="290" height="12" font="2"><a href="1082.full.html#25">. </a>Discussion and recommendations on triple ther-</text>
<text top="566" left="468" width="333" height="12" font="2">apy are provided in the 2014 ACC/AHA NSTE-ACS guide-</text>
<text top="584" left="468" width="22" height="12" font="2">line</text>
<text top="584" left="493" width="21" height="12" font="4"><a href="1082.full.html#23">(14)</a></text>
<text top="584" left="514" width="257" height="12" font="2">, a 2014 European joint consensus document</text>
<text top="584" left="774" width="23" height="12" font="4"><a href="1082.full.html#25">(88)</a></text>
<text top="584" left="798" width="3" height="12" font="2"><a href="1082.full.html#25">,</a></text>
<text top="602" left="468" width="231" height="12" font="2">a North American consensus document</text>
<text top="602" left="704" width="22" height="12" font="4"><a href="1082.full.html#25">(85)</a></text>
<text top="602" left="726" width="75" height="12" font="2"><a href="1082.full.html#25">, </a>and several</text>
<text top="620" left="468" width="333" height="12" font="2">comprehensive state-of-the-art papers and reviews. A</text>
<text top="638" left="468" width="333" height="12" font="2">partial summary and synthesis of these recommendations</text>
<text top="656" left="468" width="69" height="12" font="2">are given in</text>
<text top="656" left="541" width="42" height="11" font="4"><a href="1082.full.html#11">Table 6</a></text>
<text top="656" left="583" width="3" height="12" font="2">.</text>
<text top="674" left="483" width="116" height="12" font="2">One trial comparing</text>
<text top="672" left="604" width="198" height="15" font="2">“double therapy” (oral anticoagu-</text>
<text top="692" left="468" width="333" height="12" font="2">lant plus clopidogrel) with triple therapy (oral anticoag-</text>
<text top="709" left="468" width="223" height="12" font="2">ulant plus aspirin and clopidogrel)</text>
<text top="709" left="700" width="23" height="12" font="4"><a href="1082.full.html#25">(89)</a></text>
<text top="709" left="732" width="69" height="12" font="2">and 1 trial</text>
<text top="727" left="468" width="333" height="12" font="2">comparing differing durations of triple therapy have been</text>
<text top="745" left="468" width="57" height="12" font="2">published</text>
<text top="745" left="529" width="23" height="12" font="4"><a href="1082.full.html#25">(90)</a></text>
<text top="745" left="552" width="249" height="12" font="2">. Several more similar trials comparing oral</text>
<text top="763" left="468" width="193" height="12" font="2">anticoagulant therapy plus P2Y</text>
<text top="768" left="662" width="9" height="8" font="7">12</text>
<text top="763" left="678" width="123" height="12" font="2">inhibitor with triple</text>
<text top="781" left="468" width="121" height="12" font="2">therapy are ongoing.</text>
<text top="806" left="468" width="320" height="16" font="15">4. PERCUTANEOUS CORONARY INTERVENTION</text>
<text top="844" left="468" width="333" height="11" font="12">4.1. Duration of DAPT in Patients With SIHD Treated With PCI:</text>
<text top="862" left="491" width="97" height="11" font="12">Recommendations</text>
<text top="884" left="468" width="20" height="12" font="2">See</text>
<text top="884" left="491" width="235" height="12" font="4"><a href="http://jaccjacc.acc.org/Clinical_Document/DAPT_Data_Supplement_1.pdf">Online Data Supplements 1 to 3 and 6 to 9</a></text>
<text top="884" left="730" width="72" height="12" font="2">for evidence</text>
<text top="902" left="468" width="210" height="12" font="2">supporting these recommendations.</text>
<text top="163" left="115" width="48" height="10" font="16">T A B L E 4</text>
<text top="149" left="179" width="253" height="10" font="17">Clinical and Procedural Factors Associated With</text>
<text top="163" left="179" width="214" height="10" font="17">Increased Ischemic Risk (Including Stent</text>
<text top="177" left="179" width="208" height="10" font="17">Thrombosis) or Increased Bleeding Risk</text>
<text top="177" left="391" width="17" height="10" font="27"><a href="1082.full.html#25">(62</a></text>
<text top="176" left="409" width="23" height="14" font="27"><a href="1082.full.html#25">–70)</a></text>
<text top="202" left="108" width="175" height="9" font="14">Increased Ischemic Risk/Risk of Stent</text>
<text top="214" left="108" width="145" height="9" font="14">Thrombosis (may favor longer-</text>
<text top="226" left="108" width="72" height="9" font="14">duration DAPT)</text>
<text top="214" left="296" width="137" height="9" font="14">Increased Bleeding Risk (may</text>
<text top="226" left="296" width="138" height="9" font="14">favor shorter-duration DAPT)</text>
<text top="245" left="108" width="98" height="9" font="14">Increased ischemic risk</text>
<text top="245" left="289" width="103" height="9" font="14">History of prior bleeding</text>
<text top="264" left="117" width="59" height="9" font="14">Advanced age</text>
<text top="264" left="289" width="112" height="9" font="14">Oral anticoagulant therapy</text>
<text top="283" left="117" width="72" height="9" font="14">ACS presentation</text>
<text top="283" left="289" width="47" height="9" font="14">Female sex</text>
<text top="302" left="117" width="75" height="9" font="14">Multiple prior MIs</text>
<text top="302" left="289" width="58" height="9" font="14">Advanced age</text>
<text top="322" left="117" width="61" height="9" font="14">Extensive CAD</text>
<text top="322" left="289" width="73" height="9" font="14">Low body weight</text>
<text top="341" left="117" width="72" height="9" font="14">Diabetes mellitus</text>
<text top="341" left="289" width="18" height="9" font="14">CKD</text>
<text top="360" left="117" width="18" height="9" font="14">CKD</text>
<text top="360" left="289" width="72" height="9" font="14">Diabetes mellitus</text>
<text top="379" left="108" width="147" height="9" font="14">Increased risk of stent thrombosis</text>
<text top="379" left="289" width="31" height="9" font="14">Anemia</text>
<text top="398" left="117" width="72" height="9" font="14">ACS presentation</text>
<text top="398" left="289" width="139" height="9" font="14">Chronic steroid or NSAID therapy</text>
<text top="418" left="117" width="72" height="9" font="14">Diabetes mellitus</text>
<text top="437" left="117" width="135" height="9" font="14">Left ventricular ejection fraction</text>
<text top="435" left="255" width="28" height="12" font="14">&lt;40%</text>
<text top="456" left="117" width="147" height="9" font="14">First-generation drug-eluting stent</text>
<text top="475" left="117" width="73" height="9" font="14">Stent undersizing</text>
<text top="494" left="117" width="99" height="9" font="14">Stent underdeployment</text>
<text top="514" left="117" width="87" height="9" font="14">Small stent diameter</text>
<text top="533" left="117" width="86" height="9" font="14">Greater stent length</text>
<text top="552" left="117" width="74" height="9" font="14">Bifurcation stents</text>
<text top="571" left="117" width="78" height="9" font="14">In-stent restenosis</text>
<text top="595" left="108" width="333" height="8" font="5">ACS indicates acute coronary syndrome; CAD, coronary artery disease; CKD, chronic</text>
<text top="607" left="108" width="333" height="8" font="5">kidney disease; DAPT, dual antiplatelet therapy; MI, myocardial infarction; and NSAID,</text>
<text top="619" left="108" width="76" height="8" font="5">nonsteroidal anti-in</text>
<text top="617" left="183" width="67" height="11" font="5">ﬂammatory drug.</text>
<text top="149" left="476" width="47" height="10" font="16">T A B L E 5</text>
<text top="149" left="540" width="144" height="10" font="17">Factors Used to Calculate a</text>
<text top="147" left="688" width="72" height="14" font="17">“DAPT Score”</text>
<text top="173" left="468" width="38" height="9" font="14">Variable</text>
<text top="173" left="772" width="29" height="9" font="14">Points</text>
<text top="192" left="468" width="16" height="9" font="14">Age</text>
<text top="191" left="487" width="25" height="12" font="14">$75 y</text>
<text top="192" left="782" width="9" height="9" font="14">-2</text>
<text top="212" left="468" width="42" height="9" font="14">Age 65 to</text>
<text top="210" left="513" width="25" height="12" font="14">&lt;75 y</text>
<text top="212" left="783" width="8" height="9" font="14">-1</text>
<text top="231" left="468" width="16" height="9" font="14">Age</text>
<text top="229" left="487" width="26" height="12" font="14">&lt;65 y</text>
<text top="231" left="785" width="6" height="9" font="14">0</text>
<text top="250" left="468" width="104" height="9" font="14">Current cigarette smoker</text>
<text top="250" left="787" width="4" height="9" font="14">1</text>
<text top="269" left="468" width="72" height="9" font="14">Diabetes mellitus</text>
<text top="269" left="787" width="4" height="9" font="14">1</text>
<text top="288" left="468" width="77" height="9" font="14">MI at presentation</text>
<text top="288" left="787" width="4" height="9" font="14">1</text>
<text top="308" left="468" width="84" height="9" font="14">Prior PCI or prior MI</text>
<text top="308" left="787" width="4" height="9" font="14">1</text>
<text top="327" left="468" width="62" height="9" font="14">Stent diameter</text>
<text top="325" left="533" width="31" height="12" font="14">&lt;3 mm</text>
<text top="327" left="787" width="4" height="9" font="14">1</text>
<text top="346" left="468" width="97" height="9" font="14">Paclitaxel-eluting stent</text>
<text top="346" left="787" width="4" height="9" font="14">1</text>
<text top="365" left="468" width="53" height="9" font="14">CHF or LVEF</text>
<text top="364" left="524" width="27" height="12" font="14">&lt;30%</text>
<text top="365" left="786" width="5" height="9" font="14">2</text>
<text top="385" left="468" width="105" height="9" font="14">Saphenous vein graft PCI</text>
<text top="385" left="786" width="5" height="9" font="14">2</text>
<text top="408" left="468" width="38" height="8" font="5">A score of</text>
<text top="407" left="508" width="293" height="11" font="5">$2 is associated with a favorable beneﬁt/risk ratio for prolonged DAPT while</text>
<text top="420" left="468" width="42" height="8" font="5">a score of</text>
<text top="419" left="515" width="286" height="11" font="5">&lt;2 is associated with an unfavorable beneﬁt/risk ratio. Adapted with</text>
<text top="432" left="468" width="102" height="8" font="5">permission from Yeh et al.</text>
<text top="432" left="573" width="15" height="8" font="6"><a href="1082.full.html#25">(61)</a></text>
<text top="432" left="588" width="2" height="8" font="5"><a href="1082.full.html#25">.</a></text>
<text top="446" left="476" width="325" height="8" font="5">CHF indicates congestive heart failure; DAPT, dual antiplatelet therapy; LVEF, left</text>
<text top="458" left="468" width="333" height="8" font="5">ventricular ejection fraction; MI, myocardial infarction; and PCI, percutaneous coronary</text>
<text top="470" left="468" width="49" height="8" font="5">intervention.</text>
<text top="941" left="115" width="48" height="10" font="16">T A B L E 6</text>
<text top="934" left="179" width="548" height="10" font="17">Summary and Synthesis of Guideline, Expert Consensus Documents, and Comprehensive Review Article</text>
<text top="948" left="179" width="423" height="10" font="17">Recommendations on the Management of Patients Treated With Triple Therapy</text>
<text top="948" left="606" width="50" height="10" font="27"><a href="1082.full.html#23">(14,88,91</a></text>
<text top="946" left="656" width="23" height="14" font="27"><a href="1082.full.html#23">–93)</a></text>
<text top="970" left="108" width="319" height="9" font="14">Assess ischemic and bleeding risks using validated risk predictors (e.g., CHA</text>
<text top="974" left="426" width="4" height="6" font="18">2</text>
<text top="970" left="430" width="11" height="9" font="14">DS</text>
<text top="974" left="441" width="4" height="6" font="18">2</text>
<text top="970" left="445" width="78" height="9" font="14">-VASc, HAS-BLED)</text>
<text top="989" left="108" width="594" height="9" font="14">Keep triple therapy duration as short as possible; dual therapy only (oral anticoagulant and clopidogrel) may be considered in select patients</text>
<text top="1008" left="108" width="119" height="9" font="14">Consider a target INR of 2.0</text>
<text top="1007" left="227" width="112" height="12" font="14">–2.5 when warfarin is used</text>
<text top="1028" left="108" width="93" height="9" font="14">Clopidogrel is the P2Y</text>
<text top="1032" left="201" width="7" height="6" font="18">12</text>
<text top="1028" left="211" width="76" height="9" font="14">inhibitor of choice</text>
<text top="1047" left="108" width="63" height="9" font="14">Use low-dose (</text>
<text top="1045" left="171" width="97" height="12" font="14">#100 mg daily) aspirin</text>
<text top="1066" left="108" width="669" height="9" font="14">PPIs should be used in patients with a history of gastrointestinal bleeding and are reasonable to use in patients with increased risk of gastrointestinal bleeding</text>
<text top="1090" left="108" width="17" height="8" font="5">CHA</text>
<text top="1093" left="124" width="3" height="6" font="28">2</text>
<text top="1090" left="128" width="10" height="8" font="5">DS</text>
<text top="1093" left="138" width="3" height="6" font="28">2</text>
<text top="1090" left="142" width="226" height="8" font="5">-VASc indicates congestive heart failure, hypertension, age</text>
<text top="1088" left="370" width="432" height="11" font="5">$75 years (doubled), diabetes mellitus, prior stroke or transient ischemic attack or thromboembolism (doubled),</text>
<text top="1102" left="108" width="93" height="8" font="5">vascular disease, age 65</text>
<text top="1100" left="200" width="601" height="11" font="5">–74 years, sex category; HAS-BLED, hypertension, abnormal renal/liver function, stroke, bleeding history or predisposition, labile INR, elderly, drugs/alcohol</text>
<text top="1114" left="108" width="328" height="8" font="5">concomitantly; INR, international normalized ratio; and PPIs, proton pump inhibitors.</text>
<text top="53" left="108" width="52" height="9" font="14">Levine et al.</text>
<text top="54" left="670" width="132" height="7" font="7">J A C C V O L . 6 8 , N O . 1 0 , 2 0 1 6</text>
<text top="68" left="108" width="243" height="9" font="14">Focused Update on Duration of Dual Antiplatelet Therapy</text>
<text top="69" left="665" width="117" height="7" font="7">S E P T E M B E R 6 , 2 0 1 6 : 1 0 8 2</text>
<text top="67" left="784" width="17" height="10" font="7">– 1 1 5</text>
<text top="53" left="57" width="20" height="9" font="5">1092</text>
</page>
<page number="12" position="absolute" top="0" left="0" height="1160" width="864">
<text top="542" left="63" width="330" height="11" font="12">4.2. Duration of DAPT in Patients With ACS Treated With PCI:</text>
<text top="560" left="87" width="97" height="11" font="12">Recommendations</text>
<text top="581" left="63" width="20" height="12" font="2">See</text>
<text top="581" left="85" width="171" height="12" font="4"><a href="http://jaccjacc.acc.org/Clinical_Document/DAPT_Data_Supplement_1.pdf">Online Data Supplements 1 to 9</a></text>
<text top="581" left="259" width="137" height="12" font="2">for evidence supporting</text>
<text top="599" left="63" width="142" height="12" font="2">these recommendations.</text>
<text top="149" left="63" width="448" height="11" font="20">Recommendations for Duration of DAPT in Patients With SIHD Treated With PCI</text>
<text top="190" left="89" width="19" height="10" font="14">COR</text>
<text top="190" left="161" width="18" height="10" font="14">LOE</text>
<text top="190" left="233" width="96" height="10" font="14">RECOMMENDATIONS</text>
<text top="227" left="97" width="3" height="9" font="5">I</text>
<text top="227" left="168" width="6" height="9" font="5">A</text>
<text top="215" left="233" width="351" height="11" font="12">In patients with SIHD treated with DAPT after BMS implantation, P2Y</text>
<text top="219" left="584" width="8" height="7" font="13">12</text>
<text top="215" left="596" width="205" height="11" font="12">inhibitor therapy (clopidogrel) should be</text>
<text top="230" left="233" width="163" height="11" font="12">given for a minimum of 1 month</text>
<text top="230" left="400" width="38" height="11" font="4"><a href="1082.full.html#25">(94,95)</a></text>
<text top="230" left="438" width="3" height="11" font="12">.</text>
<text top="274" left="97" width="3" height="9" font="5">I</text>
<text top="274" left="158" width="15" height="9" font="5">B-R</text>
<text top="273" left="175" width="8" height="6" font="28">SR</text>
<text top="262" left="233" width="349" height="11" font="12">In patients with SIHD treated with DAPT after DES implantation, P2Y</text>
<text top="267" left="582" width="8" height="7" font="13">12</text>
<text top="262" left="594" width="205" height="11" font="12">inhibitor therapy (clopidogrel) should be</text>
<text top="277" left="233" width="139" height="11" font="12">given for at least 6 months</text>
<text top="277" left="375" width="97" height="11" font="4"><a href="1082.full.html#24">(17,18,21,30,96,97)</a></text>
<text top="277" left="472" width="3" height="11" font="12">.</text>
<text top="323" left="97" width="3" height="9" font="5">I</text>
<text top="323" left="160" width="21" height="9" font="5">B-NR</text>
<text top="311" left="233" width="525" height="11" font="12">In patients treated with DAPT, a daily aspirin dose of 81 mg (range, 75 mg to 100 mg) is recommended</text>
<text top="326" left="233" width="17" height="11" font="4"><a href="1082.full.html#25">(56</a></text>
<text top="324" left="250" width="56" height="15" font="4"><a href="1082.full.html#25">–60,75–78)</a></text>
<text top="326" left="306" width="3" height="11" font="12">.</text>
<text top="372" left="94" width="10" height="9" font="5">IIb</text>
<text top="372" left="162" width="6" height="9" font="5">A</text>
<text top="370" left="171" width="8" height="6" font="28">SR</text>
<text top="359" left="233" width="548" height="11" font="12">In patients with SIHD treated with DAPT after BMS or DES implantation who have tolerated DAPT without a</text>
<text top="375" left="233" width="557" height="11" font="12">bleeding complication and who are not at high bleeding risk (e.g., prior bleeding on DAPT, coagulopathy, oral</text>
<text top="390" left="233" width="574" height="11" font="12">anticoagulant use), continuation of DAPT with clopidogrel for longer than 1 month in patients treated with BMS or</text>
<text top="405" left="233" width="355" height="11" font="12">longer than 6 months in patients treated with DES may be reasonable</text>
<text top="405" left="592" width="47" height="11" font="4"><a href="1082.full.html#24">(16,22,24</a></text>
<text top="403" left="639" width="56" height="15" font="4"><a href="1082.full.html#24">–26,30,50)</a></text>
<text top="405" left="695" width="3" height="11" font="12"><a href="1082.full.html#24">.</a></text>
<text top="451" left="94" width="10" height="9" font="5">IIb</text>
<text top="451" left="160" width="20" height="9" font="5">C-LD</text>
<text top="439" left="233" width="574" height="11" font="12">In patients with SIHD treated with DAPT after DES implantation who develop a high risk of bleeding (e.g., treatment</text>
<text top="454" left="233" width="574" height="11" font="12">with oral anticoagulant therapy), are at high risk of severe bleeding complication (e.g., major intracranial surgery),</text>
<text top="469" left="233" width="80" height="11" font="12">or develop signi</text>
<text top="467" left="313" width="224" height="15" font="12">ﬁcant overt bleeding, discontinuation of P2Y</text>
<text top="474" left="537" width="8" height="7" font="13">12</text>
<text top="469" left="549" width="258" height="11" font="12">inhibitor therapy after 3 months may be reasonable</text>
<text top="485" left="233" width="83" height="11" font="4"><a href="1082.full.html#24">(19,20,34,36,37)</a></text>
<text top="485" left="316" width="3" height="11" font="12">.</text>
<text top="510" left="63" width="120" height="8" font="5">SR indicates systematic review.</text>
<text top="623" left="63" width="443" height="11" font="20">Recommendations for Duration of DAPT in Patients With ACS Treated With PCI</text>
<text top="664" left="89" width="19" height="10" font="14">COR</text>
<text top="664" left="161" width="18" height="10" font="14">LOE</text>
<text top="664" left="233" width="96" height="10" font="14">RECOMMENDATIONS</text>
<text top="701" left="97" width="3" height="9" font="5">I</text>
<text top="701" left="163" width="15" height="9" font="5">B-R</text>
<text top="689" left="233" width="480" height="11" font="12">In patients with ACS (NSTE-ACS or STEMI) treated with DAPT after BMS or DES implantation, P2Y</text>
<text top="694" left="713" width="8" height="7" font="13">12</text>
<text top="689" left="724" width="83" height="11" font="12">inhibitor therapy</text>
<text top="704" left="233" width="386" height="11" font="12">(clopidogrel, prasugrel, or ticagrelor) should be given for at least 12 months</text>
<text top="704" left="623" width="32" height="11" font="4"><a href="1082.full.html#24">(16,50</a></text>
<text top="702" left="655" width="72" height="15" font="4"><a href="1082.full.html#24">–55,72,96–98)</a></text>
<text top="704" left="728" width="3" height="11" font="12"><a href="1082.full.html#24">.</a></text>
<text top="749" left="97" width="3" height="9" font="5">I</text>
<text top="749" left="160" width="21" height="9" font="5">B-NR</text>
<text top="736" left="233" width="525" height="11" font="12">In patients treated with DAPT, a daily aspirin dose of 81 mg (range, 75 mg to 100 mg) is recommended</text>
<text top="751" left="233" width="17" height="11" font="4"><a href="1082.full.html#25">(56</a></text>
<text top="749" left="250" width="56" height="15" font="4"><a href="1082.full.html#25">–60,75–78)</a></text>
<text top="751" left="306" width="3" height="11" font="12">.</text>
<text top="797" left="94" width="10" height="9" font="5">IIa</text>
<text top="797" left="163" width="15" height="9" font="5">B-R</text>
<text top="785" left="233" width="574" height="11" font="12">In patients with ACS (NSTE-ACS or STEMI) treated with DAPT after coronary stent implantation, it is reasonable to</text>
<text top="800" left="233" width="321" height="11" font="12">use ticagrelor in preference to clopidogrel for maintenance P2Y</text>
<text top="805" left="554" width="8" height="7" font="13">12</text>
<text top="800" left="566" width="84" height="11" font="12">inhibitor therapy</text>
<text top="800" left="654" width="35" height="11" font="4"><a href="1082.full.html#24">(53,72)</a></text>
<text top="800" left="689" width="3" height="11" font="12"><a href="1082.full.html#24">.</a></text>
<text top="846" left="94" width="10" height="9" font="5">IIa</text>
<text top="846" left="163" width="15" height="9" font="5">B-R</text>
<text top="834" left="233" width="574" height="11" font="12">In patients with ACS (NSTE-ACS or STEMI) treated with DAPT after coronary stent implantation who are not at high</text>
<text top="849" left="233" width="574" height="11" font="12">risk for bleeding complications and who do not have a history of stroke or TIA, it is reasonable to choose prasugrel</text>
<text top="864" left="233" width="190" height="11" font="12">over clopidogrel for maintenance P2Y</text>
<text top="869" left="424" width="8" height="7" font="13">12</text>
<text top="864" left="435" width="84" height="11" font="12">inhibitor therapy</text>
<text top="864" left="523" width="36" height="11" font="4"><a href="1082.full.html#24">(54,55)</a></text>
<text top="864" left="559" width="3" height="11" font="12"><a href="1082.full.html#24">.</a></text>
<text top="910" left="94" width="10" height="9" font="5">IIb</text>
<text top="910" left="162" width="6" height="9" font="5">A</text>
<text top="908" left="171" width="8" height="6" font="28">SR</text>
<text top="898" left="233" width="557" height="11" font="12">In patients with ACS (NSTE-ACS or STEMI) treated with coronary stent implantation who have tolerated DAPT</text>
<text top="913" left="233" width="574" height="11" font="12">without a bleeding complication and who are not at high bleeding risk (e.g., prior bleeding on DAPT, coagulopathy,</text>
<text top="928" left="233" width="574" height="11" font="12">oral anticoagulant use), continuation of DAPT (clopidogrel, prasugrel, or ticagrelor) for longer than 12 months may</text>
<text top="943" left="233" width="70" height="11" font="12">be reasonable</text>
<text top="943" left="307" width="31" height="11" font="4"><a href="1082.full.html#24">(16,22</a></text>
<text top="941" left="338" width="149" height="15" font="4"><a href="1082.full.html#24">–26,28,30,40,41,43,53,54,72)</a></text>
<text top="943" left="487" width="3" height="11" font="12">.</text>
<text top="989" left="94" width="10" height="9" font="5">IIb</text>
<text top="989" left="160" width="20" height="9" font="5">C-LD</text>
<text top="977" left="233" width="574" height="11" font="12">In patients with ACS treated with DAPT after DES implantation who develop a high risk of bleeding (e.g., treatment</text>
<text top="992" left="233" width="574" height="11" font="12">with oral anticoagulant therapy), are at high risk of severe bleeding complication (e.g., major intracranial surgery),</text>
<text top="1008" left="233" width="80" height="11" font="12">or develop signi</text>
<text top="1005" left="313" width="223" height="15" font="12">ﬁcant overt bleeding, discontinuation of P2Y</text>
<text top="1012" left="537" width="8" height="7" font="13">12</text>
<text top="1008" left="548" width="259" height="11" font="12">inhibitor therapy after 6 months may be reasonable</text>
<text top="1023" left="233" width="14" height="11" font="4"><a href="1082.full.html#24">(17</a></text>
<text top="1021" left="247" width="67" height="15" font="4"><a href="1082.full.html#24">–21,34,36,37)</a></text>
<text top="1023" left="314" width="3" height="11" font="12">.</text>
<text top="1069" left="81" width="35" height="9" font="5">III: Harm</text>
<text top="1069" left="163" width="15" height="9" font="5">B-R</text>
<text top="1056" left="233" width="431" height="11" font="12">Prasugrel should not be administered to patients with a prior history of stroke or TIA</text>
<text top="1056" left="668" width="21" height="11" font="4"><a href="1082.full.html#24">(54)</a></text>
<text top="1056" left="689" width="3" height="11" font="12"><a href="1082.full.html#24">.</a></text>
<text top="1112" left="63" width="120" height="8" font="5">SR indicates systematic review.</text>
<text top="54" left="63" width="132" height="7" font="7">J A C C V O L . 6 8 , N O . 1 0 , 2 0 1 6</text>
<text top="54" left="705" width="52" height="9" font="14">Levine et al.</text>
<text top="69" left="63" width="117" height="7" font="7">S E P T E M B E R 6 , 2 0 1 6 : 1 0 8 2</text>
<text top="67" left="182" width="17" height="10" font="7">– 1 1 5</text>
<text top="69" left="514" width="243" height="9" font="14">Focused Update on Duration of Dual Antiplatelet Therapy</text>
<text top="53" left="787" width="20" height="9" font="5">1093</text>
</page>
<page number="13" position="absolute" top="0" left="0" height="1160" width="864">
<text top="143" left="108" width="330" height="11" font="12">4.3. Duration of DAPT in Patients With SIHD and ACS Treated</text>
<text top="161" left="132" width="46" height="11" font="12">With PCI</text>
<text top="182" left="108" width="333" height="12" font="2">DAPT in patients treated with coronary stent implantation</text>
<text top="200" left="108" width="333" height="12" font="2">reduces the risk of stent thrombosis and ischemic events</text>
<text top="218" left="108" width="92" height="12" font="4"><a href="1082.full.html#24">(50,51,94,95,99)</a></text>
<text top="218" left="206" width="4" height="12" font="2">(</text>
<text top="218" left="210" width="114" height="12" font="4"><a href="http://jaccjacc.acc.org/Clinical_Document/DAPT_Data_Supplement_1.pdf">Data Supplement 7</a></text>
<text top="218" left="325" width="116" height="12" font="2"><a href="http://jaccjacc.acc.org/Clinical_Document/DAPT_Data_Supplement_1.pdf">). </a>The risk of stent</text>
<text top="236" left="108" width="333" height="12" font="2">thrombosis in patients treated with a bare metal stent</text>
<text top="254" left="108" width="138" height="12" font="2">(BMS) is greatest in the</text>
<text top="252" left="250" width="191" height="15" font="2">ﬁrst days to weeks after implan-</text>
<text top="272" left="108" width="34" height="12" font="2">tation</text>
<text top="272" left="149" width="47" height="12" font="4"><a href="1082.full.html#26">(99,100)</a></text>
<text top="272" left="196" width="245" height="12" font="2">. Cessation of DAPT during this period,</text>
<text top="290" left="108" width="333" height="12" font="2">particularly in cases of patients undergoing surgery, is</text>
<text top="308" left="108" width="333" height="12" font="2">associated with an unacceptable rate of often catastrophic</text>
<text top="326" left="108" width="98" height="12" font="2">stent thrombosis</text>
<text top="326" left="209" width="22" height="12" font="4"><a href="1082.full.html#26">(101</a></text>
<text top="324" left="232" width="29" height="15" font="4"><a href="1082.full.html#26">–103)</a></text>
<text top="326" left="261" width="180" height="12" font="2">. Thus, a minimum duration of</text>
<text top="344" left="108" width="333" height="12" font="2">DAPT of 1 month is generally recommended for patients</text>
<text top="362" left="108" width="333" height="12" font="2">treated with BMS. In current practice, BMS are generally</text>
<text top="380" left="108" width="333" height="12" font="2">reserved for patients who cannot receive DAPT for more</text>
<text top="143" left="468" width="26" height="12" font="2">than</text>
<text top="141" left="502" width="299" height="15" font="2">z1 month for reasons of active bleeding, non-</text>
<text top="161" left="468" width="296" height="12" font="2">adherence to medical therapy, or planned surgery.</text>
<text top="178" left="483" width="319" height="12" font="2">The recommended minimum duration of DAPT in pa-</text>
<text top="196" left="468" width="110" height="12" font="2">tients treated with</text>
<text top="195" left="583" width="218" height="15" font="2">ﬁrst-generation DES, based primarily</text>
<text top="214" left="468" width="333" height="12" font="2">on observational data and one subgroup analysis, has</text>
<text top="232" left="468" width="96" height="12" font="2">been 12 months</text>
<text top="232" left="570" width="95" height="12" font="4"><a href="1082.full.html#23">(9,51,97,104,105)</a></text>
<text top="232" left="666" width="101" height="12" font="2"><a href="1082.full.html#23">. </a>Compared with</text>
<text top="230" left="774" width="27" height="15" font="2">ﬁrst-</text>
<text top="250" left="468" width="333" height="12" font="2">generation DES, currently used newer-generation DES</text>
<text top="268" left="468" width="333" height="12" font="2">have a lower risk of stent thrombosis and appear to</text>
<text top="286" left="468" width="42" height="12" font="2">require</text>
<text top="286" left="525" width="6" height="12" font="2">a</text>
<text top="286" left="547" width="41" height="12" font="2">shorter</text>
<text top="286" left="604" width="56" height="12" font="2">minimum</text>
<text top="286" left="677" width="50" height="12" font="2">duration</text>
<text top="286" left="742" width="11" height="12" font="2">of</text>
<text top="286" left="769" width="32" height="12" font="2">DAPT</text>
<text top="304" left="468" width="105" height="12" font="4"><a href="1082.full.html#24">(17,18,21,38,96,97)</a></text>
<text top="304" left="573" width="65" height="12" font="2"><a href="1082.full.html#24">. </a>Five RCTs</text>
<text top="304" left="642" width="16" height="12" font="4"><a href="1082.full.html#24">(17</a></text>
<text top="302" left="658" width="21" height="15" font="4"><a href="1082.full.html#24">–21)</a></text>
<text top="304" left="683" width="119" height="12" font="2">of primarily low-risk</text>
<text top="322" left="468" width="333" height="12" font="2">(non-ACS) patients treated with DES comparing shorter-</text>
<text top="340" left="468" width="333" height="12" font="2">duration (3 to 6 months) DAPT with 12 months of DAPT,</text>
<text top="358" left="468" width="191" height="12" font="2">as well as several meta-analyses</text>
<text top="358" left="664" width="18" height="12" font="4"><a href="1082.full.html#24">(34</a></text>
<text top="356" left="682" width="22" height="15" font="4"><a href="1082.full.html#24">–37)</a></text>
<text top="358" left="710" width="92" height="12" font="2">and an analysis</text>
<text top="376" left="468" width="67" height="12" font="2">by the ERC</text>
<text top="376" left="540" width="22" height="12" font="4"><a href="1082.full.html#24">(30)</a></text>
<text top="376" left="563" width="52" height="12" font="2"><a href="1082.full.html#24">, </a>did not</text>
<text top="374" left="621" width="181" height="15" font="2">ﬁnd an increased risk of stent</text>
<text top="421" left="125" width="45" height="11" font="22">FIGURE 2</text>
<text top="422" left="178" width="184" height="9" font="23">Treatment Algorithm for Duration of P2Y</text>
<text top="426" left="362" width="7" height="6" font="24">12</text>
<text top="422" left="373" width="206" height="9" font="23">Inhibitor Therapy in Patients Treated With PCI</text>
<text top="1002" left="125" width="213" height="9" font="14">Colors correspond to Class of Recommendation in</text>
<text top="1002" left="341" width="31" height="9" font="19"><a href="1082.full.html#4">Table 1</a></text>
<text top="1002" left="372" width="127" height="9" font="14">. Arrows at the bottom of the</text>
<text top="1000" left="503" width="280" height="12" font="14">ﬁgure denote that the optimal duration of prolonged DAPT is not</text>
<text top="1017" left="125" width="232" height="9" font="14">established. Clopidogrel is the only currently used P2Y</text>
<text top="1021" left="357" width="7" height="6" font="18">12</text>
<text top="1017" left="367" width="416" height="9" font="14">inhibitor studied in patients with SIHD undergoing PCI. Aspirin therapy is almost always continued</text>
<text top="1032" left="125" width="18" height="9" font="14">inde</text>
<text top="1030" left="143" width="636" height="12" font="14">ﬁnitely in patients with coronary artery disease. *High bleeding risk denotes those who have or develop a high risk of bleeding (e.g., treatment with</text>
<text top="1047" left="125" width="658" height="9" font="14">oral anticoagulant therapy) or are at increased risk of severe bleeding complication (e.g., major intracranial surgery). ACS indicates acute coronary syndrome;</text>
<text top="1062" left="125" width="636" height="9" font="14">BMS, bare metal stent; DAPT, dual antiplatelet therapy; DES, drug-eluting stent; PCI, percutaneous coronary intervention; and SIHD, stable ischemic</text>
<text top="1077" left="125" width="59" height="9" font="14">heart disease.</text>
<text top="53" left="108" width="52" height="9" font="14">Levine et al.</text>
<text top="54" left="670" width="132" height="7" font="7">J A C C V O L . 6 8 , N O . 1 0 , 2 0 1 6</text>
<text top="68" left="108" width="243" height="9" font="14">Focused Update on Duration of Dual Antiplatelet Therapy</text>
<text top="69" left="665" width="117" height="7" font="7">S E P T E M B E R 6 , 2 0 1 6 : 1 0 8 2</text>
<text top="67" left="784" width="17" height="10" font="7">– 1 1 5</text>
<text top="53" left="57" width="21" height="9" font="5">1094</text>
</page>
<page number="14" position="absolute" top="0" left="0" height="1160" width="864">
<text top="143" left="63" width="333" height="12" font="2">thrombosis with shorter-duration DAPT, although the</text>
<text top="161" left="63" width="333" height="12" font="2">individual trials were underpowered to detect such a</text>
<text top="178" left="63" width="68" height="12" font="2">difference (</text>
<text top="178" left="131" width="153" height="12" font="4"><a href="http://jaccjacc.acc.org/Clinical_Document/DAPT_Data_Supplement_1.pdf">Data Supplements 1 and 3</a></text>
<text top="178" left="284" width="112" height="12" font="2">). Therefore, in pa-</text>
<text top="196" left="63" width="333" height="12" font="2">tients with SIHD treated with DES, the minimum recom-</text>
<text top="214" left="63" width="333" height="12" font="2">mended duration of DAPT has been decreased from 12 to 6</text>
<text top="232" left="63" width="47" height="12" font="2">months.</text>
<text top="250" left="78" width="138" height="12" font="2">The PCI-CURE analysis</text>
<text top="250" left="222" width="20" height="12" font="4"><a href="1082.full.html#24">(51)</a></text>
<text top="250" left="249" width="147" height="12" font="2">of patients in the CURE</text>
<text top="268" left="63" width="333" height="12" font="2">(Clopidogrel in Unstable Angina to Prevent Recurrent</text>
<text top="286" left="63" width="71" height="12" font="2">Events) trial</text>
<text top="286" left="137" width="21" height="12" font="4"><a href="1082.full.html#24">(52)</a></text>
<text top="286" left="162" width="234" height="12" font="2">demonstrated that treatment with DAPT</text>
<text top="304" left="63" width="333" height="12" font="2">for up to 12 months in patients with NSTE-ACS treated</text>
<text top="322" left="63" width="333" height="12" font="2">with BMS reduced ischemic events compared with aspirin</text>
<text top="340" left="63" width="88" height="12" font="2">monotherapy (</text>
<text top="340" left="151" width="116" height="12" font="4"><a href="http://jaccjacc.acc.org/Clinical_Document/DAPT_Data_Supplement_1.pdf">Data Supplement 4</a></text>
<text top="340" left="267" width="129" height="12" font="2">). Based primarily on</text>
<text top="358" left="63" width="333" height="12" font="2">the CURE trial and PCI-CURE analyses, the prior recom-</text>
<text top="376" left="63" width="333" height="12" font="2">mendation that patients with NSTE-ACS treated with</text>
<text top="394" left="63" width="333" height="12" font="2">coronary stent implantation be treated with DAPT for at</text>
<text top="412" left="63" width="333" height="12" font="2">least 12 months is continued in this update and has been</text>
<text top="430" left="63" width="333" height="12" font="2">extrapolated to patients with STEMI treated with PCI as</text>
<text top="447" left="63" width="333" height="12" font="2">well, on the basis of the consideration that NSTE-ACS and</text>
<text top="465" left="63" width="229" height="12" font="2">STEMI are part of the spectrum of ACS.</text>
<text top="483" left="78" width="87" height="12" font="2">As detailed in</text>
<text top="483" left="172" width="56" height="12" font="4"><a href="1082.full.html#6">Section 2</a></text>
<text top="483" left="228" width="168" height="12" font="2">, treatment with prolonged</text>
<text top="501" left="63" width="16" height="12" font="2">(or</text>
<text top="499" left="83" width="313" height="15" font="2">“extended”) DAPT beyond a minimum recommended</text>
<text top="519" left="63" width="50" height="12" font="2">duration</text>
<text top="519" left="128" width="11" height="12" font="2">of</text>
<text top="519" left="155" width="45" height="12" font="2">therapy</text>
<text top="519" left="215" width="70" height="12" font="2">necessitates</text>
<text top="519" left="300" width="6" height="12" font="2">a</text>
<text top="519" left="322" width="74" height="12" font="2">fundamental</text>
<text top="537" left="63" width="333" height="12" font="2">tradeoff between decreasing ischemic risk (e.g., MI</text>
<text top="555" left="63" width="333" height="12" font="2">and stent thrombosis) and increasing bleeding risk</text>
<text top="573" left="63" width="108" height="12" font="4"><a href="1082.full.html#24">(16,30,34,36,37,46)</a></text>
<text top="573" left="172" width="225" height="12" font="2"><a href="1082.full.html#24">. </a>Prolonged or extended DAPT for an</text>
<text top="591" left="63" width="333" height="12" font="2">additional 18 to 36 months (after an initial 6 to 12 months</text>
<text top="609" left="63" width="333" height="12" font="2">of DAPT) in patients treated with DES implantation</text>
<text top="627" left="63" width="333" height="12" font="2">results in an absolute decrease in stent thrombosis</text>
<text top="645" left="63" width="174" height="12" font="2">and ischemic complications of</text>
<text top="643" left="240" width="156" height="15" font="2">z1% to 2% and an absolute</text>
<text top="663" left="63" width="48" height="12" font="2">increase</text>
<text top="663" left="123" width="11" height="12" font="2">in</text>
<text top="663" left="147" width="50" height="12" font="2">bleeding</text>
<text top="663" left="209" width="81" height="12" font="2">complications</text>
<text top="663" left="302" width="11" height="12" font="2">of</text>
<text top="661" left="326" width="44" height="15" font="2">z1% (</text>
<text top="663" left="370" width="26" height="12" font="4"><a href="http://jaccjacc.acc.org/Clinical_Document/DAPT_Data_Supplement_1.pdf">Data</a></text>
<text top="681" left="63" width="145" height="12" font="4"><a href="http://jaccjacc.acc.org/Clinical_Document/DAPT_Data_Supplement_1.pdf">Supplements 1, 2, and 3</a></text>
<text top="681" left="208" width="4" height="12" font="2"><a href="http://jaccjacc.acc.org/Clinical_Document/DAPT_Data_Supplement_1.pdf">)</a></text>
<text top="681" left="218" width="33" height="12" font="4"><a href="1082.full.html#24">(16,22</a></text>
<text top="679" left="251" width="94" height="15" font="4"><a href="1082.full.html#24">–27,30,35–37,46)</a></text>
<text top="681" left="345" width="51" height="12" font="2"><a href="1082.full.html#24">. </a>Newer-</text>
<text top="698" left="63" width="333" height="12" font="2">generation stents, particularly everolimus-eluting stents,</text>
<text top="716" left="63" width="333" height="12" font="2">are associated with lower rates of stent thrombosis, and</text>
<text top="734" left="63" width="333" height="12" font="2">the absolute reduction in the rate of stent thrombosis</text>
<text top="752" left="63" width="333" height="12" font="2">with prolonged DAPT in patients treated with everolimus-</text>
<text top="770" left="63" width="140" height="12" font="2">eluting stents is modest</text>
<text top="770" left="207" width="41" height="12" font="4"><a href="1082.full.html#24">(39,106</a></text>
<text top="768" left="248" width="30" height="15" font="4"><a href="1082.full.html#24">–109)</a></text>
<text top="770" left="278" width="3" height="12" font="2"><a href="1082.full.html#24">.</a></text>
<text top="788" left="78" width="56" height="12" font="2">The bene</text>
<text top="786" left="134" width="262" height="15" font="2">ﬁt/risk ratio of prolonged DAPT in patients</text>
<text top="806" left="63" width="333" height="12" font="2">treated with PCI may be more favorable for those with</text>
<text top="143" left="423" width="267" height="12" font="2">prior MI (or ACS) than for those with SIHD</text>
<text top="143" left="696" width="56" height="12" font="4"><a href="1082.full.html#24">(28,41,43)</a></text>
<text top="143" left="753" width="3" height="12" font="2"><a href="1082.full.html#24">.</a></text>
<text top="161" left="423" width="333" height="12" font="2">Preliminary data suggest that in patients with a high</text>
<text top="178" left="423" width="127" height="12" font="2">DAPT score the bene</text>
<text top="177" left="550" width="206" height="15" font="2">ﬁt/risk ratio with prolonged DAPT</text>
<text top="196" left="423" width="333" height="12" font="2">may be favorable and that in those with a low DAPT score</text>
<text top="214" left="423" width="52" height="12" font="2">the bene</text>
<text top="213" left="475" width="282" height="15" font="2">ﬁt/risk ratio with prolonged DAPT is not favor-</text>
<text top="232" left="423" width="24" height="12" font="2">able</text>
<text top="232" left="451" width="21" height="12" font="4"><a href="1082.full.html#25">(61)</a></text>
<text top="232" left="472" width="284" height="12" font="2">. In patients treated with coronary stent implan-</text>
<text top="250" left="423" width="333" height="12" font="2">tation who have increased bleeding risk (e.g., oral</text>
<text top="268" left="423" width="333" height="12" font="2">anticoagulation), increased risk of severe bleeding com-</text>
<text top="286" left="423" width="300" height="12" font="2">plications (e.g., major intracranial surgery), or signi</text>
<text top="284" left="724" width="32" height="15" font="2">ﬁcant</text>
<text top="304" left="423" width="146" height="12" font="2">overt bleeding, the bene</text>
<text top="302" left="570" width="187" height="15" font="2">ﬁt/risk ratio may favor shorter-</text>
<text top="322" left="423" width="225" height="12" font="2">than-recommended duration of DAPT</text>
<text top="322" left="654" width="16" height="12" font="4"><a href="1082.full.html#24">(17</a></text>
<text top="320" left="670" width="56" height="15" font="4"><a href="1082.full.html#24">–21,34,36)</a></text>
<text top="322" left="727" width="29" height="12" font="2">. De-</text>
<text top="340" left="423" width="333" height="12" font="2">cisions about treatment with and duration of DAPT</text>
<text top="358" left="423" width="260" height="12" font="2">require a thoughtful assessment of the bene</text>
<text top="356" left="683" width="73" height="15" font="2">ﬁt/risk ratio,</text>
<text top="376" left="423" width="333" height="12" font="2">integration of current and future study data, and</text>
<text top="394" left="423" width="210" height="12" font="2">consideration of patient preference.</text>
<text top="412" left="438" width="318" height="12" font="2">In studies of drug-eluting bioabsorbable polymer</text>
<text top="430" left="423" width="333" height="12" font="2">stents and bioabsorbable stents (third- and fourth-</text>
<text top="447" left="423" width="62" height="12" font="2">generation</text>
<text top="447" left="498" width="43" height="12" font="2">stents),</text>
<text top="447" left="554" width="14" height="12" font="2">by</text>
<text top="447" left="580" width="32" height="12" font="2">study</text>
<text top="447" left="625" width="52" height="12" font="2">protocol,</text>
<text top="447" left="690" width="32" height="12" font="2">DAPT</text>
<text top="447" left="734" width="22" height="12" font="2">was</text>
<text top="465" left="423" width="213" height="12" font="2">continued for at least 6 to 12 months</text>
<text top="465" left="641" width="22" height="12" font="4"><a href="1082.full.html#26">(110</a></text>
<text top="464" left="663" width="28" height="15" font="4"><a href="1082.full.html#26">–116)</a></text>
<text top="465" left="691" width="65" height="12" font="2"><a href="1082.full.html#26">. </a>In a study</text>
<text top="483" left="423" width="333" height="12" font="2">of a novel polymer-free and carrier-free drug-coated</text>
<text top="501" left="423" width="333" height="12" font="2">stent in patients at high risk of bleeding complications,</text>
<text top="519" left="423" width="333" height="12" font="2">by study protocol, DAPT was continued for only 1 month</text>
<text top="537" left="423" width="25" height="12" font="4"><a href="1082.full.html#26">(117)</a></text>
<text top="537" left="449" width="308" height="12" font="2"><a href="1082.full.html#26">. </a>These stents have not been included in the studies</text>
<text top="555" left="423" width="333" height="12" font="2">of shorter- or longer-duration (prolonged/extended)</text>
<text top="573" left="423" width="333" height="12" font="2">DAPT discussed in this focused update. Because none of</text>
<text top="591" left="423" width="333" height="12" font="2">these stents (except one biodegradable polymer DES)</text>
<text top="609" left="423" width="333" height="12" font="2">was approved by the US Food and Drug Administration</text>
<text top="627" left="423" width="333" height="12" font="2">at the time this focused update was written, recom-</text>
<text top="645" left="423" width="333" height="12" font="2">mendations for duration of DAPT for such stents are not</text>
<text top="663" left="423" width="54" height="12" font="2">included.</text>
<text top="681" left="438" width="318" height="12" font="2">Recommendations for duration of DAPT in patients</text>
<text top="698" left="423" width="207" height="12" font="2">treated with PCI are summarized in</text>
<text top="699" left="635" width="46" height="11" font="4"><a href="1082.full.html#13">Figure 2</a></text>
<text top="698" left="681" width="3" height="12" font="2"><a href="1082.full.html#13">.</a></text>
<text top="732" left="423" width="331" height="16" font="15">5. RECOMMENDATIONS FOR DURATION OF DAPT</text>
<text top="750" left="423" width="226" height="16" font="15">IN PATIENTS UNDERGOING CABG</text>
<text top="788" left="423" width="20" height="12" font="2">See</text>
<text top="788" left="447" width="233" height="12" font="4"><a href="http://jaccjacc.acc.org/Clinical_Document/DAPT_Data_Supplement_1.pdf">Online Data Supplements 4, 6, 10, and 11</a></text>
<text top="788" left="684" width="72" height="12" font="2">for evidence</text>
<text top="806" left="423" width="210" height="12" font="2">supporting these recommendations.</text>
<text top="845" left="63" width="392" height="11" font="20">Recommendations for Duration of DAPT in Patients Undergoing CABG</text>
<text top="886" left="89" width="19" height="10" font="14">COR</text>
<text top="886" left="161" width="18" height="10" font="14">LOE</text>
<text top="886" left="233" width="96" height="10" font="14">RECOMMENDATIONS</text>
<text top="923" left="97" width="3" height="9" font="5">I</text>
<text top="923" left="160" width="20" height="9" font="5">C-EO</text>
<text top="910" left="233" width="520" height="11" font="12">In patients treated with DAPT after coronary stent implantation who subsequently undergo CABG, P2Y</text>
<text top="915" left="753" width="8" height="7" font="13">12</text>
<text top="910" left="765" width="42" height="11" font="12">inhibitor</text>
<text top="926" left="233" width="574" height="11" font="12">therapy should be resumed postoperatively so that DAPT continues until the recommended duration of therapy is</text>
<text top="941" left="233" width="56" height="11" font="12">completed.</text>
<text top="985" left="97" width="3" height="9" font="5">I</text>
<text top="985" left="160" width="20" height="9" font="5">C-LD</text>
<text top="973" left="233" width="471" height="11" font="12">In patients with ACS (NSTE-ACS or STEMI) being treated with DAPT who undergo CABG, P2Y</text>
<text top="977" left="704" width="8" height="7" font="13">12</text>
<text top="973" left="716" width="84" height="11" font="12">inhibitor therapy</text>
<text top="988" left="233" width="414" height="11" font="12">should be resumed after CABG to complete 12 months of DAPT therapy after ACS</text>
<text top="988" left="651" width="16" height="11" font="4"><a href="1082.full.html#24">(52</a></text>
<text top="986" left="667" width="65" height="15" font="4"><a href="1082.full.html#24">–54,118–120)</a></text>
<text top="988" left="732" width="3" height="11" font="12">.</text>
<text top="1034" left="97" width="3" height="9" font="5">I</text>
<text top="1034" left="160" width="21" height="9" font="5">B-NR</text>
<text top="1021" left="233" width="525" height="11" font="12">In patients treated with DAPT, a daily aspirin dose of 81 mg (range, 75 mg to 100 mg) is recommended</text>
<text top="1037" left="233" width="17" height="11" font="4"><a href="1082.full.html#25">(56</a></text>
<text top="1035" left="250" width="56" height="15" font="4"><a href="1082.full.html#25">–60,75–78)</a></text>
<text top="1037" left="306" width="3" height="11" font="12">.</text>
<text top="1083" left="94" width="10" height="9" font="5">IIb</text>
<text top="1083" left="160" width="21" height="9" font="5">B-NR</text>
<text top="1070" left="233" width="564" height="11" font="12">In patients with SIHD, DAPT (with clopidogrel initiated early postoperatively) for 12 months after CABG may be</text>
<text top="1085" left="233" width="209" height="11" font="12">reasonable to improve vein graft patency</text>
<text top="1085" left="446" width="19" height="11" font="4"><a href="1082.full.html#26">(121</a></text>
<text top="1083" left="465" width="26" height="15" font="4"><a href="1082.full.html#26">–125)</a></text>
<text top="1085" left="491" width="3" height="11" font="12"><a href="1082.full.html#26">.</a></text>
<text top="54" left="63" width="132" height="7" font="7">J A C C V O L . 6 8 , N O . 1 0 , 2 0 1 6</text>
<text top="54" left="705" width="52" height="9" font="14">Levine et al.</text>
<text top="69" left="63" width="117" height="7" font="7">S E P T E M B E R 6 , 2 0 1 6 : 1 0 8 2</text>
<text top="67" left="182" width="17" height="10" font="7">– 1 1 5</text>
<text top="69" left="514" width="243" height="9" font="14">Focused Update on Duration of Dual Antiplatelet Therapy</text>
<text top="53" left="787" width="20" height="9" font="5">1095</text>
</page>
<page number="15" position="absolute" top="0" left="0" height="1160" width="864">
<text top="143" left="108" width="333" height="12" font="2">Aspirin therapy after CABG improves vein graft patency,</text>
<text top="161" left="108" width="143" height="12" font="2">particularly during the</text>
<text top="159" left="260" width="181" height="15" font="2">ﬁrst postoperative year, and</text>
<text top="178" left="108" width="87" height="12" font="2">reduces MACE</text>
<text top="178" left="202" width="23" height="12" font="4"><a href="1082.full.html#26">(126</a></text>
<text top="177" left="225" width="29" height="15" font="4"><a href="1082.full.html#26">–130)</a></text>
<text top="178" left="255" width="128" height="12" font="2"><a href="1082.full.html#26">. </a>In the CURE study</text>
<text top="178" left="390" width="21" height="12" font="4"><a href="1082.full.html#24">(52)</a></text>
<text top="178" left="412" width="29" height="12" font="2"><a href="1082.full.html#24">, </a>the</text>
<text top="196" left="108" width="333" height="12" font="2">reduction in ischemic events in patients treated with</text>
<text top="214" left="108" width="333" height="12" font="2">aspirin plus clopidogrel who underwent CABG was</text>
<text top="232" left="108" width="333" height="12" font="2">consistent with the study population as a whole, although</text>
<text top="250" left="108" width="28" height="12" font="2">bene</text>
<text top="248" left="136" width="305" height="15" font="2">ﬁt was primarily observed mainly before the proce-</text>
<text top="268" left="108" width="27" height="12" font="2">dure</text>
<text top="268" left="143" width="26" height="12" font="4"><a href="1082.full.html#26">(118)</a></text>
<text top="268" left="170" width="271" height="12" font="2"><a href="1082.full.html#26">. </a>A propensity score analysis of a Danish</text>
<text top="286" left="108" width="144" height="12" font="2">administrative database</text>
<text top="286" left="261" width="28" height="12" font="4"><a href="1082.full.html#26">(120)</a></text>
<text top="286" left="298" width="143" height="12" font="2">demonstrated during a</text>
<text top="304" left="108" width="141" height="12" font="2">mean follow-up of 466</text>
<text top="302" left="255" width="186" height="15" font="2"> 144 days signiﬁcantly fewer</text>
<text top="322" left="108" width="333" height="12" font="2">deaths in patients treated with aspirin plus clopidogrel</text>
<text top="340" left="108" width="333" height="12" font="2">than in those treated with aspirin alone, although there</text>
<text top="358" left="108" width="295" height="12" font="2">was no reduction in the incidence of recurrent MI.</text>
<text top="376" left="123" width="318" height="12" font="2">The impact of clopidogrel on graft occlusion after</text>
<text top="394" left="108" width="307" height="12" font="2">on-pump CABG has been evaluated in 5 studies (</text>
<text top="394" left="415" width="26" height="12" font="4"><a href="http://jaccjacc.acc.org/Clinical_Document/DAPT_Data_Supplement_1.pdf">Data</a></text>
<text top="412" left="108" width="70" height="12" font="4"><a href="http://jaccjacc.acc.org/Clinical_Document/DAPT_Data_Supplement_1.pdf">Supplement</a></text>
<text top="412" left="194" width="13" height="12" font="4"><a href="http://jaccjacc.acc.org/Clinical_Document/DAPT_Data_Supplement_1.pdf">10</a></text>
<text top="412" left="207" width="8" height="12" font="2"><a href="http://jaccjacc.acc.org/Clinical_Document/DAPT_Data_Supplement_1.pdf">)</a>.</text>
<text top="412" left="231" width="42" height="12" font="2">Several</text>
<text top="412" left="290" width="69" height="12" font="2">randomized</text>
<text top="412" left="376" width="21" height="12" font="2">and</text>
<text top="412" left="414" width="27" height="12" font="2">non-</text>
<text top="430" left="108" width="333" height="12" font="2">randomized trials and a post hoc substudy analysis of</text>
<text top="447" left="108" width="333" height="12" font="2">patients predominantly undergoing on-pump CABG did</text>
<text top="465" left="108" width="333" height="12" font="2">not demonstrate any differences in graft patency between</text>
<text top="483" left="108" width="333" height="12" font="2">antiplatelet monotherapy and DAPT when assessed at</text>
<text top="501" left="108" width="333" height="12" font="2">follow-up ranging from 1 month to 1 year after CABG</text>
<text top="519" left="108" width="21" height="12" font="4"><a href="1082.full.html#26">(131</a></text>
<text top="517" left="129" width="29" height="15" font="4"><a href="1082.full.html#26">–134)</a></text>
<text top="519" left="158" width="253" height="12" font="2">. In the only RCT to demonstrate a bene</text>
<text top="517" left="411" width="30" height="15" font="2">ﬁt of</text>
<text top="537" left="108" width="333" height="12" font="2">DAPT, vein graft patency 3 months after CABG was</text>
<text top="555" left="108" width="27" height="12" font="2">signi</text>
<text top="553" left="135" width="306" height="15" font="2">ﬁcantly higher in patients treated with clopidogrel</text>
<text top="143" left="468" width="333" height="12" font="2">and aspirin (100 mg) than in those receiving aspirin</text>
<text top="161" left="468" width="78" height="12" font="2">monotherapy</text>
<text top="161" left="550" width="25" height="12" font="4"><a href="1082.full.html#26">(121)</a></text>
<text top="161" left="575" width="3" height="12" font="2">.</text>
<text top="178" left="483" width="319" height="12" font="2">Two meta-analyses and 1 systematic overview assessed</text>
<text top="196" left="468" width="109" height="12" font="2">the potential bene</text>
<text top="195" left="577" width="224" height="15" font="2">ﬁts of DAPT after CABG and reported</text>
<text top="214" left="468" width="80" height="12" font="2">mixed results</text>
<text top="214" left="553" width="70" height="12" font="4"><a href="1082.full.html#26">(122,123,135)</a></text>
<text top="214" left="629" width="4" height="12" font="2">(</text>
<text top="214" left="633" width="119" height="12" font="4"><a href="http://jaccjacc.acc.org/Clinical_Document/DAPT_Data_Supplement_1.pdf">Data Supplement 10</a></text>
<text top="214" left="753" width="49" height="12" font="2"><a href="http://jaccjacc.acc.org/Clinical_Document/DAPT_Data_Supplement_1.pdf">). </a>In the</text>
<text top="232" left="468" width="333" height="12" font="2">largest meta-analysis of patients pooled from 5 RCTs and</text>
<text top="250" left="468" width="137" height="12" font="2">6 observational studies</text>
<text top="250" left="610" width="26" height="12" font="4"><a href="1082.full.html#26">(122)</a></text>
<text top="250" left="637" width="164" height="12" font="2">, DAPT was associated with</text>
<text top="268" left="468" width="333" height="12" font="2">reduced vein graft occlusion and 30-day mortality rate as</text>
<text top="286" left="468" width="333" height="12" font="2">compared with aspirin monotherapy. A meta-analysis of</text>
<text top="304" left="468" width="95" height="12" font="2">only the 5 RCTs</text>
<text top="304" left="568" width="26" height="12" font="4"><a href="1082.full.html#26">(123)</a></text>
<text top="304" left="599" width="202" height="12" font="2">showed that DAPT was associated</text>
<text top="322" left="468" width="71" height="12" font="2">with a signi</text>
<text top="320" left="539" width="262" height="15" font="2">ﬁcantly lower vein graft occlusion at 1 year</text>
<text top="340" left="468" width="333" height="12" font="2">versus antiplatelet monotherapy but with no improve-</text>
<text top="358" left="468" width="333" height="12" font="2">ment in arterial graft patency. Major bleeding after sur-</text>
<text top="376" left="468" width="205" height="12" font="2">gery was more frequent with DAPT</text>
<text top="376" left="677" width="70" height="12" font="4"><a href="1082.full.html#26">(122,123,135)</a></text>
<text top="376" left="747" width="3" height="12" font="2">.</text>
<text top="394" left="483" width="54" height="12" font="2">The bene</text>
<text top="392" left="537" width="264" height="15" font="2">ﬁts of DAPT in off-pump CABG patients were</text>
<text top="412" left="468" width="251" height="12" font="2">noted in terms of improved graft patency</text>
<text top="412" left="725" width="49" height="12" font="4"><a href="1082.full.html#26">(124,125)</a></text>
<text top="412" left="780" width="21" height="12" font="2">and</text>
<text top="430" left="468" width="101" height="12" font="2">clinical outcome</text>
<text top="430" left="579" width="27" height="12" font="4"><a href="1082.full.html#26">(136)</a></text>
<text top="430" left="616" width="185" height="12" font="2">in single-center observational</text>
<text top="447" left="468" width="41" height="12" font="2">studies</text>
<text top="447" left="513" width="50" height="12" font="4"><a href="1082.full.html#26">(124,136)</a></text>
<text top="447" left="568" width="67" height="12" font="2">and an RCT</text>
<text top="447" left="639" width="26" height="12" font="4"><a href="1082.full.html#26">(125)</a></text>
<text top="447" left="670" width="4" height="12" font="2">(</text>
<text top="447" left="674" width="117" height="12" font="4"><a href="http://jaccjacc.acc.org/Clinical_Document/DAPT_Data_Supplement_1.pdf">Data Supplement 10</a></text>
<text top="447" left="791" width="8" height="12" font="2">).</text>
<text top="465" left="483" width="318" height="12" font="2">Only data from post hoc analyses are available on the</text>
<text top="483" left="468" width="115" height="12" font="2">utility of newer P2Y</text>
<text top="488" left="583" width="9" height="8" font="7">12</text>
<text top="483" left="595" width="206" height="12" font="2">inhibitors in patients with ACS who</text>
<text top="501" left="468" width="333" height="12" font="2">undergo CABG. In a retrospective analysis of patients in</text>
<text top="519" left="468" width="163" height="12" font="2">the TRITON-TIMI 38 study</text>
<text top="519" left="638" width="22" height="12" font="4"><a href="1082.full.html#24">(54)</a></text>
<text top="519" left="667" width="134" height="12" font="2">who underwent CABG</text>
<text top="537" left="468" width="26" height="12" font="4"><a href="1082.full.html#26">(137)</a></text>
<text top="537" left="495" width="294" height="12" font="2"><a href="1082.full.html#26">, </a>prasugrel treatment was associated with a signi</text>
<text top="535" left="789" width="12" height="15" font="2">ﬁ-</text>
<text top="555" left="468" width="333" height="12" font="2">cantly lower 30-day mortality rate than that of clopidogrel</text>
<text top="618" left="125" width="45" height="11" font="22">FIGURE 3</text>
<text top="619" left="178" width="263" height="9" font="23">Treatment Algorithm for Management and Duration of P2Y</text>
<text top="623" left="442" width="7" height="6" font="24">12</text>
<text top="619" left="452" width="209" height="9" font="23">Inhibitor Therapy in Patients Undergoing CABG</text>
<text top="1032" left="125" width="212" height="9" font="14">Colors correspond to Class of Recommendation in</text>
<text top="1032" left="341" width="31" height="9" font="19"><a href="1082.full.html#4">Table 1</a></text>
<text top="1032" left="371" width="209" height="9" font="14">. Aspirin therapy is almost always continued inde</text>
<text top="1030" left="580" width="203" height="12" font="14">ﬁnitely in patients with coronary artery disease.</text>
<text top="1047" left="125" width="264" height="9" font="14">*Duration of DAPT therapy can vary from as little as 4 weeks to</text>
<text top="1045" left="392" width="391" height="12" font="14">&gt;12 months, depending on the clinical setting and bleeding risk. ACS indicates acute coronary</text>
<text top="1062" left="125" width="444" height="9" font="14">syndrome; CABG, coronary artery bypass graft surgery; DAPT, dual antiplatelet therapy; NSTE-ACS, non</text>
<text top="1060" left="570" width="195" height="12" font="14">–ST-elevation acute coronary syndromes; PCI,</text>
<text top="1077" left="125" width="513" height="9" font="14">percutaneous coronary intervention; post-op, postoperatively; SIHD, stable ischemic heart disease; and S/P, status post.</text>
<text top="53" left="108" width="52" height="9" font="14">Levine et al.</text>
<text top="54" left="670" width="132" height="7" font="7">J A C C V O L . 6 8 , N O . 1 0 , 2 0 1 6</text>
<text top="68" left="108" width="243" height="9" font="14">Focused Update on Duration of Dual Antiplatelet Therapy</text>
<text top="69" left="665" width="117" height="7" font="7">S E P T E M B E R 6 , 2 0 1 6 : 1 0 8 2</text>
<text top="67" left="784" width="17" height="10" font="7">– 1 1 5</text>
<text top="53" left="57" width="21" height="9" font="5">1096</text>
</page>
<page number="16" position="absolute" top="0" left="0" height="1160" width="864">
<text top="143" left="63" width="333" height="12" font="2">and more postoperative blood loss. A post hoc analysis of</text>
<text top="161" left="63" width="307" height="12" font="2">patients who underwent CABG in the PLATO study</text>
<text top="161" left="375" width="21" height="12" font="4"><a href="1082.full.html#24">(53)</a></text>
<text top="178" left="63" width="333" height="12" font="2">showed that the primary endpoint at 1 year was similar</text>
<text top="196" left="63" width="193" height="12" font="2">for both treatments, but a signi</text>
<text top="195" left="256" width="140" height="15" font="2">ﬁcant reduction in car-</text>
<text top="214" left="63" width="333" height="12" font="2">diovascular mortality was noted with ticagrelor compared</text>
<text top="232" left="63" width="95" height="12" font="2">with clopidogrel</text>
<text top="232" left="162" width="50" height="12" font="4"><a href="1082.full.html#26">(138,139)</a></text>
<text top="232" left="212" width="3" height="12" font="2">.</text>
<text top="250" left="78" width="318" height="12" font="2">Issues related to the timing of discontinuation of DAPT</text>
<text top="268" left="63" width="333" height="12" font="2">before CABG are beyond the scope of this update but are</text>
<text top="286" left="63" width="221" height="12" font="2">addressed in the 2011 CABG guideline</text>
<text top="286" left="288" width="21" height="12" font="4"><a href="1082.full.html#23">(10)</a></text>
<text top="286" left="309" width="3" height="12" font="2">.</text>
<text top="286" left="317" width="46" height="11" font="4"><a href="1082.full.html#15">Figure 3</a></text>
<text top="286" left="367" width="29" height="12" font="2">sum-</text>
<text top="304" left="63" width="333" height="12" font="2">marizes recommendations for the management and</text>
<text top="322" left="63" width="89" height="12" font="2">duration of P2Y</text>
<text top="327" left="152" width="9" height="8" font="7">12</text>
<text top="322" left="164" width="232" height="12" font="2">inhibitor therapy in patients undergoing</text>
<text top="340" left="63" width="36" height="12" font="2">CABG.</text>
<text top="374" left="63" width="331" height="16" font="15">6. RECOMMENDATIONS FOR DURATION OF DAPT</text>
<text top="391" left="63" width="163" height="16" font="15">IN PATIENTS WITH SIHD</text>
<text top="429" left="63" width="20" height="12" font="2">See</text>
<text top="429" left="86" width="236" height="12" font="4"><a href="http://jaccjacc.acc.org/Clinical_Document/DAPT_Data_Supplement_1.pdf">Online Data Supplements 1 to 4 and 6 to 11</a></text>
<text top="429" left="325" width="71" height="12" font="2">for evidence</text>
<text top="447" left="63" width="210" height="12" font="2">supporting these recommendations.</text>
<text top="143" left="438" width="318" height="12" font="2">For the purposes of this update, patients with a his-</text>
<text top="161" left="423" width="71" height="12" font="2">tory of ACS</text>
<text top="159" left="501" width="255" height="15" font="2">&gt;1 year prior who have remained free of</text>
<text top="178" left="423" width="333" height="12" font="2">recurrent ACS are considered to have transitioned to</text>
<text top="196" left="423" width="33" height="12" font="2">SIHD.</text>
<text top="214" left="438" width="318" height="12" font="2">In the CHARISMA trial, which randomized patients</text>
<text top="232" left="423" width="333" height="12" font="2">with established atherosclerosis or at high risk of clin-</text>
<text top="250" left="423" width="333" height="12" font="2">ical atherosclerotic disease to either DAPT (with clopi-</text>
<text top="268" left="423" width="240" height="12" font="2">dogrel) or aspirin monotherapy, no signi</text>
<text top="266" left="663" width="93" height="15" font="2">ﬁcant reduction</text>
<text top="286" left="423" width="333" height="12" font="2">was found in ischemic effects at a median follow-up of</text>
<text top="304" left="423" width="333" height="12" font="2">28 months with DAPT, but a 0.4% absolute increase was</text>
<text top="322" left="423" width="143" height="12" font="2">seen in severe bleeding</text>
<text top="322" left="572" width="23" height="12" font="4"><a href="1082.full.html#24">(40)</a></text>
<text top="322" left="596" width="161" height="12" font="2"><a href="1082.full.html#24">. </a>In a post hoc analysis of</text>
<text top="340" left="423" width="333" height="12" font="2">patients enrolled in the study with prior MI, a 1.7%</text>
<text top="358" left="423" width="333" height="12" font="2">absolute decrease in the composite endpoint of cardio-</text>
<text top="376" left="423" width="333" height="12" font="2">vascular death, MI, or stroke events was observed with</text>
<text top="394" left="423" width="125" height="12" font="2">DAPT, but no bene</text>
<text top="392" left="548" width="208" height="15" font="2">ﬁt was seen in those with CAD</text>
<text top="412" left="423" width="115" height="12" font="2">without prior MI (</text>
<text top="412" left="538" width="118" height="12" font="4"><a href="http://jaccjacc.acc.org/Clinical_Document/DAPT_Data_Supplement_1.pdf">Data Supplement 4</a></text>
<text top="412" left="656" width="4" height="12" font="2">)</text>
<text top="412" left="667" width="40" height="12" font="4"><a href="1082.full.html#24">(40,41)</a></text>
<text top="412" left="708" width="49" height="12" font="2"><a href="1082.full.html#24">. </a>In the</text>
<text top="430" left="423" width="333" height="12" font="2">PEGASUS-TIMI 54 trial, in which stable patients 1 to 3</text>
<text top="447" left="423" width="333" height="12" font="2">years after MI with additional high-risk features were</text>
<text top="528" left="63" width="349" height="11" font="20">Recommendations for Duration of DAPT in Patients With SIHD</text>
<text top="569" left="89" width="19" height="10" font="14">COR</text>
<text top="569" left="161" width="18" height="10" font="14">LOE</text>
<text top="569" left="233" width="96" height="10" font="14">RECOMMENDATIONS</text>
<text top="606" left="97" width="3" height="9" font="5">I</text>
<text top="606" left="168" width="6" height="9" font="5">A</text>
<text top="593" left="233" width="351" height="11" font="12">In patients with SIHD treated with DAPT after BMS implantation, P2Y</text>
<text top="598" left="584" width="8" height="7" font="13">12</text>
<text top="593" left="596" width="205" height="11" font="12">inhibitor therapy (clopidogrel) should be</text>
<text top="609" left="233" width="163" height="11" font="12">given for a minimum of 1 month</text>
<text top="609" left="400" width="38" height="11" font="4"><a href="1082.full.html#25">(94,95)</a></text>
<text top="609" left="438" width="3" height="11" font="12">.</text>
<text top="653" left="97" width="3" height="9" font="5">I</text>
<text top="653" left="158" width="15" height="9" font="5">B-R</text>
<text top="651" left="175" width="8" height="6" font="28">SR</text>
<text top="641" left="233" width="349" height="11" font="12">In patients with SIHD treated with DAPT after DES implantation, P2Y</text>
<text top="645" left="582" width="8" height="7" font="13">12</text>
<text top="641" left="594" width="205" height="11" font="12">inhibitor therapy (clopidogrel) should be</text>
<text top="656" left="233" width="139" height="11" font="12">given for at least 6 months</text>
<text top="656" left="375" width="97" height="11" font="4"><a href="1082.full.html#24">(17,18,21,30,96,97)</a></text>
<text top="656" left="472" width="3" height="11" font="12">.</text>
<text top="702" left="97" width="3" height="9" font="5">I</text>
<text top="702" left="160" width="21" height="9" font="5">B-NR</text>
<text top="689" left="233" width="525" height="11" font="12">In patients treated with DAPT, a daily aspirin dose of 81 mg (range, 75 mg to 100 mg) is recommended</text>
<text top="705" left="233" width="17" height="11" font="4"><a href="1082.full.html#25">(56</a></text>
<text top="703" left="250" width="56" height="15" font="4"><a href="1082.full.html#25">–60,75–78)</a></text>
<text top="705" left="306" width="3" height="11" font="12">.</text>
<text top="751" left="94" width="10" height="9" font="5">IIb</text>
<text top="751" left="162" width="6" height="9" font="5">A</text>
<text top="749" left="171" width="8" height="6" font="28">SR</text>
<text top="738" left="233" width="574" height="11" font="12">In patients with SIHD being treated with DAPT for an MI that occurred 1 to 3 years earlier who have tolerated DAPT</text>
<text top="753" left="233" width="574" height="11" font="12">without a bleeding complication and who are not at high bleeding risk (e.g., prior bleeding on DAPT, coagulopathy,</text>
<text top="769" left="233" width="368" height="11" font="12">oral anticoagulant use), further continuation of DAPT may be reasonable</text>
<text top="769" left="605" width="87" height="11" font="4"><a href="1082.full.html#24">(28,30,40,41,44)</a></text>
<text top="769" left="691" width="3" height="11" font="12">.</text>
<text top="815" left="94" width="10" height="9" font="5">IIb</text>
<text top="815" left="162" width="6" height="9" font="5">A</text>
<text top="813" left="171" width="8" height="6" font="28">SR</text>
<text top="802" left="233" width="536" height="11" font="12">In patients with SIHD treated with BMS or DES implantation who have tolerated DAPT without a bleeding</text>
<text top="817" left="233" width="574" height="11" font="12">complication and who are not at high bleeding risk (e.g., prior bleeding on DAPT, coagulopathy, oral anticoagulant</text>
<text top="833" left="233" width="574" height="11" font="12">use), continuation of DAPT with clopidogrel for longer than 1 month in patients treated with BMS or longer than 6</text>
<text top="848" left="233" width="282" height="11" font="12">months in patients treated with DES may be reasonable</text>
<text top="848" left="519" width="47" height="11" font="4"><a href="1082.full.html#24">(16,22,24</a></text>
<text top="846" left="566" width="56" height="15" font="4"><a href="1082.full.html#24">–26,30,50)</a></text>
<text top="848" left="622" width="3" height="11" font="12"><a href="1082.full.html#24">.</a></text>
<text top="894" left="94" width="10" height="9" font="5">IIb</text>
<text top="894" left="160" width="20" height="9" font="5">C-LD</text>
<text top="881" left="233" width="574" height="11" font="12">In patients with SIHD treated with DAPT after DES implantation who develop a high risk of bleeding (e.g., treatment</text>
<text top="897" left="233" width="574" height="11" font="12">with oral anticoagulant therapy), are at high risk of severe bleeding complication (e.g., major intracranial surgery),</text>
<text top="912" left="233" width="80" height="11" font="12">or develop signi</text>
<text top="910" left="313" width="224" height="15" font="12">ﬁcant overt bleeding, discontinuation of P2Y</text>
<text top="917" left="537" width="8" height="7" font="13">12</text>
<text top="912" left="549" width="258" height="11" font="12">inhibitor therapy after 3 months may be reasonable</text>
<text top="927" left="233" width="83" height="11" font="4"><a href="1082.full.html#24">(19,20,34,36,37)</a></text>
<text top="927" left="316" width="3" height="11" font="12">.</text>
<text top="973" left="94" width="10" height="9" font="5">IIb</text>
<text top="973" left="160" width="21" height="9" font="5">B-NR</text>
<text top="961" left="233" width="571" height="11" font="12">In patients with SIHD, treatment with DAPT (with clopidogrel initiated early postoperatively) for 12 months after</text>
<text top="976" left="233" width="281" height="11" font="12">CABG may be reasonable to improve vein graft patency</text>
<text top="976" left="518" width="19" height="11" font="4"><a href="1082.full.html#26">(121</a></text>
<text top="974" left="537" width="26" height="15" font="4"><a href="1082.full.html#26">–125)</a></text>
<text top="976" left="563" width="3" height="11" font="12">.</text>
<text top="1022" left="71" width="47" height="9" font="5">III: No Bene</text>
<text top="1020" left="118" width="9" height="12" font="5">ﬁt</text>
<text top="1022" left="163" width="15" height="9" font="5">B-R</text>
<text top="1010" left="233" width="574" height="11" font="12">In patients with SIHD without prior history of ACS, coronary stent implantation, or recent (within 12 months) CABG,</text>
<text top="1025" left="233" width="167" height="11" font="12">treatment with DAPT is not bene</text>
<text top="1023" left="400" width="23" height="15" font="12">ﬁcial</text>
<text top="1025" left="427" width="35" height="11" font="4"><a href="1082.full.html#24">(28,40</a></text>
<text top="1023" left="462" width="22" height="15" font="4"><a href="1082.full.html#24">–42)</a></text>
<text top="1025" left="484" width="3" height="11" font="12"><a href="1082.full.html#24">.</a></text>
<text top="1065" left="63" width="120" height="8" font="5">SR indicates systematic review.</text>
<text top="54" left="63" width="132" height="7" font="7">J A C C V O L . 6 8 , N O . 1 0 , 2 0 1 6</text>
<text top="54" left="705" width="52" height="9" font="14">Levine et al.</text>
<text top="69" left="63" width="117" height="7" font="7">S E P T E M B E R 6 , 2 0 1 6 : 1 0 8 2</text>
<text top="67" left="182" width="17" height="10" font="7">– 1 1 5</text>
<text top="69" left="514" width="243" height="9" font="14">Focused Update on Duration of Dual Antiplatelet Therapy</text>
<text top="53" left="788" width="20" height="9" font="5">1097</text>
</page>
<page number="17" position="absolute" top="0" left="0" height="1160" width="864">
	<fontspec id="29" size="5" family="Times" color="#231f20"/>
	<fontspec id="30" size="5" family="Times" color="#231f20"/>
<text top="816" left="108" width="333" height="12" font="2">randomized to either DAPT (with ticagrelor 60 mg or 90</text>
<text top="834" left="108" width="333" height="12" font="2">mg twice daily) or continued aspirin monotherapy, a</text>
<text top="852" left="108" width="333" height="12" font="2">mean of 33 months of DAPT led to a 1.2% to 1.3% absolute</text>
<text top="870" left="108" width="333" height="12" font="2">reduction in ischemic events and a 1.2% to 1.5% increase</text>
<text top="888" left="108" width="102" height="12" font="2">in major bleeding</text>
<text top="888" left="214" width="22" height="12" font="4"><a href="1082.full.html#24">(28)</a></text>
<text top="888" left="236" width="205" height="12" font="2">. In subgroup analysis, the greatest</text>
<text top="906" left="108" width="333" height="12" font="2">reduction in ischemic events was in patients in whom</text>
<text top="924" left="108" width="21" height="12" font="2">P2Y</text>
<text top="929" left="129" width="9" height="8" font="7">12</text>
<text top="924" left="142" width="299" height="12" font="2">inhibitor therapy either had not been discontinued</text>
<text top="942" left="108" width="150" height="12" font="2">or had been discontinued</text>
<text top="940" left="262" width="179" height="15" font="2">#30 days before enrollment in</text>
<text top="960" left="108" width="333" height="12" font="2">the study (absolute reduction in MACE: 1.9% to 2.5%),</text>
<text top="978" left="108" width="75" height="12" font="2">and no bene</text>
<text top="976" left="183" width="227" height="15" font="2">ﬁt was seen in patients in whom P2Y</text>
<text top="983" left="411" width="9" height="8" font="7">12</text>
<text top="978" left="425" width="16" height="12" font="2">in-</text>
<text top="996" left="108" width="237" height="12" font="2">hibitor therapy had been discontinued</text>
<text top="994" left="351" width="90" height="15" font="2">&gt;1 year before</text>
<text top="1014" left="108" width="141" height="12" font="2">enrollment in the study</text>
<text top="1014" left="254" width="22" height="12" font="4"><a href="1082.full.html#24">(42)</a></text>
<text top="1014" left="277" width="164" height="12" font="2"><a href="1082.full.html#24">. </a>On the basis of all studies</text>
<text top="1032" left="108" width="333" height="12" font="2">of DAPT in post-MI patients, extended DAPT for</text>
<text top="816" left="468" width="333" height="12" font="2">approximately 18 to 36 months leads to an absolute</text>
<text top="834" left="468" width="230" height="12" font="2">decrease in ischemic complications of</text>
<text top="833" left="705" width="97" height="15" font="2">z1% to 3% and</text>
<text top="852" left="468" width="300" height="12" font="2">an absolute increase in bleeding complications of</text>
<text top="850" left="774" width="27" height="15" font="2">z1%</text>
<text top="870" left="468" width="4" height="12" font="2">(</text>
<text top="870" left="472" width="112" height="12" font="4"><a href="http://jaccjacc.acc.org/Clinical_Document/DAPT_Data_Supplement_1.pdf">Data Supplement 4</a></text>
<text top="870" left="584" width="4" height="12" font="2">)</text>
<text top="870" left="593" width="94" height="12" font="4"><a href="1082.full.html#24">(28,40,41,43,44)</a></text>
<text top="870" left="687" width="3" height="12" font="2">.</text>
<text top="888" left="483" width="318" height="12" font="2">DAPT is not recommended in patients with SIHD</text>
<text top="906" left="468" width="333" height="12" font="2">without prior stent implantation and no history of ACS or</text>
<text top="924" left="468" width="333" height="12" font="2">MI. Decisions about treatment with and duration of DAPT</text>
<text top="942" left="468" width="333" height="12" font="2">in patients with SIHD with a history of MI or coronary</text>
<text top="960" left="468" width="333" height="12" font="2">stent implantation require a thoughtful assessment of the</text>
<text top="978" left="468" width="28" height="12" font="2">bene</text>
<text top="976" left="496" width="305" height="15" font="2">ﬁt/risk ratio, integration of study data, and consid-</text>
<text top="996" left="468" width="172" height="12" font="2">eration of patient preference.</text>
<text top="1014" left="483" width="47" height="11" font="4"><a href="1082.full.html#17">Figure 4</a></text>
<text top="1014" left="534" width="267" height="12" font="2">summarizes recommendations on duration of</text>
<text top="1032" left="468" width="21" height="12" font="2">P2Y</text>
<text top="1037" left="490" width="9" height="8" font="7">12</text>
<text top="1032" left="502" width="232" height="12" font="2">inhibitor therapy in patients with SIHD.</text>
<text top="153" left="125" width="46" height="11" font="22">FIGURE 4</text>
<text top="154" left="179" width="184" height="9" font="23">Treatment Algorithm for Duration of P2Y</text>
<text top="158" left="363" width="7" height="6" font="24">12</text>
<text top="154" left="373" width="377" height="9" font="23">Inhibitor Therapy in Patients With SIHD (Without ACS Within the Past Several Years)</text>
<text top="203" left="416" width="16" height="8" font="29">SIHD</text>
<text top="259" left="232" width="62" height="8" font="29">No Hx of MI, PCI or </text>
<text top="267" left="229" width="64" height="8" font="29">recent (within 12 mo)</text>
<text top="275" left="252" width="19" height="8" font="29">CABG</text>
<text top="270" left="579" width="14" height="8" font="29">DES</text>
<text top="443" left="175" width="15" height="8" font="29">6 mo</text>
<text top="507" left="173" width="19" height="8" font="29">12 mo</text>
<text top="270" left="382" width="33" height="8" font="29">S/P CABG</text>
<text top="270" left="484" width="15" height="8" font="29">BMS</text>
<text top="454" left="551" width="73" height="8" font="29">No high risk of bleeding </text>
<text top="462" left="551" width="71" height="8" font="29">and no significant overt</text>
<text top="471" left="558" width="58" height="8" font="29"> bleeding on DAPT</text>
<text top="345" left="656" width="16" height="8" font="29">High </text>
<text top="353" left="650" width="28" height="8" font="29">bleeding </text>
<text top="361" left="650" width="27" height="8" font="29">risks* or </text>
<text top="370" left="648" width="32" height="8" font="29">significant </text>
<text top="378" left="655" width="17" height="8" font="29">overt </text>
<text top="386" left="650" width="26" height="8" font="29">bleeding</text>
<text top="300" left="175" width="15" height="8" font="29">0 mo</text>
<text top="491" left="571" width="31" height="8" font="30"><b>Class IIb:</b></text>
<text top="499" left="547" width="81" height="8" font="29">&gt;6 mo may be reasonable </text>
<text top="354" left="712" width="31" height="8" font="30"><b>Class IIb:</b></text>
<text top="362" left="706" width="44" height="7" font="25">Discontinuation </text>
<text top="370" left="706" width="43" height="7" font="25">after 3 mo may </text>
<text top="378" left="707" width="39" height="7" font="25">be reasonable</text>
<text top="395" left="175" width="15" height="8" font="29">3 mo</text>
<text top="266" left="310" width="56" height="8" font="29">Prior MI, currently </text>
<text top="274" left="323" width="28" height="8" font="29">on DAPT</text>
<text top="521" left="321" width="31" height="8" font="30"><b>Class IIb:</b></text>
<text top="530" left="326" width="24" height="8" font="29">Further </text>
<text top="538" left="318" width="39" height="8" font="29">continuation </text>
<text top="546" left="325" width="24" height="8" font="29">may be </text>
<text top="554" left="320" width="34" height="8" font="29">reasonable</text>
<text top="315" left="247" width="28" height="8" font="30"><b>Class III:</b></text>
<text top="324" left="243" width="36" height="8" font="30"><b> No Benefit</b></text>
<text top="391" left="383" width="31" height="8" font="30"><b>Class IIb:</b></text>
<text top="399" left="377" width="46" height="8" font="29">12 mo may be </text>
<text top="408" left="382" width="36" height="8" font="29">reasonable </text>
<text top="416" left="380" width="38" height="8" font="29">(clopidogrel)</text>
<text top="310" left="479" width="24" height="8" font="30"><b>Class I:</b></text>
<text top="318" left="471" width="42" height="8" font="29">At least 1 mo </text>
<text top="326" left="472" width="38" height="8" font="29">(clopidogrel)</text>
<text top="363" left="574" width="24" height="8" font="30"><b>Class I:</b></text>
<text top="371" left="567" width="42" height="8" font="29">At least 6 mo </text>
<text top="380" left="568" width="38" height="8" font="29">(clopidogrel)</text>
<text top="339" left="175" width="15" height="8" font="29">1 mo</text>
<text top="353" left="455" width="72" height="8" font="29">No high risk of bleeding</text>
<text top="361" left="455" width="74" height="8" font="29"> and no significant overt </text>
<text top="370" left="463" width="56" height="8" font="29">bleeding on DAPT</text>
<text top="390" left="476" width="31" height="8" font="30"><b>Class IIb:</b></text>
<text top="398" left="451" width="81" height="8" font="29">&gt;1 mo may be reasonable </text>
<text top="604" left="125" width="224" height="9" font="14">Colors correspond to Class of Recommendation in</text>
<text top="604" left="353" width="32" height="9" font="19"><a href="1082.full.html#4">Table 1</a></text>
<text top="604" left="386" width="141" height="9" font="14"><a href="1082.full.html#4">. </a>Patients with a history of ACS</text>
<text top="602" left="530" width="253" height="12" font="14">&gt;1 year prior who have since remained free of recurrent</text>
<text top="619" left="125" width="356" height="9" font="14">ACS are considered to have transitioned to SIHD. Arrows at the bottom of the</text>
<text top="617" left="485" width="298" height="12" font="14">ﬁgure denote that the optimal duration of prolonged DAPT is not</text>
<text top="634" left="125" width="248" height="9" font="14">established. Clopidogrel is the only currently used P2Y</text>
<text top="638" left="374" width="7" height="6" font="18">12</text>
<text top="634" left="385" width="398" height="9" font="14">inhibitor studied in patients with SIHD undergoing PCI. Aspirin therapy is almost always</text>
<text top="649" left="125" width="67" height="9" font="14">continued inde</text>
<text top="647" left="192" width="590" height="12" font="14">ﬁnitely in patients with coronary artery disease. *High bleeding risk denotes those who have or develop a high risk of bleeding</text>
<text top="664" left="125" width="639" height="9" font="14">(e.g., treatment with oral anticoagulant therapy) or are at increased risk of severe bleeding complication (e.g., major intracranial surgery).</text>
<text top="679" left="125" width="651" height="9" font="14">ACS indicates acute coronary syndrome; BMS, bare metal stent; CABG, coronary artery bypass graft surgery; DAPT, dual antiplatelet therapy;</text>
<text top="694" left="125" width="647" height="9" font="14">DES, drug-eluting stent; Hx, history; MI, myocardial infarction; PCI, percutaneous coronary intervention; SIHD, stable ischemic heart disease;</text>
<text top="709" left="125" width="96" height="9" font="14">and S/P, status post.</text>
<text top="53" left="108" width="52" height="9" font="14">Levine et al.</text>
<text top="54" left="670" width="132" height="7" font="7">J A C C V O L . 6 8 , N O . 1 0 , 2 0 1 6</text>
<text top="68" left="108" width="243" height="9" font="14">Focused Update on Duration of Dual Antiplatelet Therapy</text>
<text top="69" left="665" width="117" height="7" font="7">S E P T E M B E R 6 , 2 0 1 6 : 1 0 8 2</text>
<text top="67" left="784" width="17" height="10" font="7">– 1 1 5</text>
<text top="53" left="57" width="21" height="9" font="5">1098</text>
</page>
<page number="18" position="absolute" top="0" left="0" height="1160" width="864">
<text top="141" left="63" width="227" height="16" font="15">7. ACUTE CORONARY SYNDROME</text>
<text top="159" left="63" width="159" height="16" font="15">(NSTE-ACS AND STEMI)</text>
<text top="197" left="63" width="304" height="11" font="12">7.1. Duration of DAPT in Patients With ACS Treated With</text>
<text top="215" left="85" width="284" height="11" font="12">Medical Therapy Alone (Without Revascularization or</text>
<text top="233" left="85" width="215" height="11" font="12">Fibrinolytic Therapy): Recommendations</text>
<text top="254" left="63" width="20" height="12" font="2">See</text>
<text top="254" left="89" width="193" height="12" font="4"><a href="http://jaccjacc.acc.org/Clinical_Document/DAPT_Data_Supplement_1.pdf">Online Data Supplements 4 to 6</a></text>
<text top="254" left="289" width="107" height="12" font="2">for evidence sup-</text>
<text top="272" left="63" width="189" height="12" font="2">porting these recommendations.</text>
<text top="703" left="63" width="317" height="11" font="12">7.2. Duration of DAPT in Patients With STEMI Treated With</text>
<text top="721" left="86" width="210" height="11" font="12">Fibrinolytic Therapy: Recommendations</text>
<text top="742" left="63" width="20" height="12" font="2">See</text>
<text top="742" left="88" width="198" height="12" font="4"><a href="http://jaccjacc.acc.org/Clinical_Document/DAPT_Data_Supplement_1.pdf">Online Data Supplements 4 and 6</a></text>
<text top="742" left="292" width="104" height="12" font="2">for evidence sup-</text>
<text top="760" left="63" width="189" height="12" font="2">porting these recommendations.</text>
<text top="321" left="63" width="553" height="11" font="20">Recommendations for Duration of DAPT in Patients With ACS Treated With Medical Therapy Alone</text>
<text top="362" left="89" width="19" height="10" font="14">COR</text>
<text top="362" left="161" width="18" height="10" font="14">LOE</text>
<text top="362" left="233" width="96" height="10" font="14">RECOMMENDATIONS</text>
<text top="399" left="97" width="3" height="9" font="5">I</text>
<text top="399" left="163" width="15" height="9" font="5">B-R</text>
<text top="386" left="233" width="472" height="11" font="12">In patients with ACS who are managed with medical therapy alone (without revascularization or</text>
<text top="384" left="708" width="99" height="15" font="12">ﬁbrinolytic therapy)</text>
<text top="402" left="233" width="137" height="11" font="12">and treated with DAPT, P2Y</text>
<text top="407" left="370" width="8" height="7" font="13">12</text>
<text top="402" left="381" width="426" height="11" font="12">inhibitor therapy (clopidogrel or ticagrelor) should be continued for at least 12 months</text>
<text top="417" left="233" width="75" height="11" font="4"><a href="1082.full.html#24">(52,71,140,141)</a></text>
<text top="417" left="308" width="3" height="11" font="12">.</text>
<text top="462" left="97" width="3" height="9" font="5">I</text>
<text top="462" left="160" width="21" height="9" font="5">B-NR</text>
<text top="449" left="233" width="525" height="11" font="12">In patients treated with DAPT, a daily aspirin dose of 81 mg (range, 75 mg to 100 mg) is recommended</text>
<text top="464" left="233" width="17" height="11" font="4"><a href="1082.full.html#25">(56</a></text>
<text top="462" left="250" width="56" height="15" font="4"><a href="1082.full.html#25">–60,75–78)</a></text>
<text top="464" left="306" width="3" height="11" font="12">.</text>
<text top="510" left="94" width="10" height="9" font="5">IIa</text>
<text top="510" left="163" width="15" height="9" font="5">B-R</text>
<text top="498" left="233" width="109" height="11" font="12">In patients with NSTE</text>
<text top="496" left="343" width="464" height="15" font="12">–ACS who are managed with medical therapy alone (without revascularization or ﬁbrinolytic</text>
<text top="513" left="233" width="566" height="11" font="12">therapy) and treated with DAPT, it is reasonable to use ticagrelor in preference to clopidogrel for maintenance P2Y</text>
<text top="518" left="799" width="8" height="7" font="13">12</text>
<text top="528" left="233" width="84" height="11" font="12">inhibitor therapy</text>
<text top="528" left="321" width="33" height="11" font="4"><a href="1082.full.html#24">(53,71)</a></text>
<text top="528" left="354" width="3" height="11" font="12">.</text>
<text top="574" left="94" width="10" height="9" font="5">IIb</text>
<text top="574" left="162" width="6" height="9" font="5">A</text>
<text top="573" left="171" width="8" height="6" font="28">SR</text>
<text top="562" left="233" width="422" height="11" font="12">In patients with ACS treated with medical therapy alone (without revascularization or</text>
<text top="560" left="658" width="149" height="15" font="12">ﬁbrinolytic therapy) who have</text>
<text top="577" left="233" width="574" height="11" font="12">tolerated DAPT without bleeding complication and who are not at high bleeding risk (e.g., prior bleeding on DAPT,</text>
<text top="592" left="233" width="540" height="11" font="12">coagulopathy, oral anticoagulant use), continuation of DAPT for longer than 12 months may be reasonable</text>
<text top="608" left="233" width="134" height="11" font="4"><a href="1082.full.html#24">(28,30,40,41,43,53,71,141)</a></text>
<text top="608" left="367" width="3" height="11" font="12"><a href="1082.full.html#24">.</a></text>
<text top="633" left="63" width="120" height="8" font="5">SR indicates systematic review.</text>
<text top="840" left="63" width="550" height="11" font="20">Recommendations for Duration of DAPT in Patients With STEMI Treated With Fibrinolytic Therapy</text>
<text top="881" left="89" width="19" height="10" font="14">COR</text>
<text top="881" left="161" width="18" height="10" font="14">LOE</text>
<text top="881" left="233" width="96" height="10" font="14">RECOMMENDATIONS</text>
<text top="919" left="97" width="3" height="9" font="5">I</text>
<text top="912" left="168" width="6" height="9" font="5">A</text>
<text top="928" left="160" width="20" height="9" font="5">C-EO</text>
<text top="905" left="233" width="311" height="11" font="12">In patients with STEMI treated with DAPT in conjunction with</text>
<text top="903" left="548" width="122" height="15" font="12">ﬁbrinolytic therapy, P2Y</text>
<text top="910" left="670" width="8" height="7" font="13">12</text>
<text top="905" left="682" width="84" height="11" font="12">inhibitor therapy</text>
<text top="921" left="233" width="411" height="11" font="12">(clopidogrel) should be continued for a minimum of 14 days (Level of Evidence: A)</text>
<text top="921" left="647" width="48" height="11" font="4"><a href="1082.full.html#27">(140,142)</a></text>
<text top="921" left="698" width="109" height="11" font="12">and ideally at least 12</text>
<text top="936" left="233" width="172" height="11" font="12">months (Level of Evidence: C-EO).</text>
<text top="988" left="97" width="3" height="9" font="5">I</text>
<text top="988" left="160" width="21" height="9" font="5">B-NR</text>
<text top="976" left="233" width="525" height="11" font="12">In patients treated with DAPT, a daily aspirin dose of 81 mg (range, 75 mg to 100 mg) is recommended</text>
<text top="991" left="233" width="17" height="11" font="4"><a href="1082.full.html#25">(56</a></text>
<text top="989" left="250" width="56" height="15" font="4"><a href="1082.full.html#25">–60,75–78)</a></text>
<text top="991" left="306" width="3" height="11" font="12">.</text>
<text top="1037" left="94" width="10" height="9" font="5">IIb</text>
<text top="1037" left="162" width="6" height="9" font="5">A</text>
<text top="1035" left="171" width="8" height="6" font="28">SR</text>
<text top="1024" left="233" width="180" height="11" font="12">In patients with STEMI treated with</text>
<text top="1022" left="417" width="386" height="15" font="12">ﬁbrinolytic therapy who have tolerated DAPT without bleeding complication</text>
<text top="1040" left="233" width="542" height="11" font="12">and who are not at high bleeding risk (e.g., prior bleeding on DAPT, coagulopathy, oral anticoagulant use),</text>
<text top="1055" left="233" width="343" height="11" font="12">continuation of DAPT for longer than 12 months may be reasonable</text>
<text top="1055" left="579" width="31" height="11" font="4"><a href="1082.full.html#24">(16,22</a></text>
<text top="1053" left="610" width="182" height="15" font="4"><a href="1082.full.html#24">–26,28,30,40,41,43,53,54,71,72,141)</a></text>
<text top="1055" left="792" width="3" height="11" font="12">.</text>
<text top="1080" left="63" width="120" height="8" font="5">SR indicates systematic review.</text>
<text top="54" left="63" width="132" height="7" font="7">J A C C V O L . 6 8 , N O . 1 0 , 2 0 1 6</text>
<text top="54" left="705" width="52" height="9" font="14">Levine et al.</text>
<text top="69" left="63" width="117" height="7" font="7">S E P T E M B E R 6 , 2 0 1 6 : 1 0 8 2</text>
<text top="67" left="182" width="17" height="10" font="7">– 1 1 5</text>
<text top="69" left="514" width="243" height="9" font="14">Focused Update on Duration of Dual Antiplatelet Therapy</text>
<text top="53" left="786" width="21" height="9" font="5">1099</text>
</page>
<page number="19" position="absolute" top="0" left="0" height="1160" width="864">
<text top="143" left="108" width="329" height="11" font="12">7.3. Duration of DAPT in Patients With ACS Treated With PCI:</text>
<text top="161" left="131" width="97" height="11" font="12">Recommendations</text>
<text top="182" left="108" width="20" height="12" font="2">See</text>
<text top="182" left="130" width="171" height="12" font="4"><a href="http://jaccjacc.acc.org/Clinical_Document/DAPT_Data_Supplement_1.pdf">Online Data Supplements 1 to 9</a></text>
<text top="182" left="304" width="137" height="12" font="2">for evidence supporting</text>
<text top="200" left="108" width="142" height="12" font="2">these recommendations.</text>
<text top="735" left="108" width="333" height="11" font="12">7.4. Duration of DAPT in Patients With ACS Treated With CABG:</text>
<text top="753" left="132" width="92" height="11" font="12">Recommendation</text>
<text top="774" left="108" width="20" height="12" font="2">See</text>
<text top="774" left="136" width="219" height="12" font="4"><a href="http://jaccjacc.acc.org/Clinical_Document/DAPT_Data_Supplement_1.pdf">Online Data Supplements 4 and 11</a></text>
<text top="774" left="364" width="77" height="12" font="2">for evidence</text>
<text top="792" left="108" width="195" height="12" font="2">supporting this recommendation.</text>
<text top="1034" left="108" width="231" height="11" font="12">7.5. Duration of DAPT in Patients With ACS</text>
<text top="1056" left="108" width="333" height="12" font="2">Aspirin remains the cornerstone of antiplatelet therapy in</text>
<text top="1074" left="108" width="333" height="12" font="2">patients with ACS. Further platelet inhibition, with an</text>
<text top="1092" left="108" width="333" height="12" font="2">associated reduction in ischemic risk, can be achieved by</text>
<text top="734" left="468" width="98" height="12" font="2">blocking the P2Y</text>
<text top="739" left="566" width="9" height="8" font="7">12</text>
<text top="734" left="579" width="222" height="12" font="2">receptor. In the CURE trial of patients</text>
<text top="752" left="468" width="333" height="12" font="2">with NSTE-ACS, the addition of clopidogrel (for up to 1</text>
<text top="770" left="468" width="333" height="12" font="2">year) to aspirin monotherapy resulted in a 2.1% absolute</text>
<text top="788" left="468" width="333" height="12" font="2">reduction in subsequent ischemic events but also a 1.0%</text>
<text top="806" left="468" width="209" height="12" font="2">absolute increase in major bleeding</text>
<text top="806" left="681" width="21" height="12" font="4"><a href="1082.full.html#24">(52)</a></text>
<text top="806" left="703" width="99" height="12" font="2"><a href="1082.full.html#24">. </a>The majority of</text>
<text top="824" left="468" width="333" height="12" font="2">patients in this study were treated without revasculari-</text>
<text top="842" left="468" width="115" height="12" font="2">zation, though bene</text>
<text top="840" left="584" width="218" height="15" font="2">ﬁt was observed both in those treated</text>
<text top="860" left="468" width="333" height="12" font="2">with revascularization (PCI or CABG) and in those treated</text>
<text top="878" left="468" width="167" height="12" font="2">with medical therapy alone</text>
<text top="878" left="642" width="37" height="12" font="4"><a href="1082.full.html#24">(51,52)</a></text>
<text top="878" left="679" width="122" height="12" font="2"><a href="1082.full.html#24">. </a>Available evidence</text>
<text top="896" left="468" width="244" height="12" font="2">from this trial, as well as from PLATO</text>
<text top="896" left="719" width="53" height="12" font="4"><a href="1082.full.html#24">(53,71,72)</a></text>
<text top="896" left="780" width="21" height="12" font="2">and</text>
<text top="914" left="468" width="98" height="12" font="2">TRITON-TIMI 38</text>
<text top="914" left="572" width="39" height="12" font="4"><a href="1082.full.html#24">(54,55)</a></text>
<text top="914" left="612" width="190" height="12" font="2"><a href="1082.full.html#24">, </a>supports DAPT duration of at</text>
<text top="932" left="468" width="259" height="12" font="2">least 12 months for patients with NSTE-ACS.</text>
<text top="950" left="483" width="159" height="12" font="2">The results of the CURE trial</text>
<text top="950" left="645" width="21" height="12" font="4"><a href="1082.full.html#24">(52)</a></text>
<text top="950" left="669" width="133" height="12" font="2">and PCI-CURE analyses</text>
<text top="968" left="468" width="106" height="12" font="2">of the CURE trial</text>
<text top="968" left="581" width="20" height="12" font="4"><a href="1082.full.html#24">(51)</a></text>
<text top="968" left="607" width="4" height="12" font="2">(</text>
<text top="968" left="612" width="116" height="12" font="4"><a href="http://jaccjacc.acc.org/Clinical_Document/DAPT_Data_Supplement_1.pdf">Data Supplement 4</a></text>
<text top="968" left="729" width="73" height="12" font="2"><a href="http://jaccjacc.acc.org/Clinical_Document/DAPT_Data_Supplement_1.pdf">) </a>have been</text>
<text top="985" left="468" width="333" height="12" font="2">extrapolated to patients with STEMI on the basis of the</text>
<text top="1003" left="468" width="333" height="12" font="2">consideration that NSTE-ACS and STEMI are both part of</text>
<text top="1021" left="468" width="333" height="12" font="2">the spectrum of ACS and usually caused by coronary pla-</text>
<text top="1039" left="468" width="333" height="12" font="2">que rupture. Based on this consideration, as well as the</text>
<text top="1057" left="468" width="333" height="12" font="2">results from the PLATO and TRITON-TIMI 38 trials, it is</text>
<text top="1075" left="468" width="333" height="12" font="2">recommended that patients with STEMI treated with cor-</text>
<text top="1093" left="468" width="333" height="12" font="2">onary stent implantation or medical therapy alone</text>
<text top="232" left="57" width="443" height="11" font="20">Recommendations for Duration of DAPT in Patients With ACS Treated With PCI</text>
<text top="273" left="83" width="19" height="10" font="14">COR</text>
<text top="273" left="156" width="18" height="10" font="14">LOE</text>
<text top="273" left="227" width="96" height="10" font="14">RECOMMENDATIONS</text>
<text top="309" left="92" width="3" height="9" font="5">I</text>
<text top="309" left="157" width="15" height="9" font="5">B-R</text>
<text top="297" left="227" width="384" height="11" font="12">In patients with ACS treated with DAPT after BMS or DES implantation, P2Y</text>
<text top="302" left="612" width="8" height="7" font="13">12</text>
<text top="297" left="623" width="151" height="11" font="12">inhibitor therapy (clopidogrel,</text>
<text top="312" left="227" width="319" height="11" font="12">prasugrel, or ticagrelor) should be given for at least 12 months</text>
<text top="312" left="550" width="32" height="11" font="4"><a href="1082.full.html#24">(16,50</a></text>
<text top="310" left="582" width="72" height="15" font="4"><a href="1082.full.html#24">–55,72,96–98)</a></text>
<text top="312" left="655" width="3" height="11" font="12"><a href="1082.full.html#24">.</a></text>
<text top="357" left="92" width="3" height="9" font="5">I</text>
<text top="357" left="154" width="21" height="9" font="5">B-NR</text>
<text top="344" left="227" width="525" height="11" font="12">In patients treated with DAPT, a daily aspirin dose of 81 mg (range, 75 mg to 100 mg) is recommended</text>
<text top="360" left="227" width="17" height="11" font="4"><a href="1082.full.html#25">(56</a></text>
<text top="357" left="244" width="56" height="15" font="4"><a href="1082.full.html#25">–60,75–78)</a></text>
<text top="360" left="301" width="3" height="11" font="12"><a href="1082.full.html#25">.</a></text>
<text top="405" left="88" width="10" height="9" font="5">IIa</text>
<text top="405" left="157" width="15" height="9" font="5">B-R</text>
<text top="393" left="227" width="554" height="11" font="12">In patients with ACS treated with DAPT after coronary stent implantation, it is reasonable to use ticagrelor in</text>
<text top="408" left="227" width="236" height="11" font="12">preference to clopidogrel for maintenance P2Y</text>
<text top="413" left="464" width="8" height="7" font="13">12</text>
<text top="408" left="475" width="84" height="11" font="12">inhibitor therapy</text>
<text top="408" left="563" width="35" height="11" font="4"><a href="1082.full.html#24">(53,72)</a></text>
<text top="408" left="598" width="3" height="11" font="12"><a href="1082.full.html#24">.</a></text>
<text top="454" left="88" width="10" height="9" font="5">IIa</text>
<text top="454" left="157" width="15" height="9" font="5">B-R</text>
<text top="442" left="227" width="564" height="11" font="12">In patients with ACS treated with DAPT after coronary stent implantation, who are not at high risk for bleeding</text>
<text top="457" left="227" width="574" height="11" font="12">complications and who do not have a history of stroke or TIA, it is reasonable to choose prasugrel over clopidogrel</text>
<text top="472" left="227" width="105" height="11" font="12">for maintenance P2Y</text>
<text top="477" left="332" width="8" height="7" font="13">12</text>
<text top="472" left="344" width="84" height="11" font="12">inhibitor therapy</text>
<text top="472" left="431" width="36" height="11" font="4"><a href="1082.full.html#24">(54,55)</a></text>
<text top="472" left="467" width="3" height="11" font="12">.</text>
<text top="518" left="88" width="10" height="9" font="5">IIb</text>
<text top="518" left="156" width="6" height="9" font="5">A</text>
<text top="517" left="165" width="8" height="6" font="28">SR</text>
<text top="506" left="227" width="535" height="11" font="12">In patients with ACS treated with coronary stent implantation who have tolerated DAPT without bleeding</text>
<text top="521" left="227" width="574" height="11" font="12">complication and who are not at high bleeding risk (e.g., prior bleeding on DAPT, coagulopathy, oral anticoagulant</text>
<text top="536" left="227" width="367" height="11" font="12">use) continuation of DAPT for longer than 12 months may be reasonable</text>
<text top="536" left="598" width="31" height="11" font="4"><a href="1082.full.html#24">(16,22</a></text>
<text top="534" left="629" width="149" height="15" font="4"><a href="1082.full.html#24">–26,28,30,40,41,43,53,54,72)</a></text>
<text top="536" left="779" width="3" height="11" font="12"><a href="1082.full.html#24">.</a></text>
<text top="582" left="88" width="10" height="9" font="5">IIb</text>
<text top="582" left="155" width="20" height="9" font="5">C-LD</text>
<text top="570" left="227" width="574" height="11" font="12">In patients with ACS treated with DAPT after DES implantation who develop a high risk of bleeding (e.g., treatment</text>
<text top="585" left="227" width="574" height="11" font="12">with oral anticoagulant therapy), are at high risk of severe bleeding complication (e.g., major intracranial surgery),</text>
<text top="600" left="227" width="81" height="11" font="12">or develop signi</text>
<text top="598" left="308" width="226" height="15" font="12">ﬁcant overt bleeding, discontinuation of P2Y</text>
<text top="605" left="534" width="8" height="7" font="13">12</text>
<text top="600" left="545" width="216" height="11" font="12">therapy after 6 months may be reasonable</text>
<text top="616" left="227" width="14" height="11" font="4"><a href="1082.full.html#24">(17</a></text>
<text top="614" left="242" width="67" height="15" font="4"><a href="1082.full.html#24">–21,34,36,37)</a></text>
<text top="616" left="308" width="3" height="11" font="12">.</text>
<text top="662" left="76" width="35" height="9" font="5">III: Harm</text>
<text top="662" left="157" width="15" height="9" font="5">B-R</text>
<text top="649" left="227" width="431" height="11" font="12">Prasugrel should not be administered to patients with a prior history of stroke or TIA</text>
<text top="649" left="662" width="21" height="11" font="4"><a href="1082.full.html#24">(54)</a></text>
<text top="649" left="683" width="3" height="11" font="12">.</text>
<text top="705" left="57" width="120" height="8" font="5">SR indicates systematic review.</text>
<text top="824" left="108" width="324" height="11" font="20">Recommendation for Duration of DAPT in Patients With</text>
<text top="838" left="108" width="133" height="11" font="20">ACS Treated With CABG</text>
<text top="879" left="134" width="19" height="10" font="14">COR</text>
<text top="879" left="206" width="18" height="10" font="14">LOE</text>
<text top="879" left="278" width="91" height="10" font="14">RECOMMENDATION</text>
<text top="916" left="142" width="3" height="9" font="5">I</text>
<text top="916" left="205" width="20" height="9" font="5">C-LD</text>
<text top="903" left="278" width="134" height="11" font="12">In patients with ACS being</text>
<text top="919" left="278" width="163" height="11" font="12">treated with DAPT who undergo</text>
<text top="934" left="278" width="54" height="11" font="12">CABG, P2Y</text>
<text top="939" left="332" width="8" height="7" font="13">12</text>
<text top="934" left="344" width="84" height="11" font="12">inhibitor therapy</text>
<text top="949" left="278" width="155" height="11" font="12">should be resumed after CABG</text>
<text top="964" left="278" width="131" height="11" font="12">to complete 12 months of</text>
<text top="980" left="278" width="121" height="11" font="12">DAPT therapy after ACS</text>
<text top="995" left="278" width="16" height="11" font="4"><a href="1082.full.html#24">(52</a></text>
<text top="993" left="294" width="65" height="15" font="4"><a href="1082.full.html#24">–54,118–120)</a></text>
<text top="995" left="359" width="3" height="11" font="12"><a href="1082.full.html#24">.</a></text>
<text top="53" left="108" width="52" height="9" font="14">Levine et al.</text>
<text top="54" left="670" width="132" height="7" font="7">J A C C V O L . 6 8 , N O . 1 0 , 2 0 1 6</text>
<text top="68" left="108" width="243" height="9" font="14">Focused Update on Duration of Dual Antiplatelet Therapy</text>
<text top="69" left="665" width="117" height="7" font="7">S E P T E M B E R 6 , 2 0 1 6 : 1 0 8 2</text>
<text top="67" left="784" width="17" height="10" font="7">– 1 1 5</text>
<text top="53" left="57" width="20" height="9" font="5">1100</text>
</page>
<page number="20" position="absolute" top="0" left="0" height="1160" width="864">
<text top="143" left="63" width="333" height="12" font="2">(without revascularization or reperfusion therapy) be</text>
<text top="161" left="63" width="252" height="12" font="2">treated with DAPT for at least 12 months</text>
<text top="161" left="321" width="17" height="12" font="4"><a href="1082.full.html#24">(53</a></text>
<text top="159" left="338" width="54" height="15" font="4"><a href="1082.full.html#24">–55,71,72)</a></text>
<text top="161" left="393" width="3" height="12" font="2"><a href="1082.full.html#24">.</a></text>
<text top="178" left="63" width="179" height="12" font="2">Ticagrelor is considered a P2Y</text>
<text top="183" left="242" width="9" height="8" font="7">12</text>
<text top="178" left="256" width="140" height="12" font="2">treatment option in pa-</text>
<text top="196" left="63" width="333" height="12" font="2">tients with STEMI not treated with revascularization (or</text>
<text top="214" left="63" width="333" height="12" font="2">reperfusion therapy) on the basis of a similar extrapolation</text>
<text top="232" left="63" width="119" height="12" font="2">of the results of the</text>
<text top="230" left="187" width="209" height="15" font="2">“medically managed” patients with</text>
<text top="250" left="63" width="137" height="12" font="2">ACS in the PLATO trial</text>
<text top="250" left="205" width="20" height="12" font="4"><a href="1082.full.html#25">(71)</a></text>
<text top="250" left="225" width="171" height="12" font="2">. On the basis of CURE, PCI-</text>
<text top="268" left="63" width="333" height="12" font="2">CURE, PLATO, and TRITON-TIMI 38, clopidogrel, prasu-</text>
<text top="286" left="63" width="177" height="12" font="2">grel, and ticagrelor are all P2Y</text>
<text top="291" left="240" width="9" height="8" font="7">12</text>
<text top="286" left="253" width="143" height="12" font="2">treatment options in pa-</text>
<text top="304" left="63" width="189" height="12" font="2">tients with ACS treated with PCI.</text>
<text top="322" left="78" width="318" height="12" font="2">In the CLARITY-TIMI 28 (Clopidogrel as Adjunctive</text>
<text top="340" left="63" width="70" height="12" font="2">Reperfusion</text>
<text top="340" left="150" width="48" height="12" font="2">Therapy</text>
<text top="338" left="198" width="88" height="15" font="2">—Thrombolysis</text>
<text top="340" left="303" width="12" height="12" font="2">In</text>
<text top="340" left="332" width="64" height="12" font="2">Myocardial</text>
<text top="358" left="63" width="333" height="12" font="2">Infarction 28) trial, short-term treatment (up to 8 days)</text>
<text top="376" left="63" width="333" height="12" font="2">with clopidogrel (in addition to aspirin) in patients with</text>
<text top="394" left="63" width="111" height="12" font="2">STEMI undergoing</text>
<text top="392" left="182" width="214" height="15" font="2">ﬁbrinolytic therapy improved TIMI</text>
<text top="410" left="63" width="333" height="15" font="2">ﬂow grade in the culprit artery and decreased the com-</text>
<text top="430" left="63" width="333" height="12" font="2">posite endpoint of cardiovascular death, reinfarction, or</text>
<text top="447" left="63" width="223" height="12" font="2">the need for urgent revascularization</text>
<text top="447" left="291" width="27" height="12" font="4"><a href="1082.full.html#27">(142)</a></text>
<text top="447" left="319" width="77" height="12" font="2"><a href="1082.full.html#27">. </a>In COMMIT</text>
<text top="465" left="63" width="333" height="12" font="2">(Clopidogrel and Metoprolol in Myocardial Infarction</text>
<text top="483" left="63" width="333" height="12" font="2">Trial) (93% with STEMI not managed with primary PCI),</text>
<text top="501" left="63" width="79" height="12" font="2">treatment for</text>
<text top="499" left="146" width="250" height="15" font="2">z2 weeks with clopidogrel (in addition to</text>
<text top="519" left="63" width="333" height="12" font="2">aspirin 162 mg) resulted in a 0.9% absolute reduction of</text>
<text top="537" left="63" width="333" height="12" font="2">the 28-day composite endpoint of death, reinfarction, or</text>
<text top="555" left="63" width="281" height="12" font="2">stroke and a 0.6% absolute reduction in death</text>
<text top="555" left="350" width="29" height="12" font="4"><a href="1082.full.html#27">(140)</a></text>
<text top="555" left="379" width="17" height="12" font="2"><a href="1082.full.html#27">. </a>A</text>
<text top="573" left="63" width="333" height="12" font="2">1.1% absolute risk reduction in the composite endpoint</text>
<text top="591" left="63" width="333" height="12" font="2">was seen in the subgroup of patients who received</text>
<text top="607" left="63" width="333" height="15" font="2">ﬁbrinolytic therapy. On the basis of these trials and</text>
<text top="627" left="63" width="333" height="12" font="2">extrapolation of the results of CURE, DAPT with aspirin</text>
<text top="645" left="63" width="333" height="12" font="2">and clopidogrel is recommended for a minimum of 14</text>
<text top="663" left="63" width="333" height="12" font="2">days and ideally at least 12 months in patients with</text>
<text top="681" left="63" width="37" height="12" font="2">STEMI</text>
<text top="681" left="118" width="41" height="12" font="2">treated</text>
<text top="681" left="178" width="26" height="12" font="2">with</text>
<text top="679" left="222" width="64" height="15" font="2">ﬁbrinolytic</text>
<text top="681" left="303" width="44" height="12" font="2">therapy</text>
<text top="681" left="366" width="4" height="12" font="2">(</text>
<text top="681" left="370" width="26" height="12" font="4"><a href="http://jaccjacc.acc.org/Clinical_Document/DAPT_Data_Supplement_1.pdf">Data</a></text>
<text top="698" left="63" width="82" height="12" font="4"><a href="http://jaccjacc.acc.org/Clinical_Document/DAPT_Data_Supplement_1.pdf">Supplement 4</a></text>
<text top="698" left="145" width="8" height="12" font="2"><a href="http://jaccjacc.acc.org/Clinical_Document/DAPT_Data_Supplement_1.pdf">).</a></text>
<text top="716" left="78" width="93" height="12" font="2">As discussed in</text>
<text top="716" left="177" width="55" height="12" font="4"><a href="1082.full.html#8">Section 3</a></text>
<text top="716" left="232" width="164" height="12" font="2">, treatment with prolonged</text>
<text top="734" left="63" width="333" height="12" font="2">(extended) DAPT beyond a minimum recommended</text>
<text top="143" left="423" width="333" height="12" font="2">duration necessitates a fundamental tradeoff between</text>
<text top="161" left="423" width="333" height="12" font="2">decreasing ischemic risk (e.g., MI and stent thrombosis)</text>
<text top="178" left="423" width="165" height="12" font="2">and increasing bleeding risk</text>
<text top="178" left="593" width="144" height="12" font="4"><a href="1082.full.html#24">(16,24,28,30,34,36,37,46)</a></text>
<text top="178" left="737" width="20" height="12" font="2"><a href="1082.full.html#24">. </a>In</text>
<text top="196" left="423" width="333" height="12" font="2">post-MI patients, extended DAPT for approximately 18 to</text>
<text top="214" left="423" width="333" height="12" font="2">36 months leads to an absolute decrease in ischemic com-</text>
<text top="232" left="423" width="75" height="12" font="2">plications of</text>
<text top="230" left="506" width="251" height="15" font="2">z1% to 3% and an absolute increase in</text>
<text top="250" left="423" width="159" height="12" font="2">bleeding complications of</text>
<text top="248" left="591" width="40" height="15" font="2">z1% (</text>
<text top="250" left="632" width="121" height="12" font="4"><a href="http://jaccjacc.acc.org/Clinical_Document/DAPT_Data_Supplement_1.pdf">Data Supplement 4</a></text>
<text top="250" left="752" width="4" height="12" font="2">)</text>
<text top="268" left="423" width="94" height="12" font="4"><a href="1082.full.html#24">(28,40,41,43,44)</a></text>
<text top="268" left="517" width="239" height="12" font="2">. An analysis from the PEGASUS-TIMI 54</text>
<text top="286" left="423" width="333" height="12" font="2">trial found that the greatest reduction in ischemic events</text>
<text top="304" left="423" width="333" height="12" font="2">with prolonged DAPT in post-MI patients was in patients in</text>
<text top="322" left="423" width="63" height="12" font="2">whom P2Y</text>
<text top="327" left="487" width="9" height="8" font="7">12</text>
<text top="322" left="501" width="255" height="12" font="2">inhibitor therapy either had not been dis-</text>
<text top="340" left="423" width="223" height="12" font="2">continued or had been discontinued for</text>
<text top="338" left="649" width="108" height="15" font="2">#30 days (absolute</text>
<text top="358" left="423" width="251" height="12" font="2">reduction in MACE: 1.9 % to 2.5%). No bene</text>
<text top="356" left="674" width="82" height="15" font="2">ﬁt was seen in</text>
<text top="376" left="423" width="132" height="12" font="2">patients in whom P2Y</text>
<text top="381" left="555" width="9" height="8" font="7">12</text>
<text top="376" left="569" width="187" height="12" font="2">inhibitor therapy had been dis-</text>
<text top="394" left="423" width="59" height="12" font="2">continued</text>
<text top="392" left="488" width="237" height="15" font="2">&gt;1 year before enrollment in the study</text>
<text top="394" left="730" width="22" height="12" font="4"><a href="1082.full.html#24">(42)</a></text>
<text top="394" left="753" width="3" height="12" font="2"><a href="1082.full.html#24">.</a></text>
<text top="412" left="423" width="333" height="12" font="2">Decisions about treatment with and duration of DAPT in</text>
<text top="430" left="423" width="333" height="12" font="2">patients with ACS require a thoughtful assessment of the</text>
<text top="447" left="423" width="28" height="12" font="2">bene</text>
<text top="446" left="451" width="305" height="15" font="2">ﬁt/risk ratio, integration of study data, and consider-</text>
<text top="465" left="423" width="158" height="12" font="2">ation of patient preference.</text>
<text top="483" left="438" width="318" height="12" font="2">In patients treated with DAPT with high bleeding risk</text>
<text top="501" left="423" width="333" height="12" font="2">(e.g., oral anticoagulation), increased risk of severe bleed-</text>
<text top="519" left="423" width="333" height="12" font="2">ing complications (e.g., major intracranial surgery), or sig-</text>
<text top="537" left="423" width="11" height="12" font="2">ni</text>
<text top="535" left="434" width="322" height="15" font="2">ﬁcant overt bleeding, the beneﬁt/risk ratio may favor</text>
<text top="555" left="423" width="256" height="12" font="2">shorter-than-recommended duration of DAPT</text>
<text top="555" left="681" width="15" height="12" font="4"><a href="1082.full.html#24">(17</a></text>
<text top="553" left="697" width="56" height="15" font="4"><a href="1082.full.html#24">–21,34,36)</a></text>
<text top="555" left="753" width="3" height="12" font="2"><a href="1082.full.html#24">.</a></text>
<text top="573" left="438" width="318" height="12" font="2">Recommendations for DAPT in patients with ACS</text>
<text top="591" left="423" width="212" height="12" font="2">treated with medical therapy alone,</text>
<text top="589" left="640" width="117" height="15" font="2">ﬁbrinolytic therapy,</text>
<text top="609" left="423" width="198" height="12" font="2">PCI, and CABG are summarized in</text>
<text top="609" left="625" width="46" height="11" font="4"><a href="1082.full.html#21">Figure 5</a></text>
<text top="609" left="671" width="3" height="12" font="2">.</text>
<text top="643" left="423" width="294" height="16" font="15">8. PERIOPERATIVE MANAGEMENT–TIMING OF</text>
<text top="660" left="423" width="307" height="16" font="15">ELECTIVE NONCARDIAC SURGERY IN PATIENTS</text>
<text top="678" left="423" width="333" height="16" font="15">TREATED WITH PCI AND DAPT: RECOMMENDATIONS</text>
<text top="716" left="423" width="20" height="12" font="2">See</text>
<text top="716" left="449" width="159" height="12" font="4"><a href="http://jaccjacc.acc.org/Clinical_Document/DAPT_Data_Supplement_1.pdf">Online Data Supplement 12</a></text>
<text top="716" left="613" width="143" height="12" font="2">for evidence supporting</text>
<text top="734" left="423" width="143" height="12" font="2">these recommendations.</text>
<text top="766" left="63" width="277" height="11" font="20">Recommendations for Perioperative Management</text>
<text top="764" left="340" width="440" height="15" font="20">–Timing of Elective Noncardiac Surgery in Patients Treated With PCI and DAPT</text>
<text top="807" left="89" width="19" height="10" font="14">COR</text>
<text top="807" left="161" width="18" height="10" font="14">LOE</text>
<text top="807" left="233" width="96" height="10" font="14">RECOMMENDATIONS</text>
<text top="844" left="97" width="3" height="9" font="5">I</text>
<text top="844" left="160" width="21" height="9" font="5">B-NR</text>
<text top="832" left="233" width="574" height="11" font="12">Elective noncardiac surgery should be delayed 30 days after BMS implantation and optimally 6 months after DES</text>
<text top="847" left="233" width="63" height="11" font="12">implantation</text>
<text top="847" left="300" width="21" height="11" font="4"><a href="1082.full.html#26">(101</a></text>
<text top="845" left="321" width="71" height="15" font="4"><a href="1082.full.html#26">–103,143–146)</a></text>
<text top="847" left="392" width="3" height="11" font="12">.</text>
<text top="891" left="97" width="3" height="9" font="5">I</text>
<text top="891" left="160" width="20" height="9" font="5">C-EO</text>
<text top="879" left="233" width="547" height="11" font="12">In patients treated with DAPT after coronary stent implantation who must undergo surgical procedures that</text>
<text top="894" left="233" width="179" height="11" font="12">mandate the discontinuation of P2Y</text>
<text top="899" left="412" width="8" height="7" font="13">12</text>
<text top="894" left="423" width="384" height="11" font="12">inhibitor therapy, it is recommended that aspirin be continued if possible and</text>
<text top="910" left="233" width="39" height="11" font="12">the P2Y</text>
<text top="914" left="272" width="8" height="7" font="13">12</text>
<text top="910" left="284" width="368" height="11" font="12">platelet receptor inhibitor be restarted as soon as possible after surgery.</text>
<text top="955" left="94" width="10" height="9" font="5">IIa</text>
<text top="955" left="160" width="20" height="9" font="5">C-EO</text>
<text top="943" left="233" width="338" height="11" font="12">When noncardiac surgery is required in patients currently taking a P2Y</text>
<text top="948" left="572" width="8" height="7" font="13">12</text>
<text top="943" left="581" width="225" height="11" font="12">inhibitor, a consensus decision among treating</text>
<text top="958" left="233" width="574" height="11" font="12">clinicians as to the relative risks of surgery and discontinuation or continuation of antiplatelet therapy can be useful.</text>
<text top="1004" left="94" width="10" height="9" font="5">IIb</text>
<text top="1004" left="160" width="20" height="9" font="5">C-EO</text>
<text top="992" left="233" width="389" height="11" font="12">Elective noncardiac surgery after DES implantation in patients for whom P2Y</text>
<text top="996" left="622" width="8" height="7" font="13">12</text>
<text top="992" left="634" width="164" height="11" font="12">inhibitor therapy will need to be</text>
<text top="1007" left="233" width="574" height="11" font="12">discontinued may be considered after 3 months if the risk of further delay of surgery is greater than the expected</text>
<text top="1022" left="233" width="128" height="11" font="12">risks of stent thrombosis.</text>
<text top="1068" left="81" width="35" height="9" font="5">III: Harm</text>
<text top="1068" left="160" width="21" height="9" font="5">B-NR</text>
<text top="1056" left="233" width="567" height="11" font="12">Elective noncardiac surgery should not be performed within 30 days after BMS implantation or within 3 months</text>
<text top="1071" left="233" width="475" height="11" font="12">after DES implantation in patients in whom DAPT will need to be discontinued perioperatively</text>
<text top="1071" left="712" width="21" height="11" font="4"><a href="1082.full.html#26">(101</a></text>
<text top="1069" left="733" width="71" height="15" font="4"><a href="1082.full.html#26">–103,143–146)</a></text>
<text top="1071" left="804" width="3" height="11" font="12"><a href="1082.full.html#26">.</a></text>
<text top="54" left="63" width="132" height="7" font="7">J A C C V O L . 6 8 , N O . 1 0 , 2 0 1 6</text>
<text top="54" left="705" width="52" height="9" font="14">Levine et al.</text>
<text top="69" left="63" width="117" height="7" font="7">S E P T E M B E R 6 , 2 0 1 6 : 1 0 8 2</text>
<text top="67" left="182" width="17" height="10" font="7">– 1 1 5</text>
<text top="69" left="514" width="243" height="9" font="14">Focused Update on Duration of Dual Antiplatelet Therapy</text>
<text top="53" left="790" width="17" height="9" font="5">1101</text>
</page>
<page number="21" position="absolute" top="0" left="0" height="1160" width="864">
<text top="824" left="123" width="318" height="12" font="2">The timing of noncardiac surgery in patients treated</text>
<text top="842" left="108" width="333" height="12" font="2">with coronary stent implantation involves consideration</text>
<text top="860" left="108" width="333" height="12" font="2">of: (1) the risk of stent thrombosis (particularly if DAPT</text>
<text top="878" left="108" width="333" height="12" font="2">needs to be interrupted); (2) the consequences of</text>
<text top="896" left="108" width="49" height="12" font="2">delaying</text>
<text top="896" left="170" width="19" height="12" font="2">the</text>
<text top="896" left="202" width="43" height="12" font="2">desired</text>
<text top="896" left="258" width="45" height="12" font="2">surgical</text>
<text top="896" left="316" width="63" height="12" font="2">procedure;</text>
<text top="896" left="392" width="21" height="12" font="2">and</text>
<text top="896" left="426" width="15" height="12" font="2">(3)</text>
<text top="914" left="108" width="333" height="12" font="2">increased the intra- and peri-procedural bleeding risk</text>
<text top="932" left="108" width="333" height="12" font="2">and the consequences of such bleeding if DAPT is</text>
<text top="950" left="108" width="59" height="12" font="2">continued</text>
<text top="950" left="178" width="67" height="12" font="4"><a href="1082.full.html#24">(15,147,148)</a></text>
<text top="950" left="256" width="4" height="12" font="2">(</text>
<text top="950" left="260" width="130" height="12" font="4"><a href="http://jaccjacc.acc.org/Clinical_Document/DAPT_Data_Supplement_1.pdf">Data Supplement 12</a></text>
<text top="950" left="390" width="51" height="12" font="2"><a href="http://jaccjacc.acc.org/Clinical_Document/DAPT_Data_Supplement_1.pdf">). </a>DAPT</text>
<text top="968" left="108" width="27" height="12" font="2">signi</text>
<text top="966" left="135" width="306" height="15" font="2">ﬁcantly reduces the risk of stent thrombosis</text>
<text top="985" left="108" width="92" height="12" font="4"><a href="1082.full.html#24">(50,51,94,95,99)</a></text>
<text top="985" left="200" width="241" height="12" font="2"><a href="1082.full.html#24">, </a>and discontinuation of DAPT in the</text>
<text top="1003" left="108" width="333" height="12" font="2">weeks after stent implantation is one of the strongest</text>
<text top="1021" left="108" width="333" height="12" font="2">risk factors for stent thrombosis, with the magnitude of</text>
<text top="1039" left="108" width="333" height="12" font="2">risk and impact on mortality rate inversely proportional</text>
<text top="1057" left="108" width="11" height="12" font="2">to</text>
<text top="1057" left="131" width="19" height="12" font="2">the</text>
<text top="1057" left="163" width="38" height="12" font="2">timing</text>
<text top="1057" left="213" width="11" height="12" font="2">of</text>
<text top="1057" left="236" width="63" height="12" font="2">occurrence</text>
<text top="1057" left="312" width="27" height="12" font="2">after</text>
<text top="1057" left="351" width="19" height="12" font="2">the</text>
<text top="1057" left="382" width="59" height="12" font="2">procedure</text>
<text top="1075" left="108" width="74" height="12" font="4"><a href="1082.full.html#27">(145,149,150)</a></text>
<text top="1075" left="182" width="259" height="12" font="2">. Older observational studies found that the</text>
<text top="1093" left="108" width="333" height="12" font="2">risk of stent-related thrombotic complications is highest</text>
<text top="824" left="468" width="37" height="12" font="2">in the</text>
<text top="822" left="512" width="290" height="15" font="2">ﬁrst 4 to 6 weeks after stent implantation but</text>
<text top="842" left="468" width="333" height="12" font="2">continues to be elevated at least 1 year after DES place-</text>
<text top="860" left="468" width="30" height="12" font="2">ment</text>
<text top="860" left="504" width="22" height="12" font="4"><a href="1082.full.html#26">(101</a></text>
<text top="858" left="526" width="53" height="15" font="4"><a href="1082.full.html#26">–103,149)</a></text>
<text top="860" left="579" width="222" height="12" font="2">. Data from more recent large obser-</text>
<text top="878" left="468" width="333" height="12" font="2">vational studies suggest that the time frame of increased</text>
<text top="896" left="468" width="333" height="12" font="2">risk of stent thrombosis is on the order of 6 months,</text>
<text top="914" left="468" width="243" height="12" font="2">irrespective of stent type (BMS or DES)</text>
<text top="914" left="717" width="21" height="12" font="4"><a href="1082.full.html#27">(151</a></text>
<text top="912" left="738" width="28" height="15" font="4"><a href="1082.full.html#27">–153)</a></text>
<text top="914" left="767" width="35" height="12" font="2"><a href="1082.full.html#27">. </a>In a</text>
<text top="932" left="468" width="333" height="12" font="2">large cohort of patients from the Veterans Health</text>
<text top="950" left="468" width="333" height="12" font="2">Administration hospitals, the increased risk of surgery</text>
<text top="968" left="468" width="333" height="12" font="2">for the 6 months after stent placement was most pro-</text>
<text top="985" left="468" width="333" height="12" font="2">nounced in those patients in whom the indication for</text>
<text top="1003" left="468" width="89" height="12" font="2">PCI was an MI</text>
<text top="1003" left="562" width="28" height="12" font="4"><a href="1082.full.html#27">(146)</a></text>
<text top="1003" left="591" width="210" height="12" font="2">. An additional consideration, irre-</text>
<text top="1021" left="468" width="333" height="12" font="2">spective of the timing of surgery, is that surgery is</text>
<text top="1039" left="468" width="128" height="12" font="2">associated with proin</text>
<text top="1037" left="597" width="205" height="15" font="2">ﬂammatory and prothrombotic ef-</text>
<text top="1057" left="468" width="333" height="12" font="2">fects that may increase the risk of coronary thrombosis</text>
<text top="1075" left="468" width="333" height="12" font="2">at the level of the stented vascular segment as well as</text>
<text top="1093" left="468" width="217" height="12" font="2">throughout the coronary vasculature</text>
<text top="1093" left="690" width="49" height="12" font="4"><a href="1082.full.html#27">(154,155)</a></text>
<text top="1093" left="740" width="3" height="12" font="2"><a href="1082.full.html#27">.</a></text>
<text top="153" left="125" width="46" height="11" font="22">FIGURE 5</text>
<text top="154" left="178" width="184" height="9" font="23">Treatment Algorithm for Duration of P2Y</text>
<text top="158" left="363" width="7" height="6" font="24">12</text>
<text top="154" left="373" width="302" height="9" font="23">Inhibitor Therapy in Patients With Recent ACS (NSTE-ACS or STEMI)</text>
<text top="693" left="125" width="213" height="9" font="14">Colors correspond to Class of Recommendation in</text>
<text top="693" left="341" width="31" height="9" font="19"><a href="1082.full.html#4">Table 1</a></text>
<text top="693" left="372" width="127" height="9" font="14">. Arrows at the bottom of the</text>
<text top="691" left="503" width="280" height="12" font="14">ﬁgure denote that the optimal duration of prolonged DAPT is not</text>
<text top="708" left="125" width="255" height="9" font="14">established. Aspirin therapy is almost always continued inde</text>
<text top="706" left="380" width="403" height="12" font="14">ﬁnitely in patients with coronary artery disease. *High bleeding risk denotes those who have or</text>
<text top="723" left="125" width="635" height="9" font="14">develop a high risk of bleeding (e.g., treatment with oral anticoagulant therapy) or are at increased risk of severe bleeding complication (e.g., major</text>
<text top="738" left="125" width="657" height="9" font="14">intracranial surgery). ACS indicates acute coronary syndrome; BMS, bare metal stent; CABG, coronary artery bypass graft surgery; DAPT, dual antiplatelet</text>
<text top="753" left="125" width="163" height="9" font="14">therapy; DES, drug-eluting stent; lytic,</text>
<text top="751" left="290" width="493" height="12" font="14">ﬁbrinolytic therapy; NSTE-ACS, non–ST-elevation acute coronary syndrome; PCI, percutaneous coronary intervention;</text>
<text top="768" left="125" width="200" height="9" font="14">and STEMI, ST-elevation myocardial infarction.</text>
<text top="53" left="108" width="52" height="9" font="14">Levine et al.</text>
<text top="54" left="670" width="132" height="7" font="7">J A C C V O L . 6 8 , N O . 1 0 , 2 0 1 6</text>
<text top="68" left="108" width="243" height="9" font="14">Focused Update on Duration of Dual Antiplatelet Therapy</text>
<text top="69" left="665" width="117" height="7" font="7">S E P T E M B E R 6 , 2 0 1 6 : 1 0 8 2</text>
<text top="67" left="784" width="17" height="10" font="7">– 1 1 5</text>
<text top="53" left="57" width="18" height="9" font="5">1102</text>
</page>
<page number="22" position="absolute" top="0" left="0" height="1160" width="864">
<text top="769" left="78" width="318" height="12" font="2">Prior recommendations with regard to duration of DAPT</text>
<text top="787" left="63" width="40" height="12" font="4"><a href="1082.full.html#23">(9,104)</a></text>
<text top="787" left="108" width="223" height="12" font="2">and the timing of noncardiac surgery</text>
<text top="787" left="337" width="43" height="12" font="4"><a href="1082.full.html#24">(15,156)</a></text>
<text top="787" left="385" width="11" height="12" font="2">in</text>
<text top="805" left="63" width="333" height="12" font="2">patients treated with DES were based on observations of</text>
<text top="823" left="63" width="110" height="12" font="2">those treated with</text>
<text top="821" left="178" width="218" height="15" font="2">ﬁrst-generation DES. Compared with</text>
<text top="839" left="63" width="333" height="15" font="2">ﬁrst-generation DES, currently used newer-generation</text>
<text top="859" left="63" width="333" height="12" font="2">DES are associated with a lower risk of stent thrombosis</text>
<text top="876" left="63" width="333" height="12" font="2">and appear to require a shorter minimum duration of DAPT</text>
<text top="894" left="63" width="105" height="12" font="4"><a href="1082.full.html#24">(17,18,21,38,96,97)</a></text>
<text top="894" left="174" width="222" height="12" font="2">Several studies of DAPT duration in</text>
<text top="912" left="63" width="333" height="12" font="2">patients treated with newer-generation DES did not detect</text>
<text top="930" left="63" width="333" height="12" font="2">any difference in the risk of stent thrombosis between</text>
<text top="948" left="63" width="333" height="12" font="2">patients treated with 3 to 6 months of DAPT or patients</text>
<text top="966" left="63" width="333" height="12" font="2">treated with longer durations of DAPT (although these</text>
<text top="984" left="63" width="333" height="12" font="2">studies were underpowered to detect such differences)</text>
<text top="1002" left="63" width="16" height="12" font="4"><a href="1082.full.html#24">(17</a></text>
<text top="1000" left="79" width="21" height="15" font="4"><a href="1082.full.html#24">–21)</a></text>
<text top="1002" left="103" width="4" height="12" font="2">(</text>
<text top="1002" left="108" width="108" height="12" font="4"><a href="http://jaccjacc.acc.org/Clinical_Document/DAPT_Data_Supplement_1.pdf">Data Supplement 1</a></text>
<text top="1002" left="216" width="180" height="12" font="2"><a href="http://jaccjacc.acc.org/Clinical_Document/DAPT_Data_Supplement_1.pdf">)</a>. Moreover, the safety of treat-</text>
<text top="1020" left="63" width="333" height="12" font="2">ing selected patients with newer-generation DES for</text>
<text top="1038" left="63" width="333" height="12" font="2">shorter durations (3 or 6 months) of DAPT has been shown</text>
<text top="1056" left="63" width="333" height="12" font="2">in a patient-level analysis pooling 4 trials evaluating DAPT</text>
<text top="1074" left="63" width="55" height="12" font="2">durations</text>
<text top="1074" left="125" width="22" height="12" font="4"><a href="1082.full.html#24">(34)</a></text>
<text top="1074" left="147" width="249" height="12" font="2">. Furthermore, in the PARIS (Patterns of</text>
<text top="1092" left="63" width="333" height="12" font="2">Nonadherence to Antiplatelet Regimens in Stented</text>
<text top="769" left="423" width="333" height="12" font="2">Patients) registry, interruption of DAPT according to</text>
<text top="787" left="423" width="333" height="12" font="2">physician judgment in patients undergoing surgery at any</text>
<text top="805" left="423" width="333" height="12" font="2">time point after PCI was not associated with an increased</text>
<text top="823" left="423" width="72" height="12" font="2">risk of MACE</text>
<text top="823" left="497" width="27" height="12" font="4"><a href="1082.full.html#27">(145)</a></text>
<text top="823" left="525" width="232" height="12" font="2"><a href="1082.full.html#27">. </a>On the basis of these considerations, the</text>
<text top="841" left="423" width="333" height="12" font="2">prior Class I recommendation that elective noncardiac</text>
<text top="859" left="423" width="310" height="12" font="2">surgery in patients treated with DES be delayed 1 year</text>
<text top="859" left="736" width="20" height="12" font="4"><a href="1082.full.html#24">(15)</a></text>
<text top="876" left="423" width="84" height="12" font="2">has been modi</text>
<text top="875" left="507" width="249" height="15" font="2">ﬁed to “optimally at least 6 months.” Simi-</text>
<text top="894" left="423" width="333" height="12" font="2">larly, the prior Class IIb recommendation that elective</text>
<text top="912" left="423" width="333" height="12" font="2">noncardiac surgery in patients treated with DES may be</text>
<text top="930" left="423" width="145" height="12" font="2">considered after 180 days</text>
<text top="930" left="571" width="20" height="12" font="4"><a href="1082.full.html#24">(15)</a></text>
<text top="930" left="593" width="82" height="12" font="2">has been modi</text>
<text top="929" left="676" width="81" height="15" font="2">ﬁed to “after 3</text>
<text top="948" left="423" width="47" height="12" font="2">months.</text>
<text top="946" left="471" width="6" height="15" font="2">”</text>
<text top="949" left="487" width="52" height="11" font="4"><a href="1082.full.html#22">Figure 6</a></text>
<text top="948" left="549" width="208" height="12" font="2">summarizes recommendations on</text>
<text top="966" left="423" width="333" height="12" font="2">timing of elective noncardiac surgery in patients with</text>
<text top="984" left="423" width="93" height="12" font="2">coronary stents.</text>
<text top="1002" left="438" width="318" height="12" font="2">The magnitude of incremental bleeding risk in patients</text>
<text top="1020" left="423" width="333" height="12" font="2">treated with antiplatelet therapy who undergo surgery is</text>
<text top="1038" left="423" width="55" height="12" font="2">uncertain</text>
<text top="1038" left="483" width="49" height="12" font="4"><a href="1082.full.html#27">(157,158)</a></text>
<text top="1038" left="532" width="42" height="12" font="2">. If P2Y</text>
<text top="1043" left="574" width="9" height="8" font="7">12</text>
<text top="1038" left="587" width="170" height="12" font="2">inhibitor therapy needs to be</text>
<text top="1056" left="423" width="333" height="12" font="2">held in patients being treated with DAPT after stent im-</text>
<text top="1074" left="423" width="333" height="12" font="2">plantation, continuation of aspirin therapy if possible is</text>
<text top="1092" left="423" width="333" height="12" font="2">recommended, though this is based primarily on expert</text>
<text top="153" left="80" width="46" height="11" font="22">FIGURE 6</text>
<text top="154" left="134" width="449" height="9" font="23">Treatment Algorithm for the Timing of Elective Noncardiac Surgery in Patients With Coronary Stents</text>
<text top="700" left="80" width="209" height="9" font="14">Colors correspond to Class of Recommendation in</text>
<text top="700" left="291" width="30" height="9" font="19"><a href="1082.full.html#4">Table 1</a></text>
<text top="700" left="322" width="416" height="9" font="14"><a href="1082.full.html#4">. </a>BMS indicates bare metal stent; DAPT, dual antiplatelet therapy; DES, drug-eluting stent; and PCI,</text>
<text top="715" left="80" width="154" height="9" font="14">percutaneous coronary intervention.</text>
<text top="54" left="63" width="132" height="7" font="7">J A C C V O L . 6 8 , N O . 1 0 , 2 0 1 6</text>
<text top="54" left="705" width="52" height="9" font="14">Levine et al.</text>
<text top="69" left="63" width="117" height="7" font="7">S E P T E M B E R 6 , 2 0 1 6 : 1 0 8 2</text>
<text top="67" left="182" width="17" height="10" font="7">– 1 1 5</text>
<text top="69" left="514" width="243" height="9" font="14">Focused Update on Duration of Dual Antiplatelet Therapy</text>
<text top="53" left="789" width="18" height="9" font="5">1103</text>
</page>
<page number="23" position="absolute" top="0" left="0" height="1160" width="864">
	<fontspec id="31" size="7" family="Times" color="#e3202b"/>
<text top="143" left="108" width="100" height="12" font="2">opinion. If a P2Y</text>
<text top="148" left="208" width="9" height="8" font="7">12</text>
<text top="143" left="222" width="219" height="12" font="2">inhibitor has been held before a sur-</text>
<text top="161" left="108" width="333" height="12" font="2">gical procedure, therapy is restarted as soon as possible,</text>
<text top="178" left="108" width="333" height="12" font="2">given the substantial thrombotic hazard associated with</text>
<text top="196" left="108" width="333" height="12" font="2">lack of platelet inhibition early after surgery in patients</text>
<text top="214" left="108" width="333" height="12" font="2">with recent stent implantation. Although several small</text>
<text top="232" left="108" width="333" height="12" font="2">studies have used intravenous antiplatelet agents as a</text>
<text top="250" left="108" width="57" height="12" font="2">means of</text>
<text top="248" left="174" width="267" height="15" font="2">“bridging” in patients requiring temporary</text>
<text top="268" left="108" width="333" height="12" font="2">discontinuation of DAPT before surgery, there is no</text>
<text top="286" left="108" width="300" height="12" font="2">convincing clinical evidence demonstrating the ef</text>
<text top="284" left="408" width="33" height="15" font="2">ﬁcacy</text>
<text top="304" left="108" width="333" height="12" font="2">of bridging with either parenteral antiplatelet or antico-</text>
<text top="322" left="108" width="92" height="12" font="2">agulant therapy</text>
<text top="322" left="204" width="23" height="12" font="4"><a href="1082.full.html#27">(159</a></text>
<text top="320" left="227" width="29" height="15" font="4"><a href="1082.full.html#27">–163)</a></text>
<text top="322" left="256" width="3" height="12" font="2"><a href="1082.full.html#27">.</a></text>
<text top="340" left="123" width="318" height="12" font="2">Decisions about the timing of surgery and whether to</text>
<text top="358" left="108" width="333" height="12" font="2">discontinue DAPT after coronary stent implantation are</text>
<text top="376" left="108" width="333" height="12" font="2">best individualized. Such decisions involve weighing the</text>
<text top="394" left="108" width="333" height="12" font="2">particular surgical procedure and the risks of delaying the</text>
<text top="412" left="108" width="333" height="12" font="2">procedure, the risks of ischemia and stent thrombosis,</text>
<text top="430" left="108" width="333" height="12" font="2">and the risk and consequences of bleeding. Given the</text>
<text top="447" left="108" width="333" height="12" font="2">complexity of these considerations, decisions are best</text>
<text top="465" left="108" width="333" height="12" font="2">determined by a consensus of the surgeon, anesthesiolo-</text>
<text top="483" left="108" width="175" height="12" font="2">gist, cardiologist, and patient.</text>
<text top="518" left="108" width="166" height="16" font="15">PRESIDENTS AND STAFF</text>
<text top="556" left="108" width="188" height="12" font="2">American College of Cardiology</text>
<text top="573" left="108" width="285" height="12" font="2">Kim A. Williams, Sr, MD, FACC, FAHA, President</text>
<text top="143" left="468" width="225" height="12" font="2">Shalom Jacobovitz, Chief Executive Of</text>
<text top="141" left="693" width="25" height="15" font="2">ﬁcer</text>
<text top="161" left="468" width="333" height="12" font="2">William J. Oetgen, MD, MBA, FACC, Executive Vice</text>
<text top="178" left="482" width="318" height="12" font="2">President, Science, Education, Quality, and Publishing</text>
<text top="196" left="468" width="333" height="12" font="2">Amelia Scholtz, PhD, Publications Manager, Science,</text>
<text top="214" left="482" width="203" height="12" font="2">Education, Quality, and Publishing</text>
<text top="241" left="468" width="333" height="12" font="2">American College of Cardiology/American Heart Association</text>
<text top="259" left="468" width="333" height="12" font="2">Melanie Stephens-Lyman, MSc, Director, Guideline Operations</text>
<text top="277" left="482" width="68" height="12" font="2">and Strategy</text>
<text top="295" left="468" width="53" height="12" font="2">Lisa Brad</text>
<text top="293" left="522" width="280" height="15" font="2">ﬁeld, CAE, Director, Guideline Methodology and</text>
<text top="313" left="482" width="35" height="12" font="2">Policy</text>
<text top="331" left="468" width="333" height="12" font="2">Abdul R. Abdullah, MD, Associate Science and Medicine</text>
<text top="349" left="482" width="44" height="12" font="2">Advisor</text>
<text top="367" left="468" width="333" height="12" font="2">Clara Fitzgerald, Project Manager, Science and Clinical Policy</text>
<text top="394" left="468" width="168" height="12" font="2">American Heart Association</text>
<text top="412" left="468" width="265" height="12" font="2">Mark A. Creager, MD, FAHA, FACC, President</text>
<text top="430" left="468" width="195" height="12" font="2">Nancy Brown, Chief Executive Of</text>
<text top="428" left="663" width="25" height="15" font="2">ﬁcer</text>
<text top="447" left="468" width="333" height="12" font="2">Rose Marie Robertson, MD, FAHA, Chief Science and</text>
<text top="465" left="482" width="62" height="12" font="2">Medical Of</text>
<text top="464" left="545" width="25" height="15" font="2">ﬁcer</text>
<text top="483" left="468" width="333" height="12" font="2">Gayle R. Whitman, PhD, RN, FAHA, FAAN, Senior Vice</text>
<text top="501" left="482" width="76" height="12" font="2">President, Of</text>
<text top="499" left="559" width="150" height="15" font="2">ﬁce of Science Operations</text>
<text top="519" left="468" width="333" height="12" font="2">Comilla Sasson, MD, PhD, FACEP, Vice President for Science</text>
<text top="537" left="482" width="74" height="12" font="2">and Medicine</text>
<text top="555" left="468" width="245" height="12" font="2">Jody Hundley, Production Manager, Scienti</text>
<text top="553" left="713" width="89" height="15" font="2">ﬁc Publications,</text>
<text top="573" left="482" width="13" height="12" font="2">Of</text>
<text top="571" left="495" width="140" height="15" font="2">ﬁce of Science Operations</text>
<text top="627" left="108" width="82" height="12" font="31">R E F E R E N C E S</text>
<text top="652" left="108" width="218" height="9" font="5">1. ACCF/AHA Task Force on Practice Guidelines.</text>
<text top="666" left="108" width="218" height="9" font="5">Methodology Manual and Policies From the ACCF/AHA</text>
<text top="679" left="108" width="218" height="9" font="5">Task Force on Practice Guidelines. Available at:</text>
<text top="692" left="108" width="218" height="9" font="6"><a href="http://assets.cardiosource.com/Methodology_Manual_for_ACC_AHA_Writing_Committees.pdf">http://assets.cardiosource.com/Methodology_Manual_</a></text>
<text top="706" left="108" width="153" height="9" font="6"><a href="http://assets.cardiosource.com/Methodology_Manual_for_ACC_AHA_Writing_Committees.pdf">for_ACC_AHA_Writing_Committees.pdf</a></text>
<text top="706" left="265" width="15" height="9" font="5">and</text>
<text top="706" left="285" width="41" height="9" font="6"><a href="http://my.americanheart.org/idc/groups/ahamah-public/@wcm/@sop/documents/downloadable/ucm_319826.pdf">http://my.</a></text>
<text top="719" left="108" width="218" height="9" font="6"><a href="http://my.americanheart.org/idc/groups/ahamah-public/@wcm/@sop/documents/downloadable/ucm_319826.pdf">americanheart.org/idc/groups/ahamah-public/@wcm/@</a></text>
<text top="733" left="108" width="186" height="9" font="6"><a href="http://my.americanheart.org/idc/groups/ahamah-public/@wcm/@sop/documents/downloadable/ucm_319826.pdf">sop/documents/downloadable/ucm_319826.pdf</a></text>
<text top="733" left="294" width="32" height="9" font="5"><a href="http://my.americanheart.org/idc/groups/ahamah-public/@wcm/@sop/documents/downloadable/ucm_319826.pdf">. </a>Amer-</text>
<text top="746" left="108" width="218" height="9" font="5">ican College of Cardiology and American Heart Asso-</text>
<text top="760" left="108" width="142" height="9" font="5">ciation. Accessed January 23, 2015.</text>
<text top="778" left="108" width="7" height="9" font="5">2.</text>
<text top="778" left="118" width="208" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref2">Committee on Standards for Developing Trust-</a></text>
<text top="792" left="108" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref2">worthy Clinical Practice Guidelines, Institute of Medi-</a></text>
<text top="805" left="108" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref2">cine (US). Clinical Practice Guidelines We Can Trust.</a></text>
<text top="819" left="108" width="196" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref2">Washington, DC: National Academies Press, 2011</a></text>
<text top="819" left="304" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref2">.</a></text>
<text top="837" left="108" width="7" height="9" font="5">3.</text>
<text top="837" left="118" width="208" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref3">Committee on Standards for Systematic Reviews of</a></text>
<text top="851" left="108" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref3">Comparative Effectiveness Research, Institute of</a></text>
<text top="864" left="108" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref3">Medicine (US). Finding What Works in Health Care:</a></text>
<text top="878" left="108" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref3">Standards for Systematic Reviews. Washington, DC:</a></text>
<text top="891" left="108" width="127" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref3">National Academies Press, 2011</a></text>
<text top="891" left="234" width="3" height="9" font="5">.</text>
<text top="909" left="108" width="8" height="9" font="5">4.</text>
<text top="909" left="119" width="207" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref4">Anderson JL, Heidenreich PA, Barnett PG, et al.</a></text>
<text top="923" left="108" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref4">ACC/AHA statement on cost/value methodology in</a></text>
<text top="936" left="108" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref4">clinical practice guidelines and performance measures:</a></text>
<text top="950" left="108" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref4">a report of the American College of Cardiology/</a></text>
<text top="963" left="108" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref4">American Heart Association Task Force on Performance</a></text>
<text top="977" left="108" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref4">Measures and Task Force on Practice Guidelines. J Am</a></text>
<text top="990" left="108" width="109" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref4">Coll Cardiol. 2014;63:2304</a></text>
<text top="989" left="216" width="14" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref4">–22</a></text>
<text top="990" left="230" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref4">.</a></text>
<text top="1009" left="108" width="7" height="9" font="5">5.</text>
<text top="1009" left="118" width="208" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref5">Arnett DK, Goodman RA, Halperin JL, et al. AHA/</a></text>
<text top="1022" left="108" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref5">ACC/HHS strategies to enhance application of clinical</a></text>
<text top="1036" left="108" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref5">practice guidelines in patients with cardiovascular</a></text>
<text top="1049" left="108" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref5">disease and comorbid conditions: from the American</a></text>
<text top="1062" left="108" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref5">Heart Association, American College of Cardiology, and</a></text>
<text top="1076" left="108" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref5">U.S. Department of Health and Human Services. J Am</a></text>
<text top="1089" left="108" width="106" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref5">Coll Cardiol. 2014;64:1851</a></text>
<text top="1088" left="214" width="10" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref5">–6</a></text>
<text top="1089" left="223" width="3" height="9" font="5">.</text>
<text top="652" left="345" width="8" height="9" font="5">6.</text>
<text top="652" left="356" width="207" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref6">Jacobs AK, Kushner FG, Ettinger SM, et al. ACCF/</a></text>
<text top="666" left="345" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref6">AHA clinical practice guideline methodology summit</a></text>
<text top="679" left="345" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref6">report: a report of the American College of Cardiology</a></text>
<text top="692" left="345" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref6">Foundation/American Heart Association Task Force on</a></text>
<text top="706" left="345" width="201" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref6">Practice Guidelines. J Am Coll Cardiol. 2013;61:213</a></text>
<text top="704" left="547" width="14" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref6">–65</a></text>
<text top="706" left="561" width="3" height="9" font="5">.</text>
<text top="724" left="345" width="7" height="9" font="5">7.</text>
<text top="724" left="355" width="208" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref7">Jacobs AK, Anderson JL, Halperin JL. The evolution</a></text>
<text top="738" left="345" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref7">and future of ACC/AHA clinical practice guidelines: a</a></text>
<text top="751" left="345" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref7">30-year journey: a report of the American College</a></text>
<text top="765" left="345" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref7">of Cardiology/American Heart Association Task Force</a></text>
<text top="778" left="345" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref7">on Practice Guidelines. J Am Coll Cardiol. 2014;64:</a></text>
<text top="792" left="345" width="18" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref7">1373</a></text>
<text top="790" left="363" width="15" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref7">–84</a></text>
<text top="792" left="378" width="3" height="9" font="5">.</text>
<text top="810" left="345" width="8" height="9" font="5">8.</text>
<text top="810" left="356" width="207" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref8">Halperin JL, Levine GN, Al-Khatib SM, et al. Further</a></text>
<text top="824" left="345" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref8">evolution of the ACC/AHA clinical practice guideline</a></text>
<text top="837" left="345" width="92" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref8">recommendation classi</a></text>
<text top="836" left="437" width="127" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref8">ﬁcation system: a report of the</a></text>
<text top="851" left="345" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref8">American College of Cardiology/American Heart Asso-</a></text>
<text top="864" left="345" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref8">ciation Task Force on Clinical Practice Guidelines. J Am</a></text>
<text top="878" left="345" width="106" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref8">Coll Cardiol. 2016;67:1572</a></text>
<text top="876" left="451" width="9" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref8">–4</a></text>
<text top="878" left="460" width="3" height="9" font="5">.</text>
<text top="896" left="345" width="8" height="9" font="5">9.</text>
<text top="896" left="356" width="207" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref9">Levine GN, Bates ER, Blankenship JC, et al. 2011</a></text>
<text top="909" left="345" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref9">ACCF/AHA/SCAI guideline for percutaneous coronary</a></text>
<text top="923" left="345" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref9">intervention: a report of the American College of Car-</a></text>
<text top="936" left="345" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref9">diology Foundation/American Heart Association Task</a></text>
<text top="950" left="345" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref9">Force on Practice Guidelines and the Society for Car-</a></text>
<text top="963" left="345" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref9">diovascular Angiography and Interventions. J Am Coll</a></text>
<text top="977" left="345" width="83" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref9">Cardiol. 2011;58:e44</a></text>
<text top="975" left="428" width="17" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref9">–122</a></text>
<text top="977" left="446" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref9">.</a></text>
<text top="995" left="345" width="12" height="9" font="5">10.</text>
<text top="995" left="361" width="203" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref10">Hillis LD, Smith PK, Anderson JL, et al., 2011 ACCF/</a></text>
<text top="1009" left="345" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref10">AHA guideline for coronary artery bypass graft surgery: a</a></text>
<text top="1022" left="345" width="24" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref10">report</a></text>
<text top="1022" left="379" width="8" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref10">of</a></text>
<text top="1022" left="397" width="13" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref10">the</a></text>
<text top="1022" left="419" width="36" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref10">American</a></text>
<text top="1022" left="465" width="30" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref10">College</a></text>
<text top="1022" left="504" width="8" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref10">of</a></text>
<text top="1022" left="522" width="42" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref10">Cardiology</a></text>
<text top="1036" left="345" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref10">Foundation/American Heart Association Task Force on</a></text>
<text top="1049" left="345" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref10">Practice Guidelines. Developed in collaboration with the</a></text>
<text top="1062" left="345" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref10">American Association for Thoracic Surgery, Society of</a></text>
<text top="1076" left="345" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref10">Cardiovascular Anesthesiologists, and Society of Thoracic</a></text>
<text top="1089" left="345" width="179" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref10">Surgeons. J Am Coll Cardiol. 2011;58:e123</a></text>
<text top="1088" left="524" width="18" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref10">–210</a></text>
<text top="1089" left="542" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref10">.</a></text>
<text top="652" left="583" width="10" height="9" font="5">11.</text>
<text top="652" left="596" width="205" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref11">Fihn SD, Blankenship JC, Alexander KP, et al. 2014</a></text>
<text top="666" left="583" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref11">ACC/AHA/AATS/PCNA/SCAI/STS focused update of the</a></text>
<text top="679" left="583" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref11">guideline for the diagnosis and management of pa-</a></text>
<text top="692" left="583" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref11">tients with stable ischemic heart disease: a report of</a></text>
<text top="706" left="583" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref11">the American College of Cardiology/American Heart</a></text>
<text top="719" left="583" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref11">Association Task Force on Practice Guidelines, and the</a></text>
<text top="733" left="583" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref11">American Association for Thoracic Surgery, Preventive</a></text>
<text top="746" left="583" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref11">Cardiovascular Nurses Association, Society for Cardio-</a></text>
<text top="760" left="583" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref11">vascular Angiography and Interventions, and Society</a></text>
<text top="773" left="583" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref11">of Thoracic Surgeons. J Am Coll Cardiol. 2014;64:</a></text>
<text top="787" left="583" width="20" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref11">1929</a></text>
<text top="785" left="603" width="15" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref11">–49</a></text>
<text top="787" left="618" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref11">.</a></text>
<text top="807" left="583" width="11" height="9" font="5">12.</text>
<text top="807" left="597" width="204" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref12">Fihn SD, Gardin JM, Abrams J, et al. 2012 ACCF/</a></text>
<text top="820" left="583" width="128" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref12">AHA/ACP/AATS/PCNA/SCAI/STS</a></text>
<text top="820" left="720" width="36" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref12">guideline</a></text>
<text top="820" left="767" width="12" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref12">for</a></text>
<text top="820" left="788" width="13" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref12">the</a></text>
<text top="834" left="583" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref12">diagnosis and management of patients with stable</a></text>
<text top="847" left="583" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref12">ischemic heart disease: a report of the American Col-</a></text>
<text top="860" left="583" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref12">lege of Cardiology Foundation/American Heart Asso-</a></text>
<text top="874" left="583" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref12">ciation Task Force on Practice Guidelines, and the</a></text>
<text top="887" left="583" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref12">American College of Physicians, American Association</a></text>
<text top="901" left="583" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref12">for Thoracic Surgery, Preventive Cardiovascular Nurses</a></text>
<text top="914" left="583" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref12">Association, Society for Cardiovascular Angiography</a></text>
<text top="928" left="583" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref12">and Interventions, and Society of Thoracic Surgeons.</a></text>
<text top="941" left="583" width="132" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref12">J Am Coll Cardiol. 2012;60:2564</a></text>
<text top="940" left="715" width="20" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref12">–603</a></text>
<text top="941" left="736" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref12">.</a></text>
<text top="961" left="583" width="11" height="9" font="5">13.</text>
<text top="961" left="597" width="6" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref13">O</a></text>
<text top="960" left="603" width="198" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref13">’Gara PT, Kushner FG, Ascheim DD, et al. 2013</a></text>
<text top="975" left="583" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref13">ACCF/AHA guideline for the management of ST-</a></text>
<text top="988" left="583" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref13">elevation myocardial infarction: a report of the Amer-</a></text>
<text top="1002" left="583" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref13">ican College of Cardiology Foundation/American Heart</a></text>
<text top="1015" left="583" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref13">Association Task Force on Practice Guidelines. J Am</a></text>
<text top="1028" left="583" width="101" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref13">Coll Cardiol. 2013;61:e78</a></text>
<text top="1027" left="684" width="19" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref13">–140</a></text>
<text top="1028" left="703" width="3" height="9" font="5">.</text>
<text top="1048" left="583" width="12" height="9" font="5">14.</text>
<text top="1048" left="598" width="203" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref14">Amsterdam EA, Wenger NK, Brindis RG, et al. 2014</a></text>
<text top="1062" left="583" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref14">AHA/ACC guideline for the management of patients</a></text>
<text top="1075" left="583" width="37" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref14">with non</a></text>
<text top="1074" left="620" width="181" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref14">—ST-elevation acute coronary syndromes: a</a></text>
<text top="1089" left="583" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref14">report of the American College of Cardiology/American</a></text>
<text top="53" left="108" width="52" height="9" font="14">Levine et al.</text>
<text top="54" left="670" width="132" height="7" font="7">J A C C V O L . 6 8 , N O . 1 0 , 2 0 1 6</text>
<text top="68" left="108" width="243" height="9" font="14">Focused Update on Duration of Dual Antiplatelet Therapy</text>
<text top="69" left="665" width="117" height="7" font="7">S E P T E M B E R 6 , 2 0 1 6 : 1 0 8 2</text>
<text top="67" left="784" width="17" height="10" font="7">– 1 1 5</text>
<text top="53" left="57" width="19" height="9" font="5">1104</text>
</page>
<page number="24" position="absolute" top="0" left="0" height="1160" width="864">
	<fontspec id="32" size="3" family="Times" color="#327eb1"/>
<text top="143" left="63" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref14">Heart Association Task Force on Practice Guidelines.</a></text>
<text top="156" left="63" width="130" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref14">J Am Coll Cardiol. 2014;64:e139</a></text>
<text top="155" left="193" width="19" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref14">–228</a></text>
<text top="156" left="212" width="3" height="9" font="5">.</text>
<text top="175" left="63" width="11" height="9" font="5">15.</text>
<text top="175" left="77" width="204" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref15">Fleisher LA, Fleischmann KE, Auerbach AD, et al.</a></text>
<text top="188" left="63" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref15">2014 ACC/AHA guideline on perioperative cardiovas-</a></text>
<text top="202" left="63" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref15">cular evaluation and management of patients under-</a></text>
<text top="215" left="63" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref15">going noncardiac surgery: a report of the American</a></text>
<text top="229" left="63" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref15">College of Cardiology/American Heart Association Task</a></text>
<text top="242" left="63" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref15">Force on Practice Guidelines. J Am Coll Cardiol. 2014;</a></text>
<text top="256" left="63" width="27" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref15">64:e77</a></text>
<text top="254" left="90" width="17" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref15">–137</a></text>
<text top="256" left="107" width="3" height="9" font="5">.</text>
<text top="274" left="63" width="12" height="9" font="5">16.</text>
<text top="274" left="78" width="203" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref16">Mauri L, Kereiakes DJ, Yeh RW, et al. Twelve or 30</a></text>
<text top="288" left="63" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref16">months of dual antiplatelet therapy after drug-eluting</a></text>
<text top="301" left="63" width="147" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref16">stents. N Engl J Med. 2014;371:2155</a></text>
<text top="299" left="209" width="15" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref16">–66</a></text>
<text top="301" left="224" width="3" height="9" font="5">.</text>
<text top="320" left="63" width="11" height="9" font="5">17.</text>
<text top="320" left="77" width="204" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref17">Colombo A, Chieffo A, Frasheri A, et al. Second-</a></text>
<text top="333" left="63" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref17">generation drug-eluting stent implantation followed</a></text>
<text top="347" left="63" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref17">by 6- versus 12-month dual antiplatelet therapy: the</a></text>
<text top="360" left="63" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref17">SECURITY randomized clinical trial. J Am Coll Cardiol.</a></text>
<text top="373" left="63" width="58" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref17">2014;64:2086</a></text>
<text top="372" left="121" width="14" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref17">–97</a></text>
<text top="373" left="135" width="3" height="9" font="5">.</text>
<text top="392" left="63" width="12" height="9" font="5">18.</text>
<text top="392" left="78" width="203" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref18">Gwon H-C, Hahn J-Y, Park KW, et al. Six-month</a></text>
<text top="405" left="63" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref18">versus 12-month dual antiplatelet therapy after im-</a></text>
<text top="419" left="63" width="181" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref18">plantation of drug-eluting stents: the Ef</a></text>
<text top="417" left="243" width="37" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref18">ﬁcacy of</a></text>
<text top="432" left="63" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref18">Xience/Promus Versus Cypher to Reduce Late Loss</a></text>
<text top="446" left="63" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref18">After Stenting (EXCELLENT) randomized, multicenter</a></text>
<text top="459" left="63" width="130" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref18">study. Circulation. 2012;125:505</a></text>
<text top="458" left="192" width="13" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref18">–13</a></text>
<text top="459" left="205" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref18">.</a></text>
<text top="478" left="63" width="12" height="9" font="5">19.</text>
<text top="478" left="78" width="203" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref19">Kim B-K, Hong M-K, Shin D-H, et al. A new strategy</a></text>
<text top="491" left="63" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref19">for discontinuation of dual antiplatelet therapy: the</a></text>
<text top="505" left="63" width="127" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref19">RESET Trial (REal Safety and Ef</a></text>
<text top="503" left="189" width="91" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref19">ﬁcacy of 3-month dual</a></text>
<text top="518" left="63" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref19">antiplatelet Therapy following Endeavor zotarolimus-</a></text>
<text top="532" left="63" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref19">eluting stent implantation). J Am Coll Cardiol. 2012;</a></text>
<text top="545" left="63" width="34" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref19">60:1340</a></text>
<text top="543" left="97" width="10" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref19">–8</a></text>
<text top="545" left="107" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref19">.</a></text>
<text top="564" left="63" width="13" height="9" font="5">20.</text>
<text top="564" left="79" width="202" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref20">Feres F, Costa RA, Abizaid A, et al. Three vs twelve</a></text>
<text top="577" left="63" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref20">months of dual antiplatelet therapy after zotarolimus-</a></text>
<text top="590" left="63" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref20">eluting stents: the OPTIMIZE randomized trial. JAMA.</a></text>
<text top="604" left="63" width="59" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref20">2013;310:2510</a></text>
<text top="602" left="121" width="14" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref20">–22</a></text>
<text top="604" left="135" width="3" height="9" font="5">.</text>
<text top="622" left="63" width="11" height="9" font="5">21.</text>
<text top="622" left="77" width="204" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref21">Schulz-Schüpke S, Byrne RA, Ten Berg JM, et al.</a></text>
<text top="636" left="63" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref21">ISAR-SAFE: a randomized, double-blind, placebo-</a></text>
<text top="649" left="63" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref21">controlled trial of 6 vs. 12 months of clopidogrel</a></text>
<text top="663" left="63" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref21">therapy after drug-eluting stenting. Eur Heart J. 2015;</a></text>
<text top="676" left="63" width="31" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref21">36:1252</a></text>
<text top="675" left="94" width="14" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref21">–63</a></text>
<text top="676" left="108" width="3" height="9" font="5">.</text>
<text top="695" left="63" width="12" height="9" font="5">22.</text>
<text top="695" left="78" width="203" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref22">Park S-J, Park D-W, Kim Y-H, et al. Duration of dual</a></text>
<text top="708" left="63" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref22">antiplatelet therapy after implantation of drug-eluting</a></text>
<text top="722" left="63" width="150" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref22">stents. N Engl J Med. 2010;362:1374</a></text>
<text top="720" left="212" width="14" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref22">–82</a></text>
<text top="722" left="227" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref22">.</a></text>
<text top="740" left="63" width="12" height="9" font="5">23.</text>
<text top="740" left="78" width="203" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref23">Valgimigli M, Campo G, Monti M, et al. Short-</a></text>
<text top="754" left="63" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref23">versus long-term duration of dual-antiplatelet therapy</a></text>
<text top="767" left="63" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref23">after coronary stenting: a randomized multicenter trial.</a></text>
<text top="780" left="63" width="106" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref23">Circulation. 2012;125:2015</a></text>
<text top="779" left="168" width="14" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref23">–26</a></text>
<text top="780" left="183" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref23">.</a></text>
<text top="799" left="63" width="13" height="9" font="5">24.</text>
<text top="799" left="79" width="202" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref24">Collet J-P, Silvain J, Barthélémy O, et al. Dual-</a></text>
<text top="813" left="63" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref24">antiplatelet treatment beyond 1 year after drug-eluting</a></text>
<text top="826" left="63" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref24">stent implantation (ARCTIC-Interruption): a rando-</a></text>
<text top="839" left="63" width="139" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref24">mised trial. Lancet. 2014;384:1577</a></text>
<text top="838" left="201" width="14" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref24">–85</a></text>
<text top="839" left="216" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref24">.</a></text>
<text top="858" left="63" width="12" height="9" font="5">25.</text>
<text top="858" left="78" width="203" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref25">Gilard M, Barragan P, Noryani AAL, et al. 6- versus</a></text>
<text top="871" left="63" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref25">24-month dual antiplatelet therapy after implantation</a></text>
<text top="885" left="63" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref25">of drug-eluting stents in patients nonresistant to</a></text>
<text top="898" left="63" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref25">aspirin: the randomized, multicenter ITALIC trial. J Am</a></text>
<text top="912" left="63" width="101" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref25">Coll Cardiol. 2015;65:777</a></text>
<text top="910" left="164" width="15" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref25">–86</a></text>
<text top="912" left="179" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref25">.</a></text>
<text top="930" left="63" width="13" height="9" font="5">26.</text>
<text top="930" left="79" width="202" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref26">Lee CW, Ahn J-M, Park D-W, et al. Optimal dura-</a></text>
<text top="944" left="63" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref26">tion of dual antiplatelet therapy after drug-eluting</a></text>
<text top="957" left="63" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref26">stent implantation: a randomized, controlled trial.</a></text>
<text top="971" left="63" width="104" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref26">Circulation. 2014;129:304</a></text>
<text top="969" left="167" width="13" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref26">–12</a></text>
<text top="971" left="179" width="3" height="9" font="5">.</text>
<text top="989" left="63" width="12" height="9" font="5">27.</text>
<text top="989" left="78" width="203" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref27">Helft G, Steg PG, Le Feuvre C, et al. Stopping or</a></text>
<text top="1003" left="63" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref27">continuing clopidogrel 12 months after drug-eluting</a></text>
<text top="1016" left="63" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref27">stent placement: the OPTIDUAL randomized trial. Eur</a></text>
<text top="1029" left="63" width="85" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref27">Heart J. 2016;37:365</a></text>
<text top="1028" left="147" width="14" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref27">–74</a></text>
<text top="1029" left="161" width="3" height="9" font="5">.</text>
<text top="1048" left="63" width="13" height="9" font="5">28.</text>
<text top="1048" left="79" width="202" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref28">Bonaca MP, Bhatt DL, Cohen M, et al. Long-term</a></text>
<text top="1061" left="63" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref28">use of ticagrelor in patients with prior myocardial</a></text>
<text top="1075" left="63" width="160" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref28">infarction. N Engl J Med. 2015;372:1791</a></text>
<text top="1073" left="223" width="22" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref28">–800</a></text>
<text top="1075" left="244" width="3" height="9" font="5">.</text>
<text top="143" left="301" width="13" height="9" font="5">29.</text>
<text top="143" left="316" width="14" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref29">Rof</a></text>
<text top="141" left="330" width="189" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref29">ﬁ M, Patrono C, Collet J-P, et al. 2015 ESC</a></text>
<text top="156" left="301" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref29">guidelines for the management of acute coronary</a></text>
<text top="170" left="301" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref29">syndromes in patients presenting without persistent</a></text>
<text top="183" left="301" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref29">ST-segment elevation: Task Force for the Management</a></text>
<text top="197" left="301" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref29">of Acute Coronary Syndromes in Patients Presenting</a></text>
<text top="210" left="301" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref29">without Persistent ST-Segment Elevation of the Euro-</a></text>
<text top="224" left="301" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref29">pean Society of Cardiology (ESC). Eur Heart J. 2016;37:</a></text>
<text top="237" left="301" width="15" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref29">267</a></text>
<text top="236" left="315" width="17" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref29">–315</a></text>
<text top="237" left="333" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref29">.</a></text>
<text top="256" left="301" width="13" height="9" font="5">30.</text>
<text top="256" left="317" width="202" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref30">Bittl JA, Baber U, Bradley SM, Wijeysundera DN.</a></text>
<text top="269" left="301" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref30">Duration of dual antiplatelet therapy: a systematic</a></text>
<text top="283" left="301" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref30">review for the 2016 ACC/AHA guideline focused</a></text>
<text top="296" left="301" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref30">update on duration of dual antiplatelet therapy in</a></text>
<text top="310" left="301" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref30">patients with coronary artery disease: a report of the</a></text>
<text top="323" left="301" width="37" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref30">American</a></text>
<text top="323" left="347" width="30" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref30">College</a></text>
<text top="323" left="386" width="8" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref30">of</a></text>
<text top="323" left="404" width="83" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref30">Cardiology/American</a></text>
<text top="323" left="497" width="22" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref30">Heart</a></text>
<text top="337" left="301" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref30">Association Task Force on Clinical Practice Guidelines. J</a></text>
<text top="350" left="301" width="215" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref30">Am Coll Cardiol. 2016 Mar 22 [E-pub ahead of print].</a></text>
<text top="369" left="301" width="11" height="9" font="5">31.</text>
<text top="369" left="315" width="204" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref31">Steg PG, James SK, Atar D, et al. ESC guidelines for</a></text>
<text top="382" left="301" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref31">the management of acute myocardial infarction in pa-</a></text>
<text top="396" left="301" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref31">tients presenting with ST-segment elevation. Eur Heart</a></text>
<text top="409" left="301" width="65" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref31">J. 2012;33:2569</a></text>
<text top="407" left="365" width="19" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref31">–619</a></text>
<text top="409" left="384" width="3" height="9" font="5">.</text>
<text top="428" left="301" width="12" height="9" font="5">32.</text>
<text top="428" left="315" width="203" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref32">Wijns W, Kolh P, Danchin N, et al. Guidelines on</a></text>
<text top="441" left="301" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref32">myocardial revascularization. Eur Heart J. 2010;31:</a></text>
<text top="455" left="301" width="20" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref32">2501</a></text>
<text top="453" left="320" width="14" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref32">–55</a></text>
<text top="455" left="334" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref32">.</a></text>
<text top="473" left="301" width="12" height="9" font="5">33.</text>
<text top="473" left="315" width="203" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref33">Hamm CW, Bassand J-P, Agewall S, et al. ESC</a></text>
<text top="487" left="301" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref33">guidelines for the management of acute coronary</a></text>
<text top="500" left="301" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref33">syndromes in patients presenting without persistent</a></text>
<text top="514" left="301" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref33">ST-segment elevation: the Task Force for the Man-</a></text>
<text top="527" left="301" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref33">agement of Acute Coronary Syndromes (ACS) in Pa-</a></text>
<text top="541" left="301" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref33">tients Presenting Without Persistent ST-Segment</a></text>
<text top="554" left="301" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref33">Elevation of the European Society of Cardiology (ESC).</a></text>
<text top="567" left="301" width="106" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref33">Eur Heart J. 2011;32:2999</a></text>
<text top="566" left="406" width="25" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref33">–3054</a></text>
<text top="567" left="431" width="3" height="9" font="5">.</text>
<text top="586" left="301" width="13" height="9" font="5">34.</text>
<text top="586" left="316" width="202" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref34">Palmerini T, Sangiorgi D, Valgimigli M, et al. Short-</a></text>
<text top="600" left="301" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref34">versus long-term dual antiplatelet therapy after drug-</a></text>
<text top="613" left="301" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref34">eluting stent implantation: an individual patient data</a></text>
<text top="627" left="301" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref34">pairwise and network meta-analysis. J Am Coll Cardiol.</a></text>
<text top="640" left="301" width="55" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref34">2015;65:1092</a></text>
<text top="638" left="356" width="19" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref34">–102</a></text>
<text top="640" left="375" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref34">.</a></text>
<text top="659" left="301" width="12" height="9" font="5">35.</text>
<text top="659" left="315" width="203" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref35">Palmerini T, Benedetto U, Bacchi-Reggiani L, et al.</a></text>
<text top="672" left="301" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref35">Mortality in patients treated with extended duration</a></text>
<text top="686" left="301" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref35">dual antiplatelet therapy after drug-eluting stent</a></text>
<text top="699" left="301" width="53" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref35">implantation:</a></text>
<text top="699" left="363" width="4" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref35">a</a></text>
<text top="699" left="376" width="33" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref35">pairwise</a></text>
<text top="699" left="418" width="15" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref35">and</a></text>
<text top="699" left="442" width="35" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref35">Bayesian</a></text>
<text top="699" left="486" width="33" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref35">network</a></text>
<text top="712" left="301" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref35">meta-analysis of randomised trials. Lancet. 2015;385:</a></text>
<text top="726" left="301" width="18" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref35">2371</a></text>
<text top="724" left="318" width="14" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref35">–82</a></text>
<text top="726" left="333" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref35">.</a></text>
<text top="745" left="301" width="13" height="9" font="5">36.</text>
<text top="745" left="316" width="202" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref36">Giustino G, Baber U, Sartori S, et al. Duration of</a></text>
<text top="758" left="301" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref36">dual antiplatelet therapy after drug-eluting stent</a></text>
<text top="771" left="301" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref36">implantation: a systematic review and meta-analysis of</a></text>
<text top="785" left="301" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref36">randomized controlled trials. J Am Coll Cardiol. 2015;</a></text>
<text top="798" left="301" width="33" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref36">65:1298</a></text>
<text top="797" left="333" width="19" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref36">–310</a></text>
<text top="798" left="352" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref36">.</a></text>
<text top="817" left="301" width="12" height="9" font="5">37.</text>
<text top="817" left="316" width="203" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref37">Navarese EP, Andreotti F, Schulze V, et al. Optimal</a></text>
<text top="831" left="301" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref37">duration of dual antiplatelet therapy after percuta-</a></text>
<text top="844" left="301" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref37">neous coronary intervention with drug eluting stents:</a></text>
<text top="857" left="301" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref37">meta-analysis of randomised controlled trials. BMJ.</a></text>
<text top="871" left="301" width="64" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref37">2015;350:h1618</a></text>
<text top="871" left="365" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref37">.</a></text>
<text top="890" left="301" width="13" height="9" font="5">38.</text>
<text top="890" left="316" width="202" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref38">Navarese EP, Tandjung K, Claessen B, et al. Safety</a></text>
<text top="903" left="301" width="26" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref38">and ef</a></text>
<text top="901" left="327" width="192" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref38">ﬁcacy outcomes of ﬁrst and second generation</a></text>
<text top="916" left="301" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref38">durable polymer drug eluting stents and biodegradable</a></text>
<text top="930" left="301" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref38">polymer biolimus eluting stents in clinical practice:</a></text>
<text top="943" left="301" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref38">comprehensive network meta-analysis. BMJ. 2013;347:</a></text>
<text top="957" left="301" width="25" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref38">f6530</a></text>
<text top="957" left="325" width="3" height="9" font="5">.</text>
<text top="976" left="301" width="13" height="9" font="5">39.</text>
<text top="976" left="316" width="202" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref39">Hermiller JB, Krucoff MW, Kereiakes DJ, et al.</a></text>
<text top="989" left="301" width="20" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref39">Bene</a></text>
<text top="987" left="320" width="198" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref39">ﬁts and risks of extended dual antiplatelet ther-</a></text>
<text top="1002" left="301" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref39">apy after everolimus-eluting stents. J Am Coll Cardiol</a></text>
<text top="1016" left="301" width="66" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref39">Intv. 2016;9:138</a></text>
<text top="1014" left="367" width="14" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref39">–47</a></text>
<text top="1016" left="381" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref39">.</a></text>
<text top="1035" left="301" width="14" height="9" font="5">40.</text>
<text top="1035" left="318" width="201" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref40">Bhatt DL, Fox KAA, Hacke W, et al. Clopidogrel and</a></text>
<text top="1048" left="301" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref40">aspirin versus aspirin alone for the prevention of</a></text>
<text top="1061" left="301" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref40">atherothrombotic events. N Engl J Med. 2006;354:</a></text>
<text top="1075" left="301" width="20" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref40">1706</a></text>
<text top="1073" left="320" width="12" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref40">–17</a></text>
<text top="1075" left="333" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref40">.</a></text>
<text top="143" left="538" width="12" height="9" font="5">41.</text>
<text top="143" left="553" width="203" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref41">Bhatt DL, Flather MD, Hacke W, et al. Patients with</a></text>
<text top="156" left="538" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref41">prior myocardial infarction, stroke, or symptomatic</a></text>
<text top="170" left="538" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref41">peripheral arterial disease in the CHARISMA trial. J Am</a></text>
<text top="183" left="538" width="110" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref41">Coll Cardiol. 2007;49:1982</a></text>
<text top="182" left="648" width="10" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref41">–8</a></text>
<text top="183" left="657" width="3" height="9" font="5">.</text>
<text top="202" left="538" width="13" height="9" font="5">42.</text>
<text top="202" left="554" width="202" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref42">Bonaca MP, Bhatt DL, Steg PG, et al. Ischaemic risk</a></text>
<text top="215" left="538" width="25" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref42">and ef</a></text>
<text top="214" left="563" width="187" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref42">ﬁcacy of ticagrelor in relation to time from P2Y</a></text>
<text top="219" left="750" width="6" height="6" font="32"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref42">12</a></text>
<text top="229" left="538" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref42">inhibitor withdrawal in patients with prior myocardial</a></text>
<text top="242" left="538" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref42">infarction: insights from PEGASUS-TIMI 54. Eur Heart</a></text>
<text top="256" left="538" width="61" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref42">J. 2016;37:1133</a></text>
<text top="254" left="600" width="14" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref42">–42</a></text>
<text top="256" left="614" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref42">.</a></text>
<text top="274" left="538" width="13" height="9" font="5">43.</text>
<text top="274" left="554" width="189" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref43">Yeh RW, Kereiakes DJ, Steg PG, et al. Bene</a></text>
<text top="273" left="744" width="13" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref43">ﬁts</a></text>
<text top="288" left="538" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref43">and risks of extended duration dual antiplatelet</a></text>
<text top="301" left="538" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref43">therapy after PCI in patients with and without acute</a></text>
<text top="315" left="538" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref43">myocardial infarction. J Am Coll Cardiol. 2015;65:</a></text>
<text top="328" left="538" width="17" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref43">2211</a></text>
<text top="326" left="556" width="13" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref43">–21</a></text>
<text top="328" left="568" width="3" height="9" font="5">.</text>
<text top="347" left="538" width="14" height="9" font="5">44.</text>
<text top="347" left="555" width="201" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref44">Udell JA, Bonaca MP, Collet J-P, et al. Long-term</a></text>
<text top="360" left="538" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref44">dual antiplatelet therapy for secondary prevention of</a></text>
<text top="373" left="538" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref44">cardiovascular events in the subgroup of patients with</a></text>
<text top="387" left="538" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref44">previous myocardial infarction: a collaborative meta-</a></text>
<text top="400" left="538" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref44">analysis of randomized trials. Eur Heart J. 2016;37:</a></text>
<text top="414" left="538" width="16" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref44">390</a></text>
<text top="412" left="555" width="10" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref44">–9</a></text>
<text top="414" left="564" width="3" height="9" font="5">.</text>
<text top="432" left="538" width="13" height="9" font="5">45.</text>
<text top="432" left="554" width="202" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref45">Mauri L, Elmariah S, Yeh RW, et al. Causes of late</a></text>
<text top="446" left="538" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref45">mortality with dual antiplatelet therapy after coronary</a></text>
<text top="459" left="538" width="131" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref45">stents. Eur Heart J. 2016;37:378</a></text>
<text top="458" left="669" width="14" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref45">–85</a></text>
<text top="459" left="683" width="3" height="9" font="5">.</text>
<text top="478" left="538" width="14" height="9" font="5">46.</text>
<text top="478" left="555" width="201" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref46">Spencer FA, Prasad M, Vandvik PO, et al. Longer</a></text>
<text top="491" left="538" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref46">versus shorter-duration dual-antiplatelet therapy after</a></text>
<text top="505" left="538" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref46">drug-eluting stent placement: a systematic review and</a></text>
<text top="518" left="538" width="181" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref46">meta-analysis. Ann Intern Med. 2015;163:118</a></text>
<text top="517" left="719" width="14" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref46">–26</a></text>
<text top="518" left="733" width="3" height="9" font="5">.</text>
<text top="537" left="538" width="13" height="9" font="5">47.</text>
<text top="537" left="554" width="202" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref47">Montalescot G, Brieger D, Dalby AJ, et al. Duration</a></text>
<text top="550" left="538" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref47">of dual antiplatelet therapy after coronary stenting: a</a></text>
<text top="564" left="538" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref47">review of the evidence. J Am Coll Cardiol. 2015;66:</a></text>
<text top="577" left="538" width="15" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref47">832</a></text>
<text top="575" left="553" width="14" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref47">–47</a></text>
<text top="577" left="567" width="3" height="9" font="5">.</text>
<text top="596" left="538" width="14" height="9" font="5">48.</text>
<text top="596" left="555" width="201" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref48">Elmariah S, Mauri L, Doros G, et al. Extended</a></text>
<text top="609" left="538" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref48">duration dual antiplatelet therapy and mortality: a</a></text>
<text top="622" left="538" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref48">systematic review and meta-analysis. Lancet. 2015;</a></text>
<text top="636" left="538" width="33" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref48">385:792</a></text>
<text top="634" left="571" width="10" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref48">–8</a></text>
<text top="636" left="581" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref48">.</a></text>
<text top="654" left="538" width="218" height="9" font="5">49. U.S. Food and Drug Administration. FDA Drug</text>
<text top="668" left="538" width="148" height="9" font="5">Safety Communication: FDA review</text>
<text top="666" left="691" width="65" height="12" font="5">ﬁnds long-term</text>
<text top="681" left="538" width="218" height="9" font="5">treatment with blood-thinning medicine Plavix (clopi-</text>
<text top="695" left="538" width="218" height="9" font="5">dogrel) does not change risk of death. Available</text>
<text top="708" left="538" width="11" height="9" font="5">at:</text>
<text top="708" left="552" width="204" height="9" font="6"><a href="http://www.fda.gov/Drugs/DrugSafety/ucm471286.htm">http://www.fda.gov/Drugs/DrugSafety/ucm471286.</a></text>
<text top="722" left="538" width="16" height="9" font="6"><a href="http://www.fda.gov/Drugs/DrugSafety/ucm471286.htm">htm</a></text>
<text top="722" left="554" width="202" height="9" font="5">. Published November 6, 2015; updated December</text>
<text top="735" left="538" width="145" height="9" font="5">9, 2015 accessed February 17, 2016.</text>
<text top="754" left="538" width="13" height="9" font="5">50.</text>
<text top="754" left="554" width="202" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref50">Steinhubl SR, Berger PB, Mann JT 3rd, et al. Early</a></text>
<text top="767" left="538" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref50">and sustained dual oral antiplatelet therapy following</a></text>
<text top="780" left="538" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref50">percutaneous coronary intervention: a randomized</a></text>
<text top="794" left="538" width="155" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref50">controlled trial. JAMA. 2002;288:2411</a></text>
<text top="792" left="693" width="15" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref50">–20</a></text>
<text top="794" left="708" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref50">.</a></text>
<text top="813" left="538" width="11" height="9" font="5">51.</text>
<text top="813" left="552" width="204" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref51">Mehta SR, Yusuf S, Peters RJ, et al. Effects of</a></text>
<text top="826" left="538" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref51">pretreatment with clopidogrel and aspirin followed by</a></text>
<text top="839" left="538" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref51">long-term therapy in patients undergoing percuta-</a></text>
<text top="853" left="538" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref51">neous coronary intervention: the PCI-CURE study.</a></text>
<text top="866" left="538" width="87" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref51">Lancet. 2001;358:527</a></text>
<text top="865" left="626" width="14" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref51">–33</a></text>
<text top="866" left="639" width="3" height="9" font="5">.</text>
<text top="885" left="538" width="12" height="9" font="5">52.</text>
<text top="885" left="553" width="203" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref52">Yusuf S, Zhao F, Mehta SR, et al. Effects of clopi-</a></text>
<text top="898" left="538" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref52">dogrel in addition to aspirin in patients with acute</a></text>
<text top="912" left="538" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref52">coronary syndromes without ST-segment elevation.</a></text>
<text top="925" left="538" width="117" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref52">N Engl J Med. 2001;345:494</a></text>
<text top="924" left="655" width="20" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref52">–502</a></text>
<text top="925" left="675" width="3" height="9" font="5">.</text>
<text top="944" left="538" width="12" height="9" font="5">53.</text>
<text top="944" left="553" width="203" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref53">Wallentin L, Becker RC, Budaj A, et al. Ticagrelor</a></text>
<text top="957" left="538" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref53">versus clopidogrel in patients with acute coronary</a></text>
<text top="971" left="538" width="170" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref53">syndromes. N Engl J Med. 2009;361:1045</a></text>
<text top="969" left="709" width="13" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref53">–57</a></text>
<text top="971" left="722" width="3" height="9" font="5">.</text>
<text top="989" left="538" width="13" height="9" font="5">54.</text>
<text top="989" left="554" width="202" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref54">Wiviott SD, Braunwald E, McCabe CH, et al. Pra-</a></text>
<text top="1003" left="538" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref54">sugrel versus clopidogrel in patients with acute coro-</a></text>
<text top="1016" left="538" width="191" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref54">nary syndromes. N Engl J Med. 2007;357:2001</a></text>
<text top="1014" left="729" width="13" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref54">–15</a></text>
<text top="1016" left="741" width="3" height="9" font="5">.</text>
<text top="1035" left="538" width="12" height="9" font="5">55.</text>
<text top="1035" left="553" width="203" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref55">Montalescot G, Wiviott SD, Braunwald E, et al.</a></text>
<text top="1048" left="538" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref55">Prasugrel compared with clopidogrel in patients un-</a></text>
<text top="1061" left="538" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref55">dergoing percutaneous coronary intervention for ST-</a></text>
<text top="1075" left="538" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref55">elevation myocardial infarction (TRITON-TIMI 38):</a></text>
<text top="54" left="63" width="132" height="7" font="7">J A C C V O L . 6 8 , N O . 1 0 , 2 0 1 6</text>
<text top="54" left="705" width="52" height="9" font="14">Levine et al.</text>
<text top="69" left="63" width="117" height="7" font="7">S E P T E M B E R 6 , 2 0 1 6 : 1 0 8 2</text>
<text top="67" left="182" width="17" height="10" font="7">– 1 1 5</text>
<text top="69" left="514" width="243" height="9" font="14">Focused Update on Duration of Dual Antiplatelet Therapy</text>
<text top="53" left="789" width="18" height="9" font="5">1105</text>
</page>
<page number="25" position="absolute" top="0" left="0" height="1160" width="864">
<text top="143" left="108" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref55">double-blind, randomised controlled trial. Lancet.</a></text>
<text top="156" left="108" width="56" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref55">2009;373:723</a></text>
<text top="155" left="164" width="12" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref55">–31</a></text>
<text top="156" left="176" width="3" height="9" font="5">.</text>
<text top="175" left="108" width="13" height="9" font="5">56.</text>
<text top="175" left="123" width="95" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref56">Antithrombotic Trialists</a></text>
<text top="173" left="219" width="107" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref56">’ Collaboration. Collabora-</a></text>
<text top="188" left="108" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref56">tive meta-analysis of randomised trials of antiplatelet</a></text>
<text top="202" left="108" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref56">therapy for prevention of death, myocardial infarction,</a></text>
<text top="215" left="108" width="201" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref56">and stroke in high risk patients. BMJ. 2002;324:71</a></text>
<text top="214" left="308" width="15" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref56">–86</a></text>
<text top="215" left="323" width="3" height="9" font="5">.</text>
<text top="234" left="108" width="12" height="9" font="5">57.</text>
<text top="234" left="123" width="203" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref57">Patrono C, Baigent C, Hirsh J, et al. Antiplatelet</a></text>
<text top="247" left="108" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref57">drugs: American College of Chest Physicians Evidence-</a></text>
<text top="261" left="108" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref57">Based Clinical Practice Guidelines (8th Edition). Chest.</a></text>
<text top="274" left="108" width="61" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref57">2008;133:199S</a></text>
<text top="273" left="168" width="23" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref57">–233S</a></text>
<text top="274" left="191" width="3" height="9" font="5">.</text>
<text top="293" left="108" width="13" height="9" font="5">58.</text>
<text top="293" left="123" width="202" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref58">Peters RJG, Mehta SR, Fox KAA, et al. Effects of</a></text>
<text top="306" left="108" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref58">aspirin dose when used alone or in combination with</a></text>
<text top="320" left="108" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref58">clopidogrel in patients with acute coronary syndromes:</a></text>
<text top="333" left="108" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref58">observations from the Clopidogrel in Unstable angina</a></text>
<text top="347" left="108" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref58">to prevent Recurrent Events (CURE) study. Circulation.</a></text>
<text top="360" left="108" width="62" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref58">2003;108:1682</a></text>
<text top="358" left="170" width="9" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref58">–7</a></text>
<text top="360" left="178" width="3" height="9" font="5">.</text>
<text top="379" left="108" width="13" height="9" font="5">59.</text>
<text top="379" left="123" width="202" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref59">Steinhubl SR, Bhatt DL, Brennan DM, et al. Aspirin</a></text>
<text top="392" left="108" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref59">to prevent cardiovascular disease: the association of</a></text>
<text top="405" left="108" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref59">aspirin dose and clopidogrel with thrombosis and</a></text>
<text top="419" left="108" width="166" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref59">bleeding. Ann Intern Med. 2009;150:379</a></text>
<text top="417" left="273" width="15" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref59">–86</a></text>
<text top="419" left="289" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref59">.</a></text>
<text top="437" left="108" width="14" height="9" font="5">60.</text>
<text top="437" left="125" width="201" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref60">Mehta SR, Tanguay J-F, Eikelboom JW, et al.</a></text>
<text top="451" left="108" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref60">Double-dose versus standard-dose clopidogrel and</a></text>
<text top="464" left="108" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref60">high-dose versus low-dose aspirin in individuals un-</a></text>
<text top="478" left="108" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref60">dergoing percutaneous coronary intervention for acute</a></text>
<text top="491" left="108" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref60">coronary syndromes (CURRENT-OASIS 7): a rando-</a></text>
<text top="505" left="108" width="175" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref60">mised factorial trial. Lancet. 2010;376:1233</a></text>
<text top="503" left="282" width="14" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref60">–43</a></text>
<text top="505" left="296" width="3" height="9" font="5">.</text>
<text top="523" left="108" width="218" height="9" font="5">61. Yeh RW, Secemsky E, Kereiakes DJ, et al. Devel-</text>
<text top="537" left="108" width="210" height="9" font="5">opment and validation of a prediction rule for bene</text>
<text top="535" left="317" width="9" height="12" font="5">ﬁt</text>
<text top="550" left="108" width="218" height="9" font="5">and harm of dual antiplatelet therapy beyond one year</text>
<text top="564" left="108" width="218" height="9" font="5">after percutaneous coronary intervention: an analysis</text>
<text top="577" left="108" width="218" height="9" font="5">from the randomized Dual Antiplatelet Therapy Study.</text>
<text top="590" left="108" width="63" height="9" font="5">JAMA. In Press.</text>
<text top="609" left="108" width="13" height="9" font="5">62.</text>
<text top="609" left="123" width="202" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref62">Califf RM, Armstrong PW, Carver JR, et al. 27th</a></text>
<text top="622" left="108" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref62">Bethesda Conference: matching the intensity of risk</a></text>
<text top="636" left="108" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref62">factor management with the hazard for coronary dis-</a></text>
<text top="649" left="108" width="126" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref62">ease events. Task Force 5. Strati</a></text>
<text top="648" left="234" width="92" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref62">ﬁcation of patients into</a></text>
<text top="663" left="108" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref62">high, medium and low risk subgroups for purposes of</a></text>
<text top="676" left="108" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref62">risk factor management. J Am Coll Cardiol. 1996;27:</a></text>
<text top="690" left="108" width="20" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref62">1007</a></text>
<text top="688" left="128" width="13" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref62">–19</a></text>
<text top="690" left="141" width="3" height="9" font="5">.</text>
<text top="708" left="108" width="13" height="9" font="5">63.</text>
<text top="708" left="123" width="202" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref63">Sachdev M, Sun JL, Tsiatis AA, et al. The prognostic</a></text>
<text top="722" left="108" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref63">importance of comorbidity for mortality in patients</a></text>
<text top="735" left="108" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref63">with stable coronary artery disease. J Am Coll Cardiol.</a></text>
<text top="749" left="108" width="53" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref63">2004;43:576</a></text>
<text top="747" left="160" width="14" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref63">–82</a></text>
<text top="749" left="175" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref63">.</a></text>
<text top="767" left="108" width="14" height="9" font="5">64.</text>
<text top="767" left="124" width="104" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref64">Binder RK, Lüscher TF, O</a></text>
<text top="765" left="228" width="98" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref64">’Connor SA. Duration of</a></text>
<text top="780" left="108" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref64">dual antiplatelet therapy after coronary artery stent-</a></text>
<text top="794" left="108" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref64">ing: where is the sweet spot between ischaemia and</a></text>
<text top="807" left="108" width="147" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref64">bleeding? Eur Heart J. 2015;36:1207</a></text>
<text top="806" left="254" width="11" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref64">–11</a></text>
<text top="807" left="266" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref64">.</a></text>
<text top="826" left="108" width="13" height="9" font="5">65.</text>
<text top="826" left="123" width="202" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref65">Subherwal S, Bach RG, Chen AY, et al. Baseline risk</a></text>
<text top="839" left="108" width="8" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref65">of</a></text>
<text top="839" left="126" width="22" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref65">major</a></text>
<text top="839" left="158" width="35" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref65">bleeding</a></text>
<text top="839" left="202" width="7" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref65">in</a></text>
<text top="839" left="219" width="107" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref65">non-ST-segment-elevation</a></text>
<text top="853" left="108" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref65">myocardial infarction: the CRUSADE (Can Rapid risk</a></text>
<text top="866" left="108" width="21" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref65">strati</a></text>
<text top="865" left="128" width="197" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref65">ﬁcation of Unstable angina patients Suppress</a></text>
<text top="880" left="108" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref65">ADverse outcomes with Early implementation of the</a></text>
<text top="893" left="108" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref65">ACC/AHA Guidelines) Bleeding Score. Circulation.</a></text>
<text top="907" left="108" width="60" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref65">2009;119:1873</a></text>
<text top="905" left="167" width="14" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref65">–82</a></text>
<text top="907" left="182" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref65">.</a></text>
<text top="925" left="108" width="14" height="9" font="5">66.</text>
<text top="925" left="124" width="201" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref66">Moscucci M, Fox KA, Cannon CP, et al. Predictors</a></text>
<text top="939" left="108" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref66">of major bleeding in acute coronary syndromes: the</a></text>
<text top="952" left="108" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref66">Global Registry of Acute Coronary Events (GRACE). Eur</a></text>
<text top="966" left="108" width="90" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref66">Heart J. 2003;24:1815</a></text>
<text top="964" left="197" width="14" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref66">–23</a></text>
<text top="966" left="211" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref66">.</a></text>
<text top="984" left="108" width="13" height="9" font="5">67.</text>
<text top="984" left="123" width="202" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref67">Mehran R, Pocock SJ, Nikolsky E, et al. A risk score</a></text>
<text top="998" left="108" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref67">to predict bleeding in patients with acute coronary</a></text>
<text top="1011" left="108" width="180" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref67">syndromes. J Am Coll Cardiol. 2010;55:2556</a></text>
<text top="1009" left="287" width="15" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref67">–66</a></text>
<text top="1011" left="302" width="3" height="9" font="5">.</text>
<text top="1029" left="108" width="14" height="9" font="5">68.</text>
<text top="1029" left="124" width="201" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref68">Baber U, Mehran R, Sharma SK, et al. Impact of the</a></text>
<text top="1043" left="108" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref68">everolimus-eluting stent on stent thrombosis: a meta-</a></text>
<text top="1056" left="108" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref68">analysis of 13 randomized trials. J Am Coll Cardiol.</a></text>
<text top="1070" left="108" width="54" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref68">2011;58:1569</a></text>
<text top="1068" left="161" width="13" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref68">–77</a></text>
<text top="1070" left="174" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref68">.</a></text>
<text top="143" left="345" width="14" height="9" font="5">69.</text>
<text top="143" left="362" width="91" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref69">Cayla G, Hulot J-S, O</a></text>
<text top="141" left="453" width="110" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref69">’Connor SA, et al. Clinical,</a></text>
<text top="156" left="345" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref69">angiographic, and genetic factors associated with early</a></text>
<text top="170" left="345" width="199" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref69">coronary stent thrombosis. JAMA. 2011;306:1765</a></text>
<text top="168" left="544" width="14" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref69">–74</a></text>
<text top="170" left="558" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref69">.</a></text>
<text top="188" left="345" width="13" height="9" font="5">70.</text>
<text top="188" left="362" width="202" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref70">Campo G, Tebaldi M, Vranckx P, et al. Short- versus</a></text>
<text top="202" left="345" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref70">long-term duration of dual antiplatelet therapy in pa-</a></text>
<text top="215" left="345" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref70">tients treated for in-stent restenosis: a PRODIGY trial</a></text>
<text top="229" left="345" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref70">substudy (Prolonging Dual Antiplatelet Treatment Af-</a></text>
<text top="242" left="345" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref70">ter Grading Stent-Induced Intimal Hyperplasia). J Am</a></text>
<text top="256" left="345" width="104" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref70">Coll Cardiol. 2014;63:506</a></text>
<text top="254" left="449" width="13" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref70">–12</a></text>
<text top="256" left="462" width="3" height="9" font="5">.</text>
<text top="274" left="345" width="11" height="9" font="5">71.</text>
<text top="274" left="359" width="204" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref71">James SK, Roe MT, Cannon CP, et al. Ticagrelor</a></text>
<text top="288" left="345" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref71">versus clopidogrel in patients with acute coronary</a></text>
<text top="301" left="345" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref71">syndromes intended for non-invasive management:</a></text>
<text top="315" left="345" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref71">substudy from prospective randomised PLATelet inhi-</a></text>
<text top="328" left="345" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref71">bition and patient Outcomes (PLATO) trial. BMJ. 2011;</a></text>
<text top="342" left="345" width="42" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref71">342:d3527</a></text>
<text top="342" left="387" width="3" height="9" font="5">.</text>
<text top="360" left="345" width="12" height="9" font="5">72.</text>
<text top="360" left="360" width="203" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref72">Steg PG, James S, Harrington RA, et al. Ticagrelor</a></text>
<text top="373" left="345" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref72">versus clopidogrel in patients with ST-elevation acute</a></text>
<text top="387" left="345" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref72">coronary syndromes intended for reperfusion with</a></text>
<text top="400" left="345" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref72">primary percutaneous coronary intervention: a Platelet</a></text>
<text top="414" left="345" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref72">Inhibition and Patient Outcomes (PLATO) trial sub-</a></text>
<text top="427" left="345" width="168" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref72">group analysis. Circulation. 2010;122:2131</a></text>
<text top="426" left="513" width="13" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref72">–41</a></text>
<text top="427" left="526" width="3" height="9" font="5">.</text>
<text top="446" left="345" width="218" height="9" font="5">73. US Food and Drug Administration. Medical Device</text>
<text top="459" left="345" width="130" height="9" font="5">Reporting (MDR). Available at:</text>
<text top="459" left="480" width="83" height="9" font="6"><a href="http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm">http://www.fda.gov/</a></text>
<text top="473" left="345" width="215" height="9" font="6"><a href="http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm">MedicalDevices/Safety/ReportaProblem/default.htm</a></text>
<text top="473" left="560" width="3" height="9" font="5">.</text>
<text top="486" left="345" width="209" height="9" font="5">Updated July 16, 2015; accessed February 17, 2016.</text>
<text top="505" left="345" width="13" height="9" font="5">74.</text>
<text top="505" left="361" width="202" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref74">Abraham NS, Hlatky MA, Antman EM, et al. ACCF/</a></text>
<text top="518" left="345" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref74">ACG/AHA 2010 expert consensus document on the</a></text>
<text top="532" left="345" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref74">concomitant use of proton pump inhibitors and thie-</a></text>
<text top="545" left="345" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref74">nopyridines: a focused update of the ACCF/ACG/AHA</a></text>
<text top="558" left="345" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref74">2008 expert consensus document on reducing the</a></text>
<text top="572" left="345" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref74">gastrointestinal risks of antiplatelet therapy and NSAID</a></text>
<text top="585" left="345" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref74">use: a report of the American College of Cardiology</a></text>
<text top="599" left="345" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref74">Foundation Task Force on Expert Consensus Docu-</a></text>
<text top="612" left="345" width="161" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref74">ments. J Am Coll Cardiol. 2010;56:2051</a></text>
<text top="611" left="506" width="15" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref74">–66</a></text>
<text top="612" left="522" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref74">.</a></text>
<text top="631" left="345" width="12" height="9" font="5">75.</text>
<text top="631" left="360" width="203" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref75">Serebruany VL, Steinhubl SR, Berger PB, et al.</a></text>
<text top="644" left="345" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref75">Analysis of risk of bleeding complications after</a></text>
<text top="658" left="345" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref75">different doses of aspirin in 192,036 patients enrolled</a></text>
<text top="671" left="345" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref75">in 31 randomized controlled trials. Am J Cardiol. 2005;</a></text>
<text top="685" left="345" width="31" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref75">95:1218</a></text>
<text top="683" left="376" width="14" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref75">–22</a></text>
<text top="685" left="390" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref75">.</a></text>
<text top="703" left="345" width="13" height="9" font="5">76.</text>
<text top="703" left="361" width="202" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref76">Jolly SS, Pogue J, Haladyn K, et al. Effects of</a></text>
<text top="717" left="345" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref76">aspirin dose on ischaemic events and bleeding after</a></text>
<text top="730" left="345" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref76">percutaneous coronary intervention: insights from the</a></text>
<text top="743" left="345" width="177" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref76">PCI-CURE study. Eur Heart J. 2009;30:900</a></text>
<text top="742" left="522" width="9" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref76">–7</a></text>
<text top="743" left="530" width="3" height="9" font="5">.</text>
<text top="762" left="345" width="12" height="9" font="5">77.</text>
<text top="762" left="360" width="203" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref77">Lorenz RL, Schacky CV, Weber M, et al. Improved</a></text>
<text top="775" left="345" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref77">aortocoronary bypass patency by low-dose aspirin</a></text>
<text top="789" left="345" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref77">(100 mg daily): effects on platelet aggregation and</a></text>
<text top="802" left="345" width="180" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref77">thromboxane formation. Lancet. 1984;1:1261</a></text>
<text top="801" left="525" width="9" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref77">–4</a></text>
<text top="802" left="535" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref77">.</a></text>
<text top="821" left="345" width="13" height="9" font="5">78.</text>
<text top="821" left="361" width="202" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref78">Xian Y, Wang TY, McCoy LA, et al. Association of</a></text>
<text top="834" left="345" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref78">discharge aspirin dose with outcomes after acute</a></text>
<text top="848" left="345" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref78">myocardial infarction: insights from the Treatment</a></text>
<text top="861" left="345" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref78">with ADP Receptor Inhibitors: Longitudinal Assessment</a></text>
<text top="875" left="345" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref78">of Treatment Patterns and Events After Acute Coro-</a></text>
<text top="888" left="345" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref78">nary Syndrome (TRANSLATE-ACS) Study. Circulation.</a></text>
<text top="902" left="345" width="52" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref78">2015;132:174</a></text>
<text top="900" left="397" width="13" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref78">–81</a></text>
<text top="902" left="410" width="3" height="9" font="5">.</text>
<text top="920" left="345" width="13" height="9" font="5">79.</text>
<text top="920" left="361" width="202" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref79">Montalescot G, Drobinski G, Maclouf J, et al.</a></text>
<text top="934" left="345" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref79">Evaluation of thromboxane production and comple-</a></text>
<text top="947" left="345" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref79">ment activation during myocardial ischemia in patients</a></text>
<text top="960" left="345" width="191" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref79">with angina pectoris. Circulation. 1991;84:2054</a></text>
<text top="959" left="536" width="14" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref79">–62</a></text>
<text top="960" left="551" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref79">.</a></text>
<text top="979" left="345" width="14" height="9" font="5">80.</text>
<text top="979" left="362" width="201" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref80">Patrono C, Ciabattoni G, Patrignani P, et al. Clinical</a></text>
<text top="992" left="345" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref80">pharmacology of platelet cyclooxygenase inhibition.</a></text>
<text top="1006" left="345" width="99" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref80">Circulation. 1985;72:1177</a></text>
<text top="1004" left="444" width="15" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref80">–84</a></text>
<text top="1006" left="459" width="3" height="9" font="5">.</text>
<text top="1024" left="345" width="12" height="9" font="5">81.</text>
<text top="1024" left="360" width="203" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref81">Steinhubl SR, Berger PB. Aspirin following PCI: too</a></text>
<text top="1038" left="345" width="200" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref81">much of a good thing? Eur Heart J. 2009;30:882</a></text>
<text top="1036" left="545" width="9" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref81">–4</a></text>
<text top="1038" left="555" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref81">.</a></text>
<text top="1056" left="345" width="13" height="9" font="5">82.</text>
<text top="1056" left="361" width="202" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref82">Mahaffey KW, Wojdyla DM, Carroll K, et al. Tica-</a></text>
<text top="1070" left="345" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref82">grelor compared with clopidogrel by geographic region</a></text>
<text top="143" left="583" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref82">in the Platelet Inhibition and Patient Outcomes</a></text>
<text top="156" left="583" width="159" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref82">(PLATO) trial. Circulation. 2011;124:544</a></text>
<text top="155" left="742" width="14" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref82">–54</a></text>
<text top="156" left="756" width="3" height="9" font="5">.</text>
<text top="175" left="583" width="49" height="9" font="5">83. National</text>
<text top="175" left="644" width="68" height="9" font="5">Patient-Centered</text>
<text top="175" left="725" width="29" height="9" font="5">Clinical</text>
<text top="175" left="766" width="36" height="9" font="5">Research</text>
<text top="188" left="583" width="218" height="9" font="5">Network. ADAPTABLE, the Aspirin Study - A Patient-</text>
<text top="202" left="583" width="122" height="9" font="5">Centered Trial. Available at:</text>
<text top="202" left="711" width="90" height="9" font="6"><a href="http://theaspirinstudy.org">http://theaspirinstudy.</a></text>
<text top="215" left="583" width="13" height="9" font="6"><a href="http://theaspirinstudy.org">org</a></text>
<text top="215" left="596" width="119" height="9" font="5">. Accessed February 17, 2016.</text>
<text top="234" left="583" width="14" height="9" font="5">84.</text>
<text top="234" left="600" width="201" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref84">Dans AL, Connolly SJ, Wallentin L, et al.</a></text>
<text top="247" left="583" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref84">Concomitant use of antiplatelet therapy with dabiga-</a></text>
<text top="261" left="583" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref84">tran or warfarin in the Randomized Evaluation of</a></text>
<text top="274" left="583" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref84">Long-Term Anticoagulation Therapy (RE-LY) trial.</a></text>
<text top="288" left="583" width="102" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref84">Circulation. 2013;127:634</a></text>
<text top="286" left="685" width="15" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref84">–40</a></text>
<text top="288" left="700" width="3" height="9" font="5">.</text>
<text top="306" left="583" width="13" height="9" font="5">85.</text>
<text top="306" left="599" width="202" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref85">Faxon DP, Eikelboom JW, Berger PB, et al.</a></text>
<text top="320" left="583" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref85">Consensus document: antithrombotic therapy in pa-</a></text>
<text top="333" left="583" width="75" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref85">tients with atrial</a></text>
<text top="331" left="665" width="136" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref85">ﬁbrillation undergoing coronary</a></text>
<text top="347" left="583" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref85">stenting: a North-American perspective. Thromb Hae-</a></text>
<text top="360" left="583" width="79" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref85">most. 2011;106:572</a></text>
<text top="358" left="662" width="15" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref85">–84</a></text>
<text top="360" left="677" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref85">.</a></text>
<text top="379" left="583" width="14" height="9" font="5">86.</text>
<text top="379" left="600" width="201" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref86">Hansen ML, Srensen R, Clausen MT, et al. Risk of</a></text>
<text top="392" left="583" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref86">bleeding with single, dual, or triple therapy with</a></text>
<text top="405" left="583" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref86">warfarin, aspirin, and clopidogrel in patients with atrial</a></text>
<text top="417" left="583" width="190" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref86">ﬁbrillation. Arch Intern Med. 2010;170:1433–41</a></text>
<text top="419" left="773" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref86">.</a></text>
<text top="437" left="583" width="13" height="9" font="5">87.</text>
<text top="437" left="599" width="202" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref87">Sørensen R, Hansen ML, Abildstrom SZ, et al. Risk</a></text>
<text top="451" left="583" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref87">of bleeding in patients with acute myocardial infarction</a></text>
<text top="464" left="583" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref87">treated with different combinations of aspirin, clopi-</a></text>
<text top="478" left="583" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref87">dogrel, and vitamin K antagonists in Denmark: a</a></text>
<text top="491" left="583" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref87">retrospective analysis of nationwide registry data.</a></text>
<text top="505" left="583" width="94" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref87">Lancet. 2009;374:1967</a></text>
<text top="503" left="677" width="14" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref87">–74</a></text>
<text top="505" left="691" width="3" height="9" font="5">.</text>
<text top="523" left="583" width="14" height="9" font="5">88.</text>
<text top="523" left="600" width="201" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref88">Lip GYH, Windecker S, Huber K, et al. Management</a></text>
<text top="537" left="583" width="139" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref88">of antithrombotic therapy in atrial</a></text>
<text top="535" left="725" width="77" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref88">ﬁbrillation patients</a></text>
<text top="550" left="583" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref88">presenting with acute coronary syndrome and/or un-</a></text>
<text top="564" left="583" width="36" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref88">dergoing</a></text>
<text top="564" left="629" width="54" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref88">percutaneous</a></text>
<text top="564" left="694" width="35" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref88">coronary</a></text>
<text top="564" left="739" width="8" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref88">or</a></text>
<text top="564" left="758" width="21" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref88">valve</a></text>
<text top="564" left="790" width="11" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref88">in-</a></text>
<text top="577" left="583" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref88">terventions: a joint consensus document of the</a></text>
<text top="590" left="583" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref88">European Society of Cardiology Working Group on</a></text>
<text top="604" left="583" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref88">Thrombosis, European Heart Rhythm Association</a></text>
<text top="617" left="583" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref88">(EHRA), European Association of Percutaneous Car-</a></text>
<text top="631" left="583" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref88">diovascular Interventions (EAPCI) and European Asso-</a></text>
<text top="644" left="583" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref88">ciation of Acute Cardiac Care (ACCA). Eur Heart J.</a></text>
<text top="658" left="583" width="53" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref88">2014;35:3155</a></text>
<text top="656" left="636" width="14" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref88">–79</a></text>
<text top="658" left="650" width="3" height="9" font="5">.</text>
<text top="676" left="583" width="14" height="9" font="5">89.</text>
<text top="676" left="600" width="201" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref89">Dewilde WJM, Oirbans T, Verheugt FWA, et al. Use</a></text>
<text top="690" left="583" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref89">of clopidogrel with or without aspirin in patients taking</a></text>
<text top="703" left="583" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref89">oral anticoagulant therapy and undergoing percuta-</a></text>
<text top="717" left="583" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref89">neous coronary intervention: an open-label, rando-</a></text>
<text top="730" left="583" width="183" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref89">mised, controlled trial. Lancet. 2013;381:1107</a></text>
<text top="728" left="766" width="13" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref89">–15</a></text>
<text top="730" left="779" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref89">.</a></text>
<text top="749" left="583" width="14" height="9" font="5">90.</text>
<text top="749" left="600" width="201" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref90">Fiedler KA, Maeng M, Mehilli J, et al. Duration of</a></text>
<text top="762" left="583" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref90">triple therapy in patients requiring oral anticoagulation</a></text>
<text top="775" left="583" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref90">after drug-eluting stent implantation: the ISAR-TRIPLE</a></text>
<text top="789" left="583" width="152" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref90">Trial. J Am Coll Cardiol. 2015;65:1619</a></text>
<text top="787" left="735" width="14" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref90">–29</a></text>
<text top="789" left="750" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref90">.</a></text>
<text top="807" left="583" width="12" height="9" font="5">91.</text>
<text top="807" left="598" width="203" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref91">Dewilde WJM, Janssen PWA, Verheugt FWA, et al.</a></text>
<text top="821" left="583" width="97" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref91">Triple therapy for atrial</a></text>
<text top="819" left="684" width="117" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref91">ﬁbrillation and percutaneous</a></text>
<text top="834" left="583" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref91">coronary intervention: a contemporary review. J Am</a></text>
<text top="848" left="583" width="107" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref91">Coll Cardiol. 2014;64:1270</a></text>
<text top="846" left="691" width="16" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref91">–80</a></text>
<text top="848" left="706" width="3" height="9" font="5">.</text>
<text top="866" left="583" width="13" height="9" font="5">92.</text>
<text top="866" left="599" width="202" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref92">Moser M, Olivier CB, Bode C. Triple antithrombotic</a></text>
<text top="880" left="583" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref92">therapy in cardiac patients: more questions than an-</a></text>
<text top="893" left="583" width="128" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref92">swers. Eur Heart J. 2014;35:216</a></text>
<text top="892" left="711" width="14" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref92">–23</a></text>
<text top="893" left="725" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref92">.</a></text>
<text top="912" left="583" width="13" height="9" font="5">93.</text>
<text top="912" left="599" width="202" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref93">Capodanno D, Angiolillo DJ. Management of anti-</a></text>
<text top="925" left="583" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref93">platelet and anticoagulant therapy in patients with</a></text>
<text top="939" left="583" width="20" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref93">atrial</a></text>
<text top="937" left="607" width="194" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref93">ﬁbrillation in the setting of acute coronary syn-</a></text>
<text top="952" left="583" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref93">dromes or percutaneous coronary interventions. Circ</a></text>
<text top="966" left="583" width="117" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref93">Cardiovasc Interv. 2014;7:113</a></text>
<text top="964" left="700" width="14" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref93">–24</a></text>
<text top="966" left="714" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref93">.</a></text>
<text top="984" left="583" width="14" height="9" font="5">94.</text>
<text top="984" left="600" width="201" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref94">Leon MB, Baim DS, Popma JJ, et al. A clinical trial</a></text>
<text top="998" left="583" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref94">comparing three antithrombotic-drug regimens after</a></text>
<text top="1011" left="583" width="62" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref94">coronary-artery</a></text>
<text top="1011" left="657" width="35" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref94">stenting.</a></text>
<text top="1011" left="705" width="21" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref94">Stent</a></text>
<text top="1011" left="738" width="63" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref94">Anticoagulation</a></text>
<text top="1024" left="583" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref94">Restenosis Study Investigators. N Engl J Med. 1998;</a></text>
<text top="1038" left="583" width="38" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref94">339:1665</a></text>
<text top="1036" left="621" width="12" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref94">–71</a></text>
<text top="1038" left="633" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref94">.</a></text>
<text top="1056" left="583" width="13" height="9" font="5">95.</text>
<text top="1056" left="599" width="202" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref95">Schömig A, Neumann FJ, Kastrati A, et al.</a></text>
<text top="1070" left="583" width="6" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref95">A</a></text>
<text top="1070" left="599" width="47" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref95">randomized</a></text>
<text top="1070" left="656" width="46" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref95">comparison</a></text>
<text top="1070" left="712" width="8" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref95">of</a></text>
<text top="1070" left="730" width="46" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref95">antiplatelet</a></text>
<text top="1070" left="787" width="15" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref95">and</a></text>
<text top="53" left="108" width="52" height="9" font="14">Levine et al.</text>
<text top="54" left="670" width="132" height="7" font="7">J A C C V O L . 6 8 , N O . 1 0 , 2 0 1 6</text>
<text top="68" left="108" width="243" height="9" font="14">Focused Update on Duration of Dual Antiplatelet Therapy</text>
<text top="69" left="665" width="117" height="7" font="7">S E P T E M B E R 6 , 2 0 1 6 : 1 0 8 2</text>
<text top="67" left="784" width="17" height="10" font="7">– 1 1 5</text>
<text top="53" left="57" width="19" height="9" font="5">1106</text>
</page>
<page number="26" position="absolute" top="0" left="0" height="1160" width="864">
<text top="143" left="63" width="54" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref95">anticoagulant</a></text>
<text top="143" left="127" width="31" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref95">therapy</a></text>
<text top="143" left="168" width="19" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref95">after</a></text>
<text top="143" left="197" width="13" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref95">the</a></text>
<text top="143" left="221" width="42" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref95">placement</a></text>
<text top="143" left="273" width="8" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref95">of</a></text>
<text top="156" left="63" width="214" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref95">coronary-artery stents. N Engl J Med. 1996;334:1084</a></text>
<text top="155" left="277" width="4" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref95">–</a></text>
<text top="170" left="63" width="6" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref95">9</a></text>
<text top="170" left="68" width="3" height="9" font="5">.</text>
<text top="188" left="63" width="14" height="9" font="5">96.</text>
<text top="188" left="79" width="202" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref96">Brar SS, Kim J, Brar SK, et al. Long-term outcomes</a></text>
<text top="202" left="63" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref96">by clopidogrel duration and stent type in a diabetic</a></text>
<text top="215" left="63" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref96">population with de novo coronary artery lesions. J Am</a></text>
<text top="229" left="63" width="109" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref96">Coll Cardiol. 2008;51:2220</a></text>
<text top="227" left="172" width="9" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref96">–7</a></text>
<text top="229" left="180" width="3" height="9" font="5">.</text>
<text top="247" left="63" width="13" height="9" font="5">97.</text>
<text top="247" left="79" width="202" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref97">Eisenstein EL, Anstrom KJ, Kong DF, et al. Clopi-</a></text>
<text top="261" left="63" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref97">dogrel use and long-term clinical outcomes after drug-</a></text>
<text top="274" left="63" width="195" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref97">eluting stent implantation. JAMA. 2007;297:159</a></text>
<text top="273" left="258" width="15" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref97">–68</a></text>
<text top="274" left="273" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref97">.</a></text>
<text top="293" left="63" width="14" height="9" font="5">98.</text>
<text top="293" left="79" width="202" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref98">Sabatine MS, Cannon CP, Gibson CM, et al. Effect</a></text>
<text top="306" left="63" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref98">of clopidogrel pretreatment before percutaneous cor-</a></text>
<text top="320" left="63" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref98">onary intervention in patients with ST-elevation</a></text>
<text top="333" left="63" width="145" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref98">myocardial infarction treated with</a></text>
<text top="331" left="213" width="68" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref98">ﬁbrinolytics: the</a></text>
<text top="347" left="63" width="172" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref98">PCI-CLARITY study. JAMA. 2005;294:1224</a></text>
<text top="345" left="234" width="14" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref98">–32</a></text>
<text top="347" left="248" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref98">.</a></text>
<text top="365" left="63" width="14" height="9" font="5">99.</text>
<text top="365" left="79" width="202" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref99">Cutlip DE, Baim DS, Ho KK, et al. Stent thrombosis</a></text>
<text top="379" left="63" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref99">in the modern era: a pooled analysis of multicenter</a></text>
<text top="392" left="63" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref99">coronary stent clinical trials. Circulation. 2001;103:</a></text>
<text top="405" left="63" width="20" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref99">1967</a></text>
<text top="404" left="82" width="12" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref99">–71</a></text>
<text top="405" left="95" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref99">.</a></text>
<text top="424" left="63" width="18" height="9" font="5">100.</text>
<text top="424" left="84" width="197" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref100">Wilson SH, Rihal CS, Bell MR, et al. Timing of</a></text>
<text top="437" left="63" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref100">coronary stent thrombosis in patients treated with</a></text>
<text top="451" left="63" width="204" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref100">ticlopidine and aspirin. Am J Cardiol. 1999;83:1006</a></text>
<text top="449" left="267" width="11" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref100">–11</a></text>
<text top="451" left="278" width="3" height="9" font="5">.</text>
<text top="469" left="63" width="16" height="9" font="5">101.</text>
<text top="469" left="82" width="199" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref101">Kaluza GL, Joseph J, Lee JR, et al. Catastrophic</a></text>
<text top="483" left="63" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref101">outcomes of noncardiac surgery soon after coronary</a></text>
<text top="496" left="63" width="171" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref101">stenting. J Am Coll Cardiol. 2000;35:1288</a></text>
<text top="495" left="234" width="15" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref101">–94</a></text>
<text top="496" left="249" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref101">.</a></text>
<text top="515" left="63" width="17" height="9" font="5">102.</text>
<text top="515" left="83" width="198" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref102">Wilson SH, Fasseas P, Orford JL, et al. Clinical</a></text>
<text top="528" left="63" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref102">outcome of patients undergoing non-cardiac surgery in</a></text>
<text top="542" left="63" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref102">the two months following coronary stenting. J Am Coll</a></text>
<text top="555" left="63" width="86" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref102">Cardiol. 2003;42:234</a></text>
<text top="554" left="148" width="16" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref102">–40</a></text>
<text top="555" left="164" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref102">.</a></text>
<text top="574" left="63" width="17" height="9" font="5">103.</text>
<text top="574" left="83" width="198" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref103">Nuttall GA, Brown MJ, Stombaugh JW, et al. Time</a></text>
<text top="587" left="63" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref103">and cardiac risk of surgery after bare-metal stent</a></text>
<text top="601" left="63" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref103">percutaneous coronary intervention. Anesthesiology.</a></text>
<text top="614" left="63" width="59" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref103">2008;109:588</a></text>
<text top="612" left="122" width="14" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref103">–95</a></text>
<text top="614" left="136" width="3" height="9" font="5">.</text>
<text top="633" left="63" width="18" height="9" font="5">104.</text>
<text top="633" left="84" width="197" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref104">Grines CL, Bonow RO, Casey DE, et al. Prevention</a></text>
<text top="646" left="63" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref104">of premature discontinuation of dual antiplatelet</a></text>
<text top="659" left="63" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref104">therapy in patients with coronary artery stents: a sci-</a></text>
<text top="673" left="63" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref104">ence advisory from the American Heart Association,</a></text>
<text top="686" left="63" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref104">American College of Cardiology, Society for Cardio-</a></text>
<text top="700" left="63" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref104">vascular Angiography and Interventions, American</a></text>
<text top="713" left="63" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref104">College of Surgeons, and American Dental Association,</a></text>
<text top="727" left="63" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref104">with representation from the American College of</a></text>
<text top="740" left="63" width="147" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref104">Physicians. Circulation. 2007;115:813</a></text>
<text top="739" left="210" width="10" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref104">–8</a></text>
<text top="740" left="220" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref104">.</a></text>
<text top="759" left="63" width="17" height="9" font="5">105.</text>
<text top="759" left="83" width="5" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref105">P</a></text>
<text top="757" left="88" width="193" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref105">ﬁsterer M, Brunner-La Rocca HP, Buser PT, et al.</a></text>
<text top="772" left="63" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref105">Late clinical events after clopidogrel discontinuation</a></text>
<text top="786" left="63" width="87" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref105">may limit the bene</a></text>
<text top="784" left="150" width="131" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref105">ﬁt of drug-eluting stents: an</a></text>
<text top="799" left="63" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref105">observational study of drug-eluting versus bare-metal</a></text>
<text top="813" left="63" width="165" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref105">stents. J Am Coll Cardiol. 2006;48:2584</a></text>
<text top="811" left="227" width="13" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref105">–91</a></text>
<text top="813" left="241" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref105">.</a></text>
<text top="831" left="63" width="18" height="9" font="5">106.</text>
<text top="831" left="84" width="197" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref106">Navarese EP, Kowalewski M, Kandzari D, et al.</a></text>
<text top="845" left="63" width="64" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref106">First-generation</a></text>
<text top="845" left="138" width="25" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref106">versus</a></text>
<text top="845" left="174" width="75" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref106">second-generation</a></text>
<text top="845" left="259" width="22" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref106">drug-</a></text>
<text top="858" left="63" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref106">eluting stents in current clinical practice: updated ev-</a></text>
<text top="871" left="63" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref106">idence from a comprehensive meta-analysis of rando-</a></text>
<text top="885" left="63" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref106">mised clinical trials comprising 31 379 patients. Open</a></text>
<text top="898" left="63" width="97" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref106">Heart. 2014;1:e000064</a></text>
<text top="898" left="159" width="3" height="9" font="5">.</text>
<text top="917" left="63" width="17" height="9" font="5">107.</text>
<text top="917" left="83" width="198" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref107">Palmerini T, Kirtane AJ, Serruys PW, et al. Stent</a></text>
<text top="930" left="63" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref107">thrombosis with everolimus-eluting stents: meta-</a></text>
<text top="944" left="63" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref107">analysis of comparative randomized controlled trials.</a></text>
<text top="957" left="63" width="136" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref107">Circ Cardiovasc Interv. 2012;5:357</a></text>
<text top="956" left="199" width="15" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref107">–64</a></text>
<text top="957" left="214" width="3" height="9" font="5">.</text>
<text top="976" left="63" width="18" height="9" font="5">108.</text>
<text top="976" left="84" width="197" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref108">Räber L, Magro M, Stefanini GG, et al. Very late</a></text>
<text top="989" left="63" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref108">coronary stent thrombosis of a newer-generation</a></text>
<text top="1003" left="63" width="75" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref108">everolimus-eluting</a></text>
<text top="1003" left="148" width="21" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref108">stent</a></text>
<text top="1003" left="180" width="39" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref108">compared</a></text>
<text top="1003" left="230" width="18" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref108">with</a></text>
<text top="1003" left="258" width="23" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref108">early-</a></text>
<text top="1016" left="63" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref108">generation drug-eluting stents: a prospective cohort</a></text>
<text top="1029" left="63" width="131" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref108">study. Circulation. 2012;125:1110</a></text>
<text top="1028" left="194" width="13" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref108">–21</a></text>
<text top="1029" left="206" width="3" height="9" font="5">.</text>
<text top="1048" left="63" width="18" height="9" font="5">109.</text>
<text top="1048" left="84" width="197" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref109">Sarno G, Lagerqvist B, Nilsson J, et al. Stent</a></text>
<text top="1061" left="63" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref109">thrombosis in new-generation drug-eluting stents in</a></text>
<text top="1075" left="63" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref109">patients with STEMI undergoing primary PCI: a report</a></text>
<text top="1088" left="63" width="175" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref109">from SCAAR. J Am Coll Cardiol. 2014;64:16</a></text>
<text top="1087" left="238" width="14" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref109">–24</a></text>
<text top="1088" left="252" width="3" height="9" font="5">.</text>
<text top="143" left="301" width="16" height="9" font="5">110.</text>
<text top="143" left="320" width="11" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref110">Ko</a></text>
<text top="140" left="330" width="189" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref110">cka V, Malý M, Tousek P, et al. Bioresorbable</a></text>
<text top="156" left="301" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref110">vascular scaffolds in acute ST-segment elevation</a></text>
<text top="170" left="301" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref110">myocardial infarction: a prospective multicentre study</a></text>
<text top="182" left="301" width="169" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref110">“Prague 19”. Eur Heart J. 2014;35:787–94</a></text>
<text top="183" left="469" width="3" height="9" font="5">.</text>
<text top="203" left="301" width="14" height="9" font="5">111.</text>
<text top="203" left="318" width="201" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref111">Kereiakes DJ, Meredith IT, Windecker S, et al. Ef-</a></text>
<text top="215" left="301" width="218" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref111">ﬁcacy and safety of a novel bioabsorbable polymer-</a></text>
<text top="230" left="301" width="29" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref111">coated,</a></text>
<text top="230" left="341" width="75" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref111">everolimus-eluting</a></text>
<text top="230" left="426" width="35" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref111">coronary</a></text>
<text top="230" left="472" width="23" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref111">stent:</a></text>
<text top="230" left="506" width="13" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref111">the</a></text>
<text top="244" left="301" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref111">EVOLVE II Randomized Trial. Circ Cardiovasc Interv.</a></text>
<text top="257" left="301" width="66" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref111">2015;8:e002372</a></text>
<text top="257" left="367" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref111">.</a></text>
<text top="277" left="301" width="15" height="9" font="5">112.</text>
<text top="277" left="318" width="200" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref112">Puricel S, Arroyo D, Corpataux N, et al. Comparison</a></text>
<text top="290" left="301" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref112">of everolimus- and biolimus-eluting coronary stents</a></text>
<text top="304" left="301" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref112">with everolimus-eluting bioresorbable vascular scaf-</a></text>
<text top="317" left="301" width="150" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref112">folds. J Am Coll Cardiol. 2015;65:791</a></text>
<text top="316" left="450" width="19" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref112">–801</a></text>
<text top="317" left="470" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref112">.</a></text>
<text top="337" left="301" width="15" height="9" font="5">113.</text>
<text top="337" left="318" width="200" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref113">Gao R, Yang Y, Han Y, et al. Bioresorbable vascular</a></text>
<text top="351" left="301" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref113">scaffolds versus metallic stents in patients with coro-</a></text>
<text top="364" left="301" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref113">nary artery disease: ABSORB China Trial. J Am Coll</a></text>
<text top="378" left="301" width="90" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref113">Cardiol. 2015;66:2298</a></text>
<text top="376" left="391" width="20" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref113">–309</a></text>
<text top="378" left="411" width="3" height="9" font="5">.</text>
<text top="398" left="301" width="16" height="9" font="5">114.</text>
<text top="398" left="319" width="199" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref114">Windecker S, Serruys PW, Wandel S, et al.</a></text>
<text top="411" left="301" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref114">Biolimus-eluting stent with biodegradable polymer</a></text>
<text top="425" left="301" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref114">versus sirolimus-eluting stent with durable polymer</a></text>
<text top="438" left="301" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref114">for coronary revascularisation (LEADERS): a rando-</a></text>
<text top="451" left="301" width="24" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref114">mised</a></text>
<text top="451" left="335" width="59" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref114">non-inferiority</a></text>
<text top="451" left="405" width="19" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref114">trial.</a></text>
<text top="451" left="435" width="30" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref114">Lancet.</a></text>
<text top="451" left="476" width="43" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref114">2008;372:</a></text>
<text top="465" left="301" width="18" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref114">1163</a></text>
<text top="463" left="319" width="14" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref114">–73</a></text>
<text top="465" left="332" width="3" height="9" font="5">.</text>
<text top="485" left="301" width="15" height="9" font="5">115.</text>
<text top="485" left="318" width="200" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref115">Meredith IT, Verheye S, Dubois CL, et al. Primary</a></text>
<text top="498" left="301" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref115">endpoint results of the EVOLVE trial: a randomized</a></text>
<text top="512" left="301" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref115">evaluation of a novel bioabsorbable polymer-coated,</a></text>
<text top="525" left="301" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref115">everolimus-eluting coronary stent. J Am Coll Cardiol.</a></text>
<text top="539" left="301" width="54" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref115">2012;59:1362</a></text>
<text top="537" left="355" width="15" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref115">–70</a></text>
<text top="539" left="369" width="3" height="9" font="5">.</text>
<text top="559" left="301" width="16" height="9" font="5">116.</text>
<text top="559" left="319" width="199" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref116">Ellis SG, Kereiakes DJ, Metzger DC, et al.</a></text>
<text top="572" left="301" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref116">Everolimus-eluting bioresorbable scaffolds for coro-</a></text>
<text top="586" left="301" width="200" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref116">nary artery disease. N Engl J Med. 2015;373:1905</a></text>
<text top="584" left="501" width="13" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref116">–15</a></text>
<text top="586" left="513" width="3" height="9" font="5">.</text>
<text top="605" left="301" width="15" height="9" font="5">117.</text>
<text top="605" left="318" width="200" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref117">Urban P, Meredith IT, Abizaid A, et al. Polymer-</a></text>
<text top="619" left="301" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref117">free drug-coated coronary stents in patients at high</a></text>
<text top="632" left="301" width="177" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref117">bleeding risk. N Engl J Med. 2015;373:2038</a></text>
<text top="631" left="477" width="14" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref117">–47</a></text>
<text top="632" left="491" width="3" height="9" font="5">.</text>
<text top="652" left="301" width="16" height="9" font="5">118.</text>
<text top="652" left="319" width="169" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref118">Fox KAA, Mehta SR, Peters R, et al. Bene</a></text>
<text top="651" left="488" width="31" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref118">ﬁts and</a></text>
<text top="666" left="301" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref118">risks of the combination of clopidogrel and aspirin in</a></text>
<text top="679" left="301" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref118">patients undergoing surgical revascularization for</a></text>
<text top="693" left="301" width="15" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref118">non</a></text>
<text top="691" left="316" width="203" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref118">—ST-elevation acute coronary syndrome: the Clo-</a></text>
<text top="706" left="301" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref118">pidogrel in Unstable angina to prevent Recurrent</a></text>
<text top="720" left="301" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref118">ischemic Events (CURE) Trial. Circulation. 2004;110:</a></text>
<text top="733" left="301" width="20" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref118">1202</a></text>
<text top="731" left="320" width="10" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref118">–8</a></text>
<text top="733" left="330" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref118">.</a></text>
<text top="753" left="301" width="16" height="9" font="5">119.</text>
<text top="753" left="319" width="199" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref119">Kim DH, Daskalakis C, Silvestry SC, et al. Aspirin</a></text>
<text top="766" left="301" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref119">and clopidogrel use in the early postoperative period</a></text>
<text top="780" left="301" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref119">following on-pump and off-pump coronary artery</a></text>
<text top="793" left="301" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref119">bypass grafting. J Thorac Cardiovasc Surg. 2009;138:</a></text>
<text top="807" left="301" width="18" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref119">1377</a></text>
<text top="805" left="318" width="15" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref119">–84</a></text>
<text top="807" left="333" width="3" height="9" font="5">.</text>
<text top="827" left="301" width="17" height="9" font="5">120.</text>
<text top="827" left="321" width="198" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref120">Sørensen R, Abildstrøm SZ, Hansen PR, et al. Ef-</a></text>
<text top="839" left="301" width="218" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref120">ﬁcacy of post-operative clopidogrel treatment in pa-</a></text>
<text top="854" left="301" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref120">tients revascularized with coronary artery bypass</a></text>
<text top="867" left="301" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref120">grafting after myocardial infarction. J Am Coll Cardiol.</a></text>
<text top="881" left="301" width="53" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref120">2011;57:1202</a></text>
<text top="879" left="353" width="10" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref120">–9</a></text>
<text top="881" left="363" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref120">.</a></text>
<text top="900" left="301" width="15" height="9" font="5">121.</text>
<text top="900" left="318" width="200" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref121">Gao G, Zheng Z, Pi Y, et al. Aspirin plus clopidogrel</a></text>
<text top="914" left="301" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref121">therapy increases early venous graft patency after</a></text>
<text top="927" left="301" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref121">coronary artery bypass surgery a single-center, ran-</a></text>
<text top="941" left="301" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref121">domized, controlled trial. J Am Coll Cardiol. 2010;56:</a></text>
<text top="954" left="301" width="20" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref121">1639</a></text>
<text top="953" left="320" width="14" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref121">–43</a></text>
<text top="954" left="334" width="3" height="9" font="5">.</text>
<text top="974" left="301" width="16" height="9" font="5">122.</text>
<text top="974" left="319" width="199" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref122">Deo SV, Dunlay SM, Shah IK, et al. Dual anti-</a></text>
<text top="988" left="301" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref122">platelet therapy after coronary artery bypass graft-</a></text>
<text top="1001" left="301" width="96" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref122">ing: is there any bene</a></text>
<text top="1000" left="397" width="122" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref122">ﬁt? A systematic review and</a></text>
<text top="1015" left="301" width="163" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref122">meta-analysis. J Card Surg. 2013;28:109</a></text>
<text top="1013" left="463" width="13" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref122">–16</a></text>
<text top="1015" left="477" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref122">.</a></text>
<text top="1035" left="301" width="16" height="9" font="5">123.</text>
<text top="1035" left="319" width="199" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref123">Nocerino AG, Achenbach S, Taylor AJ. Meta-</a></text>
<text top="1048" left="301" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref123">analysis of effect of single versus dual antiplatelet</a></text>
<text top="1061" left="301" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref123">therapy on early patency of bypass conduits after</a></text>
<text top="1075" left="301" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref123">coronary artery bypass grafting. Am J Cardiol. 2013;</a></text>
<text top="1088" left="301" width="34" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref123">112:1576</a></text>
<text top="1087" left="334" width="10" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref123">–9</a></text>
<text top="1088" left="344" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref123">.</a></text>
<text top="143" left="538" width="17" height="9" font="5">124.</text>
<text top="143" left="558" width="198" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref124">Ibrahim K, Tjomsland O, Halvorsen D, et al. Effect</a></text>
<text top="156" left="538" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref124">of clopidogrel on midterm graft patency following off-</a></text>
<text top="170" left="538" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref124">pump coronary revascularization surgery. Heart Surg</a></text>
<text top="183" left="538" width="84" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref124">Forum. 2006;9:E581</a></text>
<text top="182" left="622" width="20" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref124">–856</a></text>
<text top="183" left="642" width="3" height="9" font="5">.</text>
<text top="202" left="538" width="16" height="9" font="5">125.</text>
<text top="202" left="557" width="199" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref125">Mannacio VA, Di Tommaso L, Antignan A, et al.</a></text>
<text top="215" left="538" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref125">Aspirin plus clopidogrel for optimal platelet inhibition</a></text>
<text top="229" left="538" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref125">following off-pump coronary artery bypass surgery:</a></text>
<text top="242" left="538" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref125">results from the CRYSSA (prevention of Coronary ar-</a></text>
<text top="256" left="538" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref125">teRY bypaSS occlusion After off-pump procedures)</a></text>
<text top="269" left="538" width="158" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref125">randomised study. Heart. 2012;98:1710</a></text>
<text top="268" left="697" width="9" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref125">–5</a></text>
<text top="269" left="705" width="3" height="9" font="5">.</text>
<text top="288" left="538" width="17" height="9" font="5">126.</text>
<text top="288" left="558" width="198" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref126">Farooq V, Serruys PW, Bourantas C, et al. Inci-</a></text>
<text top="301" left="538" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref126">dence and multivariable correlates of long-term mor-</a></text>
<text top="315" left="538" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref126">tality in patients treated with surgical or percutaneous</a></text>
<text top="328" left="538" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref126">revascularization in the Synergy between Percutaneous</a></text>
<text top="342" left="538" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref126">Coronary Intervention with Taxus and Cardiac Surgery</a></text>
<text top="355" left="538" width="168" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref126">(SYNTAX) trial. Eur Heart J. 2012;33:3105</a></text>
<text top="353" left="706" width="12" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref126">–13</a></text>
<text top="355" left="718" width="3" height="9" font="5">.</text>
<text top="373" left="538" width="16" height="9" font="5">127.</text>
<text top="373" left="557" width="199" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref127">Johnson WD, Kayser KL, Hartz AJ, et al. Aspirin</a></text>
<text top="387" left="538" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref127">use and survival after coronary bypass surgery. Am</a></text>
<text top="400" left="538" width="89" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref127">Heart J. 1992;123:603</a></text>
<text top="399" left="628" width="10" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref127">–8</a></text>
<text top="400" left="637" width="3" height="9" font="5">.</text>
<text top="419" left="538" width="17" height="9" font="5">128.</text>
<text top="419" left="558" width="198" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref128">Chesebro JH, Clements IP, Fuster V, et al.</a></text>
<text top="432" left="538" width="6" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref128">A</a></text>
<text top="432" left="553" width="90" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref128">platelet-inhibitor-drug</a></text>
<text top="432" left="653" width="16" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref128">trial</a></text>
<text top="432" left="678" width="7" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref128">in</a></text>
<text top="432" left="694" width="62" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref128">coronary-artery</a></text>
<text top="446" left="538" width="105" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref128">bypass operations: bene</a></text>
<text top="444" left="643" width="114" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref128">ﬁt of perioperative dipyr-</a></text>
<text top="459" left="538" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref128">idamole and aspirin therapy on early postoperative</a></text>
<text top="473" left="538" width="189" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref128">vein-graft patency. N Engl J Med. 1982;307:73</a></text>
<text top="471" left="728" width="10" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref128">–8</a></text>
<text top="473" left="737" width="3" height="9" font="5">.</text>
<text top="491" left="538" width="17" height="9" font="5">129.</text>
<text top="491" left="558" width="198" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref129">Chesebro JH, Fuster V, Elveback LR, et al. Effect</a></text>
<text top="505" left="538" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref129">of dipyridamole and aspirin on late vein-graft patency</a></text>
<text top="518" left="538" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref129">after coronary bypass operations. N Engl J Med. 1984;</a></text>
<text top="532" left="538" width="34" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref129">310:209</a></text>
<text top="530" left="572" width="13" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref129">–14</a></text>
<text top="532" left="585" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref129">.</a></text>
<text top="550" left="538" width="17" height="9" font="5">130.</text>
<text top="550" left="558" width="198" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref130">Goldman S, Copeland J, Moritz T, et al.</a></text>
<text top="564" left="538" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref130">Improvement in early saphenous vein graft patency</a></text>
<text top="577" left="538" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref130">after coronary artery bypass surgery with antiplatelet</a></text>
<text top="590" left="538" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref130">therapy: results of a Veterans Administration Cooper-</a></text>
<text top="604" left="538" width="152" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref130">ative Study. Circulation. 1988;77:1324</a></text>
<text top="602" left="691" width="14" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref130">–32</a></text>
<text top="604" left="704" width="3" height="9" font="5">.</text>
<text top="622" left="538" width="15" height="9" font="5">131.</text>
<text top="622" left="556" width="200" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref131">Ebrahimi R, Bakaeen FG, Uberoi A, et al. Effect of</a></text>
<text top="636" left="538" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref131">clopidogrel use post coronary artery bypass surgery on</a></text>
<text top="649" left="538" width="176" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref131">graft patency. Ann Thorac Surg. 2014;97:15</a></text>
<text top="648" left="714" width="13" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref131">–21</a></text>
<text top="649" left="727" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref131">.</a></text>
<text top="668" left="538" width="16" height="9" font="5">132.</text>
<text top="668" left="557" width="199" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref132">Kulik A, Le May MR, Voisine P, et al. Aspirin plus</a></text>
<text top="681" left="538" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref132">clopidogrel versus aspirin alone after coronary artery</a></text>
<text top="695" left="538" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref132">bypass grafting: the Clopidogrel After Surgery for</a></text>
<text top="708" left="538" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref132">Coronary Artery Disease (CASCADE) Trial. Circulation.</a></text>
<text top="722" left="538" width="62" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref132">2010;122:2680</a></text>
<text top="720" left="600" width="9" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref132">–7</a></text>
<text top="722" left="608" width="3" height="9" font="5">.</text>
<text top="740" left="538" width="16" height="9" font="5">133.</text>
<text top="740" left="557" width="199" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref133">Gao C, Ren C, Li D, et al. Clopidogrel and aspirin</a></text>
<text top="754" left="538" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref133">versus clopidogrel alone on graft patency after coro-</a></text>
<text top="767" left="538" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref133">nary artery bypass grafting. Ann Thorac Surg. 2009;</a></text>
<text top="780" left="538" width="24" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref133">88:59</a></text>
<text top="779" left="562" width="14" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref133">–62</a></text>
<text top="780" left="577" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref133">.</a></text>
<text top="799" left="538" width="17" height="9" font="5">134.</text>
<text top="799" left="558" width="198" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref134">Sun JCJ, Teoh KHT, Lamy A, et al. Randomized</a></text>
<text top="813" left="538" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref134">trial of aspirin and clopidogrel versus aspirin alone for</a></text>
<text top="826" left="538" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref134">the prevention of coronary artery bypass graft occlu-</a></text>
<text top="839" left="538" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref134">sion: the Preoperative Aspirin and Postoperative Anti-</a></text>
<text top="853" left="538" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref134">platelets in Coronary Artery Bypass Grafting study. Am</a></text>
<text top="866" left="538" width="94" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref134">Heart J. 2010;160:1178</a></text>
<text top="865" left="632" width="15" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref134">–84</a></text>
<text top="866" left="647" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref134">.</a></text>
<text top="885" left="538" width="16" height="9" font="5">135.</text>
<text top="885" left="557" width="199" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref135">de Leon N, Jackevicius CA. Use of aspirin and</a></text>
<text top="898" left="538" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref135">clopidogrel after coronary artery bypass graft surgery.</a></text>
<text top="912" left="538" width="131" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref135">Ann Pharmacother. 2012;46:678</a></text>
<text top="910" left="670" width="14" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref135">–87</a></text>
<text top="912" left="684" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref135">.</a></text>
<text top="930" left="538" width="17" height="9" font="5">136.</text>
<text top="930" left="558" width="198" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref136">Gurbuz AT, Zia AA, Vuran AC, et al. Postoperative</a></text>
<text top="944" left="538" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref136">clopidogrel improves mid-term outcome after off-</a></text>
<text top="957" left="538" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref136">pump coronary artery bypass graft surgery: a pro-</a></text>
<text top="971" left="538" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref136">spective study. Eur J Cardiothorac Surg. 2006;29:</a></text>
<text top="984" left="538" width="15" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref136">190</a></text>
<text top="982" left="554" width="9" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref136">–5</a></text>
<text top="984" left="562" width="3" height="9" font="5">.</text>
<text top="1003" left="538" width="16" height="9" font="5">137.</text>
<text top="1003" left="557" width="199" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref137">Smith PK, Goodnough LT, Levy JH, et al. Mortality</a></text>
<text top="1016" left="538" width="19" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref137">bene</a></text>
<text top="1014" left="558" width="199" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref137">ﬁt with prasugrel in the TRITON-TIMI 38 coronary</a></text>
<text top="1029" left="538" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref137">artery bypass grafting cohort: risk-adjusted retro-</a></text>
<text top="1043" left="538" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref137">spective data analysis. J Am Coll Cardiol. 2012;60:</a></text>
<text top="1056" left="538" width="16" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref137">388</a></text>
<text top="1055" left="554" width="15" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref137">–96</a></text>
<text top="1056" left="569" width="3" height="9" font="5">.</text>
<text top="1075" left="538" width="17" height="9" font="5">138.</text>
<text top="1075" left="558" width="198" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref138">Held C, Asenblad N, Bassand JP, et al. Ticagrelor</a></text>
<text top="1088" left="538" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref138">versus clopidogrel in patients with acute coronary</a></text>
<text top="54" left="63" width="132" height="7" font="7">J A C C V O L . 6 8 , N O . 1 0 , 2 0 1 6</text>
<text top="54" left="705" width="52" height="9" font="14">Levine et al.</text>
<text top="69" left="63" width="117" height="7" font="7">S E P T E M B E R 6 , 2 0 1 6 : 1 0 8 2</text>
<text top="67" left="182" width="17" height="10" font="7">– 1 1 5</text>
<text top="69" left="514" width="243" height="9" font="14">Focused Update on Duration of Dual Antiplatelet Therapy</text>
<text top="53" left="789" width="18" height="9" font="5">1107</text>
</page>
<page number="27" position="absolute" top="0" left="0" height="1160" width="864">
<text top="143" left="108" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref138">syndromes undergoing coronary artery bypass surgery:</a></text>
<text top="156" left="108" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref138">results from the PLATO (Platelet Inhibition and Patient</a></text>
<text top="170" left="108" width="191" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref138">Outcomes) trial. J Am Coll Cardiol. 2011;57:672</a></text>
<text top="168" left="298" width="15" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref138">–84</a></text>
<text top="170" left="313" width="3" height="9" font="5">.</text>
<text top="189" left="108" width="17" height="9" font="5">139.</text>
<text top="189" left="127" width="198" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref139">Varenhorst C, Alstrom U, Scirica BM, et al. Factors</a></text>
<text top="203" left="108" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref139">contributing to the lower mortality with ticagrelor</a></text>
<text top="216" left="108" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref139">compared with clopidogrel in patients undergoing</a></text>
<text top="230" left="108" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref139">coronary artery bypass surgery. J Am Coll Cardiol.</a></text>
<text top="243" left="108" width="55" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref139">2012;60:1623</a></text>
<text top="242" left="163" width="15" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref139">–30</a></text>
<text top="243" left="178" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref139">.</a></text>
<text top="263" left="108" width="18" height="9" font="5">140.</text>
<text top="263" left="129" width="197" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref140">Chen ZM, Jiang LX, Chen YP, et al. Addition of</a></text>
<text top="276" left="108" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref140">clopidogrel to aspirin in 45,852 patients with acute</a></text>
<text top="290" left="108" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref140">myocardial infarction: randomised placebo-controlled</a></text>
<text top="303" left="108" width="116" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref140">trial. Lancet. 2005;366:1607</a></text>
<text top="301" left="224" width="13" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref140">–21</a></text>
<text top="303" left="237" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref140">.</a></text>
<text top="323" left="108" width="16" height="9" font="5">141.</text>
<text top="323" left="127" width="199" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref141">Roe MT, Armstrong PW, Fox KAA, et al. Prasugrel</a></text>
<text top="336" left="108" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref141">versus clopidogrel for acute coronary syndromes</a></text>
<text top="350" left="108" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref141">without revascularization. N Engl J Med. 2012;367:</a></text>
<text top="363" left="108" width="19" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref141">1297</a></text>
<text top="361" left="126" width="20" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref141">–309</a></text>
<text top="363" left="147" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref141">.</a></text>
<text top="383" left="108" width="17" height="9" font="5">142.</text>
<text top="383" left="127" width="198" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref142">Sabatine MS, Cannon CP, Gibson CM, et al. Addi-</a></text>
<text top="396" left="108" width="137" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref142">tion of clopidogrel to aspirin and</a></text>
<text top="394" left="249" width="77" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref142">ﬁbrinolytic therapy</a></text>
<text top="409" left="108" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref142">for myocardial infarction with ST-segment elevation.</a></text>
<text top="423" left="108" width="119" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref142">N Engl J Med. 2005;352:1179</a></text>
<text top="421" left="227" width="15" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref142">–89</a></text>
<text top="423" left="242" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref142">.</a></text>
<text top="442" left="108" width="17" height="9" font="5">143.</text>
<text top="442" left="127" width="198" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref143">Wijeysundera DN, Wijeysundera HC, Yun L, et al.</a></text>
<text top="456" left="108" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref143">Risk of elective major noncardiac surgery after coro-</a></text>
<text top="469" left="108" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref143">nary stent insertion: a population-based study. Circu-</a></text>
<text top="483" left="108" width="85" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref143">lation. 2012;126:1355</a></text>
<text top="481" left="193" width="14" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref143">–62</a></text>
<text top="483" left="207" width="3" height="9" font="5">.</text>
<text top="502" left="108" width="18" height="9" font="5">144.</text>
<text top="502" left="128" width="197" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref144">Berger PB, Kleiman NS, Pencina MJ, et al. Fre-</a></text>
<text top="516" left="108" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref144">quency of major noncardiac surgery and subsequent</a></text>
<text top="529" left="108" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref144">adverse events in the year after drug-eluting stent</a></text>
<text top="543" left="108" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref144">placement results from the EVENT (Evaluation of</a></text>
<text top="556" left="108" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref144">Drug-Eluting Stents and Ischemic Events) Registry.</a></text>
<text top="570" left="108" width="141" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref144">J Am Coll Cardiol Intv. 2010;3:920</a></text>
<text top="568" left="249" width="9" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref144">–7</a></text>
<text top="570" left="257" width="3" height="9" font="5">.</text>
<text top="589" left="108" width="17" height="9" font="5">145.</text>
<text top="589" left="127" width="198" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref145">Mehran R, Baber U, Steg PG, et al. Cessation of</a></text>
<text top="602" left="108" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref145">dual antiplatelet treatment and cardiac events after</a></text>
<text top="616" left="108" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref145">percutaneous coronary intervention (PARIS): 2 year</a></text>
<text top="629" left="108" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref145">results from a prospective observational study. Lancet.</a></text>
<text top="643" left="108" width="57" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref145">2013;382:1714</a></text>
<text top="641" left="165" width="14" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref145">–22</a></text>
<text top="643" left="179" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref145">.</a></text>
<text top="662" left="108" width="18" height="9" font="5">146.</text>
<text top="662" left="128" width="197" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref146">Holcomb CN, Hollis RH, Graham LA, et al. Asso-</a></text>
<text top="676" left="108" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref146">ciation of coronary stent indication with postoperative</a></text>
<text top="689" left="108" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref146">outcomes following noncardiac surgery. JAMA Surg.</a></text>
<text top="703" left="108" width="26" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref146">2015:1</a></text>
<text top="701" left="133" width="10" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref146">–8</a></text>
<text top="703" left="143" width="3" height="9" font="5">.</text>
<text top="722" left="108" width="218" height="9" font="5">147. Siller-Matula JM, Petre A, Delle-Karth G, et al.</text>
<text top="736" left="108" width="136" height="9" font="5">Impact of preoperative use of P2Y</text>
<text top="739" left="243" width="6" height="6" font="28">12</text>
<text top="736" left="252" width="73" height="9" font="5">receptor inhibitors</text>
<text top="749" left="108" width="218" height="9" font="5">on clinical outcomes in cardiac and non-cardiac sur-</text>
<text top="763" left="108" width="218" height="9" font="5">gery: a systematic review and meta-analysis. Eur Heart</text>
<text top="776" left="108" width="218" height="9" font="5">J Acute Cardiovasc Care. 2015 May 5 [E-pub ahead</text>
<text top="789" left="108" width="36" height="9" font="5">of print].</text>
<text top="143" left="345" width="18" height="9" font="5">148.</text>
<text top="143" left="366" width="198" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref148">Chee YL, Crawford JC, Watson HG, et al. Guide-</a></text>
<text top="156" left="345" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref148">lines on the assessment of bleeding risk prior to sur-</a></text>
<text top="170" left="345" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref148">gery or invasive procedures. British Committee for</a></text>
<text top="183" left="345" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref148">Standards in Haematology. Br J Haematol. 2008;140:</a></text>
<text top="197" left="345" width="17" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref148">496</a></text>
<text top="195" left="362" width="20" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref148">–504</a></text>
<text top="197" left="382" width="3" height="9" font="5">.</text>
<text top="215" left="345" width="18" height="9" font="5">149.</text>
<text top="215" left="366" width="197" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref149">van Werkum JW, Heestermans AA, Zomer AC,</a></text>
<text top="229" left="345" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref149">et al. Predictors of coronary stent thrombosis: the</a></text>
<text top="242" left="345" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref149">Dutch Stent Thrombosis Registry. J Am Coll Cardiol.</a></text>
<text top="256" left="345" width="57" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref149">2009;53:1399</a></text>
<text top="254" left="402" width="21" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref149">–409</a></text>
<text top="256" left="423" width="3" height="9" font="5">.</text>
<text top="274" left="345" width="17" height="9" font="5">150.</text>
<text top="274" left="365" width="198" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref150">Secemsky EA, Matteau A, Yeh RW, et al. Com-</a></text>
<text top="288" left="345" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref150">parison of short- and long-term cardiac mortality in</a></text>
<text top="301" left="345" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref150">early versus late stent thrombosis (from Pooled PRO-</a></text>
<text top="315" left="345" width="167" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref150">TECT Trials). Am J Cardiol. 2015;115:1678</a></text>
<text top="313" left="512" width="15" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref150">–84</a></text>
<text top="315" left="527" width="3" height="9" font="5">.</text>
<text top="333" left="345" width="15" height="9" font="5">151.</text>
<text top="333" left="363" width="200" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref151">Holcomb CN, Graham LA, Richman JS, et al. The</a></text>
<text top="347" left="345" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref151">incremental risk of noncardiac surgery on adverse</a></text>
<text top="360" left="345" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref151">cardiac events following coronary stenting. J Am Coll</a></text>
<text top="374" left="345" width="90" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref151">Cardiol. 2014;64:2730</a></text>
<text top="372" left="435" width="10" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref151">–9</a></text>
<text top="374" left="445" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref151">.</a></text>
<text top="392" left="345" width="16" height="9" font="5">152.</text>
<text top="392" left="364" width="199" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref152">Cruden NLM, Harding SA, Flapan AD, et al. Pre-</a></text>
<text top="406" left="345" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref152">vious coronary stent implantation and cardiac events in</a></text>
<text top="419" left="345" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref152">patients undergoing noncardiac surgery. Circ Car-</a></text>
<text top="433" left="345" width="107" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref152">diovasc Interv. 2010;3:236</a></text>
<text top="431" left="453" width="14" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref152">–42</a></text>
<text top="433" left="467" width="3" height="9" font="5">.</text>
<text top="451" left="345" width="16" height="9" font="5">153.</text>
<text top="451" left="364" width="199" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref153">Hawn MT, Graham LA, Richman JS, et al. Risk of</a></text>
<text top="465" left="345" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref153">major adverse cardiac events following noncardiac</a></text>
<text top="478" left="345" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref153">surgery in patients with coronary stents. JAMA. 2013;</a></text>
<text top="492" left="345" width="37" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref153">310:1462</a></text>
<text top="490" left="382" width="13" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref153">–72</a></text>
<text top="492" left="396" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref153">.</a></text>
<text top="510" left="345" width="17" height="9" font="5">154.</text>
<text top="510" left="365" width="198" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref154">Rajagopalan S, Ford I, Bachoo P, et al. Platelet</a></text>
<text top="524" left="345" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref154">activation, myocardial ischemic events and post-</a></text>
<text top="537" left="345" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref154">operative non-response to aspirin in patients under-</a></text>
<text top="550" left="345" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref154">going major vascular surgery. J Thromb Haemost.</a></text>
<text top="564" left="345" width="53" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref154">2007;5:2028</a></text>
<text top="562" left="398" width="14" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref154">–35</a></text>
<text top="564" left="412" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref154">.</a></text>
<text top="583" left="345" width="16" height="9" font="5">155.</text>
<text top="583" left="364" width="199" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref155">Diamantis T, Tsiminikakis N, Skordylaki A, et al.</a></text>
<text top="596" left="345" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref155">Alterations of hemostasis after laparoscopic and open</a></text>
<text top="609" left="345" width="139" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref155">surgery. Hematology. 2007;12:561</a></text>
<text top="608" left="484" width="15" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref155">–70</a></text>
<text top="609" left="499" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref155">.</a></text>
<text top="628" left="345" width="17" height="9" font="5">156.</text>
<text top="628" left="365" width="198" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref156">Fleisher LA, Beckman JA, Brown KA, et al. ACC/</a></text>
<text top="641" left="345" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref156">AHA 2007 guidelines on perioperative cardiovascular</a></text>
<text top="655" left="345" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref156">evaluation and care for noncardiac surgery: a report of</a></text>
<text top="668" left="345" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref156">the American College of Cardiology/American Heart</a></text>
<text top="682" left="345" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref156">Association Task Force on Practice Guidelines (Writing</a></text>
<text top="695" left="345" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref156">Committee to Revise the 2002 Guidelines on Periop-</a></text>
<text top="709" left="345" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref156">erative Cardiovascular Evaluation for Noncardiac Sur-</a></text>
<text top="722" left="345" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref156">gery). Developed in collaboration with the American</a></text>
<text top="736" left="345" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref156">Society of Echocardiography, American Society of Nu-</a></text>
<text top="749" left="345" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref156">clear Cardiology, Heart Rhythm Society, Society of</a></text>
<text top="763" left="345" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref156">Cardiovascular Anesthesiologists, Society for Cardio-</a></text>
<text top="776" left="345" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref156">vascular Angiography and Interventions, Society for</a></text>
<text top="789" left="345" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref156">Vascular Medicine and Biology, and Society for</a></text>
<text top="143" left="583" width="214" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref156">Vascular Surgery. J Am Coll Cardiol. 2007;50:e159</a></text>
<text top="141" left="797" width="4" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref156">–</a></text>
<text top="156" left="583" width="14" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref156">241</a></text>
<text top="156" left="597" width="3" height="9" font="5">.</text>
<text top="175" left="583" width="16" height="9" font="5">157.</text>
<text top="175" left="602" width="199" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref157">Oscarsson A, Gupta A, Fredrikson M, et al. To</a></text>
<text top="188" left="583" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref157">continue or discontinue aspirin in the perioperative</a></text>
<text top="202" left="583" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref157">period: a randomized, controlled clinical trial. Br J</a></text>
<text top="215" left="583" width="95" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref157">Anaesth. 2010;104:305</a></text>
<text top="214" left="678" width="13" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref157">–12</a></text>
<text top="215" left="690" width="3" height="9" font="5">.</text>
<text top="234" left="583" width="17" height="9" font="5">158.</text>
<text top="234" left="603" width="198" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref158">Burger W, Chemnitius J-M, Kneissl GD, et al.</a></text>
<text top="247" left="583" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref158">Low-dose aspirin for secondary cardiovascular pre-</a></text>
<text top="261" left="583" width="30" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref158">vention</a></text>
<text top="259" left="613" width="188" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref158">–cardiovascular risks after its perioperative</a></text>
<text top="274" left="583" width="214" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref158">withdrawal versus bleeding risks with its continuation</a></text>
<text top="273" left="797" width="4" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref158">–</a></text>
<text top="288" left="583" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref158">review and meta-analysis. J Intern Med. 2005;257:</a></text>
<text top="301" left="583" width="16" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref158">399</a></text>
<text top="300" left="599" width="19" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref158">–414</a></text>
<text top="301" left="618" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref158">.</a></text>
<text top="320" left="583" width="17" height="9" font="5">159.</text>
<text top="320" left="603" width="198" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref159">Alshawabkeh LI, Prasad A, Lenkovsky F, et al.</a></text>
<text top="333" left="583" width="115" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref159">Outcomes of a preoperative</a></text>
<text top="331" left="702" width="99" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref159">“bridging” strategy with</a></text>
<text top="347" left="583" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref159">glycoprotein IIb/IIIa inhibitors to prevent perioperative</a></text>
<text top="360" left="583" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref159">stent thrombosis in patients with drug-eluting stents</a></text>
<text top="373" left="583" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref159">who undergo surgery necessitating interruption of</a></text>
<text top="387" left="583" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref159">thienopyridine administration. EuroIntervention. 2013;</a></text>
<text top="400" left="583" width="25" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref159">9:204</a></text>
<text top="399" left="608" width="11" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref159">–11</a></text>
<text top="400" left="619" width="3" height="9" font="5">.</text>
<text top="419" left="583" width="18" height="9" font="5">160.</text>
<text top="419" left="604" width="197" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref160">Angiolillo DJ, Firstenberg MS, Price MJ, et al.</a></text>
<text top="432" left="583" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref160">Bridging antiplatelet therapy with cangrelor in patients</a></text>
<text top="446" left="583" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref160">undergoing cardiac surgery: a randomized controlled</a></text>
<text top="459" left="583" width="105" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref160">trial. JAMA. 2012;307:265</a></text>
<text top="458" left="688" width="14" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref160">–74</a></text>
<text top="459" left="702" width="3" height="9" font="5">.</text>
<text top="478" left="583" width="16" height="9" font="5">161.</text>
<text top="478" left="602" width="58" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref161">Savonitto S, D</a></text>
<text top="476" left="659" width="142" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref161">’Urbano M, Caracciolo M, et al. Ur-</a></text>
<text top="491" left="583" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref161">gent surgery in patients with a recently implanted</a></text>
<text top="505" left="583" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref161">coronary drug-eluting stent: a phase II study of</a></text>
<text top="517" left="583" width="218" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref161">“bridging” antiplatelet therapy with tiroﬁban during</a></text>
<text top="532" left="583" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref161">temporary withdrawal of clopidogrel. Br J Anaesth.</a></text>
<text top="545" left="583" width="56" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref161">2010;104:285</a></text>
<text top="543" left="639" width="13" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref161">–91</a></text>
<text top="545" left="653" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref161">.</a></text>
<text top="564" left="583" width="17" height="9" font="5">162.</text>
<text top="564" left="603" width="199" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref162">Savonitto S, Caracciolo M, Cattaneo M, et al. Man-</a></text>
<text top="577" left="583" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref162">agement of patients with recently implanted coronary</a></text>
<text top="590" left="583" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref162">stents on dual antiplatelet therapy who need to undergo</a></text>
<text top="604" left="583" width="185" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref162">major surgery. J Thromb Haemost. 2011;9:2133</a></text>
<text top="602" left="768" width="14" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref162">–42</a></text>
<text top="604" left="782" width="3" height="9" font="5"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref162">.</a></text>
<text top="622" left="583" width="17" height="9" font="5">163.</text>
<text top="622" left="603" width="198" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref163">Warshauer J, Patel VG, Christopoulos G, et al.</a></text>
<text top="636" left="583" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref163">Outcomes of preoperative bridging therapy for pa-</a></text>
<text top="649" left="583" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref163">tients undergoing surgery after coronary stent im-</a></text>
<text top="663" left="583" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref163">plantation: a weighted meta-analysis of 280 patients</a></text>
<text top="676" left="583" width="218" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref163">from eight studies. Catheter Cardiovasc Interv. 2015;</a></text>
<text top="690" left="583" width="23" height="9" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref163">85:25</a></text>
<text top="688" left="606" width="12" height="12" font="6"><a href="http://refhub.elsevier.com/S0735-1097(16)01699-5/sref163">–31</a></text>
<text top="690" left="618" width="3" height="9" font="5">.</text>
<text top="734" left="583" width="62" height="12" font="23">KEY WORDS</text>
<text top="736" left="651" width="115" height="9" font="5">ACC/AHA Clinical Practice</text>
<text top="749" left="583" width="200" height="9" font="5">Guideline, acute coronary syndrome, aspirin,</text>
<text top="763" left="583" width="205" height="9" font="5">coronary artery disease, coronary stents, dual</text>
<text top="776" left="583" width="202" height="9" font="5">antiplatelet therapy (DAPT), focused update,</text>
<text top="789" left="583" width="16" height="9" font="5">P2Y</text>
<text top="793" left="600" width="7" height="6" font="28">12</text>
<text top="789" left="610" width="175" height="9" font="5">inhibitor, stable ischemic heart disease</text>
<text top="53" left="108" width="52" height="9" font="14">Levine et al.</text>
<text top="54" left="670" width="132" height="7" font="7">J A C C V O L . 6 8 , N O . 1 0 , 2 0 1 6</text>
<text top="68" left="108" width="243" height="9" font="14">Focused Update on Duration of Dual Antiplatelet Therapy</text>
<text top="69" left="665" width="117" height="7" font="7">S E P T E M B E R 6 , 2 0 1 6 : 1 0 8 2</text>
<text top="67" left="784" width="17" height="10" font="7">– 1 1 5</text>
<text top="53" left="57" width="19" height="9" font="5">1108</text>
</page>
<page number="28" position="absolute" top="0" left="0" height="1160" width="864">
<text top="139" left="63" width="625" height="16" font="15">APPENDIX 1. AUTHOR RELATIONSHIPS WITH INDUSTRY AND OTHER ENTITIES (RELEVANT)—</text>
<text top="157" left="63" width="649" height="16" font="15">2016 ACC/AHA GUIDELINE FOCUSED UPDATE ON DURATION OF DUAL ANTIPLATELET THERAPY</text>
<text top="175" left="63" width="456" height="16" font="15">IN PATIENTS WITH CORONARY ARTERY DISEASE (FEBRUARY 2015)</text>
<text top="253" left="63" width="50" height="9" font="14">Committee</text>
<text top="264" left="63" width="38" height="9" font="14">Member</text>
<text top="264" left="156" width="70" height="9" font="14">Employer/Title</text>
<text top="264" left="272" width="50" height="9" font="14">Consultant</text>
<text top="253" left="351" width="42" height="9" font="14">Speakers</text>
<text top="264" left="356" width="32" height="9" font="14">Bureau</text>
<text top="241" left="404" width="53" height="9" font="14">Ownership/</text>
<text top="253" left="401" width="58" height="9" font="14">Partnership/</text>
<text top="264" left="410" width="41" height="9" font="14">Principal</text>
<text top="253" left="500" width="40" height="9" font="14">Personal</text>
<text top="264" left="499" width="42" height="9" font="14">Research</text>
<text top="217" left="588" width="60" height="9" font="14">Institutional,</text>
<text top="229" left="583" width="71" height="9" font="14">Organizational,</text>
<text top="241" left="599" width="39" height="9" font="14">or Other</text>
<text top="253" left="598" width="41" height="9" font="14">Financial</text>
<text top="264" left="602" width="23" height="9" font="14">Bene</text>
<text top="263" left="625" width="10" height="12" font="14">ﬁt</text>
<text top="253" left="667" width="31" height="9" font="14">Expert</text>
<text top="264" left="664" width="37" height="9" font="14">Witness</text>
<text top="229" left="716" width="31" height="9" font="14">Voting</text>
<text top="241" left="712" width="40" height="9" font="14">Recusals</text>
<text top="253" left="726" width="11" height="9" font="14">by</text>
<text top="264" left="712" width="34" height="9" font="14">Section</text>
<text top="264" left="746" width="4" height="9" font="19"><a href="1082.full.html#29">*</a></text>
<text top="284" left="63" width="69" height="9" font="14">Glenn N. Levine,</text>
<text top="296" left="78" width="21" height="9" font="14">Chair</text>
<text top="284" left="154" width="73" height="9" font="14">Baylor College of</text>
<text top="296" left="143" width="37" height="9" font="14">Medicine</text>
<text top="294" left="180" width="58" height="12" font="14">—Professor of</text>
<text top="308" left="151" width="79" height="9" font="14">Medicine; Director,</text>
<text top="320" left="155" width="72" height="9" font="14">Cardiac Care Unit</text>
<text top="284" left="286" width="22" height="9" font="14">None</text>
<text top="284" left="361" width="22" height="9" font="14">None</text>
<text top="284" left="419" width="22" height="9" font="14">None</text>
<text top="284" left="509" width="22" height="9" font="14">None</text>
<text top="284" left="607" width="22" height="9" font="14">None</text>
<text top="284" left="672" width="22" height="9" font="14">None</text>
<text top="284" left="721" width="22" height="9" font="14">None</text>
<text top="339" left="63" width="55" height="9" font="14">Eric R. Bates,</text>
<text top="351" left="78" width="44" height="9" font="14">Vice Chair,</text>
<text top="363" left="78" width="14" height="9" font="14">PCI</text>
<text top="339" left="140" width="94" height="9" font="14">University of Michigan</text>
<text top="337" left="234" width="7" height="12" font="14">—</text>
<text top="351" left="145" width="91" height="9" font="14">Professor of Medicine</text>
<text top="340" left="254" width="4" height="7" font="28">n</text>
<text top="339" left="263" width="54" height="9" font="14">AstraZeneca</text>
<text top="352" left="254" width="4" height="7" font="28">n</text>
<text top="351" left="263" width="26" height="9" font="14">Merck</text>
<text top="339" left="361" width="22" height="9" font="14">None</text>
<text top="339" left="419" width="22" height="9" font="14">None</text>
<text top="339" left="509" width="22" height="9" font="14">None</text>
<text top="339" left="607" width="22" height="9" font="14">None</text>
<text top="339" left="672" width="22" height="9" font="14">None</text>
<text top="339" left="707" width="48" height="9" font="14">All sections</text>
<text top="382" left="63" width="53" height="9" font="14">John A. Bittl</text>
<text top="382" left="138" width="106" height="9" font="14">Munroe Regional Medical</text>
<text top="394" left="144" width="27" height="9" font="14">Center</text>
<text top="392" left="172" width="65" height="12" font="14">—Interventional</text>
<text top="406" left="166" width="50" height="9" font="14">Cardiologist</text>
<text top="382" left="286" width="22" height="9" font="14">None</text>
<text top="382" left="361" width="22" height="9" font="14">None</text>
<text top="382" left="419" width="22" height="9" font="14">None</text>
<text top="382" left="509" width="22" height="9" font="14">None</text>
<text top="382" left="607" width="22" height="9" font="14">None</text>
<text top="382" left="672" width="22" height="9" font="14">None</text>
<text top="382" left="721" width="22" height="9" font="14">None</text>
<text top="425" left="63" width="67" height="9" font="14">Ralph G. Brindis</text>
<text top="425" left="142" width="98" height="9" font="14">University of California,</text>
<text top="437" left="142" width="57" height="9" font="14">San Francisco</text>
<text top="435" left="198" width="41" height="12" font="14">—Philip R.</text>
<text top="449" left="142" width="99" height="9" font="14">Lee Institute for Health</text>
<text top="461" left="143" width="58" height="9" font="14">Policy Studies</text>
<text top="459" left="202" width="37" height="12" font="14">—Clinical</text>
<text top="473" left="153" width="91" height="9" font="14">Professor of Medicine</text>
<text top="425" left="286" width="22" height="9" font="14">None</text>
<text top="425" left="361" width="22" height="9" font="14">None</text>
<text top="425" left="419" width="22" height="9" font="14">None</text>
<text top="425" left="509" width="22" height="9" font="14">None</text>
<text top="425" left="607" width="22" height="9" font="14">None</text>
<text top="425" left="672" width="22" height="9" font="14">None</text>
<text top="425" left="721" width="22" height="9" font="14">None</text>
<text top="492" left="63" width="69" height="9" font="14">Stephan D. Fihn,</text>
<text top="504" left="78" width="47" height="9" font="14">Chair, SIHD</text>
<text top="492" left="140" width="101" height="9" font="14">Department of Veterans</text>
<text top="504" left="137" width="27" height="9" font="14">Affairs</text>
<text top="502" left="164" width="81" height="12" font="14">—Director, Ofﬁce of</text>
<text top="516" left="144" width="94" height="9" font="14">Analytics and Business</text>
<text top="528" left="166" width="49" height="9" font="14">Intelligence</text>
<text top="492" left="286" width="22" height="9" font="14">None</text>
<text top="492" left="361" width="22" height="9" font="14">None</text>
<text top="492" left="419" width="22" height="9" font="14">None</text>
<text top="492" left="509" width="22" height="9" font="14">None</text>
<text top="492" left="607" width="22" height="9" font="14">None</text>
<text top="492" left="672" width="22" height="9" font="14">None</text>
<text top="492" left="721" width="22" height="9" font="14">None</text>
<text top="547" left="63" width="64" height="9" font="14">Lee A. Fleisher,</text>
<text top="559" left="78" width="53" height="9" font="14">Chair, Periop</text>
<text top="547" left="164" width="53" height="9" font="14">University of</text>
<text top="559" left="162" width="57" height="9" font="14">Pennsylvania,</text>
<text top="571" left="160" width="61" height="9" font="14">Department of</text>
<text top="583" left="156" width="63" height="9" font="14">Anesthesiology</text>
<text top="581" left="219" width="7" height="12" font="14">—</text>
<text top="595" left="165" width="51" height="9" font="14">Professor of</text>
<text top="607" left="159" width="63" height="9" font="14">Anesthesiology</text>
<text top="547" left="286" width="22" height="9" font="14">None</text>
<text top="547" left="361" width="22" height="9" font="14">None</text>
<text top="547" left="419" width="22" height="9" font="14">None</text>
<text top="547" left="509" width="22" height="9" font="14">None</text>
<text top="547" left="607" width="22" height="9" font="14">None</text>
<text top="547" left="672" width="22" height="9" font="14">None</text>
<text top="547" left="721" width="22" height="9" font="14">None</text>
<text top="626" left="63" width="60" height="9" font="14">Christopher B.</text>
<text top="638" left="78" width="33" height="9" font="14">Granger</text>
<text top="626" left="144" width="94" height="9" font="14">Duke Clinical Research</text>
<text top="638" left="152" width="35" height="9" font="14">Institute</text>
<text top="636" left="187" width="43" height="12" font="14">—Director,</text>
<text top="650" left="153" width="75" height="9" font="14">Cardiac Care Unit;</text>
<text top="662" left="145" width="91" height="9" font="14">Professor of Medicine</text>
<text top="627" left="254" width="4" height="7" font="28">n</text>
<text top="626" left="263" width="54" height="9" font="14">AstraZeneca</text>
<text top="639" left="254" width="4" height="7" font="28">n</text>
<text top="638" left="263" width="25" height="9" font="14">Bayer</text>
<text top="651" left="254" width="4" height="7" font="28">n</text>
<text top="650" left="263" width="59" height="9" font="14">Bristol-Myers</text>
<text top="662" left="263" width="30" height="9" font="14">Squi<a href="1082.full.html#29">bb</a></text>
<text top="660" left="293" width="5" height="12" font="19"><a href="1082.full.html#29">‡</a></text>
<text top="675" left="254" width="4" height="7" font="28">n</text>
<text top="674" left="263" width="64" height="9" font="14">Daiichi-Sankyo</text>
<text top="687" left="254" width="4" height="7" font="28">n</text>
<text top="686" left="263" width="34" height="9" font="14">Janssen</text>
<text top="698" left="263" width="71" height="9" font="14">Pharmaceuticals</text>
<text top="711" left="254" width="4" height="7" font="28">n</text>
<text top="710" left="263" width="21" height="9" font="14">Sano</text>
<text top="708" left="285" width="42" height="12" font="14">ﬁ-Aventis</text>
<text top="723" left="254" width="4" height="7" font="28">n</text>
<text top="722" left="263" width="33" height="9" font="14">Eli Lilly</text>
<text top="626" left="361" width="22" height="9" font="14">None</text>
<text top="626" left="419" width="22" height="9" font="14">None</text>
<text top="627" left="471" width="4" height="7" font="28">n</text>
<text top="626" left="480" width="54" height="9" font="14">AstraZen<a href="1082.full.html#29">eca</a></text>
<text top="624" left="534" width="5" height="12" font="19"><a href="1082.full.html#29">‡</a></text>
<text top="639" left="471" width="4" height="7" font="28">n</text>
<text top="638" left="480" width="25" height="9" font="14">Baye<a href="1082.full.html#29">r</a></text>
<text top="636" left="505" width="5" height="12" font="19"><a href="1082.full.html#29">‡</a></text>
<text top="651" left="471" width="4" height="7" font="28">n</text>
<text top="650" left="480" width="59" height="9" font="14">Bristol-Myers</text>
<text top="662" left="480" width="30" height="9" font="14">Squibb</text>
<text top="660" left="511" width="5" height="12" font="19"><a href="1082.full.html#29">‡</a></text>
<text top="675" left="471" width="4" height="7" font="28">n</text>
<text top="674" left="480" width="64" height="9" font="14">Daiichi-Sankyo</text>
<text top="672" left="545" width="5" height="12" font="19"><a href="1082.full.html#29">‡</a></text>
<text top="687" left="471" width="4" height="7" font="28">n</text>
<text top="686" left="480" width="34" height="9" font="14">Janssen</text>
<text top="698" left="480" width="71" height="9" font="14">Pharmaceuticals</text>
<text top="696" left="552" width="5" height="12" font="19"><a href="1082.full.html#29">‡</a></text>
<text top="711" left="471" width="4" height="7" font="28">n</text>
<text top="710" left="480" width="26" height="9" font="14">Merck</text>
<text top="708" left="507" width="5" height="12" font="19"><a href="1082.full.html#29">‡</a></text>
<text top="723" left="471" width="4" height="7" font="28">n</text>
<text top="722" left="480" width="21" height="9" font="14">Sano</text>
<text top="720" left="502" width="42" height="12" font="14">ﬁ-Avent<a href="1082.full.html#29">is</a></text>
<text top="720" left="544" width="5" height="12" font="19"><a href="1082.full.html#29">‡</a></text>
<text top="626" left="607" width="22" height="9" font="14">None</text>
<text top="626" left="672" width="22" height="9" font="14">None</text>
<text top="626" left="707" width="48" height="9" font="14">All sections</text>
<text top="741" left="63" width="70" height="9" font="14">Richard A. Lange</text>
<text top="741" left="145" width="91" height="9" font="14">Texas Tech University</text>
<text top="753" left="137" width="107" height="9" font="14">Health Sciences Center El</text>
<text top="765" left="141" width="19" height="9" font="14">Paso</text>
<text top="763" left="160" width="80" height="12" font="14">—President; Paul L.</text>
<text top="777" left="156" width="69" height="9" font="14">Foster School of</text>
<text top="789" left="158" width="37" height="9" font="14">Medicine</text>
<text top="787" left="195" width="28" height="12" font="14">—Dean</text>
<text top="741" left="286" width="22" height="9" font="14">None</text>
<text top="741" left="361" width="22" height="9" font="14">None</text>
<text top="741" left="419" width="22" height="9" font="14">None</text>
<text top="741" left="509" width="22" height="9" font="14">None</text>
<text top="741" left="607" width="22" height="9" font="14">None</text>
<text top="741" left="672" width="22" height="9" font="14">None</text>
<text top="741" left="721" width="22" height="9" font="14">None</text>
<text top="808" left="63" width="67" height="9" font="14">Michael J. Mack</text>
<text top="808" left="151" width="79" height="9" font="14">The Heart Hospital</text>
<text top="820" left="157" width="27" height="9" font="14">Baylor</text>
<text top="818" left="184" width="40" height="12" font="14">—Director</text>
<text top="808" left="286" width="22" height="9" font="14">None</text>
<text top="808" left="361" width="22" height="9" font="14">None</text>
<text top="808" left="419" width="22" height="9" font="14">None</text>
<text top="809" left="471" width="4" height="7" font="28">n</text>
<text top="808" left="480" width="71" height="9" font="14">Abbott Vascul<a href="1082.full.html#29">ar</a></text>
<text top="806" left="551" width="5" height="12" font="19"><a href="1082.full.html#29">†</a></text>
<text top="808" left="607" width="22" height="9" font="14">None</text>
<text top="808" left="672" width="22" height="9" font="14">None</text>
<text top="808" left="707" width="48" height="9" font="14">All sections</text>
<text top="839" left="63" width="49" height="9" font="14">Laura Mauri</text>
<text top="839" left="148" width="78" height="9" font="14">Brigham &amp; Women</text>
<text top="837" left="227" width="6" height="12" font="14">’s</text>
<text top="851" left="145" width="34" height="9" font="14">Hospital</text>
<text top="849" left="179" width="58" height="12" font="14">—Professor of</text>
<text top="863" left="153" width="76" height="9" font="14">Medicine, Harvard</text>
<text top="875" left="159" width="63" height="9" font="14">Medical School</text>
<text top="839" left="286" width="22" height="9" font="14">None</text>
<text top="839" left="361" width="22" height="9" font="14">None</text>
<text top="839" left="419" width="22" height="9" font="14">None</text>
<text top="840" left="471" width="4" height="7" font="28">n</text>
<text top="839" left="480" width="30" height="9" font="14">Abbott</text>
<text top="837" left="511" width="5" height="12" font="19"><a href="1082.full.html#29">‡</a></text>
<text top="852" left="471" width="4" height="7" font="28">n</text>
<text top="851" left="480" width="59" height="9" font="14">Bristol-Myers</text>
<text top="863" left="480" width="30" height="9" font="14">Squibb</text>
<text top="861" left="511" width="5" height="12" font="19"><a href="1082.full.html#29">‡</a></text>
<text top="876" left="471" width="4" height="7" font="28">n</text>
<text top="875" left="480" width="64" height="9" font="14">Daiichi-Sankyo</text>
<text top="873" left="545" width="5" height="12" font="19"><a href="1082.full.html#29">‡</a></text>
<text top="888" left="471" width="4" height="7" font="28">n</text>
<text top="887" left="480" width="33" height="9" font="14">Eli Li<a href="1082.full.html#29">lly</a></text>
<text top="885" left="513" width="5" height="12" font="19"><a href="1082.full.html#29">‡</a></text>
<text top="900" left="471" width="4" height="7" font="28">n</text>
<text top="899" left="480" width="21" height="9" font="14">Sano</text>
<text top="897" left="502" width="42" height="12" font="14">ﬁ-Avent<a href="1082.full.html#29">is</a></text>
<text top="897" left="544" width="5" height="12" font="19"><a href="1082.full.html#29">‡</a></text>
<text top="839" left="607" width="22" height="9" font="14">None</text>
<text top="839" left="672" width="22" height="9" font="14">None</text>
<text top="839" left="707" width="48" height="9" font="14">All sections</text>
<text top="917" left="63" width="65" height="9" font="14">Roxana Mehran</text>
<text top="917" left="148" width="85" height="9" font="14">Mount Sinai Medical</text>
<text top="929" left="148" width="27" height="9" font="14">Center</text>
<text top="927" left="176" width="58" height="12" font="14">—Professor of</text>
<text top="940" left="172" width="37" height="9" font="14">Medicine</text>
<text top="918" left="254" width="4" height="7" font="28">n</text>
<text top="917" left="263" width="30" height="9" font="14">Abbott</text>
<text top="930" left="254" width="4" height="7" font="28">n</text>
<text top="929" left="263" width="54" height="9" font="14">AstraZeneca</text>
<text top="942" left="254" width="4" height="7" font="28">n</text>
<text top="940" left="263" width="26" height="9" font="14">Merck</text>
<text top="917" left="361" width="22" height="9" font="14">None</text>
<text top="917" left="419" width="22" height="9" font="14">None</text>
<text top="918" left="471" width="4" height="7" font="28">n</text>
<text top="917" left="480" width="54" height="9" font="14">AstraZen<a href="1082.full.html#29">eca</a></text>
<text top="915" left="534" width="5" height="12" font="19"><a href="1082.full.html#29">‡</a></text>
<text top="930" left="471" width="4" height="7" font="28">n</text>
<text top="929" left="480" width="37" height="9" font="14">Lilly/DSI</text>
<text top="927" left="518" width="5" height="12" font="19"><a href="1082.full.html#29">†</a></text>
<text top="942" left="471" width="4" height="7" font="28">n</text>
<text top="940" left="480" width="39" height="9" font="14">STENTYS</text>
<text top="939" left="520" width="5" height="12" font="19"><a href="1082.full.html#29">†</a></text>
<text top="917" left="607" width="22" height="9" font="14">None</text>
<text top="917" left="672" width="22" height="9" font="14">None</text>
<text top="917" left="707" width="48" height="9" font="14">All sections</text>
<text top="961" left="651" width="105" height="8" font="5">Continued on the next page</text>
<text top="54" left="63" width="132" height="7" font="7">J A C C V O L . 6 8 , N O . 1 0 , 2 0 1 6</text>
<text top="54" left="705" width="52" height="9" font="14">Levine et al.</text>
<text top="69" left="63" width="117" height="7" font="7">S E P T E M B E R 6 , 2 0 1 6 : 1 0 8 2</text>
<text top="67" left="182" width="17" height="10" font="7">– 1 1 5</text>
<text top="69" left="514" width="243" height="9" font="14">Focused Update on Duration of Dual Antiplatelet Therapy</text>
<text top="53" left="788" width="19" height="9" font="5">1109</text>
</page>
<page number="29" position="absolute" top="0" left="0" height="1160" width="864">
<text top="206" left="108" width="50" height="9" font="14">Committee</text>
<text top="218" left="108" width="38" height="9" font="14">Member</text>
<text top="218" left="201" width="70" height="9" font="14">Employer/Title</text>
<text top="218" left="317" width="50" height="9" font="14">Consultant</text>
<text top="206" left="396" width="42" height="9" font="14">Speakers</text>
<text top="218" left="401" width="32" height="9" font="14">Bureau</text>
<text top="194" left="448" width="53" height="9" font="14">Ownership/</text>
<text top="206" left="446" width="59" height="9" font="14">Partnership/</text>
<text top="218" left="455" width="40" height="9" font="14">Principal</text>
<text top="206" left="545" width="40" height="9" font="14">Personal</text>
<text top="218" left="544" width="42" height="9" font="14">Research</text>
<text top="170" left="633" width="60" height="9" font="14">Institutional,</text>
<text top="182" left="628" width="71" height="9" font="14">Organizational,</text>
<text top="194" left="643" width="39" height="9" font="14">or Other</text>
<text top="206" left="643" width="41" height="9" font="14">Financial</text>
<text top="218" left="646" width="23" height="9" font="14">Bene</text>
<text top="216" left="670" width="10" height="12" font="14">ﬁt</text>
<text top="206" left="712" width="31" height="9" font="14">Expert</text>
<text top="218" left="709" width="37" height="9" font="14">Witness</text>
<text top="182" left="761" width="31" height="9" font="14">Voting</text>
<text top="194" left="756" width="40" height="9" font="14">Recusals</text>
<text top="206" left="771" width="11" height="9" font="14">by</text>
<text top="218" left="757" width="34" height="9" font="14">Section</text>
<text top="218" left="791" width="4" height="9" font="19"><a href="1082.full.html#29">*</a></text>
<text top="237" left="108" width="43" height="9" font="14">Debabrata</text>
<text top="249" left="123" width="43" height="9" font="14">Mukherjee</text>
<text top="237" left="187" width="91" height="9" font="14">Texas Tech University</text>
<text top="235" left="278" width="7" height="12" font="14">—</text>
<text top="249" left="192" width="87" height="9" font="14">Chief, Cardiovascular</text>
<text top="261" left="217" width="37" height="9" font="14">Medicine</text>
<text top="237" left="331" width="22" height="9" font="14">None</text>
<text top="237" left="406" width="22" height="9" font="14">None</text>
<text top="237" left="464" width="22" height="9" font="14">None</text>
<text top="237" left="554" width="22" height="9" font="14">None</text>
<text top="237" left="652" width="22" height="9" font="14">None</text>
<text top="237" left="716" width="22" height="9" font="14">None</text>
<text top="237" left="765" width="22" height="9" font="14">None</text>
<text top="280" left="108" width="178" height="9" font="14">L. Kristin Newby Duke University Medical</text>
<text top="292" left="197" width="77" height="9" font="14">Center, Division of</text>
<text top="304" left="185" width="45" height="9" font="14">Cardiology</text>
<text top="302" left="229" width="58" height="12" font="14">—Professor of</text>
<text top="316" left="217" width="37" height="9" font="14">Medicine</text>
<text top="281" left="299" width="4" height="7" font="28">n</text>
<text top="280" left="308" width="34" height="9" font="14">Janssen</text>
<text top="292" left="308" width="71" height="9" font="14">Pharmaceuticals</text>
<text top="290" left="380" width="5" height="12" font="19"><a href="1082.full.html#29">‡</a></text>
<text top="305" left="299" width="4" height="7" font="28">n</text>
<text top="304" left="308" width="26" height="9" font="14">Merck</text>
<text top="280" left="406" width="22" height="9" font="14">None</text>
<text top="280" left="464" width="22" height="9" font="14">None</text>
<text top="281" left="516" width="4" height="7" font="28">n</text>
<text top="280" left="525" width="59" height="9" font="14">Bristol-Myers</text>
<text top="292" left="525" width="30" height="9" font="14">Squi<a href="1082.full.html#29">bb</a></text>
<text top="290" left="555" width="5" height="12" font="19"><a href="1082.full.html#29">‡</a></text>
<text top="281" left="628" width="4" height="7" font="28">n</text>
<text top="280" left="637" width="54" height="9" font="14">AstraZeneca</text>
<text top="278" left="691" width="5" height="12" font="19"><a href="1082.full.html#29">†</a></text>
<text top="280" left="716" width="22" height="9" font="14">None</text>
<text top="280" left="752" width="48" height="9" font="14">All sections</text>
<text top="335" left="108" width="39" height="9" font="14">Patrick T.</text>
<text top="347" left="123" width="7" height="9" font="14">O</text>
<text top="345" left="129" width="24" height="12" font="14">’Gara,</text>
<text top="359" left="123" width="53" height="9" font="14">Chair, STEMI</text>
<text top="335" left="183" width="99" height="9" font="14">Harvard Medical School</text>
<text top="333" left="282" width="7" height="12" font="14">—</text>
<text top="347" left="190" width="91" height="9" font="14">Professor of Medicine</text>
<text top="335" left="331" width="22" height="9" font="14">None</text>
<text top="335" left="406" width="22" height="9" font="14">None</text>
<text top="335" left="464" width="22" height="9" font="14">None</text>
<text top="335" left="554" width="22" height="9" font="14">None</text>
<text top="335" left="652" width="22" height="9" font="14">None</text>
<text top="335" left="716" width="22" height="9" font="14">None</text>
<text top="335" left="765" width="22" height="9" font="14">None</text>
<text top="378" left="108" width="70" height="9" font="14">Marc S. Sabatine</text>
<text top="378" left="189" width="87" height="9" font="14">Brigham and Women</text>
<text top="376" left="276" width="6" height="12" font="14">’s</text>
<text top="390" left="184" width="79" height="9" font="14">Hospital, Chairman</text>
<text top="388" left="262" width="25" height="12" font="14">—TIMI</text>
<text top="402" left="185" width="102" height="9" font="14">Study Group, Division of</text>
<text top="414" left="184" width="103" height="9" font="14">Cardiovascular Medicine;</text>
<text top="426" left="183" width="99" height="9" font="14">Harvard Medical School</text>
<text top="424" left="282" width="7" height="12" font="14">—</text>
<text top="438" left="190" width="91" height="9" font="14">Professor of Medicine</text>
<text top="379" left="299" width="4" height="7" font="28">n</text>
<text top="378" left="308" width="54" height="9" font="14">AstraZeneca</text>
<text top="376" left="362" width="5" height="12" font="19"><a href="1082.full.html#29">‡</a></text>
<text top="391" left="299" width="4" height="7" font="28">n</text>
<text top="390" left="308" width="26" height="9" font="14">Merck</text>
<text top="403" left="299" width="4" height="7" font="28">n</text>
<text top="402" left="308" width="21" height="9" font="14">Sano</text>
<text top="400" left="329" width="42" height="12" font="14">ﬁ-Aventis</text>
<text top="378" left="406" width="22" height="9" font="14">None</text>
<text top="378" left="464" width="22" height="9" font="14">None</text>
<text top="379" left="516" width="4" height="7" font="28">n</text>
<text top="378" left="525" width="30" height="9" font="14">Abbott</text>
<text top="376" left="556" width="5" height="12" font="19"><a href="1082.full.html#29">‡</a></text>
<text top="391" left="516" width="4" height="7" font="28">n</text>
<text top="390" left="525" width="54" height="9" font="14">AstraZeneca</text>
<text top="388" left="579" width="5" height="12" font="19"><a href="1082.full.html#29">‡</a></text>
<text top="403" left="516" width="4" height="7" font="28">n</text>
<text top="402" left="525" width="64" height="9" font="14">Daiichi-Sankyo</text>
<text top="400" left="590" width="5" height="12" font="19"><a href="1082.full.html#29">‡</a></text>
<text top="415" left="516" width="4" height="7" font="28">n</text>
<text top="414" left="525" width="20" height="9" font="14">Eisa<a href="1082.full.html#29">i</a></text>
<text top="412" left="545" width="5" height="12" font="19"><a href="1082.full.html#29">‡</a></text>
<text top="427" left="516" width="4" height="7" font="28">n</text>
<text top="426" left="525" width="26" height="9" font="14">Merck</text>
<text top="424" left="552" width="5" height="12" font="19"><a href="1082.full.html#29">‡</a></text>
<text top="439" left="516" width="4" height="7" font="28">n</text>
<text top="438" left="525" width="21" height="9" font="14">Sano</text>
<text top="436" left="547" width="42" height="12" font="14">ﬁ-Aventis</text>
<text top="436" left="589" width="5" height="12" font="19"><a href="1082.full.html#29">‡</a></text>
<text top="379" left="628" width="4" height="7" font="28">n</text>
<text top="378" left="637" width="30" height="9" font="14">Abbott</text>
<text top="376" left="668" width="5" height="12" font="19"><a href="1082.full.html#29">‡</a></text>
<text top="391" left="628" width="4" height="7" font="28">n</text>
<text top="390" left="637" width="54" height="9" font="14">AstraZeneca</text>
<text top="388" left="691" width="5" height="12" font="19"><a href="1082.full.html#29">‡</a></text>
<text top="403" left="628" width="4" height="7" font="28">n</text>
<text top="402" left="637" width="26" height="9" font="14">Merck</text>
<text top="400" left="664" width="5" height="12" font="19"><a href="1082.full.html#29">‡</a></text>
<text top="378" left="716" width="22" height="9" font="14">None</text>
<text top="378" left="752" width="48" height="9" font="14">All sections</text>
<text top="457" left="108" width="63" height="9" font="14">Peter K. Smith,</text>
<text top="469" left="123" width="44" height="9" font="14">Vice Chair,</text>
<text top="481" left="123" width="23" height="9" font="14">CABG</text>
<text top="457" left="185" width="101" height="9" font="14">Duke University Medical</text>
<text top="469" left="193" width="27" height="9" font="14">Center</text>
<text top="467" left="221" width="58" height="12" font="14">—Professor of</text>
<text top="481" left="186" width="99" height="9" font="14">Surgery; Chief, Thoracic</text>
<text top="493" left="220" width="32" height="9" font="14">Surgery</text>
<text top="457" left="331" width="22" height="9" font="14">None</text>
<text top="457" left="406" width="22" height="9" font="14">None</text>
<text top="457" left="464" width="22" height="9" font="14">None</text>
<text top="457" left="554" width="22" height="9" font="14">None</text>
<text top="457" left="652" width="22" height="9" font="14">None</text>
<text top="457" left="716" width="22" height="9" font="14">None</text>
<text top="457" left="765" width="22" height="9" font="14">None</text>
<text top="512" left="108" width="39" height="9" font="14">Sidney C.</text>
<text top="524" left="123" width="37" height="9" font="14">Smith, Jr</text>
<text top="512" left="195" width="80" height="9" font="14">University of North</text>
<text top="524" left="190" width="34" height="9" font="14">Carolina</text>
<text top="522" left="224" width="58" height="12" font="14">—Professor of</text>
<text top="536" left="193" width="85" height="9" font="14">Medicine; Center for</text>
<text top="548" left="188" width="94" height="9" font="14">Cardiovascular Science</text>
<text top="560" left="188" width="55" height="9" font="14">and Medicine</text>
<text top="558" left="243" width="40" height="12" font="14">—Director</text>
<text top="512" left="331" width="22" height="9" font="14">None</text>
<text top="512" left="406" width="22" height="9" font="14">None</text>
<text top="512" left="464" width="22" height="9" font="14">None</text>
<text top="512" left="554" width="22" height="9" font="14">None</text>
<text top="512" left="652" width="22" height="9" font="14">None</text>
<text top="512" left="716" width="22" height="9" font="14">None</text>
<text top="512" left="765" width="22" height="9" font="14">None</text>
<text top="584" left="108" width="694" height="8" font="5">This table represents the relationships of committee members with industry and other entities that were determined to be relevant to this document. These relationships were</text>
<text top="596" left="108" width="694" height="8" font="5">reviewed and updated in conjunction with all meetings and/or conference calls of the writing committee during the document development process. The table does not necessarily</text>
<text top="608" left="108" width="8" height="8" font="5">re</text>
<text top="606" left="115" width="686" height="11" font="5">ﬂect relationships with industry at the time of publication. A person is deemed to have a signiﬁcant interest in a business if the interest represents ownership of $5% of the voting</text>
<text top="619" left="108" width="201" height="8" font="5">stock or share of the business entity, or ownership of</text>
<text top="618" left="311" width="491" height="11" font="5">$$5,000 of the fair market value of the business entity, or if funds received by the person from the business entity exceed 5% of</text>
<text top="631" left="108" width="41" height="8" font="5">the person</text>
<text top="630" left="149" width="652" height="11" font="5">’s gross income for the previous year. Relationships that exist with no ﬁnancial beneﬁt are also included for the purpose of transparency. Relationships in this table are</text>
<text top="643" left="108" width="694" height="8" font="5">modest unless otherwise noted. According to the ACC/AHA, a person has a relevant relationship IF: a) the relationship or interest relates to the same or similar subject matter, in-</text>
<text top="655" left="108" width="694" height="8" font="5">tellectual property or asset, topic, or issue addressed in the document; or b) the company/entity (with whom the relationship exists) makes a drug, drug class, or device addressed in the</text>
<text top="667" left="108" width="446" height="8" font="5">document, or makes a competing drug or device addressed in the document; or c) the person or a member of the person</text>
<text top="666" left="554" width="247" height="11" font="5">’s household has a reasonable potential for ﬁnancial, professional,</text>
<text top="679" left="108" width="350" height="8" font="5">or other personal gain or loss as a result of the issues/content addressed in the document.</text>
<text top="691" left="110" width="421" height="8" font="5">*Writing committee members are required to recuse themselves from voting on sections to which their speci</text>
<text top="690" left="531" width="230" height="11" font="5">ﬁc relationships with industry and other entities may apply.</text>
<text top="702" left="110" width="82" height="11" font="5">†No ﬁnancial beneﬁt.</text>
<text top="714" left="110" width="94" height="11" font="5">‡Signiﬁcant relationship.</text>
<text top="729" left="116" width="686" height="8" font="5">ACC indicates American College of Cardiology; AHA, American Heart Association; CABG, coronary artery bypass graft surgery; periop, perioperative noncardiac surgery; SIHD, stable</text>
<text top="741" left="108" width="437" height="8" font="5">ischemic heart disease; STEMI, ST-elevation myocardial infarction; and TIMI, Thrombosis In Myocardial Infarction.</text>
<text top="141" left="108" width="156" height="16" font="15">APPENDIX 1. CONTINUED</text>
<text top="53" left="108" width="52" height="9" font="14">Levine et al.</text>
<text top="54" left="670" width="132" height="7" font="7">J A C C V O L . 6 8 , N O . 1 0 , 2 0 1 6</text>
<text top="68" left="108" width="243" height="9" font="14">Focused Update on Duration of Dual Antiplatelet Therapy</text>
<text top="69" left="665" width="117" height="7" font="7">S E P T E M B E R 6 , 2 0 1 6 : 1 0 8 2</text>
<text top="67" left="784" width="17" height="10" font="7">– 1 1 5</text>
<text top="53" left="57" width="17" height="9" font="5">1110</text>
</page>
<page number="30" position="absolute" top="0" left="0" height="864" width="1160">
	<fontspec id="33" size="9" family="Times" color="#e3202b"/>
	<fontspec id="34" size="7" family="Times" color="#000000"/>
	<fontspec id="35" size="3" family="Times" color="#000000"/>
	<fontspec id="36" size="7" family="Times" color="#327eb1"/>
	<fontspec id="37" size="6" family="Times" color="#000000"/>
<text top="105" left="59" width="955" height="16" font="33">APPENDIX 2. REVIEWER RELATIONSHIPS WITH INDUSTRY AND OTHER ENTITIES (RELEVANT)—2016 ACC/AHA GUIDELINE FOCUSED UPDATE ON DURATION</text>
<text top="123" left="59" width="642" height="16" font="33">OF DUAL ANTIPLATELET THERAPY IN PATIENTS WITH CORONARY ARTERY DISEASE (DECEMBER 2015)</text>
<text top="195" left="59" width="42" height="9" font="34">Reviewer</text>
<text top="195" left="194" width="71" height="9" font="34">Representation</text>
<text top="195" left="336" width="58" height="9" font="34">Employment</text>
<text top="195" left="480" width="50" height="9" font="34">Consultant</text>
<text top="195" left="576" width="78" height="9" font="34">Speakers Bureau</text>
<text top="171" left="669" width="53" height="9" font="34">Ownership/</text>
<text top="183" left="667" width="59" height="9" font="34">Partnership/</text>
<text top="195" left="676" width="41" height="9" font="34">Principal</text>
<text top="195" left="755" width="85" height="9" font="34">Personal Research</text>
<text top="159" left="882" width="60" height="9" font="34">Institutional,</text>
<text top="171" left="877" width="71" height="9" font="34">Organizational,</text>
<text top="183" left="892" width="39" height="9" font="34">or Other</text>
<text top="195" left="873" width="67" height="9" font="34">Financial Bene</text>
<text top="194" left="941" width="10" height="12" font="34">ﬁt</text>
<text top="183" left="975" width="31" height="9" font="34">Expert</text>
<text top="195" left="972" width="37" height="9" font="34">Witness</text>
<text top="215" left="59" width="69" height="9" font="34">Joseph S. Alpert</text>
<text top="215" left="182" width="10" height="9" font="34">Of</text>
<text top="213" left="192" width="86" height="12" font="34">ﬁcial Reviewer—AHA</text>
<text top="215" left="306" width="118" height="9" font="34">University of Arizona Health</text>
<text top="227" left="304" width="66" height="9" font="34">Sciences Center</text>
<text top="225" left="369" width="58" height="12" font="34">—Professor of</text>
<text top="238" left="301" width="129" height="9" font="34">Medicine, Head of Department</text>
<text top="250" left="341" width="49" height="9" font="34">of Medicine</text>
<text top="216" left="452" width="4" height="7" font="35">n</text>
<text top="215" left="461" width="54" height="9" font="34">AstraZeneca</text>
<text top="228" left="452" width="4" height="7" font="35">n</text>
<text top="227" left="461" width="24" height="9" font="34">Bayer</text>
<text top="240" left="452" width="4" height="7" font="35">n</text>
<text top="238" left="461" width="64" height="9" font="34">Daiichi-Sankyo</text>
<text top="252" left="452" width="4" height="7" font="35">n</text>
<text top="250" left="461" width="21" height="9" font="34">Sano</text>
<text top="249" left="483" width="42" height="12" font="34">ﬁ-Aventis</text>
<text top="264" left="452" width="4" height="7" font="35">n</text>
<text top="262" left="461" width="30" height="9" font="34">Servier</text>
<text top="274" left="461" width="71" height="9" font="34">Pharmaceuticals</text>
<text top="288" left="452" width="4" height="7" font="35">n</text>
<text top="286" left="461" width="47" height="9" font="34">ZS Pharma</text>
<text top="215" left="604" width="22" height="9" font="34">None</text>
<text top="215" left="685" width="22" height="9" font="34">None</text>
<text top="216" left="740" width="4" height="7" font="35">n</text>
<text top="215" left="749" width="97" height="9" font="34">Bayer Pharma (DS<a href="1082.full.html#34">MB)</a></text>
<text top="213" left="846" width="5" height="12" font="36"><a href="1082.full.html#34">†</a></text>
<text top="228" left="740" width="4" height="7" font="35">n</text>
<text top="227" left="749" width="109" height="9" font="34">Janssen Pharmaceuticals</text>
<text top="238" left="749" width="33" height="9" font="34">(DSMB)</text>
<text top="252" left="740" width="4" height="7" font="35">n</text>
<text top="250" left="749" width="47" height="9" font="34">ZS Pharma</text>
<text top="250" left="796" width="4" height="9" font="36"><a href="1082.full.html#34">*</a></text>
<text top="215" left="901" width="22" height="9" font="34">None</text>
<text top="215" left="980" width="22" height="9" font="34">None</text>
<text top="306" left="59" width="81" height="9" font="34">Joaquin E. Cigarroa</text>
<text top="306" left="191" width="10" height="9" font="34">Of</text>
<text top="304" left="201" width="67" height="12" font="34">ﬁcial Reviewer—</text>
<text top="317" left="180" width="100" height="9" font="34">ACC/AHA Task Force on</text>
<text top="329" left="197" width="66" height="9" font="34">Clinical Practice</text>
<text top="341" left="208" width="43" height="9" font="34">Guidelines</text>
<text top="306" left="308" width="114" height="9" font="34">Oregon Health and Science</text>
<text top="317" left="305" width="42" height="9" font="34">University</text>
<text top="316" left="347" width="79" height="12" font="34">—Clinical Professor</text>
<text top="329" left="341" width="49" height="9" font="34">of Medicine</text>
<text top="306" left="494" width="22" height="9" font="34">None</text>
<text top="306" left="604" width="22" height="9" font="34">None</text>
<text top="306" left="685" width="22" height="9" font="34">None</text>
<text top="306" left="787" width="22" height="9" font="34">None</text>
<text top="306" left="901" width="22" height="9" font="34">None</text>
<text top="306" left="980" width="22" height="9" font="34">None</text>
<text top="361" left="59" width="61" height="9" font="34">Ian C. Gilchrist</text>
<text top="361" left="182" width="10" height="9" font="34">Of</text>
<text top="359" left="192" width="86" height="12" font="34">ﬁcial Reviewer—AHA</text>
<text top="361" left="312" width="99" height="9" font="34">Hershey Medical Center</text>
<text top="359" left="412" width="7" height="12" font="34">—</text>
<text top="373" left="318" width="95" height="9" font="34">Physician, Professor of</text>
<text top="385" left="347" width="37" height="9" font="34">Medicine</text>
<text top="362" left="452" width="4" height="7" font="35">n</text>
<text top="361" left="461" width="98" height="9" font="34">Terumo Interventional</text>
<text top="373" left="461" width="36" height="9" font="34">Systems</text>
<text top="361" left="604" width="22" height="9" font="34">None</text>
<text top="361" left="685" width="22" height="9" font="34">None</text>
<text top="362" left="740" width="4" height="7" font="35">n</text>
<text top="361" left="749" width="102" height="9" font="34">Angel Medical Systems</text>
<text top="359" left="851" width="5" height="12" font="36"><a href="1082.full.html#34">†</a></text>
<text top="374" left="740" width="4" height="7" font="35">n</text>
<text top="373" left="749" width="33" height="9" font="34">Eli Lilly</text>
<text top="361" left="901" width="22" height="9" font="34">None</text>
<text top="361" left="980" width="22" height="9" font="34">None</text>
<text top="404" left="59" width="69" height="9" font="34">Dipti Itchhaporia</text>
<text top="404" left="183" width="10" height="9" font="34">Of</text>
<text top="402" left="193" width="84" height="12" font="34">ﬁcial Reviewer—ACC</text>
<text top="416" left="193" width="74" height="9" font="34">Board of Trustees</text>
<text top="404" left="293" width="109" height="9" font="34">Newport Coast Cardiology</text>
<text top="402" left="402" width="35" height="12" font="34">—Robert</text>
<text top="416" left="311" width="109" height="9" font="34">and Georgia Roth Chair of</text>
<text top="428" left="300" width="131" height="9" font="34">Cardiac Excellence; Hoag Heart</text>
<text top="440" left="300" width="91" height="9" font="34">and Vascular Institute</text>
<text top="438" left="391" width="39" height="12" font="34">—Medical</text>
<text top="452" left="301" width="127" height="9" font="34">Director, Disease Management</text>
<text top="404" left="494" width="22" height="9" font="34">None</text>
<text top="404" left="604" width="22" height="9" font="34">None</text>
<text top="404" left="685" width="22" height="9" font="34">None</text>
<text top="404" left="787" width="22" height="9" font="34">None</text>
<text top="404" left="901" width="22" height="9" font="34">None</text>
<text top="404" left="980" width="22" height="9" font="34">None</text>
<text top="471" left="59" width="77" height="9" font="34">Mladen I. Vidovich</text>
<text top="471" left="183" width="10" height="9" font="34">Of</text>
<text top="469" left="193" width="84" height="12" font="34">ﬁcial Reviewer—ACC</text>
<text top="483" left="189" width="82" height="9" font="34">Board of Governors</text>
<text top="471" left="301" width="84" height="9" font="34">University of Illinois</text>
<text top="469" left="384" width="46" height="12" font="34">—Associate</text>
<text top="483" left="306" width="119" height="9" font="34">Professor of Medicine; Jesse</text>
<text top="495" left="298" width="107" height="9" font="34">Brown VA Medical Center</text>
<text top="493" left="405" width="28" height="12" font="34">—Chief</text>
<text top="507" left="337" width="56" height="9" font="34">of Cardiology</text>
<text top="471" left="494" width="22" height="9" font="34">None</text>
<text top="472" left="578" width="4" height="7" font="35">n</text>
<text top="471" left="588" width="37" height="9" font="34">Eli Lilly/</text>
<text top="483" left="588" width="64" height="9" font="34">Daiichi-Sankyo</text>
<text top="483" left="652" width="4" height="9" font="36"><a href="1082.full.html#34">*</a></text>
<text top="471" left="685" width="22" height="9" font="34">None</text>
<text top="471" left="787" width="22" height="9" font="34">None</text>
<text top="471" left="901" width="22" height="9" font="34">None</text>
<text top="471" left="980" width="22" height="9" font="34">None</text>
<text top="526" left="59" width="66" height="9" font="34">Dawn J. Abbott</text>
<text top="526" left="176" width="101" height="9" font="34">Organizational Reviewer</text>
<text top="524" left="277" width="7" height="12" font="34">—</text>
<text top="538" left="220" width="19" height="9" font="34">SCAI</text>
<text top="526" left="304" width="71" height="9" font="34">Brown University</text>
<text top="524" left="375" width="52" height="12" font="34">—Director of</text>
<text top="538" left="312" width="106" height="9" font="34">Interventional Cardiology</text>
<text top="550" left="305" width="120" height="9" font="34">Fellowship Training Program</text>
<text top="526" left="494" width="22" height="9" font="34">None</text>
<text top="526" left="604" width="22" height="9" font="34">None</text>
<text top="526" left="685" width="22" height="9" font="34">None</text>
<text top="526" left="787" width="22" height="9" font="34">None</text>
<text top="527" left="875" width="4" height="7" font="35">n</text>
<text top="526" left="885" width="54" height="9" font="34">AstraZeneca</text>
<text top="524" left="939" width="5" height="12" font="36"><a href="1082.full.html#34">†</a></text>
<text top="526" left="980" width="22" height="9" font="34">None</text>
<text top="569" left="59" width="91" height="9" font="34">Dominick J. Angiolillo</text>
<text top="569" left="176" width="101" height="9" font="34">Organizational Reviewer</text>
<text top="567" left="277" width="7" height="12" font="34">—</text>
<text top="581" left="220" width="19" height="9" font="34">SCAI</text>
<text top="569" left="300" width="131" height="9" font="34">University of Florida College of</text>
<text top="581" left="313" width="37" height="9" font="34">Medicine</text>
<text top="579" left="350" width="67" height="12" font="34">—Cardiovascular</text>
<text top="593" left="328" width="74" height="9" font="34">Research Director</text>
<text top="570" left="452" width="4" height="7" font="35">n</text>
<text top="569" left="461" width="71" height="9" font="34">Abbott Vascular</text>
<text top="582" left="452" width="4" height="7" font="35">n</text>
<text top="581" left="461" width="52" height="9" font="34">PLx Pharma</text>
<text top="594" left="452" width="4" height="7" font="35">n</text>
<text top="593" left="461" width="21" height="9" font="34">Sano</text>
<text top="591" left="483" width="42" height="12" font="34">ﬁ-Aventis</text>
<text top="593" left="525" width="4" height="9" font="36"><a href="1082.full.html#34">*</a></text>
<text top="606" left="452" width="4" height="7" font="35">n</text>
<text top="605" left="461" width="33" height="9" font="34">Eli Lilly</text>
<text top="605" left="494" width="4" height="9" font="36"><a href="1082.full.html#34">*</a></text>
<text top="618" left="452" width="4" height="7" font="35">n</text>
<text top="617" left="461" width="64" height="9" font="34">Daiichi-Sankyo</text>
<text top="617" left="526" width="4" height="9" font="36"><a href="1082.full.html#34">*</a></text>
<text top="630" left="452" width="4" height="7" font="35">n</text>
<text top="629" left="461" width="54" height="9" font="34">AstraZeneca</text>
<text top="629" left="515" width="4" height="9" font="36"><a href="1082.full.html#34">*</a></text>
<text top="642" left="452" width="4" height="7" font="35">n</text>
<text top="641" left="461" width="26" height="9" font="34">Merck</text>
<text top="641" left="488" width="4" height="9" font="36"><a href="1082.full.html#34">*</a></text>
<text top="569" left="604" width="22" height="9" font="34">None</text>
<text top="569" left="685" width="22" height="9" font="34">None</text>
<text top="570" left="740" width="4" height="7" font="35">n</text>
<text top="569" left="749" width="33" height="9" font="34">Eli Li<a href="1082.full.html#34">lly</a></text>
<text top="569" left="782" width="4" height="9" font="36"><a href="1082.full.html#34">*</a></text>
<text top="582" left="740" width="4" height="7" font="35">n</text>
<text top="581" left="749" width="64" height="9" font="34">Daiichi-Sankyo</text>
<text top="581" left="814" width="4" height="9" font="36"><a href="1082.full.html#34">*</a></text>
<text top="594" left="740" width="4" height="7" font="35">n</text>
<text top="593" left="749" width="54" height="9" font="34">AstraZeneca</text>
<text top="606" left="740" width="4" height="7" font="35">n</text>
<text top="605" left="749" width="34" height="9" font="34">Janssen</text>
<text top="605" left="784" width="4" height="9" font="36"><a href="1082.full.html#34">*</a></text>
<text top="617" left="749" width="71" height="9" font="34">Pharmaceuticals</text>
<text top="617" left="821" width="4" height="9" font="36"><a href="1082.full.html#34">*</a></text>
<text top="630" left="740" width="4" height="7" font="35">n</text>
<text top="629" left="749" width="53" height="9" font="34">CSL Behring</text>
<text top="629" left="803" width="4" height="9" font="36"><a href="1082.full.html#34">*</a></text>
<text top="642" left="740" width="4" height="7" font="35">n</text>
<text top="641" left="749" width="78" height="9" font="34">CeloNova (DSMB)</text>
<text top="641" left="828" width="4" height="9" font="36"><a href="1082.full.html#34">*</a></text>
<text top="569" left="901" width="22" height="9" font="34">None</text>
<text top="569" left="980" width="22" height="9" font="34">None</text>
<text top="658" left="59" width="79" height="9" font="34">Herbert D. Aronow</text>
<text top="658" left="176" width="101" height="9" font="34">Organizational Reviewer</text>
<text top="657" left="277" width="7" height="12" font="34">—</text>
<text top="670" left="228" width="19" height="9" font="34">SVM</text>
<text top="658" left="293" width="92" height="9" font="34">Rhode Island Hospital</text>
<text top="657" left="385" width="52" height="12" font="34">—Director of</text>
<text top="670" left="317" width="97" height="9" font="34">Cardiac Catheterization</text>
<text top="682" left="301" width="128" height="9" font="34">Laboratory; The Warren Alpert</text>
<text top="694" left="305" width="114" height="9" font="34">School of Brown University</text>
<text top="693" left="419" width="7" height="12" font="34">—</text>
<text top="706" left="323" width="84" height="9" font="34">Clinical Professor of</text>
<text top="718" left="323" width="85" height="9" font="34">Cardiology; Lifespan</text>
<text top="730" left="313" width="98" height="9" font="34">Cardiovascular Institute</text>
<text top="728" left="411" width="7" height="12" font="34">—</text>
<text top="742" left="320" width="90" height="9" font="34">Director, Intervention</text>
<text top="754" left="343" width="45" height="9" font="34">Cardiology</text>
<text top="658" left="494" width="22" height="9" font="34">None</text>
<text top="658" left="604" width="22" height="9" font="34">None</text>
<text top="658" left="685" width="22" height="9" font="34">None</text>
<text top="660" left="740" width="4" height="7" font="35">n</text>
<text top="658" left="749" width="83" height="9" font="34">Endomax (Steering</text>
<text top="670" left="749" width="52" height="9" font="34">Committee)</text>
<text top="658" left="901" width="22" height="9" font="34">None</text>
<text top="658" left="980" width="22" height="9" font="34">None</text>
<text top="774" left="912" width="105" height="8" font="37">Continued on the next page</text>
<text top="57" left="1102" width="0" height="7" font="7">J</text>
<text top="63" left="1102" width="0" height="7" font="7">A</text>
<text top="69" left="1102" width="0" height="7" font="7">C</text>
<text top="76" left="1102" width="0" height="7" font="7">C</text>
<text top="86" left="1102" width="0" height="7" font="7">V</text>
<text top="92" left="1102" width="0" height="7" font="7">O</text>
<text top="99" left="1102" width="0" height="7" font="7">L</text>
<text top="105" left="1102" width="0" height="7" font="7">.</text>
<text top="112" left="1102" width="0" height="7" font="7">6</text>
<text top="118" left="1102" width="0" height="7" font="7">8</text>
<text top="123" left="1102" width="0" height="7" font="7">,N</text>
<text top="137" left="1102" width="0" height="7" font="7">O</text>
<text top="144" left="1102" width="0" height="7" font="7">.</text>
<text top="152" left="1102" width="0" height="7" font="7">1</text>
<text top="156" left="1102" width="0" height="7" font="7">0</text>
<text top="162" left="1102" width="0" height="7" font="7">,2</text>
<text top="175" left="1102" width="0" height="7" font="7">0</text>
<text top="181" left="1102" width="0" height="7" font="7">1</text>
<text top="185" left="1102" width="0" height="7" font="7">6</text>
<text top="698" left="1100" width="0" height="9" font="14">Levine</text>
<text top="728" left="1100" width="0" height="9" font="14">et</text>
<text top="739" left="1100" width="0" height="9" font="14">al</text>
<text top="747" left="1100" width="0" height="9" font="14">.</text>
<text top="57" left="1087" width="0" height="7" font="7">S</text>
<text top="63" left="1087" width="0" height="7" font="7">E</text>
<text top="69" left="1087" width="0" height="7" font="7">PT</text>
<text top="81" left="1087" width="0" height="7" font="7">EM</text>
<text top="94" left="1087" width="0" height="7" font="7">BE</text>
<text top="106" left="1087" width="0" height="7" font="7">R</text>
<text top="117" left="1087" width="0" height="7" font="7">6</text>
<text top="122" left="1087" width="0" height="7" font="7">,</text>
<text top="129" left="1087" width="0" height="7" font="7">2</text>
<text top="135" left="1087" width="0" height="7" font="7">01</text>
<text top="145" left="1087" width="0" height="7" font="7">6</text>
<text top="151" left="1087" width="0" height="7" font="7">:</text>
<text top="155" left="1087" width="0" height="7" font="7">1</text>
<text top="159" left="1087" width="0" height="7" font="7">0</text>
<text top="165" left="1087" width="0" height="7" font="7">8</text>
<text top="171" left="1087" width="0" height="7" font="7">2</text>
<text top="175" left="1087" width="0" height="10" font="7">–</text>
<text top="182" left="1087" width="0" height="7" font="7">115</text>
<text top="507" left="1085" width="0" height="9" font="14">Focused</text>
<text top="544" left="1085" width="0" height="9" font="14">Update</text>
<text top="578" left="1085" width="0" height="9" font="14">on</text>
<text top="591" left="1085" width="0" height="9" font="14">Duration</text>
<text top="630" left="1085" width="0" height="9" font="14">of</text>
<text top="642" left="1085" width="0" height="9" font="14">Dual</text>
<text top="664" left="1085" width="0" height="9" font="14">Antiplatelet</text>
<text top="716" left="1085" width="0" height="9" font="14">Therapy</text>
<text top="786" left="1101" width="0" height="9" font="5">1111</text>
</page>
<page number="31" position="absolute" top="0" left="0" height="864" width="1160">
<text top="172" left="59" width="43" height="9" font="34">Reviewer</text>
<text top="172" left="194" width="71" height="9" font="34">Representation</text>
<text top="172" left="336" width="58" height="9" font="34">Employment</text>
<text top="172" left="480" width="50" height="9" font="34">Consultant</text>
<text top="172" left="576" width="78" height="9" font="34">Speakers Bureau</text>
<text top="148" left="669" width="53" height="9" font="34">Ownership/</text>
<text top="160" left="667" width="59" height="9" font="34">Partnership/</text>
<text top="172" left="676" width="41" height="9" font="34">Principal</text>
<text top="172" left="755" width="85" height="9" font="34">Personal Research</text>
<text top="136" left="882" width="60" height="9" font="34">Institutional,</text>
<text top="148" left="877" width="71" height="9" font="34">Organizational,</text>
<text top="160" left="892" width="39" height="9" font="34">or Other</text>
<text top="172" left="873" width="67" height="9" font="34">Financial Bene</text>
<text top="170" left="941" width="10" height="12" font="34">ﬁt</text>
<text top="160" left="975" width="31" height="9" font="34">Expert</text>
<text top="172" left="972" width="37" height="9" font="34">Witness</text>
<text top="191" left="59" width="62" height="9" font="34">Vinay Badhwar</text>
<text top="191" left="176" width="101" height="9" font="34">Organizational Reviewer</text>
<text top="189" left="277" width="7" height="12" font="34">—</text>
<text top="203" left="222" width="15" height="9" font="34">STS</text>
<text top="191" left="298" width="135" height="9" font="34">University of Pittsburgh Medical</text>
<text top="203" left="294" width="27" height="9" font="34">Center</text>
<text top="201" left="321" width="116" height="12" font="34">—Director, Center for Mitral</text>
<text top="215" left="337" width="57" height="9" font="34">Valve Disease</text>
<text top="191" left="494" width="22" height="9" font="34">None</text>
<text top="191" left="604" width="22" height="9" font="34">None</text>
<text top="191" left="685" width="22" height="9" font="34">None</text>
<text top="191" left="787" width="22" height="9" font="34">None</text>
<text top="192" left="875" width="4" height="7" font="35">n</text>
<text top="191" left="885" width="30" height="9" font="34">Abbott</text>
<text top="204" left="875" width="4" height="7" font="35">n</text>
<text top="203" left="885" width="42" height="9" font="34">On-X Life</text>
<text top="215" left="885" width="58" height="9" font="34">Technologies</text>
<text top="191" left="980" width="22" height="9" font="34">None</text>
<text top="234" left="59" width="79" height="9" font="34">Geoffrey D. Barnes</text>
<text top="234" left="176" width="101" height="9" font="34">Organizational Reviewer</text>
<text top="232" left="277" width="7" height="12" font="34">—</text>
<text top="246" left="221" width="19" height="9" font="34">SVM</text>
<text top="234" left="315" width="94" height="9" font="34">University of Michigan</text>
<text top="232" left="409" width="7" height="12" font="34">—</text>
<text top="246" left="300" width="130" height="9" font="34">Cardiologist, Vascular Medicine</text>
<text top="258" left="346" width="39" height="9" font="34">Specialist</text>
<text top="235" left="452" width="4" height="7" font="35">n</text>
<text top="234" left="461" width="32" height="9" font="34">Portola</text>
<text top="234" left="604" width="22" height="9" font="34">None</text>
<text top="234" left="685" width="22" height="9" font="34">None</text>
<text top="235" left="740" width="4" height="7" font="35">n</text>
<text top="234" left="749" width="111" height="9" font="34">Blue Cross/Blue Shield of</text>
<text top="246" left="749" width="39" height="9" font="34">Michigan</text>
<text top="246" left="789" width="4" height="9" font="36"><a href="1082.full.html#34">*</a></text>
<text top="234" left="901" width="22" height="9" font="34">None</text>
<text top="234" left="980" width="22" height="9" font="34">None</text>
<text top="277" left="59" width="49" height="9" font="34">Kathy Berra</text>
<text top="277" left="176" width="101" height="9" font="34">Organizational Reviewer</text>
<text top="275" left="277" width="7" height="12" font="34">—</text>
<text top="289" left="218" width="23" height="9" font="34">PCNA</text>
<text top="277" left="303" width="124" height="9" font="34">Stanford Prevention Research</text>
<text top="289" left="304" width="27" height="9" font="34">Center</text>
<text top="287" left="332" width="94" height="12" font="34">—Clinical Trial Director</text>
<text top="278" left="452" width="4" height="7" font="35">n</text>
<text top="277" left="461" width="95" height="9" font="34">Abor Pharmaceuticals</text>
<text top="277" left="604" width="22" height="9" font="34">None</text>
<text top="277" left="685" width="22" height="9" font="34">None</text>
<text top="277" left="787" width="22" height="9" font="34">None</text>
<text top="277" left="901" width="22" height="9" font="34">None</text>
<text top="277" left="980" width="22" height="9" font="34">None</text>
<text top="308" left="59" width="53" height="9" font="34">Lola A. Coke</text>
<text top="308" left="176" width="101" height="9" font="34">Organizational Reviewer</text>
<text top="306" left="277" width="7" height="12" font="34">—</text>
<text top="320" left="218" width="23" height="9" font="34">PCNA</text>
<text top="308" left="297" width="131" height="9" font="34">Rush University Medical Center</text>
<text top="306" left="427" width="7" height="12" font="34">—</text>
<text top="320" left="305" width="120" height="9" font="34">Cardiovascular Clinical Nurse</text>
<text top="332" left="346" width="39" height="9" font="34">Specialist</text>
<text top="308" left="494" width="22" height="9" font="34">None</text>
<text top="308" left="604" width="22" height="9" font="34">None</text>
<text top="308" left="685" width="22" height="9" font="34">None</text>
<text top="308" left="787" width="22" height="9" font="34">None</text>
<text top="308" left="901" width="22" height="9" font="34">None</text>
<text top="308" left="980" width="22" height="9" font="34">None</text>
<text top="351" left="59" width="64" height="9" font="34">Harold L. Lazar</text>
<text top="351" left="176" width="101" height="9" font="34">Organizational Reviewer</text>
<text top="350" left="277" width="7" height="12" font="34">—</text>
<text top="363" left="219" width="22" height="9" font="34">AATS</text>
<text top="351" left="296" width="140" height="9" font="34">Boston University Medical Center</text>
<text top="363" left="307" width="109" height="9" font="34">Department of Cardiology</text>
<text top="362" left="416" width="7" height="12" font="34">—</text>
<text top="375" left="309" width="113" height="9" font="34">Professor of Cardiothoracic</text>
<text top="387" left="349" width="32" height="9" font="34">Surgery</text>
<text top="351" left="494" width="22" height="9" font="34">None</text>
<text top="351" left="604" width="22" height="9" font="34">None</text>
<text top="351" left="685" width="22" height="9" font="34">None</text>
<text top="353" left="740" width="4" height="7" font="35">n</text>
<text top="351" left="749" width="92" height="9" font="34">Paraxel International</text>
<text top="363" left="749" width="33" height="9" font="34">(DSMB)</text>
<text top="377" left="740" width="4" height="7" font="35">n</text>
<text top="375" left="749" width="33" height="9" font="34">Eli Lilly</text>
<text top="351" left="901" width="22" height="9" font="34">None</text>
<text top="351" left="980" width="22" height="9" font="34">None</text>
<text top="406" left="59" width="63" height="9" font="34">David C. Mazer</text>
<text top="406" left="176" width="101" height="9" font="34">Organizational Reviewer</text>
<text top="405" left="277" width="7" height="12" font="34">—</text>
<text top="418" left="222" width="16" height="9" font="34">SCA</text>
<text top="406" left="297" width="46" height="9" font="34">St. Michael</text>
<text top="405" left="343" width="91" height="12" font="34">’s Hospital, University</text>
<text top="418" left="314" width="45" height="9" font="34">of Toronto</text>
<text top="417" left="359" width="58" height="12" font="34">—Professor of</text>
<text top="430" left="343" width="45" height="9" font="34">Anesthesia</text>
<text top="406" left="494" width="22" height="9" font="34">None</text>
<text top="406" left="604" width="22" height="9" font="34">None</text>
<text top="406" left="685" width="22" height="9" font="34">None</text>
<text top="408" left="740" width="4" height="7" font="35">n</text>
<text top="406" left="749" width="53" height="9" font="34">CSL Behring</text>
<text top="405" left="803" width="5" height="12" font="36"><a href="1082.full.html#34">†</a></text>
<text top="406" left="901" width="22" height="9" font="34">None</text>
<text top="406" left="980" width="22" height="9" font="34">None</text>
<text top="449" left="59" width="63" height="9" font="34">John D. Puskas</text>
<text top="449" left="176" width="101" height="9" font="34">Organizational Reviewer</text>
<text top="448" left="277" width="7" height="12" font="34">—</text>
<text top="461" left="219" width="22" height="9" font="34">AATS</text>
<text top="449" left="294" width="143" height="9" font="34">Icahn School of Medicine at Mount</text>
<text top="461" left="307" width="117" height="9" font="34">Sinai, Emory Crawford Long</text>
<text top="473" left="312" width="34" height="9" font="34">Hospital</text>
<text top="472" left="346" width="73" height="12" font="34">—Chief of Cardiac</text>
<text top="485" left="349" width="32" height="9" font="34">Surgery</text>
<text top="449" left="494" width="22" height="9" font="34">None</text>
<text top="449" left="604" width="22" height="9" font="34">None</text>
<text top="449" left="685" width="22" height="9" font="34">None</text>
<text top="449" left="787" width="22" height="9" font="34">None</text>
<text top="449" left="901" width="22" height="9" font="34">None</text>
<text top="449" left="980" width="22" height="9" font="34">None</text>
<text top="504" left="59" width="65" height="9" font="34">Joseph F. Sabik</text>
<text top="504" left="176" width="101" height="9" font="34">Organizational Reviewer</text>
<text top="503" left="277" width="7" height="12" font="34">—</text>
<text top="516" left="222" width="15" height="9" font="34">STS</text>
<text top="504" left="299" width="133" height="9" font="34">Cleveland Clinic, Department of</text>
<text top="516" left="307" width="116" height="9" font="34">Thoracic and Cardiovascular</text>
<text top="528" left="309" width="32" height="9" font="34">Surgery</text>
<text top="527" left="341" width="81" height="12" font="34">—Department Chair</text>
<text top="506" left="452" width="4" height="7" font="35">n</text>
<text top="504" left="461" width="43" height="9" font="34">Medistem</text>
<text top="504" left="604" width="22" height="9" font="34">None</text>
<text top="504" left="685" width="22" height="9" font="34">None</text>
<text top="506" left="740" width="4" height="7" font="35">n</text>
<text top="504" left="749" width="30" height="9" font="34">Abbott</text>
<text top="503" left="780" width="5" height="12" font="36"><a href="1082.full.html#34">†</a></text>
<text top="504" left="901" width="22" height="9" font="34">None</text>
<text top="504" left="980" width="22" height="9" font="34">None</text>
<text top="548" left="59" width="94" height="9" font="34">Linda Shore-Lesserson</text>
<text top="548" left="176" width="101" height="9" font="34">Organizational Reviewer</text>
<text top="546" left="277" width="7" height="12" font="34">—</text>
<text top="560" left="212" width="37" height="9" font="34">ASA/SCA</text>
<text top="548" left="306" width="118" height="9" font="34">Hofstra Northwell School of</text>
<text top="560" left="325" width="37" height="9" font="34">Medicine</text>
<text top="558" left="362" width="43" height="12" font="34">—Director,</text>
<text top="572" left="302" width="127" height="9" font="34">Cardiovascular Anesthesiology</text>
<text top="549" left="452" width="4" height="7" font="35">n</text>
<text top="548" left="461" width="63" height="9" font="34">Elcam Medical</text>
<text top="561" left="452" width="4" height="7" font="35">n</text>
<text top="560" left="461" width="29" height="9" font="34">Grifols</text>
<text top="548" left="604" width="22" height="9" font="34">None</text>
<text top="548" left="685" width="22" height="9" font="34">None</text>
<text top="548" left="787" width="22" height="9" font="34">None</text>
<text top="548" left="901" width="22" height="9" font="34">None</text>
<text top="548" left="980" width="22" height="9" font="34">None</text>
<text top="591" left="59" width="65" height="9" font="34">Scott M. Silvers</text>
<text top="591" left="176" width="101" height="9" font="34">Organizational Reviewer</text>
<text top="589" left="277" width="7" height="12" font="34">—</text>
<text top="603" left="219" width="22" height="9" font="34">ACEP</text>
<text top="591" left="297" width="137" height="9" font="34">Mayo Clinic College of Medicine,</text>
<text top="603" left="308" width="86" height="9" font="34">Emergency Medicine</text>
<text top="601" left="394" width="28" height="12" font="34">—Chair</text>
<text top="615" left="315" width="100" height="9" font="34">and Associate Professor</text>
<text top="591" left="494" width="22" height="9" font="34">None</text>
<text top="591" left="604" width="22" height="9" font="34">None</text>
<text top="591" left="685" width="22" height="9" font="34">None</text>
<text top="591" left="787" width="22" height="9" font="34">None</text>
<text top="591" left="901" width="22" height="9" font="34">None</text>
<text top="591" left="980" width="22" height="9" font="34">None</text>
<text top="634" left="59" width="105" height="9" font="34">Christian A. Tomaszewski</text>
<text top="634" left="176" width="101" height="9" font="34">Organizational Reviewer</text>
<text top="632" left="277" width="7" height="12" font="34">—</text>
<text top="646" left="219" width="22" height="9" font="34">ACEP</text>
<text top="634" left="295" width="141" height="9" font="34">University of California San Diego</text>
<text top="646" left="304" width="28" height="9" font="34">Health</text>
<text top="644" left="331" width="96" height="12" font="34">—Emergency Medicine,</text>
<text top="658" left="304" width="122" height="9" font="34">Medical Toxicology Specialist</text>
<text top="634" left="494" width="22" height="9" font="34">None</text>
<text top="634" left="604" width="22" height="9" font="34">None</text>
<text top="634" left="685" width="22" height="9" font="34">None</text>
<text top="634" left="787" width="22" height="9" font="34">None</text>
<text top="634" left="901" width="22" height="9" font="34">None</text>
<text top="634" left="980" width="22" height="9" font="34">None</text>
<text top="677" left="59" width="76" height="9" font="34">Sana M. Al-Khatib</text>
<text top="677" left="189" width="74" height="9" font="34">Content Reviewer</text>
<text top="675" left="264" width="7" height="12" font="34">—</text>
<text top="689" left="180" width="100" height="9" font="34">ACC/AHA Task Force on</text>
<text top="701" left="197" width="66" height="9" font="34">Clinical Practice</text>
<text top="713" left="209" width="43" height="9" font="34">Guidelines</text>
<text top="677" left="296" width="131" height="9" font="34">Duke University Medical Center</text>
<text top="675" left="428" width="7" height="12" font="34">—</text>
<text top="689" left="319" width="93" height="9" font="34">Associate Professor of</text>
<text top="701" left="347" width="37" height="9" font="34">Medicine</text>
<text top="677" left="494" width="22" height="9" font="34">None</text>
<text top="677" left="604" width="22" height="9" font="34">None</text>
<text top="677" left="685" width="22" height="9" font="34">None</text>
<text top="677" left="787" width="22" height="9" font="34">None</text>
<text top="677" left="901" width="22" height="9" font="34">None</text>
<text top="677" left="980" width="22" height="9" font="34">None</text>
<text top="731" left="59" width="68" height="9" font="34">Saif Anwaruddin</text>
<text top="731" left="181" width="74" height="9" font="34">Content Reviewer</text>
<text top="729" left="255" width="24" height="12" font="34">—ACC</text>
<text top="743" left="181" width="89" height="9" font="34">Interventional Scienti</text>
<text top="741" left="269" width="10" height="12" font="34">ﬁc</text>
<text top="754" left="215" width="30" height="9" font="34">Council</text>
<text top="731" left="307" width="110" height="9" font="34">University of Pennsylvania</text>
<text top="729" left="417" width="7" height="12" font="34">—</text>
<text top="743" left="304" width="122" height="9" font="34">Transcatheter Valve Program</text>
<text top="754" left="320" width="91" height="9" font="34">Co-Director, Assistant</text>
<text top="766" left="320" width="91" height="9" font="34">Professor of Medicine</text>
<text top="731" left="494" width="22" height="9" font="34">None</text>
<text top="731" left="604" width="22" height="9" font="34">None</text>
<text top="731" left="685" width="22" height="9" font="34">None</text>
<text top="731" left="787" width="22" height="9" font="34">None</text>
<text top="731" left="901" width="22" height="9" font="34">None</text>
<text top="731" left="980" width="22" height="9" font="34">None</text>
<text top="787" left="912" width="105" height="8" font="37">Continued on the next page</text>
<text top="105" left="59" width="158" height="16" font="33">APPENDIX 2. CONTINUED</text>
<text top="100" left="1100" width="0" height="9" font="14">Levine</text>
<text top="130" left="1100" width="0" height="9" font="14">et</text>
<text top="142" left="1100" width="0" height="9" font="14">al</text>
<text top="149" left="1100" width="0" height="9" font="14">.</text>
<text top="664" left="1102" width="0" height="7" font="7">J</text>
<text top="669" left="1102" width="0" height="7" font="7">A</text>
<text top="676" left="1102" width="0" height="7" font="7">C</text>
<text top="682" left="1102" width="0" height="7" font="7">C</text>
<text top="692" left="1102" width="0" height="7" font="7">V</text>
<text top="699" left="1102" width="0" height="7" font="7">O</text>
<text top="706" left="1102" width="0" height="7" font="7">L</text>
<text top="711" left="1102" width="0" height="7" font="7">.</text>
<text top="719" left="1102" width="0" height="7" font="7">6</text>
<text top="724" left="1102" width="0" height="7" font="7">8</text>
<text top="730" left="1102" width="0" height="7" font="7">,N</text>
<text top="744" left="1102" width="0" height="7" font="7">O</text>
<text top="751" left="1102" width="0" height="7" font="7">.</text>
<text top="758" left="1102" width="0" height="7" font="7">1</text>
<text top="762" left="1102" width="0" height="7" font="7">0</text>
<text top="769" left="1102" width="0" height="7" font="7">,2</text>
<text top="781" left="1102" width="0" height="7" font="7">0</text>
<text top="788" left="1102" width="0" height="7" font="7">1</text>
<text top="792" left="1102" width="0" height="7" font="7">6</text>
<text top="100" left="1085" width="0" height="9" font="14">Focused</text>
<text top="138" left="1085" width="0" height="9" font="14">Update</text>
<text top="171" left="1085" width="0" height="9" font="14">on</text>
<text top="184" left="1085" width="0" height="9" font="14">Duration</text>
<text top="223" left="1085" width="0" height="9" font="14">of</text>
<text top="235" left="1085" width="0" height="9" font="14">Dual</text>
<text top="257" left="1085" width="0" height="9" font="14">Antiplatelet</text>
<text top="310" left="1085" width="0" height="9" font="14">Therapy</text>
<text top="659" left="1087" width="0" height="7" font="7">SEPTEMB</text>
<text top="702" left="1087" width="0" height="7" font="7">E</text>
<text top="708" left="1087" width="0" height="7" font="7">R</text>
<text top="718" left="1087" width="0" height="7" font="7">6</text>
<text top="724" left="1087" width="0" height="7" font="7">,</text>
<text top="731" left="1087" width="0" height="7" font="7">2</text>
<text top="737" left="1087" width="0" height="7" font="7">016:</text>
<text top="757" left="1087" width="0" height="7" font="7">10</text>
<text top="767" left="1087" width="0" height="7" font="7">82</text>
<text top="777" left="1087" width="0" height="10" font="7">–</text>
<text top="784" left="1087" width="0" height="7" font="7">115</text>
<text top="50" left="1101" width="0" height="9" font="5">1112</text>
</page>
<page number="32" position="absolute" top="0" left="0" height="864" width="1160">
<text top="127" left="59" width="43" height="9" font="34">Reviewer</text>
<text top="127" left="194" width="71" height="9" font="34">Representation</text>
<text top="127" left="336" width="58" height="9" font="34">Employment</text>
<text top="127" left="480" width="50" height="9" font="34">Consultant</text>
<text top="127" left="576" width="78" height="9" font="34">Speakers Bureau</text>
<text top="103" left="669" width="53" height="9" font="34">Ownership/</text>
<text top="115" left="667" width="59" height="9" font="34">Partnership/</text>
<text top="127" left="676" width="41" height="9" font="34">Principal</text>
<text top="127" left="755" width="85" height="9" font="34">Personal Research</text>
<text top="92" left="882" width="60" height="9" font="34">Institutional,</text>
<text top="103" left="877" width="71" height="9" font="34">Organizational,</text>
<text top="115" left="892" width="39" height="9" font="34">or Other</text>
<text top="127" left="873" width="67" height="9" font="34">Financial Bene</text>
<text top="126" left="941" width="10" height="12" font="34">ﬁt</text>
<text top="115" left="975" width="31" height="9" font="34">Expert</text>
<text top="127" left="972" width="37" height="9" font="34">Witness</text>
<text top="147" left="59" width="67" height="9" font="34">Deepak L. Bhatt</text>
<text top="147" left="193" width="74" height="9" font="34">Content Reviewer</text>
<text top="147" left="296" width="87" height="9" font="34">Brigham and Women</text>
<text top="145" left="384" width="51" height="12" font="34">’s Hospital—</text>
<text top="159" left="321" width="88" height="9" font="34">Executive Director of</text>
<text top="171" left="304" width="122" height="9" font="34">Interventional Cardiovascular</text>
<text top="182" left="309" width="113" height="9" font="34">Programs; Harvard Medical</text>
<text top="194" left="302" width="28" height="9" font="34">School</text>
<text top="193" left="330" width="98" height="12" font="34">—Professor of Medicine</text>
<text top="147" left="494" width="22" height="9" font="34">None</text>
<text top="147" left="604" width="22" height="9" font="34">None</text>
<text top="147" left="685" width="22" height="9" font="34">None</text>
<text top="148" left="740" width="4" height="7" font="35">n</text>
<text top="147" left="749" width="31" height="9" font="34">Amar<a href="1082.full.html#34">in</a></text>
<text top="147" left="780" width="4" height="9" font="36"><a href="1082.full.html#34">*</a></text>
<text top="160" left="740" width="4" height="7" font="35">n</text>
<text top="159" left="749" width="54" height="9" font="34">AstraZeneca</text>
<text top="159" left="803" width="4" height="9" font="36"><a href="1082.full.html#34">*</a></text>
<text top="172" left="740" width="4" height="7" font="35">n</text>
<text top="171" left="749" width="92" height="9" font="34">Bristol-Myers Squibb</text>
<text top="171" left="842" width="4" height="9" font="36"><a href="1082.full.html#34">*</a></text>
<text top="184" left="740" width="4" height="7" font="35">n</text>
<text top="182" left="749" width="30" height="9" font="34">Card<a href="1082.full.html#34">ax</a></text>
<text top="181" left="779" width="5" height="12" font="36"><a href="1082.full.html#34">†</a></text>
<text top="196" left="740" width="4" height="7" font="35">n</text>
<text top="194" left="749" width="20" height="9" font="34">Elsai</text>
<text top="194" left="770" width="4" height="9" font="36"><a href="1082.full.html#34">*</a></text>
<text top="208" left="740" width="4" height="7" font="35">n</text>
<text top="206" left="749" width="33" height="9" font="34">Ethicon</text>
<text top="206" left="783" width="4" height="9" font="36"><a href="1082.full.html#34">*</a></text>
<text top="220" left="740" width="4" height="7" font="35">n</text>
<text top="218" left="749" width="32" height="9" font="34">FlowCo</text>
<text top="217" left="782" width="5" height="12" font="36"><a href="1082.full.html#34">†</a></text>
<text top="232" left="740" width="4" height="7" font="35">n</text>
<text top="230" left="749" width="86" height="9" font="34">Forest Laboratorie<a href="1082.full.html#34">s</a></text>
<text top="230" left="835" width="4" height="9" font="36"><a href="1082.full.html#34">*</a></text>
<text top="244" left="740" width="4" height="7" font="35">n</text>
<text top="242" left="749" width="38" height="9" font="34">Ischemix</text>
<text top="242" left="788" width="4" height="9" font="36"><a href="1082.full.html#34">*</a></text>
<text top="256" left="740" width="4" height="7" font="35">n</text>
<text top="254" left="749" width="52" height="9" font="34">PLx Pharma</text>
<text top="253" left="801" width="5" height="12" font="36"><a href="1082.full.html#34">†</a></text>
<text top="267" left="740" width="4" height="7" font="35">n</text>
<text top="266" left="749" width="86" height="9" font="34">Regado Biosciences</text>
<text top="264" left="836" width="5" height="12" font="36"><a href="1082.full.html#34">†</a></text>
<text top="279" left="740" width="4" height="7" font="35">n</text>
<text top="278" left="749" width="21" height="9" font="34">Sano</text>
<text top="276" left="771" width="42" height="12" font="34">ﬁ-Aventis</text>
<text top="278" left="813" width="4" height="9" font="36"><a href="1082.full.html#34">*</a></text>
<text top="147" left="901" width="22" height="9" font="34">None</text>
<text top="147" left="980" width="22" height="9" font="34">None</text>
<text top="297" left="59" width="63" height="9" font="34">Kim K. Birtcher</text>
<text top="297" left="189" width="74" height="9" font="34">Content Reviewer</text>
<text top="296" left="264" width="7" height="12" font="34">—</text>
<text top="309" left="180" width="100" height="9" font="34">ACC/AHA Task Force on</text>
<text top="321" left="197" width="66" height="9" font="34">Clinical Practice</text>
<text top="333" left="208" width="43" height="9" font="34">Guidelines</text>
<text top="297" left="296" width="138" height="9" font="34">University of Houston College of</text>
<text top="309" left="306" width="40" height="9" font="34">Pharmacy</text>
<text top="308" left="346" width="79" height="12" font="34">—Clinical Professor</text>
<text top="297" left="494" width="22" height="9" font="34">None</text>
<text top="297" left="604" width="22" height="9" font="34">None</text>
<text top="297" left="685" width="22" height="9" font="34">None</text>
<text top="297" left="787" width="22" height="9" font="34">None</text>
<text top="297" left="901" width="22" height="9" font="34">None</text>
<text top="297" left="980" width="22" height="9" font="34">None</text>
<text top="352" left="59" width="65" height="9" font="34">Biykem Bozkurt</text>
<text top="352" left="189" width="74" height="9" font="34">Content Reviewer</text>
<text top="351" left="264" width="7" height="12" font="34">—</text>
<text top="364" left="180" width="100" height="9" font="34">ACC/AHA Task Force on</text>
<text top="376" left="197" width="66" height="9" font="34">Clinical Practice</text>
<text top="388" left="208" width="43" height="9" font="34">Guidelines</text>
<text top="352" left="299" width="132" height="9" font="34">Michael E. DeBakey VA Medical</text>
<text top="364" left="302" width="27" height="9" font="34">Center</text>
<text top="363" left="330" width="98" height="12" font="34">—The Mary and Gordon</text>
<text top="376" left="308" width="114" height="9" font="34">Cain Chair and Professor of</text>
<text top="388" left="347" width="37" height="9" font="34">Medicine</text>
<text top="352" left="494" width="22" height="9" font="34">None</text>
<text top="352" left="604" width="22" height="9" font="34">None</text>
<text top="352" left="685" width="22" height="9" font="34">None</text>
<text top="352" left="787" width="22" height="9" font="34">None</text>
<text top="352" left="901" width="22" height="9" font="34">None</text>
<text top="352" left="980" width="22" height="9" font="34">None</text>
<text top="407" left="59" width="75" height="9" font="34">Michael A. Borger</text>
<text top="407" left="189" width="74" height="9" font="34">Content Reviewer</text>
<text top="406" left="264" width="7" height="12" font="34">—</text>
<text top="419" left="179" width="58" height="9" font="34">ACC Surgeons</text>
<text top="418" left="238" width="43" height="12" font="34">’ Scientiﬁc</text>
<text top="431" left="215" width="31" height="9" font="34">Council</text>
<text top="407" left="306" width="119" height="9" font="34">Columbia University Medical</text>
<text top="419" left="308" width="27" height="9" font="34">Center</text>
<text top="418" left="335" width="87" height="12" font="34">—Division of Cardiac,</text>
<text top="431" left="301" width="129" height="9" font="34">Vascular and Thoracic Surgery,</text>
<text top="443" left="317" width="97" height="9" font="34">Cardiothoracic Surgeon</text>
<text top="407" left="494" width="22" height="9" font="34">None</text>
<text top="407" left="604" width="22" height="9" font="34">None</text>
<text top="407" left="685" width="22" height="9" font="34">None</text>
<text top="407" left="787" width="22" height="9" font="34">None</text>
<text top="407" left="901" width="22" height="9" font="34">None</text>
<text top="407" left="980" width="22" height="9" font="34">None</text>
<text top="462" left="59" width="76" height="9" font="34">Mauricio G. Cohen</text>
<text top="462" left="193" width="74" height="9" font="34">Content Reviewer</text>
<text top="462" left="303" width="124" height="9" font="34">University of Miami School of</text>
<text top="474" left="304" width="37" height="9" font="34">Medicine</text>
<text top="473" left="341" width="85" height="12" font="34">—Director of Cardiac</text>
<text top="486" left="309" width="112" height="9" font="34">Catheterization Laboratory</text>
<text top="464" left="452" width="4" height="7" font="35">n</text>
<text top="462" left="461" width="70" height="9" font="34">Terumo Medical</text>
<text top="462" left="604" width="22" height="9" font="34">None</text>
<text top="462" left="685" width="22" height="9" font="34">None</text>
<text top="464" left="740" width="4" height="7" font="35">n</text>
<text top="462" left="749" width="54" height="9" font="34">AstraZeneca</text>
<text top="462" left="901" width="22" height="9" font="34">None</text>
<text top="462" left="980" width="22" height="9" font="34">None</text>
<text top="506" left="59" width="72" height="9" font="34">Frederico Gentile</text>
<text top="506" left="189" width="74" height="9" font="34">Content Reviewer</text>
<text top="504" left="264" width="7" height="12" font="34">—</text>
<text top="518" left="180" width="100" height="9" font="34">ACC/AHA Task Force on</text>
<text top="530" left="197" width="66" height="9" font="34">Clinical Practice</text>
<text top="541" left="208" width="43" height="9" font="34">Guidelines</text>
<text top="506" left="306" width="112" height="9" font="34">Centro Medico Diagnostico</text>
<text top="504" left="418" width="7" height="12" font="34">—</text>
<text top="518" left="315" width="99" height="9" font="34">Director, Cardiovascular</text>
<text top="530" left="350" width="31" height="9" font="34">Disease</text>
<text top="506" left="494" width="22" height="9" font="34">None</text>
<text top="506" left="604" width="22" height="9" font="34">None</text>
<text top="506" left="685" width="22" height="9" font="34">None</text>
<text top="506" left="787" width="22" height="9" font="34">None</text>
<text top="506" left="901" width="22" height="9" font="34">None</text>
<text top="506" left="980" width="22" height="9" font="34">None</text>
<text top="561" left="59" width="76" height="9" font="34">Samuel S. Gidding</text>
<text top="561" left="189" width="74" height="9" font="34">Content Reviewer</text>
<text top="559" left="264" width="7" height="12" font="34">—</text>
<text top="573" left="180" width="100" height="9" font="34">ACC/AHA Task Force on</text>
<text top="585" left="197" width="66" height="9" font="34">Clinical Practice</text>
<text top="597" left="208" width="43" height="9" font="34">Guidelines</text>
<text top="561" left="293" width="144" height="9" font="34">Nemours/Alfred I. DuPont Hospital</text>
<text top="573" left="301" width="50" height="9" font="34">for Children</text>
<text top="571" left="351" width="78" height="12" font="34">—Chief, Division of</text>
<text top="585" left="323" width="84" height="9" font="34">Pediatric Cardiology</text>
<text top="561" left="494" width="22" height="9" font="34">None</text>
<text top="561" left="604" width="22" height="9" font="34">None</text>
<text top="561" left="685" width="22" height="9" font="34">None</text>
<text top="561" left="787" width="22" height="9" font="34">None</text>
<text top="561" left="901" width="22" height="9" font="34">None</text>
<text top="561" left="980" width="22" height="9" font="34">None</text>
<text top="616" left="59" width="77" height="9" font="34">Alan L. Hinderliter</text>
<text top="616" left="193" width="74" height="9" font="34">Content Reviewer</text>
<text top="616" left="303" width="117" height="9" font="34">University of North Carolina</text>
<text top="614" left="420" width="7" height="12" font="34">—</text>
<text top="628" left="319" width="92" height="9" font="34">Division of Cardiology</text>
<text top="616" left="494" width="22" height="9" font="34">None</text>
<text top="616" left="604" width="22" height="9" font="34">None</text>
<text top="616" left="685" width="22" height="9" font="34">None</text>
<text top="616" left="787" width="22" height="9" font="34">None</text>
<text top="616" left="901" width="22" height="9" font="34">None</text>
<text top="616" left="980" width="22" height="9" font="34">None</text>
<text top="647" left="59" width="69" height="9" font="34">David R. Holmes</text>
<text top="647" left="189" width="74" height="9" font="34">Content Reviewer</text>
<text top="645" left="264" width="7" height="12" font="34">—</text>
<text top="659" left="179" width="58" height="9" font="34">ACC Surgeons</text>
<text top="657" left="238" width="43" height="12" font="34">’ Scientiﬁc</text>
<text top="671" left="215" width="31" height="9" font="34">Council</text>
<text top="647" left="314" width="48" height="9" font="34">Mayo Clinic</text>
<text top="645" left="362" width="54" height="12" font="34">—Consultant,</text>
<text top="659" left="318" width="94" height="9" font="34">Cardiovascular Disease</text>
<text top="647" left="494" width="22" height="9" font="34">None</text>
<text top="647" left="604" width="22" height="9" font="34">None</text>
<text top="647" left="685" width="22" height="9" font="34">None</text>
<text top="647" left="787" width="22" height="9" font="34">None</text>
<text top="647" left="901" width="22" height="9" font="34">None</text>
<text top="647" left="980" width="22" height="9" font="34">None</text>
<text top="689" left="59" width="59" height="9" font="34">José A. Joglar</text>
<text top="689" left="189" width="74" height="9" font="34">Content Reviewer</text>
<text top="687" left="264" width="7" height="12" font="34">—</text>
<text top="701" left="180" width="100" height="9" font="34">ACC/AHA Task Force on</text>
<text top="712" left="197" width="66" height="9" font="34">Clinical Practice</text>
<text top="724" left="208" width="43" height="9" font="34">Guidelines</text>
<text top="689" left="295" width="140" height="9" font="34">University of Texas Southwestern</text>
<text top="701" left="305" width="63" height="9" font="34">Medical Center</text>
<text top="699" left="368" width="58" height="12" font="34">—Professor of</text>
<text top="712" left="329" width="72" height="9" font="34">Internal Medicine</text>
<text top="689" left="494" width="22" height="9" font="34">None</text>
<text top="689" left="604" width="22" height="9" font="34">None</text>
<text top="689" left="685" width="22" height="9" font="34">None</text>
<text top="689" left="787" width="22" height="9" font="34">None</text>
<text top="689" left="901" width="22" height="9" font="34">None</text>
<text top="689" left="980" width="22" height="9" font="34">None</text>
<text top="745" left="912" width="105" height="8" font="37">Continued on the next page</text>
<text top="60" left="59" width="158" height="16" font="33">APPENDIX 2. CONTINUED</text>
<text top="57" left="1102" width="0" height="7" font="7">J</text>
<text top="63" left="1102" width="0" height="7" font="7">A</text>
<text top="69" left="1102" width="0" height="7" font="7">C</text>
<text top="76" left="1102" width="0" height="7" font="7">C</text>
<text top="86" left="1102" width="0" height="7" font="7">V</text>
<text top="92" left="1102" width="0" height="7" font="7">O</text>
<text top="99" left="1102" width="0" height="7" font="7">L</text>
<text top="105" left="1102" width="0" height="7" font="7">.</text>
<text top="112" left="1102" width="0" height="7" font="7">6</text>
<text top="118" left="1102" width="0" height="7" font="7">8</text>
<text top="123" left="1102" width="0" height="7" font="7">,N</text>
<text top="137" left="1102" width="0" height="7" font="7">O</text>
<text top="144" left="1102" width="0" height="7" font="7">.</text>
<text top="152" left="1102" width="0" height="7" font="7">1</text>
<text top="156" left="1102" width="0" height="7" font="7">0</text>
<text top="162" left="1102" width="0" height="7" font="7">,2</text>
<text top="175" left="1102" width="0" height="7" font="7">0</text>
<text top="181" left="1102" width="0" height="7" font="7">1</text>
<text top="185" left="1102" width="0" height="7" font="7">6</text>
<text top="698" left="1100" width="0" height="9" font="14">Levine</text>
<text top="728" left="1100" width="0" height="9" font="14">et</text>
<text top="739" left="1100" width="0" height="9" font="14">al</text>
<text top="747" left="1100" width="0" height="9" font="14">.</text>
<text top="57" left="1087" width="0" height="7" font="7">S</text>
<text top="63" left="1087" width="0" height="7" font="7">E</text>
<text top="69" left="1087" width="0" height="7" font="7">PT</text>
<text top="81" left="1087" width="0" height="7" font="7">EM</text>
<text top="94" left="1087" width="0" height="7" font="7">BE</text>
<text top="106" left="1087" width="0" height="7" font="7">R</text>
<text top="117" left="1087" width="0" height="7" font="7">6</text>
<text top="122" left="1087" width="0" height="7" font="7">,</text>
<text top="129" left="1087" width="0" height="7" font="7">2</text>
<text top="135" left="1087" width="0" height="7" font="7">01</text>
<text top="145" left="1087" width="0" height="7" font="7">6</text>
<text top="151" left="1087" width="0" height="7" font="7">:</text>
<text top="155" left="1087" width="0" height="7" font="7">1</text>
<text top="159" left="1087" width="0" height="7" font="7">0</text>
<text top="165" left="1087" width="0" height="7" font="7">8</text>
<text top="171" left="1087" width="0" height="7" font="7">2</text>
<text top="175" left="1087" width="0" height="10" font="7">–</text>
<text top="182" left="1087" width="0" height="7" font="7">115</text>
<text top="507" left="1085" width="0" height="9" font="14">Focused</text>
<text top="544" left="1085" width="0" height="9" font="14">Update</text>
<text top="578" left="1085" width="0" height="9" font="14">on</text>
<text top="591" left="1085" width="0" height="9" font="14">Duration</text>
<text top="630" left="1085" width="0" height="9" font="14">of</text>
<text top="642" left="1085" width="0" height="9" font="14">Dual</text>
<text top="664" left="1085" width="0" height="9" font="14">Antiplatelet</text>
<text top="716" left="1085" width="0" height="9" font="14">Therapy</text>
<text top="785" left="1101" width="0" height="9" font="5">1113</text>
</page>
<page number="33" position="absolute" top="0" left="0" height="864" width="1160">
<text top="173" left="59" width="43" height="9" font="34">Reviewer</text>
<text top="173" left="195" width="71" height="9" font="34">Representation</text>
<text top="173" left="337" width="58" height="9" font="34">Employment</text>
<text top="173" left="481" width="50" height="9" font="34">Consultant</text>
<text top="173" left="577" width="77" height="9" font="34">Speakers Bureau</text>
<text top="149" left="670" width="53" height="9" font="34">Ownership/</text>
<text top="161" left="667" width="58" height="9" font="34">Partnership/</text>
<text top="173" left="676" width="41" height="9" font="34">Principal</text>
<text top="173" left="756" width="85" height="9" font="34">Personal Research</text>
<text top="137" left="883" width="60" height="9" font="34">Institutional,</text>
<text top="149" left="877" width="71" height="9" font="34">Organizational,</text>
<text top="161" left="893" width="39" height="9" font="34">or Other</text>
<text top="173" left="874" width="67" height="9" font="34">Financial Bene</text>
<text top="171" left="941" width="10" height="12" font="34">ﬁt</text>
<text top="161" left="976" width="31" height="9" font="34">Expert</text>
<text top="173" left="973" width="36" height="9" font="34">Witness</text>
<text top="192" left="59" width="60" height="9" font="34">Ajay J. Kirtane</text>
<text top="192" left="193" width="74" height="9" font="34">Content Reviewer</text>
<text top="192" left="306" width="119" height="9" font="34">Columbia University Medical</text>
<text top="204" left="302" width="27" height="9" font="34">Center</text>
<text top="202" left="330" width="100" height="12" font="34">—Associate Professor of</text>
<text top="216" left="323" width="85" height="9" font="34">Medicine; Center for</text>
<text top="228" left="318" width="96" height="9" font="34">Interventional Vascular</text>
<text top="240" left="314" width="34" height="9" font="34">Therapy</text>
<text top="238" left="347" width="71" height="12" font="34">—Chief Academic</text>
<text top="252" left="302" width="10" height="9" font="34">Of</text>
<text top="250" left="312" width="117" height="12" font="34">ﬁcer; NYC/Columbia Cardiac</text>
<text top="263" left="303" width="118" height="9" font="34">Catheterization Laboratories</text>
<text top="262" left="421" width="7" height="12" font="34">—</text>
<text top="275" left="357" width="33" height="9" font="34">Director</text>
<text top="192" left="495" width="22" height="9" font="34">None</text>
<text top="192" left="605" width="22" height="9" font="34">None</text>
<text top="192" left="686" width="22" height="9" font="34">None</text>
<text top="193" left="741" width="4" height="7" font="35">n</text>
<text top="192" left="750" width="71" height="9" font="34">Abbott Vascular</text>
<text top="192" left="821" width="4" height="9" font="36"><a href="1082.full.html#34">*</a></text>
<text top="205" left="741" width="4" height="7" font="35">n</text>
<text top="204" left="750" width="33" height="9" font="34">Eli Lilly</text>
<text top="204" left="783" width="4" height="9" font="36"><a href="1082.full.html#34">*</a></text>
<text top="193" left="876" width="4" height="7" font="35">n</text>
<text top="192" left="885" width="30" height="9" font="34">Abbott</text>
<text top="204" left="885" width="37" height="9" font="34"><a href="1082.full.html#34">Vascular</a></text>
<text top="204" left="922" width="4" height="9" font="36"><a href="1082.full.html#34">*</a></text>
<text top="217" left="876" width="4" height="7" font="35">n</text>
<text top="216" left="885" width="33" height="9" font="34">Eli Lill<a href="1082.full.html#34">y</a></text>
<text top="216" left="918" width="4" height="9" font="36"><a href="1082.full.html#34">*</a></text>
<text top="192" left="980" width="22" height="9" font="34">None</text>
<text top="295" left="59" width="61" height="9" font="34">Lloyd W. Klein</text>
<text top="295" left="181" width="74" height="9" font="34">Content Reviewer</text>
<text top="293" left="256" width="24" height="12" font="34">—ACC</text>
<text top="307" left="209" width="58" height="9" font="34">Interventional</text>
<text top="319" left="203" width="27" height="9" font="34">Scienti</text>
<text top="317" left="230" width="43" height="12" font="34">ﬁc Council</text>
<text top="295" left="298" width="90" height="9" font="34">Rush Medical College</text>
<text top="293" left="388" width="46" height="12" font="34">—Professor</text>
<text top="307" left="341" width="49" height="9" font="34">of Medicine</text>
<text top="295" left="495" width="22" height="9" font="34">None</text>
<text top="295" left="605" width="22" height="9" font="34">None</text>
<text top="295" left="686" width="22" height="9" font="34">None</text>
<text top="295" left="787" width="22" height="9" font="34">None</text>
<text top="295" left="902" width="22" height="9" font="34">None</text>
<text top="295" left="980" width="22" height="9" font="34">None</text>
<text top="338" left="59" width="63" height="9" font="34">David J. Maron</text>
<text top="338" left="193" width="74" height="9" font="34">Content Reviewer</text>
<text top="338" left="304" width="123" height="9" font="34">Stanford University School of</text>
<text top="350" left="302" width="37" height="9" font="34">Medicine</text>
<text top="348" left="339" width="90" height="12" font="34">—Clinical Professor of</text>
<text top="362" left="294" width="143" height="9" font="34">Medicine and Emergency Medicine</text>
<text top="338" left="495" width="22" height="9" font="34">None</text>
<text top="338" left="605" width="22" height="9" font="34">None</text>
<text top="338" left="686" width="22" height="9" font="34">None</text>
<text top="338" left="787" width="22" height="9" font="34">None</text>
<text top="338" left="902" width="22" height="9" font="34">None</text>
<text top="338" left="980" width="22" height="9" font="34">None</text>
<text top="381" left="59" width="77" height="9" font="34">Gilles Montalescot</text>
<text top="381" left="193" width="74" height="9" font="34">Content Reviewer</text>
<text top="381" left="310" width="112" height="9" font="34">Pitie-Salpetriere University</text>
<text top="393" left="304" width="34" height="9" font="34">Hospital</text>
<text top="391" left="338" width="90" height="12" font="34">—Head of Institute of</text>
<text top="405" left="344" width="45" height="9" font="34">Cardiology</text>
<text top="382" left="452" width="4" height="7" font="35">n</text>
<text top="381" left="462" width="39" height="9" font="34">Acuitude</text>
<text top="394" left="452" width="4" height="7" font="35">n</text>
<text top="393" left="462" width="54" height="9" font="34">AstraZeneca</text>
<text top="406" left="452" width="4" height="7" font="35">n</text>
<text top="405" left="462" width="25" height="9" font="34">Bayer</text>
<text top="418" left="452" width="4" height="7" font="35">n</text>
<text top="417" left="462" width="92" height="9" font="34">Bristol-Myers Squibb</text>
<text top="430" left="452" width="4" height="7" font="35">n</text>
<text top="429" left="462" width="64" height="9" font="34">Daiichi-Sankyo</text>
<text top="442" left="452" width="4" height="7" font="35">n</text>
<text top="441" left="462" width="33" height="9" font="34">Eli Lilly</text>
<text top="454" left="452" width="4" height="7" font="35">n</text>
<text top="453" left="462" width="36" height="9" font="34">Lead-up</text>
<text top="466" left="452" width="4" height="7" font="35">n</text>
<text top="465" left="462" width="94" height="9" font="34">Medcon International</text>
<text top="478" left="452" width="4" height="7" font="35">n</text>
<text top="476" left="462" width="38" height="9" font="34">Menarini</text>
<text top="490" left="452" width="4" height="7" font="35">n</text>
<text top="488" left="462" width="20" height="9" font="34">MSD</text>
<text top="502" left="452" width="4" height="7" font="35">n</text>
<text top="500" left="462" width="21" height="9" font="34">Sano</text>
<text top="499" left="483" width="42" height="12" font="34">ﬁ-Aventis</text>
<text top="514" left="452" width="4" height="7" font="35">n</text>
<text top="512" left="462" width="33" height="9" font="34">Stentys</text>
<text top="381" left="605" width="22" height="9" font="34">None</text>
<text top="381" left="686" width="22" height="9" font="34">None</text>
<text top="382" left="741" width="4" height="7" font="35">n</text>
<text top="381" left="750" width="54" height="9" font="34">AstraZeneca</text>
<text top="381" left="804" width="4" height="9" font="36"><a href="1082.full.html#34">*</a></text>
<text top="394" left="741" width="4" height="7" font="35">n</text>
<text top="393" left="750" width="92" height="9" font="34">Bristol-Myers Squibb</text>
<text top="393" left="843" width="4" height="9" font="36"><a href="1082.full.html#34">*</a></text>
<text top="406" left="741" width="4" height="7" font="35">n</text>
<text top="405" left="750" width="38" height="9" font="34">Celladon</text>
<text top="418" left="741" width="4" height="7" font="35">n</text>
<text top="417" left="750" width="64" height="9" font="34">Daiichi-Sankyo</text>
<text top="417" left="815" width="4" height="9" font="36"><a href="1082.full.html#34">*</a></text>
<text top="430" left="741" width="4" height="7" font="35">n</text>
<text top="429" left="750" width="33" height="9" font="34">Eli Lilly</text>
<text top="429" left="783" width="4" height="9" font="36"><a href="1082.full.html#34">*</a></text>
<text top="442" left="741" width="4" height="7" font="35">n</text>
<text top="441" left="750" width="86" height="9" font="34">Janseen-CilagRecor</text>
<text top="454" left="741" width="4" height="7" font="35">n</text>
<text top="453" left="750" width="21" height="9" font="34">Sano</text>
<text top="451" left="771" width="42" height="12" font="34">ﬁ-Aventis</text>
<text top="466" left="741" width="4" height="7" font="35">n</text>
<text top="465" left="750" width="33" height="9" font="34">Stentys</text>
<text top="465" left="783" width="4" height="9" font="36"><a href="1082.full.html#34">*</a></text>
<text top="381" left="902" width="22" height="9" font="34">None</text>
<text top="381" left="980" width="22" height="9" font="34">None</text>
<text top="532" left="59" width="67" height="9" font="34">Mark A. Munger</text>
<text top="532" left="193" width="74" height="9" font="34">Content Reviewer</text>
<text top="532" left="299" width="76" height="9" font="34">University of Utah</text>
<text top="530" left="375" width="58" height="12" font="34">—Professor of</text>
<text top="544" left="328" width="76" height="9" font="34">Pharmacy Practice</text>
<text top="532" left="495" width="22" height="9" font="34">None</text>
<text top="532" left="605" width="22" height="9" font="34">None</text>
<text top="532" left="686" width="22" height="9" font="34">None</text>
<text top="532" left="787" width="22" height="9" font="34">None</text>
<text top="532" left="902" width="22" height="9" font="34">None</text>
<text top="532" left="980" width="22" height="9" font="34">None</text>
<text top="563" left="59" width="76" height="9" font="34">E. Magnus Ohman</text>
<text top="563" left="193" width="74" height="9" font="34">Content Reviewer</text>
<text top="563" left="304" width="66" height="9" font="34">Duke University</text>
<text top="561" left="370" width="58" height="12" font="34">—Professor of</text>
<text top="575" left="295" width="141" height="9" font="34">Medicine, Director of Program for</text>
<text top="587" left="308" width="115" height="9" font="34">Advanced Coronary Disease</text>
<text top="564" left="452" width="4" height="7" font="35">n</text>
<text top="563" left="462" width="54" height="9" font="34">AstraZeneca</text>
<text top="576" left="452" width="4" height="7" font="35">n</text>
<text top="575" left="462" width="34" height="9" font="34">Janssen</text>
<text top="587" left="462" width="71" height="9" font="34">Pharmaceutical<a href="1082.full.html#34">s</a></text>
<text top="587" left="533" width="4" height="9" font="36"><a href="1082.full.html#34">*</a></text>
<text top="563" left="605" width="22" height="9" font="34">None</text>
<text top="563" left="686" width="22" height="9" font="34">None</text>
<text top="564" left="741" width="4" height="7" font="35">n</text>
<text top="563" left="750" width="64" height="9" font="34">Daiichi-Sankyo</text>
<text top="563" left="815" width="4" height="9" font="36"><a href="1082.full.html#34">*</a></text>
<text top="576" left="741" width="4" height="7" font="35">n</text>
<text top="575" left="750" width="33" height="9" font="34">Eli Lilly</text>
<text top="575" left="783" width="4" height="9" font="36"><a href="1082.full.html#34">*</a></text>
<text top="588" left="741" width="4" height="7" font="35">n</text>
<text top="587" left="750" width="34" height="9" font="34">Janssen</text>
<text top="599" left="750" width="71" height="9" font="34">Pharmaceutic<a href="1082.full.html#34">als</a></text>
<text top="599" left="821" width="4" height="9" font="36"><a href="1082.full.html#34">*</a></text>
<text top="563" left="902" width="22" height="9" font="34">None</text>
<text top="563" left="980" width="22" height="9" font="34">None</text>
<text top="618" left="59" width="60" height="9" font="34">Eric R. Powers</text>
<text top="618" left="193" width="74" height="9" font="34">Content Reviewer</text>
<text top="618" left="308" width="116" height="9" font="34">Medical University of South</text>
<text top="630" left="303" width="34" height="9" font="34">Carolina</text>
<text top="628" left="337" width="92" height="12" font="34">—Service Line Medical</text>
<text top="642" left="349" width="33" height="9" font="34">Director</text>
<text top="618" left="495" width="22" height="9" font="34">None</text>
<text top="618" left="605" width="22" height="9" font="34">None</text>
<text top="618" left="686" width="22" height="9" font="34">None</text>
<text top="618" left="787" width="22" height="9" font="34">None</text>
<text top="618" left="902" width="22" height="9" font="34">None</text>
<text top="618" left="980" width="22" height="9" font="34">None</text>
<text top="661" left="59" width="70" height="9" font="34">Susan J. Pressler</text>
<text top="661" left="190" width="74" height="9" font="34">Content Reviewer</text>
<text top="659" left="264" width="7" height="12" font="34">—</text>
<text top="673" left="180" width="100" height="9" font="34">ACC/AHA Task Force on</text>
<text top="685" left="198" width="66" height="9" font="34">Clinical Practice</text>
<text top="697" left="209" width="43" height="9" font="34">Guidelines</text>
<text top="661" left="309" width="108" height="9" font="34">Indiana School of Nursing</text>
<text top="659" left="416" width="7" height="12" font="34">—</text>
<text top="673" left="307" width="117" height="9" font="34">Professor and Sally Reahard</text>
<text top="685" left="310" width="112" height="9" font="34">Chair; Center of Enhancing</text>
<text top="697" left="313" width="105" height="9" font="34">Quality of Life in Chronic</text>
<text top="709" left="333" width="26" height="9" font="34">Illness</text>
<text top="707" left="359" width="40" height="12" font="34">—Director</text>
<text top="661" left="495" width="22" height="9" font="34">None</text>
<text top="661" left="605" width="22" height="9" font="34">None</text>
<text top="661" left="686" width="22" height="9" font="34">None</text>
<text top="661" left="787" width="22" height="9" font="34">None</text>
<text top="661" left="902" width="22" height="9" font="34">None</text>
<text top="661" left="980" width="22" height="9" font="34">None</text>
<text top="726" left="59" width="51" height="9" font="34">Sunil V. Rao</text>
<text top="726" left="193" width="74" height="9" font="34">Content Reviewer</text>
<text top="726" left="297" width="131" height="9" font="34">Duke University Medical Center</text>
<text top="725" left="428" width="7" height="12" font="34">—</text>
<text top="738" left="319" width="93" height="9" font="34">Associate Professor of</text>
<text top="750" left="347" width="37" height="9" font="34">Medicine</text>
<text top="726" left="495" width="22" height="9" font="34">None</text>
<text top="726" left="605" width="22" height="9" font="34">None</text>
<text top="726" left="686" width="22" height="9" font="34">None</text>
<text top="726" left="787" width="22" height="9" font="34">None</text>
<text top="726" left="902" width="22" height="9" font="34">None</text>
<text top="726" left="980" width="22" height="9" font="34">None</text>
<text top="771" left="913" width="105" height="8" font="37">Continued on the next page</text>
<text top="105" left="59" width="158" height="16" font="33">APPENDIX 2. CONTINUED</text>
<text top="100" left="1100" width="0" height="9" font="14">Levine</text>
<text top="130" left="1100" width="0" height="9" font="14">et</text>
<text top="142" left="1100" width="0" height="9" font="14">al</text>
<text top="149" left="1100" width="0" height="9" font="14">.</text>
<text top="664" left="1102" width="0" height="7" font="7">J</text>
<text top="669" left="1102" width="0" height="7" font="7">A</text>
<text top="676" left="1102" width="0" height="7" font="7">C</text>
<text top="682" left="1102" width="0" height="7" font="7">C</text>
<text top="692" left="1102" width="0" height="7" font="7">V</text>
<text top="699" left="1102" width="0" height="7" font="7">O</text>
<text top="706" left="1102" width="0" height="7" font="7">L</text>
<text top="711" left="1102" width="0" height="7" font="7">.</text>
<text top="719" left="1102" width="0" height="7" font="7">6</text>
<text top="724" left="1102" width="0" height="7" font="7">8</text>
<text top="730" left="1102" width="0" height="7" font="7">,N</text>
<text top="744" left="1102" width="0" height="7" font="7">O</text>
<text top="751" left="1102" width="0" height="7" font="7">.</text>
<text top="758" left="1102" width="0" height="7" font="7">1</text>
<text top="762" left="1102" width="0" height="7" font="7">0</text>
<text top="769" left="1102" width="0" height="7" font="7">,2</text>
<text top="781" left="1102" width="0" height="7" font="7">0</text>
<text top="788" left="1102" width="0" height="7" font="7">1</text>
<text top="792" left="1102" width="0" height="7" font="7">6</text>
<text top="100" left="1085" width="0" height="9" font="14">Focused</text>
<text top="138" left="1085" width="0" height="9" font="14">Update</text>
<text top="171" left="1085" width="0" height="9" font="14">on</text>
<text top="184" left="1085" width="0" height="9" font="14">Duration</text>
<text top="223" left="1085" width="0" height="9" font="14">of</text>
<text top="235" left="1085" width="0" height="9" font="14">Dual</text>
<text top="257" left="1085" width="0" height="9" font="14">Antiplatelet</text>
<text top="310" left="1085" width="0" height="9" font="14">Therapy</text>
<text top="659" left="1087" width="0" height="7" font="7">SEPTEMB</text>
<text top="702" left="1087" width="0" height="7" font="7">E</text>
<text top="708" left="1087" width="0" height="7" font="7">R</text>
<text top="718" left="1087" width="0" height="7" font="7">6</text>
<text top="724" left="1087" width="0" height="7" font="7">,</text>
<text top="731" left="1087" width="0" height="7" font="7">2</text>
<text top="737" left="1087" width="0" height="7" font="7">016:</text>
<text top="757" left="1087" width="0" height="7" font="7">10</text>
<text top="767" left="1087" width="0" height="7" font="7">82</text>
<text top="777" left="1087" width="0" height="10" font="7">–</text>
<text top="784" left="1087" width="0" height="7" font="7">115</text>
<text top="50" left="1101" width="0" height="9" font="5">1114</text>
</page>
<page number="34" position="absolute" top="0" left="0" height="864" width="1160">
<text top="127" left="59" width="42" height="9" font="34">Reviewer</text>
<text top="127" left="195" width="71" height="9" font="34">Representation</text>
<text top="127" left="336" width="58" height="9" font="34">Employment</text>
<text top="127" left="480" width="50" height="9" font="34">Consultant</text>
<text top="127" left="576" width="78" height="9" font="34">Speakers Bureau</text>
<text top="103" left="669" width="53" height="9" font="34">Ownership/</text>
<text top="115" left="667" width="58" height="9" font="34">Partnership/</text>
<text top="127" left="676" width="41" height="9" font="34">Principal</text>
<text top="127" left="755" width="85" height="9" font="34">Personal Research</text>
<text top="91" left="882" width="60" height="9" font="34">Institutional,</text>
<text top="103" left="877" width="71" height="9" font="34">Organizational,</text>
<text top="115" left="893" width="39" height="9" font="34">or Other</text>
<text top="127" left="874" width="67" height="9" font="34">Financial Bene</text>
<text top="125" left="941" width="10" height="12" font="34">ﬁt</text>
<text top="115" left="975" width="31" height="9" font="34">Expert</text>
<text top="127" left="972" width="37" height="9" font="34">Witness</text>
<text top="146" left="59" width="88" height="9" font="34">Philippe Gabriel Steg</text>
<text top="146" left="193" width="74" height="9" font="34">Content Reviewer</text>
<text top="146" left="312" width="100" height="9" font="34">Université Paris-Diderot</text>
<text top="144" left="412" width="7" height="12" font="34">—</text>
<text top="158" left="346" width="39" height="9" font="34">Professor</text>
<text top="147" left="452" width="4" height="7" font="35">n</text>
<text top="146" left="461" width="54" height="9" font="34">AstraZeneca</text>
<text top="159" left="452" width="4" height="7" font="35">n</text>
<text top="158" left="461" width="92" height="9" font="34">Bristol-Myers Squibb</text>
<text top="158" left="554" width="4" height="9" font="36"><a href="1082.full.html#34">*</a></text>
<text top="171" left="452" width="4" height="7" font="35">n</text>
<text top="170" left="461" width="64" height="9" font="34">Daiichi-Sankyo</text>
<text top="183" left="452" width="4" height="7" font="35">n</text>
<text top="182" left="461" width="33" height="9" font="34">Eli Lilly</text>
<text top="195" left="452" width="4" height="7" font="35">n</text>
<text top="194" left="461" width="26" height="9" font="34">Merck</text>
<text top="146" left="604" width="22" height="9" font="34">None</text>
<text top="146" left="685" width="22" height="9" font="34">None</text>
<text top="147" left="740" width="4" height="7" font="35">n</text>
<text top="146" left="750" width="54" height="9" font="34">AstraZenec<a href="1082.full.html#34">a</a></text>
<text top="146" left="803" width="4" height="9" font="36"><a href="1082.full.html#34">*</a></text>
<text top="146" left="901" width="22" height="9" font="34">None</text>
<text top="146" left="980" width="22" height="9" font="34">None</text>
<text top="213" left="59" width="60" height="9" font="34">Tracy Y. Wang</text>
<text top="213" left="193" width="74" height="9" font="34">Content Reviewer</text>
<text top="213" left="296" width="131" height="9" font="34">Duke University Medical Center</text>
<text top="211" left="428" width="7" height="12" font="34">—</text>
<text top="225" left="319" width="93" height="9" font="34">Associate Professor of</text>
<text top="237" left="347" width="37" height="9" font="34">Medicine</text>
<text top="214" left="452" width="4" height="7" font="35">n</text>
<text top="213" left="461" width="54" height="9" font="34">AstraZenec<a href="1082.full.html#34">a</a></text>
<text top="213" left="515" width="4" height="9" font="36"><a href="1082.full.html#34">*</a></text>
<text top="226" left="452" width="4" height="7" font="35">n</text>
<text top="225" left="461" width="33" height="9" font="34">Eli Lilly</text>
<text top="213" left="604" width="22" height="9" font="34">None</text>
<text top="213" left="685" width="22" height="9" font="34">None</text>
<text top="214" left="740" width="4" height="7" font="35">n</text>
<text top="213" left="750" width="54" height="9" font="34">AstraZenec<a href="1082.full.html#34">a</a></text>
<text top="213" left="803" width="4" height="9" font="36"><a href="1082.full.html#34">*</a></text>
<text top="226" left="740" width="4" height="7" font="35">n</text>
<text top="225" left="750" width="92" height="9" font="34">Bristol-Myers Squibb</text>
<text top="225" left="842" width="4" height="9" font="36"><a href="1082.full.html#34">*</a></text>
<text top="238" left="740" width="4" height="7" font="35">n</text>
<text top="237" left="750" width="101" height="9" font="34">Eli Lilly/Daiichi-Sankyo</text>
<text top="249" left="750" width="35" height="9" font="34">Allianc<a href="1082.full.html#34">e</a></text>
<text top="249" left="784" width="4" height="9" font="36"><a href="1082.full.html#34">*</a></text>
<text top="213" left="901" width="22" height="9" font="34">None</text>
<text top="213" left="980" width="22" height="9" font="34">None</text>
<text top="272" left="59" width="783" height="8" font="37">This table represents the relationships of reviewers with industry and other entities that were disclosed at the time of peer review and determined to be relevant to this document. It does not necessarily re</text>
<text top="271" left="842" width="176" height="11" font="37">ﬂect relationships with industry at the time of</text>
<text top="284" left="59" width="177" height="8" font="37">publication. A person is deemed to have a signi</text>
<text top="283" left="236" width="781" height="11" font="37">ﬁcant interest in a business if the interest represents ownership of $5% of the voting stock or share of the business entity, or ownership of $$5,000 of the fair market value of the business entity, or if funds</text>
<text top="296" left="59" width="279" height="8" font="37">received by the person from the business entity exceed 5% of the person</text>
<text top="295" left="338" width="680" height="11" font="37">’s gross income for the previous year. A relationship is considered to be modest if it is less than signiﬁcant under the preceding deﬁnition. Relationships that exist with no ﬁnancial</text>
<text top="308" left="59" width="19" height="8" font="37">bene</text>
<text top="307" left="77" width="940" height="11" font="37">ﬁt are also included for the purpose of transparency. Relationships in this table are modest unless otherwise noted. Names are listed in alphabetical order within each category of review. According to the ACC/AHA, a person has a relevant relationship</text>
<text top="320" left="59" width="959" height="8" font="37">IF: a) the relationship or interest relates to the same or similar subject matter, intellectual property or asset, topic, or issue addressed in the document; or b) the company/entity (with whom the relationship exists) makes a drug, drug class, or device</text>
<text top="332" left="59" width="510" height="8" font="37">addressed in the document, or makes a competing drug or device addressed in the document; or c) the person or a member of the person</text>
<text top="331" left="568" width="449" height="11" font="37">’s household has a reasonable potential for ﬁnancial, professional or other personal gain or loss as a result of the issues/</text>
<text top="344" left="59" width="138" height="8" font="37">content addressed in the document.</text>
<text top="356" left="62" width="22" height="8" font="37">*Signi</text>
<text top="355" left="84" width="72" height="11" font="37">ﬁcant relationship.</text>
<text top="367" left="62" width="82" height="11" font="37">†No ﬁnancial beneﬁt.</text>
<text top="382" left="67" width="951" height="8" font="37">AATS indicates American Association for Thoracic Surgery; ACC, American College of Cardiology; ACEP, American College of Emergency Physicians; AHA, American Heart Association; CSL, Coordinated Science Laboratory; DSMB, data safety monitoring</text>
<text top="394" left="59" width="959" height="8" font="37">board; PCNA; Preventive Cardiovascular Nurses Association; SCA, Society of Cardiovascular Anesthesiologist; SCAI, Society for Cardiovascular Angiography and Interventions; STS, Society of Thoracic Surgeons; and SVM, Society for Vascular Medicine.</text>
<text top="60" left="59" width="158" height="16" font="33">APPENDIX 2. CONTINUED</text>
<text top="57" left="1102" width="0" height="7" font="7">J</text>
<text top="63" left="1102" width="0" height="7" font="7">A</text>
<text top="69" left="1102" width="0" height="7" font="7">C</text>
<text top="76" left="1102" width="0" height="7" font="7">C</text>
<text top="86" left="1102" width="0" height="7" font="7">V</text>
<text top="92" left="1102" width="0" height="7" font="7">O</text>
<text top="99" left="1102" width="0" height="7" font="7">L</text>
<text top="105" left="1102" width="0" height="7" font="7">.</text>
<text top="112" left="1102" width="0" height="7" font="7">6</text>
<text top="118" left="1102" width="0" height="7" font="7">8</text>
<text top="123" left="1102" width="0" height="7" font="7">,N</text>
<text top="137" left="1102" width="0" height="7" font="7">O</text>
<text top="144" left="1102" width="0" height="7" font="7">.</text>
<text top="152" left="1102" width="0" height="7" font="7">1</text>
<text top="156" left="1102" width="0" height="7" font="7">0</text>
<text top="162" left="1102" width="0" height="7" font="7">,2</text>
<text top="175" left="1102" width="0" height="7" font="7">0</text>
<text top="181" left="1102" width="0" height="7" font="7">1</text>
<text top="185" left="1102" width="0" height="7" font="7">6</text>
<text top="698" left="1100" width="0" height="9" font="14">Levine</text>
<text top="728" left="1100" width="0" height="9" font="14">et</text>
<text top="739" left="1100" width="0" height="9" font="14">al</text>
<text top="747" left="1100" width="0" height="9" font="14">.</text>
<text top="57" left="1087" width="0" height="7" font="7">S</text>
<text top="63" left="1087" width="0" height="7" font="7">E</text>
<text top="69" left="1087" width="0" height="7" font="7">PT</text>
<text top="81" left="1087" width="0" height="7" font="7">EM</text>
<text top="94" left="1087" width="0" height="7" font="7">BE</text>
<text top="106" left="1087" width="0" height="7" font="7">R</text>
<text top="117" left="1087" width="0" height="7" font="7">6</text>
<text top="122" left="1087" width="0" height="7" font="7">,</text>
<text top="129" left="1087" width="0" height="7" font="7">2</text>
<text top="135" left="1087" width="0" height="7" font="7">01</text>
<text top="145" left="1087" width="0" height="7" font="7">6</text>
<text top="151" left="1087" width="0" height="7" font="7">:</text>
<text top="155" left="1087" width="0" height="7" font="7">1</text>
<text top="159" left="1087" width="0" height="7" font="7">0</text>
<text top="165" left="1087" width="0" height="7" font="7">8</text>
<text top="171" left="1087" width="0" height="7" font="7">2</text>
<text top="175" left="1087" width="0" height="10" font="7">–</text>
<text top="182" left="1087" width="0" height="7" font="7">115</text>
<text top="507" left="1085" width="0" height="9" font="14">Focused</text>
<text top="544" left="1085" width="0" height="9" font="14">Update</text>
<text top="578" left="1085" width="0" height="9" font="14">on</text>
<text top="591" left="1085" width="0" height="9" font="14">Duration</text>
<text top="630" left="1085" width="0" height="9" font="14">of</text>
<text top="642" left="1085" width="0" height="9" font="14">Dual</text>
<text top="664" left="1085" width="0" height="9" font="14">Antiplatelet</text>
<text top="716" left="1085" width="0" height="9" font="14">Therapy</text>
<text top="785" left="1101" width="0" height="9" font="5">1115</text>
</page>
<outline>
<item page="1">2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease</item>
<outline>
<item page="2">Table of Contents</item>
<item page="3">Preamble</item>
<outline>
<item page="3">Modernization</item>
<item page="3">Class of Recommendation and Level of Evidence</item>
<item page="3">Relationships With Industry and Other Entities</item>
<item page="3">Intended Use</item>
<item page="4">Related Issues</item>
</outline>
<item page="5">1. Introduction</item>
<outline>
<item page="5">1.1. Methodology and Evidence Review</item>
<item page="6">1.2. Organization of the Writing Group</item>
<item page="6">1.3. Review and Approval</item>
</outline>
<item page="6">2. Critical Questions and Systematic Review Findings</item>
<outline>
<item page="6">2.1. Critical Questions on Duration of DAPT</item>
<item page="6">2.2. Studies of Shorter-Duration DAPT After Stent Implantation</item>
<item page="6">2.3. Studies of Longer-Duration DAPT After Stent Implantation</item>
<item page="7">2.4. Other Studies Relevant to DAPT ﹥1 Year After MI</item>
<item page="7">2.5. Prolonged/Extended DAPT and Mortality Rate</item>
</outline>
<item page="8">3. Overriding Concepts and Recommendations for DAPT and Duration of Therapy</item>
<outline>
<item page="8">3.1. General Overriding Concepts</item>
<item page="8">3.2. Factors Associated With Increased Ischemic and Bleeding Risk</item>
<item page="9">3.3. Specific P2Y12 Inhibitors: Recommendations</item>
<item page="9">3.4. Platelet Function Testing, Genetic Testing, and Switching of P2Y12 Inhibitors</item>
<item page="9">3.5. Proton Pump Inhibitors and DAPT</item>
<item page="9">3.6. Aspirin Dosing in Patients Treated With DAPT: Recommendation</item>
<item page="11">3.7. Triple Therapy (Aspirin, P2Y12 Inhibitor, and Oral Anticoagulant)</item>
</outline>
<item page="11">4. Percutaneous Coronary Intervention</item>
<outline>
<item page="11">4.1. Duration of DAPT in Patients With SIHD Treated With PCI: Recommendations</item>
<item page="12">4.2. Duration of DAPT in Patients With ACS Treated With PCI: Recommendations</item>
<item page="13">4.3. Duration of DAPT in Patients With SIHD and ACS Treated With PCI</item>
</outline>
<item page="14">5. Recommendations for Duration of DAPT in Patients Undergoing CABG</item>
<item page="16">6. Recommendations for Duration of DAPT in Patients With SIHD</item>
<item page="18">7. Acute Coronary Syndrome (NSTE-ACS and STEMI)</item>
<outline>
<item page="18">7.1. Duration of DAPT in Patients With ACS Treated With Medical Therapy Alone (Without Revascularization or Fibrinolytic Therapy ...</item>
<item page="18">7.2. Duration of DAPT in Patients With STEMI Treated With Fibrinolytic Therapy: Recommendations</item>
<item page="19">7.3. Duration of DAPT in Patients With ACS Treated With PCI: Recommendations</item>
<item page="19">7.4. Duration of DAPT in Patients With ACS Treated With CABG: Recommendation</item>
<item page="19">7.5. Duration of DAPT in Patients With ACS</item>
</outline>
<item page="20">8. Perioperative Management–Timing of Elective Noncardiac Surgery in Patients Treated With PCI and DAPT: Recommendations</item>
<item page="23">Presidents and Staff</item>
<item page="23">References</item>
</outline>
</outline>
</pdf2xml>
